

1 UNITED STATES DISTRICT COURT  
2 FOR THE NORTHERN DISTRICT OF OHIO  
3 EASTERN DIVISION  
4 - - -  
5 IN RE: NATIONAL )  
6 PRESCRIPTION OPIATE ) MDL No. 2804  
7 LITIGATION )  
8 \_\_\_\_\_ ) Case No. 1:17-MD-2804  
9 )  
10 THIS DOCUMENT RELATES )  
11 TO ALL CASES ) Hon. Dan A. Polster  
12  
13  
14 - - -

15  
16 Tuesday, November 27, 2018  
17 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER  
18 CONFIDENTIALITY REVIEW  
19 - - -

20 Videotaped deposition of Eric Brantley,  
21 held at the Durham Hotel, 315 East Chapel Hill  
22 Street, Durham, North Carolina, commencing  
23 at 9:01 a.m., on the above date, before Karen  
24 Kidwell, Registered Merit Reporter and Notary Public.  
25 - - -

26 GOLKOW LITIGATION SERVICES  
27 877.370.3377 ph | 917.591.5672 fax  
28  
29 deps@golkow.com

Page 2

1 APPEARANCES:  
2 On behalf of the Plaintiffs:  
3 MCHUGH FULLER LAW GROUP  
4 BY: MICHAEL J. FULLER, JR., ESQUIRE  
5 mike@mchughfuller.com  
6 97 Elias Whiddon Road  
7 Hattiesburg, Mississippi 39402  
8 601-261-2220  
9  
10 and  
11 LEVIN PAPANTONIO THOMAS MITCHELL  
12 RAFFERTY & PROCTOR P.A.  
13 BY: MICHAEL PAPANTONIO, ESQUIRE  
14 mpapantonio@levinlaw.com  
15 BY: ARCHIE C. LAMB, ESQUIRE  
16 alamb@levinlaw.com  
17 316 South Baylen Street, Suite 600  
18 Pensacola, Florida 32502  
19 205-435-7000  
20  
21 and  
22 SEEGER WEISS LLP  
23 BY: DAVID R. BUCHANAN, ESQUIRE  
24 dbuchanan@seegerweiss.com  
25 77 Water Street, 8th Floor  
New York, NY 10005  
212-584-0700

On behalf of the Cardinal Health, Inc.:

WILLIAMS & CONNOLLY LLP  
BY: STEVEN M. PYSER, ESQUIRE  
spyser@wc.com  
BY: MATTHEW MONAHAN, ESQUIRE  
mmonahan@wc.com  
725 Twelfth Street, N.W.  
Washington, DC 20005  
202-434-5899

Page 3

1 APPEARANCES CONTINUED:  
2 On behalf of the AmerisourceBergen:  
3 REED SMITH LLP  
4 BY: ABIGAIL M. PIERCE, ESQUIRE  
5 apierce@reedsmith.com  
6 Three Logan Square  
7 1717 Arch Street, Suite 3100  
8 Philadelphia, Pennsylvania 19103  
9 215-241-7947  
10  
11 On behalf of HBC Service Company:  
12 MARCUS & SHAPIRA LLP  
13 BY: DARLENE M. NOWAK, ESQUIRE  
14 (Via Teleconference)  
15 nowak@marcus-shapira.com  
16 BY: PAUL MANNIX, ESQUIRE  
17 (Via Teleconference)  
18 pmannix@marcus-shapira.com  
19 One Oxford Center, 35th Floor  
20 301 Grant Street  
21 Pittsburgh, Pennsylvania 15219-6401  
22 412-338-5214  
23  
24 On behalf of Walmart:  
25 JONES DAY  
BY: LOUIS P. GABEL, ESQUIRE  
lgabel@jonesday.com  
150 West Jefferson Street  
Suite 2100  
Detroit, MI 48226-4438  
313-733-3939

On behalf of Prescription Supply, Inc.:

PELINI, CAMPBELL & WILLIAMS LLC  
BY: PAUL B. RICARD, ESQUIRE  
pbricard@pelini-law.com  
8040 Cleveland Avenue NW, Suite 400  
North Canton, Ohio 44720  
330-305-6400

Page 4

1 APPEARANCES CONTINUED:  
2 On behalf of McKesson:  
3 COVINGTON & BURLING, LLP  
4 BY: AMBER CHARLES, ESQUIRE  
5 acharles@cov.com  
6 850 Tenth Street, NW  
7 Washington, DC 20001  
8 202-662-5531  
9  
10 On behalf of Endo Pharmaceuticals, Inc., and  
11 Endo Health Solutions Inc. and Par:  
12 McCARTER & ENGLISH, LLP  
13 BY: AMY M. VANNI, ESQUIRE  
14 avanni@mccarter.com  
15 1600 Market Street, Suite 3900  
16 Philadelphia, PA 19103  
17 215-979-3848  
18 On behalf of Purdue Pharma:  
19 DECHERT LLP  
20 BY: PAUL A. LAFATA, ESQUIRE  
21 paul.lafata@dechert.com  
22 Three Bryant Park  
23 1095 Avenue of the Americas  
24 New York, NY 10036  
25 212-698-3539

On behalf of C&R Pharmacy:  
COLLINSON, DAEHNKE, INLOW & GRECO  
BY: AMANDA E. ROSENTHAL, ESQUIRE  
(Via Telephone)  
amanda.rosenthal@cdiglaw.com  
2110 East Flamingo Road  
Suite 305  
Las Vegas, NV 89119  
702-979-2132

Page 5

1 APPEARANCES CONTINUED:  
2 On behalf of Rochester Drug Cooperative, Inc.:  
3 ALLEGAERT BERGER & VOGEL LLP  
4 BY: DAVID A. SHAIMAN, ESQUIRE  
5 (Via Telephone)  
6 dshaiman@abv.com  
7 111 Broadway, 20th Floor  
8 New York, NY 10006  
9 212-571-0550  
10  
11 On behalf of Validus Pharmaceuticals:  
12 FOX ROTHSCHILD LLP  
13 BY: MAURA L. BURKE, ESQUIRE  
14 (Via Telephone)  
15 mburke@foxrothschild.com  
16 2000 Market Street, 20th Floor  
17 Philadelphia, PA 19103  
18 215-299-2872  
19  
20 ALSO PRESENT:  
21 Lauren E. Massey, Levin Papantonio  
22 Sarah Merced, Levin Papantonio  
23 Carol Moore, Levin Papantonio  
24 Sandra Di Iorio, In-house counsel, Endo  
25 Edna Johnson Jamison, McHugh Fuller  
Scott Seigel, Seeger Weiss  
Elina Rakhlin, Seeger Weiss  
Evan J. Wolfe, Trial Technician  
Dan Lawlor, Videographer  
---







Page 14		
1	E X H I B I T S (Cont'd)	
2	Number	Description Page
3	Cardinal-Brantley 43	.....682
4		E-mail chain, top e-mail 3/22/2013,
5		Jill Connell to Tracey Hernandez,
6		Subject: FW: composite risk
7		assessment, Confidential-Subject to
8		Protective Order, Bates
9		PAR_OPIOID_MDL_0000035162-164, with
10		attachment E0573
11	Cardinal-Brantley 44	.....696
12		4/17/2014 E-mail, Eric Brantley to
13		Tracey Hernandez, Subject: SOM
14		update, with Qualitest SOM update
15		attachment, Confidential-Subject to
16		Protective Order, Bates
17		PAR_OPIOID_MDL_0000021256-72
18		
19		
20		
21		
22		
23		
24		
25		

Page 15

1 TUESDAY, NOVEMBER 27, 2018, DURHAM, NORTH CAROLINA

2 P R O C E E D I N G S

3 -oOo-

4 VIDEOGRAPHER: We are now on the record.

5 My name is Dan Lawlor. I'm a videographer with

6 Golkow Litigation Services. Today's date is

7 November 27th, 2018, and the time is 9:01 a.m.

8 This video deposition is being held in

9 Durham, North Carolina, in the matter of

10 National Prescription Opiate Litigation, MDL

11 Number 2804. The deponent is Eric Brantley.

12 Counsel will be noted on stenographic

13 record.

14 The court reporter is Karen Kidwell, who

15 will now swear in the witness.

16 ERIC BRANTLEY

17 being first duly sworn, testified as follows:

18 EXAMINATION

19 BY MR. PAPANTONIO:

20 Q. Sir, state your name, please.

21 A. Eric Brantley.

22 Q. Put up document 3751, please.

23 MS. MOORE: Cardinal-Brantley Number 1.

24 (Cardinal-Brantley 1 was marked for

25 identification.)

Page 16

1 (Cardinal-Brantley 1 clawed back by Cardinal

2 Health counsel.)

3 BY MR. PAPANTONIO:

4 Q. Mr. Brown, take a look at that document,

5 would you?

6 Do you know who Corey Goldsand is?

7 A. Yes.

8 Q. Tell the jury who Corey Goldsand is.

9 MR. PYSER: Objection. Counsel, this is a

10 privileged document that was inadvertently

11 produced and has been clawed back.

12 MR. PAPANTONIO: Well, we will take that

13 up with the court.

14 MR. PYSER: Well, it's already been clawed

15 back, so there's no --

16 MR. PAPANTONIO: When you say it's been

17 "clawed back," nobody has given me notice it's

18 been clawed back. I've used it in -- in the

19 line of discovery, and we're going to use it in

20 the deposition.

21 MR. PYSER: Well, no, we're not, Counsel,

22 because it's a communication between two

23 attorneys for Cardinal Health. It's a clearly

24 privileged document. We're clawing it back now.

25 Everyone on the document is a -- is an attorney.

Page 17

1 MR. PAPANTONIO: No, they're not. We'll

2 put it -- you can take it -- this portion of the

3 deposition you can put under camera if you want

4 to, but I'm going to ask this witness questions

5 about it.

6 MR. PYSER: Counsel, we've clawed the

7 document back. There's no basis to ask

8 questions about it.

9 MR. PAPANTONIO: Well, I think the judge

10 has already ruled on the point of

11 attorney-client privilege. He just ruled

12 Friday, if you were at the hearing, okay?

13 MR. PYSER: That ruling has nothing to do

14 with this document.

15 MR. PAPANTONIO: Well --

16 MR. PYSER: That's an attorney-client

17 communication. Upon discovery of this document,

18 it should have been produced -- it should have

19 been noted to the Defendants under the ethical

20 rules, because it's a clearly privileged

21 document.

22 MR. PAPANTONIO: No. No, this was one

23 of -- this was one of the documents that you all

24 tried to bury in stacks of other documents.

25 Now, I'm going to ask the question. You

Page 18

1 can instruct him not to answer the question, at  
2 which time we will reset the deposition and get  
3 into this document another time.  
4 I'm going to finish the deposition today;  
5 don't get me wrong.  
6 MR. PYSER: You can finish the  
7 deposition --  
8 MR. PAPANTONIO: But if you want --  
9 MR. PYSER: -- but you can't use this  
10 document.  
11 MR. PAPANTONIO: If you want to put on the  
12 record -- well, I'm going to ask the question,  
13 and you can object as you see fit.  
14 BY MR. PAPANTONIO:  
15 Q. Sir, you -- you were a -- you were in  
16 charge of regulatory -- regulatory is one of your  
17 responsibilities with Cardinal; is that correct?  
18 A. I worked in the quality and regulatory  
19 affairs department.  
20 Q. And -- and with you was a fellow named  
21 Reardon; is that right?  
22 A. Steve Reardon was my boss.  
23 Q. And how many years was he your boss?  
24 A. I would say 2005 to 2008, maybe.  
25 Q. And did you have a system when you worked

Page 19

1 with Mr. Reardon where you would actually -- you'd  
2 have a suspicious order that you would have in-house,  
3 and then you would ship the product, even after being  
4 notified that it might be suspicious?  
5 Do you recall ever doing that,  
6 Mr. Brantley?  
7 A. No.  
8 Q. Okay. And do you have any idea that the  
9 company was carrying on a monitoring system where  
10 they would identify and report potentially suspicious  
11 excessive purchases of controlled substances after  
12 the substances were shipped?  
13 Had anybody ever told you that that was  
14 going on with Cardinal?  
15 A. We had ingredient limit reports that  
16 were -- that were ran every month and submitted to  
17 the DEA. And those ingredient limit reports were the  
18 potentially suspicious orders --  
19 Q. Okay --  
20 A. -- and I reviewed those reports.  
21 Q. Yeah, you reviewed them, and after you  
22 reviewed them, you would ship anyway; is that  
23 correct?  
24 A. I would review the reports, and I would  
25 conduct investigations of any downstream -- any

Page 20

1 pharmacies that I needed to investigate.  
2 Q. And --  
3 A. And I would conduct a site visit of those  
4 pharmacies.  
5 Q. And my question is, sir, there were times  
6 when you, Brantley, saw suspicious orders and decided  
7 to ship the orders anyway. That's a yes-or-no  
8 question.  
9 A. That is incorrect.  
10 Q. Okay. So what -- what system did you use  
11 before you would ship?  
12 A. My job was to review the ingredient limit  
13 reports on a monthly basis, and if I noticed any  
14 pharmacies that I wanted to further investigate, I  
15 would contact those pharmacies and I would conduct a  
16 site visit. If those pharmacies were deemed  
17 suspicious, they were shut off from controlled  
18 substances, and they were reported to -- to Kyle  
19 Wright at the DEA.  
20 Q. And so --  
21 A. That was my job.  
22 Q. That was your job?  
23 A. Yes.  
24 Q. And you feel like you carried your job out  
25 appropriately?

Page 21

1 A. Yes.  
2 Q. Were you there -- what were the years that  
3 you were in charge of that job?  
4 A. I was never in charge of the -- the job.  
5 But I was at the corporate office -- from 2005 till  
6 about 2008, I had responsibility for reviewing the  
7 ingredient limit reports and conducting  
8 investigations.  
9 Q. Had anybody told you that -- that within  
10 management there was a feeling that few, if any,  
11 directives from the company leadership were ever  
12 passed down regarding controlled substances and  
13 shipment of controlled substances?  
14 MR. PYSER: Objection to the question to  
15 the extent it comes from a document that's been  
16 clawed back. It's an inappropriate question.  
17 BY MR. PAPANTONIO:  
18 Q. Is that the first --  
19 MR. PYSER: And counsel -- and counsel's  
20 violating ethical rules by continuing to use a  
21 document that's been clawed back by the defense.  
22 BY MR. PAPANTONIO:  
23 Q. Is that the first time you've heard that,  
24 sir?  
25 A. Can you please repeat what you --

Page 22

1 Q. Yes. Where management clearly understood  
2 that there was few, if any, directives at all from  
3 the company leadership regarding substances being  
4 shipped after they were deemed suspicious orders?  
5 MR. PYSER: Same objections.  
6 THE WITNESS: This is my first time  
7 hearing that, and I don't agree with that.  
8 BY MR. PAPANTONIO:  
9 Q. Okay. First time you've heard that is  
10 today, though, right?  
11 A. As far as I -- I can recall, yes.  
12 Q. How long did you prepare for this  
13 deposition?  
14 A. What do you mean, how long did I prepare?  
15 Q. How long did you sit down with anybody  
16 from the company and prepare for this deposition?  
17 A. Well, I didn't sit down with anyone from  
18 the company, but I did sit down with --  
19 Q. How many hours?  
20 A. -- with attorneys.  
21 Several hours. I don't know the exact  
22 number of hours.  
23 Q. Okay. So today -- and you're no longer  
24 with Cardinal; is that correct?  
25 A. No, I'm not.

Page 23

1 Q. Okay. So today, what I'm going to be  
2 asking you is what you have reviewed prior to the  
3 time you came here and what you knew at the time that  
4 you were an employee with Cardinal. All right?  
5 A. Okay.  
6 Q. And so, sir, had anybody ever told you  
7 that -- that your company was giving discounts to  
8 people -- to -- to customers who were ordering large  
9 bulk orders of narcotics?  
10 MR. PYSER: Counsel, same objection. To  
11 the extent you're reading from a document that's  
12 been clawed back, it's inappropriate, and we  
13 should cease the practice. It's a violation of  
14 the ethical rules and a violation of deposition  
15 protocol that allows clawbacks of documents that  
16 are clearly privileged.  
17 MR. PAPANTONIO: You're going to be able  
18 to put this under camera if you want, Counselor.  
19 BY MR. PAPANTONIO:  
20 Q. Had anybody ever told you that?  
21 A. No.  
22 MR. PYSER: Object to form.  
23 BY MR. PAPANTONIO:  
24 Q. First time you ever heard it; is that  
25 right?

Page 24

1 MR. PYSER: Object to form.  
2 THE WITNESS: As far as I can recall.  
3 MR. PAPANTONIO: Okay. Put up  
4 document 4195.  
5 MS. MOORE: This will be  
6 Cardinal-Brantley 2.  
7 (Cardinal-Brantley 2 was marked for  
8 identification.)  
9 BY MR. PAPANTONIO:  
10 Q. Sir, state your name again for the record.  
11 A. Eric Brantley.  
12 Q. Okay. And you're looking at document  
13 number 4195. Take a look at it.  
14 Do you see it? You're welcome to use the  
15 screen, or you're welcome to use the hard copy we  
16 give you, or you're welcome to use this screen up  
17 here; this is easy to read. However you want to do  
18 it. Feel free.  
19 A. That's blurry up there. I'll -- I'll read  
20 this.  
21 Q. All right. Who is -- who is Steve  
22 Reardon?  
23 A. Steve Reardon was my boss at the time.  
24 Q. And you see your name on there -- you see,  
25 Mr. Brantley, where it says "To Brantley"?

Page 25

1 A. Yes.  
2 Q. And who is McPherson?  
3 A. I don't know what her position was at the  
4 time, but she was in the quality and regulatory  
5 affairs department, I believe.  
6 Q. Do you recognize everybody on the -- on  
7 the line where it says "To"?  
8 A. No.  
9 Q. Who don't you recognize?  
10 A. Al M-o-h-n, Mohn, Mohn.  
11 Q. You don't recognize Al Mohn; you never had  
12 any contact with Al Mohn?  
13 A. I don't remember that name.  
14 Q. All right. Let's read this first  
15 paragraph.  
16 It says: "HDMA met with DEA officials  
17 last Friday, September 7th, to discuss the agency's  
18 current policy positions on suspicious orders."  
19 Did you know that that meeting had taken  
20 place?  
21 A. No.  
22 Q. Okay. And in your review before you came  
23 in here today, did any -- did you -- you weren't  
24 shown this document, I take it?  
25 A. This particular --

<p style="text-align: right;">Page 26</p> <p>1 Q. Yes.</p> <p>2 A. -- e-mail?</p> <p>3 Q. Right.</p> <p>4 A. This is my first time seeing this e-mail.</p> <p>5 Q. But it's got your name on it?</p> <p>6 A. It does.</p> <p>7 Q. Okay. And it says: "A summary</p> <p>8 highlighting the key points made during the meeting</p> <p>9 are attached for your review."</p> <p>10 It says: "DEA is setting a new standard</p> <p>11 with which we must comply. This is all coming about</p> <p>12 as a result of the problem with Internet pharmacies</p> <p>13 and controlled substance diversion."</p> <p>14 Now, you -- you had some -- part of your</p> <p>15 job was to be involved with Internet pharmacies,</p> <p>16 wasn't it?</p> <p>17 A. Part my job was to try to identify</p> <p>18 potential Internet activity from the ingredient limit</p> <p>19 reports and investigate, yes.</p> <p>20 MR. PAPANTONIO: All right. So would you</p> <p>21 underline "Internet pharmacies" for me there,</p> <p>22 Evan?</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. And it says: "Controlled substance</p> <p>25 diversion."</p>	<p style="text-align: right;">Page 28</p> <p>1 A. -- security, you know --</p> <p>2 Q. Now, I'm just going to ask you</p> <p>3 questions -- I'm going to ask you questions, okay?</p> <p>4 A. And I'm going to answer the questions.</p> <p>5 Q. If you're not clear about the question,</p> <p>6 you tell me you're not clear. If you want to give a</p> <p>7 speech, Mr. Pyser is going to be able to talk to you</p> <p>8 after the end of it; you can give your speeches.</p> <p>9 So if I ask you a yes-or-no question, I</p> <p>10 really want a yes-or-no answer. Okay?</p> <p>11 MR. PYSER: Counsel, object -- object to</p> <p>12 that speech. The witness was answering your</p> <p>13 question. You cut him off.</p> <p>14 MR. PAPANTONIO: All right.</p> <p>15 MR. PYSER: He's allowed to answer your</p> <p>16 questions in full. You're not here to instruct</p> <p>17 the witness on how to answer questions. He's</p> <p>18 here to answer your questions. And that's what</p> <p>19 we're going to do.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. So now this goes on. It says:</p> <p>22 "Recently they suspended an ABC registration and used</p> <p>23 the suspension to get them to implement a complex and</p> <p>24 onerous suspicious order monitoring program that</p> <p>25 meets the requirement, meets the criteria spelled out</p>
<p style="text-align: right;">Page 27</p> <p>1 That was your job, wasn't it? To -- to be</p> <p>2 involved with controlling the substance diversion of</p> <p>3 narcotics, correct?</p> <p>4 MR. PYSER: Object to the form of the</p> <p>5 question.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Is that true?</p> <p>8 A. My job was to review ingredient limit</p> <p>9 reports and search for pharmacies that needed further</p> <p>10 investigation and shut those pharmacies off if deemed</p> <p>11 necessary and report that to the DEA.</p> <p>12 Q. And that's controlling substance abuse of</p> <p>13 narcotics, true?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. That's -- part of your goal was to stop</p> <p>17 diversion of narcotics; yes or no?</p> <p>18 A. Part of our job was to help to prevent</p> <p>19 diversion through the -- potential Internet</p> <p>20 pharmacies, as well as the physical security in the</p> <p>21 distribution centers and the cage and the vault and</p> <p>22 everything else.</p> <p>23 Q. Right. And --</p> <p>24 A. There was a lot to --</p> <p>25 Q. Well, sir --</p>	<p style="text-align: right;">Page 29</p> <p>1 in HDMA."</p> <p>2 Now, sir, you would agree it's a good idea</p> <p>3 to have a system in place that -- that actually</p> <p>4 monitors suspicious orders; you would agree with</p> <p>5 that, wouldn't you?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 THE WITNESS: It is required in the</p> <p>8 regulation to have a system to help identify</p> <p>9 suspicious orders --</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. And --</p> <p>12 A. -- and to report those orders to the DEA.</p> <p>13 Q. And you knew that the day you went to work</p> <p>14 with Cardinal; you understood that that was the law.</p> <p>15 Correct?</p> <p>16 A. The day that I went to work with Cardinal</p> <p>17 Health?</p> <p>18 Q. Yeah.</p> <p>19 A. I was not in this capacity. And no, I</p> <p>20 can't say that I was familiar with all the</p> <p>21 regulations.</p> <p>22 Q. At some time you learned that that was the</p> <p>23 law, though, to report suspicious orders, correct?</p> <p>24 MR. PYSER: Object to form. Calls for</p> <p>25 legal conclusion.</p>



<p style="text-align: right;">Page 30</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Is that true?</p> <p>3 A. At one point during my employment with</p> <p>4 Cardinal Health, I learned that it was the -- the</p> <p>5 requirement to report --</p> <p>6 Q. And you --</p> <p>7 A. -- suspicious orders.</p> <p>8 Q. And you understood not to do that would be</p> <p>9 breaking the law -- I mean, simply put: If you don't</p> <p>10 follow the law, you break the law, true?</p> <p>11 MR. PYSER: Object to form. Calls for a</p> <p>12 legal conclusion.</p> <p>13 THE WITNESS: I understand that the</p> <p>14 regulation was that we were to design a system</p> <p>15 to identify and report suspicious orders, which</p> <p>16 we did.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. And if you don't do it, though, you're</p> <p>19 breaking the law, right? That's all I'm asking. If</p> <p>20 you don't do that, you and I can agree you're</p> <p>21 breaking the law?</p> <p>22 A. If a company --</p> <p>23 MR. PYSER: Object --</p> <p>24 THE WITNESS: -- fails to do that --</p> <p>25 MR. PYSER: Object --</p>	<p style="text-align: right;">Page 32</p> <p>1 A. I understood --</p> <p>2 MR. PYSER: Object to the form.</p> <p>3 THE WITNESS: I understood there was a</p> <p>4 regulation around identifying and reporting</p> <p>5 suspicious orders.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. You knew it was law, CFR. You knew it was</p> <p>8 a CFR, right?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Did you know that or didn't you?</p> <p>12 A. It is in the -- the CFR.</p> <p>13 Q. Okay.</p> <p>14 A. 1301.74(b).</p> <p>15 Q. Oh, you even know it by heart, right?</p> <p>16 A. I know that it's 1301.74(b).</p> <p>17 Q. And you know that it's a law, true?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Correct? It's the law?</p> <p>21 A. It's the regulation in -- in CFR,</p> <p>22 21 CFR 1301.74(b).</p> <p>23 Q. And not to do -- not to conform with the</p> <p>24 regulation -- you're going to be seeing this a lot;</p> <p>25 I'm glad you know it by heart.</p>
<p style="text-align: right;">Page 31</p> <p>1 THE WITNESS: -- they're outside of the</p> <p>2 regulation.</p> <p>3 MR. PYSER: Object to form. Calls for a</p> <p>4 legal conclusion. Asked and answered.</p> <p>5 MR. PAPANTONIO: Okay. You're going to</p> <p>6 object as to form, and that's it. Okay? It's a</p> <p>7 form -- your role is to object as to form, not</p> <p>8 to tell him -- not to give him any indication of</p> <p>9 what you want him to say.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Now, Mr. Brantley --</p> <p>12 MR. PAPANTONIO: Would you read back the</p> <p>13 part of his response that we actually got?</p> <p>14 You didn't get it, did you?</p> <p>15 THE REPORTER: I didn't get it, because --</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. What's the last thing you said before</p> <p>18 your -- your attorney jumped in there and started</p> <p>19 talking? What -- what did -- what did you want to</p> <p>20 tell me?</p> <p>21 A. I don't recall. You have to ask the</p> <p>22 question again.</p> <p>23 Q. Okay. You understood, sir, that there was</p> <p>24 a law that said that you had to report suspicious</p> <p>25 orders; yes or no?</p>	<p style="text-align: right;">Page 33</p> <p>1 But that's the regulation you're talking</p> <p>2 about, right?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 THE WITNESS: If that is 1301.74(b), yes.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. You -- you know it by heart. And to break</p> <p>7 that regulation would be breaking a regulatory law;</p> <p>8 correct or incorrect?</p> <p>9 MR. PYSER: Object to form. Asked and</p> <p>10 answered.</p> <p>11 MR. PAPANTONIO: Not -- no, it hasn't</p> <p>12 been.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Not to -- not to do this as you're</p> <p>15 instructed to do would be breaking a regulation,</p> <p>16 correct?</p> <p>17 MR. PYSER: Object to form. Asked and</p> <p>18 answered, repeatedly.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Yes or no?</p> <p>21 A. If one does not follow a regulation and</p> <p>22 one is not following that regulation -- I cannot</p> <p>23 answer to whether it is objecting a law. It is a</p> <p>24 regulation. I don't know the legal terminology</p> <p>25 between laws, regulation.</p>

<p style="text-align: right;">Page 34</p> <p>1 I -- I do know that that's in the CFR as a  2 regulation. And I do know the language of that  3 regulation was being followed.  4 Q. Okay. And you think it was being  5 followed, and we're going to be talking about whether  6 it was followed or not.  7 So you and I might disagree with that, but  8 you would agree, not to do it would be a violation of  9 a regulation, correct?  10 MR. PYSER: Object to form.  11 THE WITNESS: Not to follow the  12 regulation --  13 BY MR. PAPANTONIO:  14 Q. Would be a violation?  15 A. -- would not be following the regulation.  16 Q. Yeah. Are you -- are you afraid to use  17 the word "violation"?  18 MR. PYSER: Object to form.  19 BY MR. PAPANTONIO:  20 Q. I mean, you know what the term "violation"  21 means?  22 A. I am not afraid to --  23 Q. Well --  24 A. -- use any word.  25 Q. Okay. Well, "violation" --</p>	<p style="text-align: right;">Page 36</p> <p>1 BY MR. PAPANTONIO:  2 Q. True? I mean, look at the camera and tell  3 me if that's not true or not.  4 A. If one does not follow the regulation,  5 then they are not following that regulation.  6 Q. Great. Okay.  7 So we picked up with -- "Recently they  8 suspended an ABC registration and used the suspension  9 to get them to implement a complex and onerous  10 suspicious order monitoring."  11 Would you underline "complex" and  12 "onerous"? We're going to come back to those  13 words.  14 ". . . complex and onerous suspicious  15 order monitoring program that meets the criteria  16 spelled out in the HDMA meeting summary."  17 Tell the jury what the "HDMA" is.  18 MR. PYSER: Object to form.  19 THE WITNESS: HDMA is a -- an agency  20 comprised of pharmaceutical distributors.  21 BY MR. PAPANTONIO:  22 Q. And your company was part of the HDMA,  23 true? Cardinal was part of the HDMA?  24 A. Cardinal Health, I believe, was part of  25 HDMA, yes.</p>
<p style="text-align: right;">Page 35</p> <p>1 A. That's your words.  2 Q. Well, let's say "violation." Can you  3 use --  4 A. I'm saying --  5 Q. -- the word "violation" here?  6 MR. PYSER: Object to form.  7 Give me a chance to object before you  8 answer his question.  9 Counsel, stop being argumentative with the  10 witness.  11 MR. PAPANTONIO: I'm not.  12 BY MR. PAPANTONIO:  13 Q. Sir, the word "violation": Do you  14 understand what it means? I take it you do. You're  15 a bright man. You understand what "violation" means,  16 right?  17 MR. PYSER: Object to form.  18 THE WITNESS: "Violate" means not to do  19 something --  20 BY MR. PAPANTONIO:  21 Q. Right. So if you don't --  22 A. -- as -- as written. Yes.  23 Q. Right. So if you don't follow the law as  24 it's written, you violate that law, right?  25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 37</p> <p>1 Q. And did you ever go to HDMA meetings?  2 A. I've been to HDMA meetings. I do not  3 think I attended any while I was at Cardinal, but I  4 don't remember.  5 Q. Okay. But you've been with other  6 companies besides Cardinal, right?  7 You've been with Kinray, correct?  8 A. Yes. Kinray is a Cardinal company.  9 Q. And you're now with Purdue?  10 A. Yes.  11 Q. And both of those companies, one's a --  12 one is a narcotic distributor, and the other is a  13 narcotic manufacturer, correct?  14 MR. PYSER: Object to form.  15 BY MR. PAPANTONIO:  16 Q. True?  17 MR. PYSER: Misstates evidence.  18 THE WITNESS: Kinray is a distributor of  19 pharmaceuticals, over-the-counter controlled  20 substances. Purdue is a manufacturer of  21 controlled substances.  22 BY MR. PAPANTONIO:  23 Q. Well, I want to use the term -- it's a  24 narcotic, isn't it?  25 A. It's not just a narcotic company, as you</p>

<p style="text-align: right;">Page 38</p> <p>1 said.</p> <p>2 Q. Yeah.</p> <p>3 A. It manufactures controlled substances --</p> <p>4 Q. But -- but --</p> <p>5 A. -- prescription drugs.</p> <p>6 Q. Right. But Purdue manufactures narcotics,</p> <p>7 correct?</p> <p>8 A. Purdue -- that is one of the things that</p> <p>9 Purdue manufactures, yes.</p> <p>10 Q. And Kinray distributed narcotics, right?</p> <p>11 A. That is one of the many things that --</p> <p>12 that Kinray distributed.</p> <p>13 Q. And Cardinal distributed narcotics?</p> <p>14 A. That is one of the many things that</p> <p>15 Cardinal distributed.</p> <p>16 Q. When we talk about "opioid," that's a</p> <p>17 narcotic, isn't it?</p> <p>18 A. I believe so.</p> <p>19 Q. Okay. All right.</p> <p>20 Then it goes on to say: "ABC presented</p> <p>21 their program at the DEA industry conference this</p> <p>22 week that I attended, and I have attached a copy of</p> <p>23 the presentation."</p> <p>24 Now, you see Steve Reardon sent that to</p> <p>25 you, didn't he?</p>	<p style="text-align: right;">Page 40</p> <p>1 worked with industry standards, both with -- well,</p> <p>2 with Cardinal, industry standards with Kinray,</p> <p>3 industry standards with Purdue, I take it? You've</p> <p>4 worked with industry standards with all three of</p> <p>5 those companies, right?</p> <p>6 A. Yes.</p> <p>7 MR. PYSER: Object to form. Vague.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. How many years have you been working with</p> <p>10 industry standards within the distribution of</p> <p>11 narcotics?</p> <p>12 A. Well, an industry standard is -- is what,</p> <p>13 exactly? I mean, an industry standard is what one</p> <p>14 company may be doing.</p> <p>15 Q. Okay. And it says: "The DEA referred to</p> <p>16 the ABC program as the new industry standard."</p> <p>17 Do you see that?</p> <p>18 A. Yes.</p> <p>19 Q. All right. It says: "I will be setting</p> <p>20 up a meeting to initiate discussions on this topic in</p> <p>21 the near future."</p> <p>22 Did you attend that meeting where there</p> <p>23 were discussions about the industry standards for</p> <p>24 narcotics?</p> <p>25 A. I don't recall if I was present at --</p>
<p style="text-align: right;">Page 39</p> <p>1 A. Yes.</p> <p>2 Q. All right. And he sent it back in 2007,</p> <p>3 true? September 2007, right?</p> <p>4 A. Yes.</p> <p>5 Q. And it says -- goes on to say,</p> <p>6 "Suspicious" -- let me read it. It says: "A complex</p> <p>7 and onerous" -- pick up from there:</p> <p>8 ". . . complex and onerous suspicious</p> <p>9 order monitoring program that meets the criteria</p> <p>10 spelled out by the HDMA meeting summary. ABC</p> <p>11 presented their program at the DEA industry</p> <p>12 conference this week."</p> <p>13 Were you there when they presented that?</p> <p>14 A. No, I was not.</p> <p>15 Q. And -- "And I attended, and I have a copy</p> <p>16 attached to the presentation."</p> <p>17 So you didn't attend, but Steve Reardon</p> <p>18 did, correct?</p> <p>19 A. Apparently. That's what he says, yes.</p> <p>20 Q. Yeah. It says: "DEA referred to the ABC</p> <p>21 program as the new industry standard."</p> <p>22 MR. PAPANTONIO: Underline that term, "the</p> <p>23 new industry standard."</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Sir, you know what a -- you've -- you've</p>	<p style="text-align: right;">Page 41</p> <p>1 Q. That's fair enough. That was a long time</p> <p>2 ago, wasn't it?</p> <p>3 A. Yes.</p> <p>4 MR. PYSER: Counsel, please allow the</p> <p>5 witness to answer your question --</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And it says --</p> <p>8 MR. PYSER: -- before you ask the next</p> <p>9 one.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. It says: "Additionally, I am aware that</p> <p>12 MKC is in ongoing negotiations with DEA relating to</p> <p>13 order to show cause."</p> <p>14 Do you know who "MCK" is?</p> <p>15 A. I will take that to mean McKesson.</p> <p>16 Q. Okay. And you worked with McKesson; you</p> <p>17 were familiar with their business. True?</p> <p>18 MR. PYSER: Object --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. What they did?</p> <p>21 MR. PYSER: Object to form.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Or you didn't?</p> <p>24 A. I knew -- I knew that they were a</p> <p>25 wholesale distributor. I did not know the details of</p>

<p style="text-align: right;">Page 42</p> <p>1 their business, no.</p> <p>2 Q. They were a competitor of yours, weren't</p> <p>3 they?</p> <p>4 A. They were another wholesale distributor,</p> <p>5 just like Cardinal Health.</p> <p>6 Q. It says "an order to show cause." What is</p> <p>7 "an order to show cause"? You've -- you've dealt</p> <p>8 with those before, haven't you?</p> <p>9 MR. PYSER: Object to form. Legal</p> <p>10 conclusion.</p> <p>11 THE WITNESS: I have not dealt directly</p> <p>12 with an order to show cause.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Do you know what one is? I mean, you've</p> <p>15 worked around regulatory long enough to know what an</p> <p>16 "order to show cause" is?</p> <p>17 A. I --</p> <p>18 MR. PYSER: Object to form.</p> <p>19 THE WITNESS: I have a general idea.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Tell me what you think it is.</p> <p>22 A. I -- I think an order to show cause in</p> <p>23 this case is if DEA has allegations against a</p> <p>24 registrant, it gives the registrant an opportunity to</p> <p>25 answer to those allegations.</p>	<p style="text-align: right;">Page 44</p> <p>1 MR. PYSER: Object to form. Vague.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Do you understand what I'm saying?</p> <p>4 A. I understand that by "customers," you mean</p> <p>5 the hospitals, pharmacies, that --</p> <p>6 Q. Yeah.</p> <p>7 A. -- that Cardinal Health was shipping drugs</p> <p>8 to.</p> <p>9 Q. Right.</p> <p>10 A. Yes. I do not recall any pharmacies</p> <p>11 having suspensions revoked.</p> <p>12 Q. Do you -- did you work with Internet</p> <p>13 pharmacies?</p> <p>14 A. I did not work with Internet pharmacies.</p> <p>15 I, during the course of my job, identify pharmacies</p> <p>16 that were engaged with Internet activity.</p> <p>17 Q. Okay. So --</p> <p>18 A. And we -- and we discontinued business</p> <p>19 with those pharmacies, and we reported them to the</p> <p>20 DEA.</p> <p>21 Q. Right. We're going to talk about that as</p> <p>22 we go along.</p> <p>23 Did you talk -- but prior to coming in</p> <p>24 here, did you review documents where Cardinal had</p> <p>25 actual suspensions of their ability to sell</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. That's what it says; it says, "An order to</p> <p>2 show cause affords a registrant the opportunity to</p> <p>3 argue why a registration should not be suspended or</p> <p>4 revoked." Right?</p> <p>5 Now, while you were with the company, with</p> <p>6 Cardinal, there were -- your customers that you</p> <p>7 worked with, they had suspensions and revocations of</p> <p>8 their license to sell narcotics, people you worked</p> <p>9 with, correct?</p> <p>10 MR. PYSER: Object to form.</p> <p>11 THE WITNESS: Can you reask the question?</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Yeah. While you were charge of</p> <p>14 regulatory, along with Reardon -- Reardon was your</p> <p>15 boss, correct?</p> <p>16 A. Steve Reardon was my boss, correct.</p> <p>17 Q. That's the first part. Now let me ask you</p> <p>18 the second part: While you were in that role, some</p> <p>19 of the customers that you were working with actually</p> <p>20 had their licenses suspended or revoked, true?</p> <p>21 A. I cannot recall any customers that had</p> <p>22 licenses suspended or revoked.</p> <p>23 Q. Well, who -- who -- you say "customers."</p> <p>24 Who had their -- who had their licenses</p> <p>25 suspended or revoked for Cardinal?</p>	<p style="text-align: right;">Page 45</p> <p>1 narcotics?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 Instruct you not to answer the question to</p> <p>4 the extent that it's anything you reviewed with</p> <p>5 counsel. If you reviewed it outside counsel,</p> <p>6 you're free to answer the question.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. You understand?</p> <p>9 A. According to my attorney, I will not</p> <p>10 answer the question on what documents I saw during my</p> <p>11 meeting with counsel.</p> <p>12 Q. Sir, the first time you saw any documents</p> <p>13 about suspension was when?</p> <p>14 MR. PYSER: You can -- you can answer the</p> <p>15 question about when you might have seen -- if</p> <p>16 you saw documents regarding suspensions. Just</p> <p>17 don't include in your answer any documents you</p> <p>18 might have reviewed with counsel. That make</p> <p>19 sense?</p> <p>20 THE WITNESS: Yes.</p> <p>21 MR. PYSER: Okay.</p> <p>22 THE WITNESS: I do not recall when I have</p> <p>23 reviewed documents concerning suspension.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Matter of fact, you don't recall</p>



<p style="text-align: right;">Page 46</p> <p>1 suspensions at all, do you?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Is that what you told me a minute ago?</p> <p>5 You don't -- you don't recall suspensions?</p> <p>6 A. I recall suspensions. You asked had I</p> <p>7 recall suspensions of customers. And my answer was</p> <p>8 no.</p> <p>9 Q. Oh, okay. Well, who do you recall</p> <p>10 suspensions of?</p> <p>11 A. I recall that at some point, there were</p> <p>12 suspensions of DEA registrations for Cardinal Health.</p> <p>13 Q. Explain to the jury what that means.</p> <p>14 MR. PYSER: Object to form. Calls for a</p> <p>15 legal conclusion.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Explain to the jury what you just -- what</p> <p>18 you just said. Break it down for the jury right now</p> <p>19 so they understand, before we go through this</p> <p>20 deposition, what you recall about suspensions, before</p> <p>21 I start asking you questions about it. Tell the</p> <p>22 jury.</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: I do not remember the time</p> <p>25 frame. But there were allegations -- it was</p>	<p style="text-align: right;">Page 48</p> <p>1 A. I would take ABC to be AmerisourceBergen.</p> <p>2 Q. Okay. It says: "Also at the industry</p> <p>3 meeting, the H.D. Smith director of regulatory</p> <p>4 compliance was pulled aside and told that the DEA has</p> <p>5 concern with some of their customers and to schedule</p> <p>6 a meeting with DEA in D.C. to discuss that he should</p> <p>7 bring his IT people with him."</p> <p>8 See that?</p> <p>9 A. Yes.</p> <p>10 Q. Okay. And then this last paragraph, it</p> <p>11 says -- put a box around this, if you can, because</p> <p>12 this is where we're going to be spending some time.</p> <p>13 It says: "We need to be proactive and</p> <p>14 implement a program that we develop that will satisfy</p> <p>15 DEA expectations, and this is not -- and is not</p> <p>16 dictated to us by the Agency pursuant to regulatory</p> <p>17 actions. The ABC program is not customer friendly</p> <p>18 and results in delayed filing and delivery of</p> <p>19 controlled substances -- substance orders to the</p> <p>20 customer."</p> <p>21 Do you see that? You see where I read</p> <p>22 that? You got --</p> <p>23 A. Yes.</p> <p>24 Q. You got this letter, didn't you?</p> <p>25 A. My name is on the address list, yes.</p>
<p style="text-align: right;">Page 47</p> <p>1 alleged -- I don't remember the details around</p> <p>2 shipments to customers.</p> <p>3 I remember that during the course of my</p> <p>4 job, identifying pharmacies, shutting those</p> <p>5 pharmacies off from receiving controlled</p> <p>6 substances, and reporting those pharmacies to</p> <p>7 the DEA. And then at some point, I remember</p> <p>8 those same pharmacies being a part of whatever</p> <p>9 the documents were around the -- the suspension,</p> <p>10 pharmacies that we had shut off 12 to 18 months</p> <p>11 prior.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. We'll show you documents, and we'll -- the</p> <p>14 jury will be able to see what you cut off and when.</p> <p>15 But we'll -- we'll leave that for the jury to look</p> <p>16 at, but let me go ahead with what this says right</p> <p>17 here.</p> <p>18 MR. PYSER: Object to form on that last</p> <p>19 speech.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Let me ask you a question. It says: "I</p> <p>22 think it would be safe to assume that the DEA will</p> <p>23 use this opportunity to get MCK to implement an</p> <p>24 ABC-like program."</p> <p>25 Who is "ABC"? Do you know?</p>	<p style="text-align: right;">Page 49</p> <p>1 Q. And then if you'll go to the next page,</p> <p>2 let's take a look at what the -- actually let's go</p> <p>3 right -- go to page 4, and we'll -- we'll just review</p> <p>4 what the ABC -- the new program for ABC was. Page 4.</p> <p>5 You see that? Looks like this</p> <p>6 (indicating).</p> <p>7 A. Yes.</p> <p>8 Q. Okay. So AmerisourceBergen, which is the</p> <p>9 company that we're talking about here, their</p> <p>10 programs, it says: "Drug Enforcement Administration</p> <p>11 Pharmaceutical Industry Conference."</p> <p>12 You see that? September 11th, 2007?</p> <p>13 A. Yes.</p> <p>14 Q. And if you'll go to -- if you will go then</p> <p>15 to the bottom of that page, it says: "Regulatory</p> <p>16 responsibility. Title 21 of code -- of the Code of</p> <p>17 Federal Regulations," and it gives 1301.71.</p> <p>18 "All applicants and registrants shall</p> <p>19 provide effective controls and procedures to guard</p> <p>20 against theft and diversion of a controlled</p> <p>21 substance."</p> <p>22 Right? See that?</p> <p>23 A. Yes.</p> <p>24 Q. And you knew that -- you knew about that</p> <p>25 statute, didn't you? When you were working, you knew</p>

<p style="text-align: right;">Page 50</p> <p>1 about the statute, right?</p> <p>2 A. At the time that I was responsible for</p> <p>3 reviewing the ingredient limit reports and</p> <p>4 identifying pharmacies, yes.</p> <p>5 Q. And so what you were supposed to do --</p> <p>6 MR. PAPANTONIO: Underline, please,</p> <p>7 Evan --</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. "Provide effective controls and guard</p> <p>10 against diversion."</p> <p>11 See that?</p> <p>12 A. Yes.</p> <p>13 Q. "Guard against diversion of controlled</p> <p>14 substances." Right?</p> <p>15 And it says: "Distributor response:</p> <p>16 Develop policy" -- and then it goes on to the next</p> <p>17 page: "Develop policy. This is what a" -- do you</p> <p>18 understand what I'm asking you here?</p> <p>19 A. No. I'm listening to you read this --</p> <p>20 Q. Do you --</p> <p>21 A. -- slides.</p> <p>22 Q. Do you understand that ABC had a -- had</p> <p>23 something in place to deal with diversion? That's</p> <p>24 what this letter is about; you understand that?</p> <p>25 MR. PYSER: Object to form. Calls for</p>	<p style="text-align: right;">Page 52</p> <p>1 right? You would agree with that, wouldn't you, sir?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: It's our job to comply with</p> <p>4 federal regulations.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. And that's not onerous, is it?</p> <p>7 A. It's our job to comply with the federal</p> <p>8 regulations.</p> <p>9 Q. Okay. And -- and according to the ABC</p> <p>10 program, they say "physical security controls."</p> <p>11 You had physical security controls?</p> <p>12 Cardinal?</p> <p>13 A. Yes.</p> <p>14 Q. Do you know who Mike Williams is?</p> <p>15 A. That name does not ring a bell.</p> <p>16 Q. We'll talk about it in just a minute.</p> <p>17 How about ". . . records and reports of</p> <p>18 registrants, information, maintenance, and inventory</p> <p>19 requirements." See that?</p> <p>20 A. Yes.</p> <p>21 Q. Does that seem onerous to do that? I</p> <p>22 mean, you did it as a regulator.</p> <p>23 Does that seem onerous, to have records</p> <p>24 and reports of registrants with information about</p> <p>25 maintenance and inventory?</p>
<p style="text-align: right;">Page 51</p> <p>1 speculation.</p> <p>2 MR. PAPANTONIO: Well, no, it doesn't.</p> <p>3 THE WITNESS: I understand that Cardinal</p> <p>4 Health had a program in place --</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Well --</p> <p>7 A. -- to help identify and --</p> <p>8 Q. Do you understand, ABC laid out examples</p> <p>9 of what they're doing in their program; and in the</p> <p>10 letter, Reardon says it's "onerous"?</p> <p>11 Do you recall that? Do you want to go --</p> <p>12 look at the letter again?</p> <p>13 A. No, I remember you reading that.</p> <p>14 Q. Okay. You remember that Reardon said that</p> <p>15 that would be too complex and too onerous? Remember</p> <p>16 that?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: I remember you reading that</p> <p>19 slide.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. Well, then, let's look at what</p> <p>22 these onerous things were.</p> <p>23 "Distributors usually implement policies</p> <p>24 that mirror the Code of Federal Regulations."</p> <p>25 That's something that's a good idea,</p>	<p style="text-align: right;">Page 53</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Does that seem onerous?</p> <p>4 A. First, I'm not a regulator, and I never</p> <p>5 have been a regulator. And -- can you repeat</p> <p>6 everything you said --</p> <p>7 Q. Yeah. Does -- does it seem onerous --</p> <p>8 A. -- referring to --</p> <p>9 Q. Does it seem onerous to you for a company</p> <p>10 that's selling narcotics all over the country to have</p> <p>11 a system that reports and -- reports registrants'</p> <p>12 information, maintenance, and inventory? Does that</p> <p>13 seem onerous to you?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 THE WITNESS: I -- I will say that a</p> <p>16 company has to comply with the -- the</p> <p>17 regulations.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. And that's what you -- that -- that was</p> <p>20 part of your job, right?</p> <p>21 A. Part of my job was to help design and</p> <p>22 implement a program to identify suspicious orders and</p> <p>23 report those orders.</p> <p>24 Q. So would you disagree with Mr. Reardon</p> <p>25 when he says that recording and reporting</p>

Page 54

1 registrants' information and maintenance is onerous?  
 2 MR. PYSER: Object to form. Misstates  
 3 evidence.  
 4 THE WITNESS: I can't speak to Steve's  
 5 wording or his thinking at the time.  
 6 BY MR. PAPANTONIO:  
 7 Q. Does that seem onerous to you, sir, to  
 8 report records and information and maintenance and  
 9 inventory requirements? Does that seem onerous to  
 10 you?  
 11 MR. PYSER: Object to form.  
 12 VIDEOGRAPHER: It seems like something  
 13 that -- that we did.  
 14 BY MR. PAPANTONIO:  
 15 Q. And we'll see in a minute, but --  
 16 A. Okay.  
 17 Q. So you don't think that's onerous, right?  
 18 MR. PYSER: Object to form.  
 19 THE WITNESS: I think it's something that  
 20 is in the CFR, that we did.  
 21 BY MR. PAPANTONIO:  
 22 Q. Okay. Well, we'll look at that in a  
 23 minute.  
 24 A. Okay.  
 25 Q. But right now, you don't think that's

Page 55

1 onerous, correct?  
 2 MR. PYSER: Object to form. Asked and  
 3 answered.  
 4 THE WITNESS: Again, I can't speak to  
 5 Steve's wording.  
 6 BY MR. PAPANTONIO:  
 7 Q. How about this? "Orders for Schedule I  
 8 and II controlled substances, ordering, filling,  
 9 executing, and endorsing DEA Forms 222."  
 10 See that?  
 11 A. Yes.  
 12 Q. Does that seem onerous to you, and  
 13 complex?  
 14 A. Again, that is something that we did. And  
 15 that is something that's in the CFR.  
 16 Q. And you think you did that successfully?  
 17 A. I would say that we put forth our best  
 18 effort and did it successfully.  
 19 Q. Okay. So right now, your testimony,  
 20 Mr. Brantley, would be that your system was  
 21 successful in controlling narcotic distribution in  
 22 America? Is that your testimony?  
 23 A. I will say --  
 24 MR. PYSER: Object to form. Misstates  
 25 testimony.

Page 56

1 THE WITNESS: I will -- I will say that  
 2 the system was compliant with the regulation.  
 3 BY MR. PAPANTONIO:  
 4 Q. Was it successful in keeping control of  
 5 narcotics that were distributed throughout the  
 6 country; yes or no? That's all I'm asking for.  
 7 MR. PYSER: Object to form.  
 8 THE WITNESS: Well, so far what you've  
 9 mentioned is the -- the cage and vault  
 10 construction. And yes, that was compliant and  
 11 safe, as far as the security of the controlled  
 12 substances.  
 13 You also mentioned maintenance and  
 14 inventory requirements. And we kept records for  
 15 Schedule II as well as Schedule III through V  
 16 controlled substances.  
 17 Then you mentioned the order filling and  
 18 executing and endorsing of 222 forms, which  
 19 again, we did, and we were successful with  
 20 properly executing those 222 forms.  
 21 BY MR. PAPANTONIO:  
 22 Q. And you think you were successful in all  
 23 that, huh? Is that -- is that Eric Brantley's  
 24 testimony, that Cardinal was successful in  
 25 controlling the diverted -- diversion with the

Page 57

1 narcotics that it distributed? Is that your  
 2 testimony here today? That's the only thing I'm  
 3 wondering.  
 4 A. I can speak --  
 5 MR. PYSER: Object --  
 6 THE WITNESS: -- to what I did.  
 7 MR. PYSER: Object to form.  
 8 Argumentative. Asked and answered.  
 9 BY MR. PAPANTONIO:  
 10 Q. You can speak to what you did. And did  
 11 you think you did it successfully?  
 12 A. I believe I did it successfully --  
 13 Q. All right. Well, we'll --  
 14 A. -- yes.  
 15 Q. We'll go through some of that and let the  
 16 jury decide that.  
 17 MR. PYSER: Object to form.  
 18 BY MR. PAPANTONIO:  
 19 Q. Next -- next thing on here that -- when  
 20 we're talking about things that are onerous, that  
 21 Mr. Reardon determined was onerous, "other security  
 22 controls. Make a good faith inquiry. Report  
 23 suspicious orders. Report significant losses. Gray  
 24 area."  
 25 You think it's -- you think it's onerous

<p style="text-align: right;">Page 58</p> <p>1 to make a good faith inquiry to report suspicious 2 orders and report significant losses? Is that 3 onerous? 4 MR. PYSER: Object to form. Misstates 5 evidence. 6 BY MR. PAPANTONIO: 7 Q. Is that onerous, sir? 8 A. Again, I think that it's our 9 responsibility to comply with the regulations and 10 identify and report suspicious orders. 11 Q. Well, then, but as far as you're 12 concerned, it's not onerous to report suspicious 13 orders, true? 14 A. Again, I can't speak to "onerous." Those 15 were Steve Reardon's words. I can't speak to his 16 words or -- 17 Q. But you can -- 18 A. -- or his mindset at the time. 19 Q. You can speak to your words. Is that 20 something you would expect Cardinal to do, the very 21 things that we've read here? Is it your testimony 22 you've done all those things? 23 MR. PYSER: Object to form. 24 THE WITNESS: We had policies and 25 procedures in place that were in compliance with</p>	<p style="text-align: right;">Page 60</p> <p>1 according to your testimony today, correct? 2 A. We reported orders that were on the 3 ingredient limit report to the DEA every month. 4 Q. Yeah. Okay. And so prior to coming here, 5 nobody showed you this document, I take it, right? 6 Take a look at this document. Look at the 7 -- let's just go right to -- to this -- bottom of 8 this. You see the bottom of the second page? I just 9 want to ask you this question. 10 A. Bottom of the second -- 11 Q. Bottom of -- 12 A. -- page? Where are you -- 13 Q. -- the second page. Yeah. 14 A. Are you referring to -- 15 MR. PAPANTONIO: Blow that to where he 16 can -- 17 THE WITNESS: -- the last paragraph? 18 MR. PAPANTONIO: Blow -- blow that up to 19 where he can read that. I can't . . . 20 BY MR. PAPANTONIO: 21 Q. Says: "Later, had dinner with the group. 22 Interesting gossip came from Reardon, Quintero . . ." 23 Who's Quintero? 24 A. I don't recall. 25 Q. ". . . who relayed that Cardinal is not</p>
<p style="text-align: right;">Page 59</p> <p>1 all of these things, and we did all of these 2 things that you've read on this slide. 3 MR. PAPANTONIO: Well, show him 1941, 4 please. 5 BY MR. PAPANTONIO: 6 Q. So your testimony is that your company at 7 that point was -- 8 MS. MOORE: Cardinal-Brantley 3. 9 (Cardinal-Brantley 3 was marked for 10 identification.) 11 BY MR. PAPANTONIO: 12 Q. Your testimony, Mr. Brantley, is at the 13 time, that your company was reporting suspicious 14 orders, right? 15 A. We generate ingredient limit reports, and 16 we submitted those reports to the DEA every month. 17 Q. So you're reporting suspicious orders, 18 according to what your testimony is here today? Is 19 that a yes or a no? 20 A. We -- 21 MR. PYSER: Object to form. 22 THE WITNESS: We filed ingredient limit 23 reports with the DEA every month. 24 BY MR. PAPANTONIO: 25 Q. So you did report suspicious orders,</p>	<p style="text-align: right;">Page 61</p> <p>1 reporting suspicious orders to the DEA on the advice 2 of outside counsel Linden Barber." 3 MR. PAPANTONIO: Would you underline this 4 line because we're going to spend some time with 5 this. 6 BY MR. PAPANTONIO: 7 Q. Okay, so before I showed you this 8 document, I think it was your testimony that you -- 9 your company was reporting suspicious orders, right? 10 MR. PYSER: Object to form. Vague as to 11 time frame, when you're showing him a 2013 12 document. 13 BY MR. PAPANTONIO: 14 Q. Your company was reporting suspicious 15 orders, according to you, in 2007; is that what you 16 told me just a minute ago? 17 A. My testimony was that we were submitting 18 ingredient limit reports to the DEA during the time 19 frame when I was reviewing the ingredient limit 20 reports from 2005 to whatever time someone else came 21 in and took that responsibility. 22 Q. And according to the law -- I'm showing 23 you this again. You know this law. You had a duty 24 as early as 1971 to report suspicious orders. 25 You know that, don't you, Mr. Brantley?</p>



Page 62

1 MR. PYSER: Object to form.  
2 BY MR. PAPANTONIO:  
3 Q. Yes or no?  
4 MR. PYSER: Object to form. Asked and  
5 answered. Legal conclusion.  
6 THE WITNESS: I know that  
7 21 CFR 1301.74(b) requires registrants to  
8 identify and report suspicious orders.  
9 BY MR. PAPANTONIO:  
10 Q. And that was all back -- all the way back  
11 to 1971, wasn't it?  
12 A. I don't recall the exact year that the  
13 regulation was written, but I do believe it was --  
14 the '70s.  
15 Q. In the '70s?  
16 A. I don't recall --  
17 Q. Okay, well --  
18 A. -- the exact time, though.  
19 Q. And so your -- and so your testimony then  
20 was that in 2007, your company was reporting  
21 suspicious orders. That's what you told me, correct?  
22 A. We were submitting ingredient limit  
23 reports to the DEA every month, as -- as required by  
24 21 CFR 1301.74(b).  
25 Q. Why don't you -- here. Take this.

Page 63

1 And why don't you tell me where it says  
2 "reporting ingredient reports" in there?  
3 MR. PYSER: Object to form.  
4 Counsel, are you going to mark it as an  
5 exhibit?  
6 MR. PAPANTONIO: No, we're going to --  
7 we're going to -- we'll mark it before it's out.  
8 BY MR. PAPANTONIO:  
9 Q. Show me where it says that it's okay to  
10 just send in ingredient reports. If you can find it  
11 in that CFR, please tell me where it is.  
12 MR. PYSER: Object to form.  
13 THE WITNESS: "The registrant shall design  
14 and operate a system to disclose to the  
15 registrant suspicious orders of the controlled  
16 substances."  
17 In the case of Cardinal, that was  
18 ingredient limit reports.  
19 BY MR. PAPANTONIO:  
20 Q. Well, you see --  
21 A. "The registrant shall inform the field  
22 division office of the administration in this area of  
23 suspicious orders when discovered by the registrant."  
24 We submitted those ingredient limit  
25 reports to the DEA every month.

Page 64

1 Q. And nevertheless, you have a document in  
2 front of you that's written as late as 2013, with  
3 your supervisor, Mr. Reardon, saying that -- hand me  
4 that back, and let's look at it again. We're --  
5 A. Mr. Reardon was not my supervisor in 2013.  
6 Q. Well, he was your supervisor in 2007,  
7 wasn't he?  
8 MR. PYSER: Object to form.  
9 BY MR. PAPANTONIO:  
10 Q. True?  
11 A. I do not recall when I transferred out of  
12 the role.  
13 Q. He was your supervisor at some point,  
14 wasn't he?  
15 A. Yes.  
16 Q. Okay. And how many years was he your  
17 supervisor?  
18 A. From 2005 until 2007-8. I don't recall  
19 the exact time.  
20 Q. And you think, when you left in 2007, that  
21 there was a system to report suspicious orders?  
22 That's what Mr. Brantley thinks today, as  
23 he's talking to the jury here, right?  
24 MR. PYSER: Object to form. Asked and  
25 answered.

Page 65

1 BY MR. PAPANTONIO:  
2 Q. True?  
3 A. Yeah.  
4 Q. I mean, in good faith -- you really  
5 believed there was a suspicious order program in  
6 place when you left the company; is that your  
7 testimony?  
8 A. There was a suspicious order program in  
9 place while I was at the company. And there is a  
10 suspicious order in -- in place at the company, yes.  
11 Q. You thought that?  
12 A. I knew that because I worked on the  
13 program.  
14 My job was to identify such orders by  
15 reviewing the ingredient limit reports, and in  
16 addition, to go above and beyond, to go out and  
17 conduct a site visit of that customer and shut that  
18 customer off from controlled substances, and then  
19 report not a suspicious order, but a customer to the  
20 DEA.  
21 Q. And you wanted to do your job, didn't you?  
22 You, Mr. Brantley, you wanted to do your job by  
23 reporting suspicious orders, true?  
24 A. I -- that was my job.  
25 Q. That's what -- you did your job. Let's

<p style="text-align: right;">Page 66</p> <p>1 read this again.</p> <p>2 "Later, at dinner with the group,</p> <p>3 interesting gossip came from Reardon, Quintero who</p> <p>4 related that Cardinal" --</p> <p>5 MR. PAPANTONIO: Let's just be very</p> <p>6 clear -- put a second line underneath it so I</p> <p>7 make sure I'm -- I'm catching this right.</p> <p>8 MS. CHARLES: Counsel, can I object that</p> <p>9 this is a McKesson confidential document, and I</p> <p>10 have no record that you asked for permission of</p> <p>11 that.</p> <p>12 MR. PAPANTONIO: Yeah, you -- you can</p> <p>13 object.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Cardinal is not --</p> <p>16 MR. PYSER: Actually, that's a valid</p> <p>17 objection. We've received no notice that this</p> <p>18 document, produced by McKesson, which is marked</p> <p>19 "highly confidential," has been designated --</p> <p>20 MR. PAPANTONIO: Yeah.</p> <p>21 MR. PYSER: -- to be used in this --</p> <p>22 MR. PAPANTONIO: All right. We're</p> <p>23 going --</p> <p>24 MR. PYSER: -- deposition.</p> <p>25 MR. PAPANTONIO: -- to use it. You take</p>	<p style="text-align: right;">Page 68</p> <p>1 2013, correct?</p> <p>2 MR. PYSER: Object to form. Calls for</p> <p>3 speculation.</p> <p>4 THE WITNESS: According to this, the</p> <p>5 e-mail was sent 2013.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And it says this is on the advice of</p> <p>8 outside counsel, Linden Barber.</p> <p>9 Have you met Linden Barber?</p> <p>10 MR. PYSER: Object to form. Misstates</p> <p>11 evidence. Speculation.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Have you met Linden Barber?</p> <p>14 A. Yes, if you narrow a -- a time frame.</p> <p>15 Q. When did you meet him?</p> <p>16 A. I met Linden Barber -- I can't say what --</p> <p>17 what year, but I was not in my role with -- as far as</p> <p>18 reporting suspicious orders. I was in a role as a</p> <p>19 compliance officer at the time, the first time I met</p> <p>20 Linden Barber.</p> <p>21 Q. And it's -- it's fair for me to say, based</p> <p>22 on what you've told me so far, that in 2007, Eric</p> <p>23 Brantley, you, believed that you had a suspicious</p> <p>24 order system in place. Correct?</p> <p>25 MR. PYSER: Object --</p>
<p style="text-align: right;">Page 67</p> <p>1 it up with the judge. This is going to be --</p> <p>2 MR. PYSER: And we're going to mark this</p> <p>3 entire area of testimony as improper, to be</p> <p>4 excluded --</p> <p>5 MR. PAPANTONIO: All right.</p> <p>6 MR. PYSER: -- and failure to follow</p> <p>7 the --</p> <p>8 MR. PAPANTONIO: That's your right --</p> <p>9 MR. PYSER: -- deposition protocol.</p> <p>10 MR. PAPANTONIO: That's your right to do</p> <p>11 it, sir.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. "Cardinal is not reporting suspicious</p> <p>14 orders to DEA on the advice of outside counsel."</p> <p>15 You see that?</p> <p>16 MR. PYSER: Object to form. Vague as</p> <p>17 to --</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. You see that?</p> <p>20 MR. PYSER: Object to form. Vague as to</p> <p>21 time frame.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Did I read that right?</p> <p>24 A. I see the line that you read.</p> <p>25 Q. Okay. And this document was written in</p>	<p style="text-align: right;">Page 69</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. You believed -- you believed that in 2007;</p> <p>3 is that true?</p> <p>4 MR. PYSER: Object to form. Asked and</p> <p>5 answered.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Correct?</p> <p>8 A. We had a system in place, reviewing</p> <p>9 ingredient limit reports and submitting those</p> <p>10 ingredient limit reports to the DEA, as well as</p> <p>11 conducting site visits of pharmacies identified on</p> <p>12 those reports, discontinuing sales of controlled</p> <p>13 substances to those pharmacies, and reporting those</p> <p>14 pharmacies to the DEA.</p> <p>15 Q. And when you -- when you left, you thought</p> <p>16 that was a successful program, didn't you? You</p> <p>17 thought, "We're doing a good job with this," didn't</p> <p>18 you?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. You thought you were doing a good job with</p> <p>22 suspicious orders, didn't you?</p> <p>23 A. Please put a time frame on when I left.</p> <p>24 Q. Well, when you left --</p> <p>25 A. Do you mean when I left the role --</p>

<p style="text-align: right;">Page 70</p> <p>1 Q. When did you leave?</p> <p>2 A. -- when I left the company?</p> <p>3 Q. When you left the company, you thought</p> <p>4 everything was good; suspicious orders are in place;</p> <p>5 we're making sure narcotics don't get out there</p> <p>6 without reporting suspicious orders.</p> <p>7 That's what -- that's what Eric Brantley</p> <p>8 thought?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. True?</p> <p>12 MR. PYSER: Object to form. Vague.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. That's a true statement, isn't it? Eric</p> <p>15 Brantley --</p> <p>16 A. When I left Cardinal Health --</p> <p>17 Q. Well, let me finish my question, just so I</p> <p>18 can be real clear.</p> <p>19 In 2007, when you left -- when you left</p> <p>20 Cardinal Health, Eric Brantley believed that he had a</p> <p>21 system in place that was a suspicious order system,</p> <p>22 yes or no?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: I did not leave Cardinal</p> <p>25 Health in 2007.</p>	<p style="text-align: right;">Page 72</p> <p>1 highly confidential document to the witness that</p> <p>2 did not provide -- showing it to him.</p> <p>3 MR. PAPANTONIO: Show Mr. Brantley 4230,</p> <p>4 please.</p> <p>5 MS. MOORE: Cardinal-Brantley 4.</p> <p>6 (Cardinal-Brantley 4 was marked for</p> <p>7 identification.)</p> <p>8 MR. PAPANTONIO: You see that settlement?</p> <p>9 You got that, Evan? Could you blow that up,</p> <p>10 that first page -- settlement release agreement</p> <p>11 and administrative memorandum of agreement.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Now, you were there when this was -- this</p> <p>14 is 2008. You were there in 2008? You were with</p> <p>15 Cardinal in 2008, weren't you?</p> <p>16 A. I was an employee of Cardinal Health in</p> <p>17 2008.</p> <p>18 Q. Okay. And then it goes on. This says</p> <p>19 "Applicability," and then it goes, "Background."</p> <p>20 Says: "Cardinal is registered with DEA in</p> <p>21 27 facilities as distributors, Schedule II to V</p> <p>22 controlled substances, under provision of the</p> <p>23 Comprehensive Drug Abuse Prevention Act, 1970."</p> <p>24 Remember, we talked about the date of the</p> <p>25 Act, and you said it was in the '70s. And you were</p>
<p style="text-align: right;">Page 71</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Well, when did --</p> <p>3 A. I did not leave Cardinal Health until 2013</p> <p>4 I believe.</p> <p>5 Q. All right. In 2013, you were still there,</p> <p>6 right? True?</p> <p>7 A. I -- I was an employee at Kinray.</p> <p>8 Q. And what's the date on that letter that</p> <p>9 you're looking at in front of you where it says:</p> <p>10 "Cardinal is not reporting suspicious orders to the</p> <p>11 DEA"?</p> <p>12 A. The e-mail apparently was sent March 11,</p> <p>13 2013.</p> <p>14 MR. PYSER: Object to form. Calls for</p> <p>15 speculation.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. All right.</p> <p>18 MS. CHARLES: Counsel, can you please put</p> <p>19 the Bates number, for clarity, on the record?</p> <p>20 MR. PAPANTONIO: No, I won't put Bates</p> <p>21 number. We'll read them in -- you're welcome to</p> <p>22 read them in. We're not going to waste time</p> <p>23 reading 15-digit --</p> <p>24 MS. CHARLES: MCKMDL00545341.</p> <p>25 I'm going to object to showing a McKesson</p>	<p style="text-align: right;">Page 73</p> <p>1 right. It was in '70s, wasn't it?</p> <p>2 A. According to this, yes.</p> <p>3 Q. Yeah.</p> <p>4 "On November 28th, 2007, the DEA, by its</p> <p>5 deputy administrator, Leon -- Michele Leonhart,</p> <p>6 issued an order to show cause . . ."</p> <p>7 And you told us you know what an order to</p> <p>8 show cause is, right?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 THE WITNESS: I spoke to -- I believe it's</p> <p>11 a chance to give the -- the registrant an</p> <p>12 opportunity to answer to allegations by the DEA.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. So you were actually involved in this,</p> <p>15 weren't you?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. In -- in the order to show cause, you --</p> <p>19 Eric Brantley was involved in that, true?</p> <p>20 A. I was not involved in the order to show</p> <p>21 cause.</p> <p>22 Q. Who was?</p> <p>23 A. I do not recall the individuals that would</p> <p>24 have been. I suspect, legal.</p> <p>25 Q. But were you working in regulatory in 2008</p>

<p style="text-align: right;">Page 74</p> <p>1 when this memorandum came through from the DEA?</p> <p>2 A. I do not know the exact -- are you saying</p> <p>3 November 28th?</p> <p>4 Q. Yeah.</p> <p>5 MR. PYSER: Object to form. Vague.</p> <p>6 What year are we talking about?</p> <p>7 MR. PAPANTONIO: It's November 28th --</p> <p>8 underline the one I -- underline that, so</p> <p>9 counsel can understand what we're doing here.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. November 28th, 2007, you were there.</p> <p>12 True?</p> <p>13 A. I was an employee of Cardinal Health, yes.</p> <p>14 Q. "The DEA, by its deputy administrator,</p> <p>15 Michele Leonhart, issued an order to show cause and</p> <p>16 immediate suspension of registration to</p> <p>17 Cardinal . . ."</p> <p>18 You see that?</p> <p>19 A. Yes.</p> <p>20 Q. Didn't I just begin this deposition by</p> <p>21 asking you whether you recalled any -- any</p> <p>22 suspensions that Cardinal was involved with?</p> <p>23 What did you tell me?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: You asked me --</p>	<p style="text-align: right;">Page 76</p> <p>1 A. There was an immediate suspension order</p> <p>2 issued, according to this document.</p> <p>3 Q. Well, the jury is going to see how we</p> <p>4 started this deposition, where you gave me answers</p> <p>5 about it, and I want to make sure that we're clear</p> <p>6 about what you said at the beginning of this</p> <p>7 deposition.</p> <p>8 In the beginning of the deposition, did</p> <p>9 you tell me that there were no suspensions of</p> <p>10 registration to Cardinal customers? That's what you</p> <p>11 said, right?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: I said I did not recall</p> <p>14 suspensions of Cardinal customers.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Right. This is -- this is a suspension of</p> <p>17 registration to the company itself, Cardinal,</p> <p>18 correct?</p> <p>19 A. This is a -- a suspension to Cardinal</p> <p>20 Health.</p> <p>21 Q. And it goes on to say: "With respect to</p> <p>22 distribution facility" -- gives the address, Auburn,</p> <p>23 Washington.</p> <p>24 You know where that is, right?</p> <p>25 A. It's in Washington state.</p>
<p style="text-align: right;">Page 75</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. What did you tell me?</p> <p>4 A. You asked me did I recall suspensions of</p> <p>5 Cardinal customers.</p> <p>6 Q. Oh.</p> <p>7 A. And I said no.</p> <p>8 Q. Oh, it was "Cardinal customers." I'm</p> <p>9 sorry, I didn't use the right word.</p> <p>10 But this says --</p> <p>11 MR. PAPANTONIO: Would you please</p> <p>12 underline this.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. It says: "Immediate suspension of</p> <p>15 registration to Cardinal."</p> <p>16 Is that clear?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Is that pretty clear to you?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Mr. Brantley, is that pretty clear to you?</p> <p>23 A. Is what pretty clear?</p> <p>24 Q. "Immediate suspension of registration to</p> <p>25 Cardinal?"</p>	<p style="text-align: right;">Page 77</p> <p>1 Q. Right. And then it -- next one, it says</p> <p>2 on December 5th, 2007 -- just so we have the dates</p> <p>3 right -- it says: "The DEA, by its administrator" --</p> <p>4 again, Michele Leonhart -- did you ever meet -- by</p> <p>5 the way, did you ever meet Michele Leonhart?</p> <p>6 A. I did not.</p> <p>7 Q. Do you know who she is?</p> <p>8 A. According to this document, she was the</p> <p>9 deputy administrator.</p> <p>10 Q. And that's all you know about it,</p> <p>11 according to this document?</p> <p>12 A. Yes.</p> <p>13 Q. Did anybody with the company -- not your</p> <p>14 lawyers, but anybody with the company review this</p> <p>15 with you before you came in here to testify and give</p> <p>16 your testimony about whether or not Cardinal had been</p> <p>17 involved in any kind of suspensions?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 THE WITNESS: Is your question did anyone</p> <p>20 review this particular document with me?</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Yeah.</p> <p>23 A. No.</p> <p>24 Q. Is this first time you've seen this</p> <p>25 document?</p>



<p style="text-align: right;">Page 78</p> <p>1 A. It is the first time I have seen this  2 document during these proceedings. It is not my  3 first time seeing this document. I have read it at  4 some point over the last several years.  5 Q. You knew about it all the way back to  6 2008, didn't you, about this document?  7 A. I did not know about this document in 2008  8 because I did not review the document then.  9 Q. Nobody with the company showed you this  10 document while you were employed as -- in regulatory,  11 correct?  12 MR. PYSER: Object to form. Vague as to  13 time.  14 BY MR. PAPANTONIO:  15 Q. Is that true, that nobody showed you this  16 document while you were employed with regulatory in  17 2008? Correct?  18 A. I do not recall anyone at the company  19 showing me this document.  20 Q. All right. Well, let's -- let's go ahead  21 and spend some time with it and see what you think.  22 MR. PYSER: Object to form. The  23 document --  24 BY MR. PAPANTONIO:  25 Q. It says -- it says --</p>	<p style="text-align: right;">Page 80</p> <p>1 BY MR. PAPANTONIO:  2 Q. And they can't sell narcotics anymore.  3 That's what that means, right?  4 MR. PYSER: Object to form.  5 BY MR. PAPANTONIO:  6 Q. They can't sell narcotics -- December 5th,  7 2007, in Lakeland, Florida, they can't sell  8 narcotics, the Cardinal operation?  9 MR. PYSER: Object to form.  10 THE WITNESS: If there is an immediate  11 suspension order in place, a registrant cannot  12 sell controlled substances.  13 BY MR. PAPANTONIO:  14 Q. And you didn't know about this prior to me  15 coming in here and asking you these questions, did  16 you?  17 MR. PYSER: Object to form.  18 BY MR. PAPANTONIO:  19 Q. True? I mean, in fairness to you, you  20 just didn't know about this?  21 MR. PYSER: Object to form. Misstates  22 evidence. Misstates testimony.  23 THE WITNESS: I knew about this prior to  24 coming in. Your question was, had anyone showed  25 me this document at Cardinal Health, and my</p>
<p style="text-align: right;">Page 79</p> <p>1 MR. PYSER: To be clear, the document's  2 dated September of 2008, if you were employed in  3 regulatory at that time.  4 You're asking a misleading question,  5 Counsel.  6 MR. PAPANTONIO: All right. We'll clear  7 the question up. I think it'll be very clear by  8 the time it's all over.  9 BY MR. PAPANTONIO:  10 Q. It says: "The DEA, by its administrator,  11 Michele Leonhart, issued an order to show cause" --  12 MR. PAPANTONIO: Underline that word, "to  13 show cause."  14 BY MR. PAPANTONIO:  15 Q. -- "and an immediate suspension of  16 registration to Cardinal."  17 Now, what does that mean, "an immediate  18 suspension"? What does that mean? Tell the jury,  19 now that you see this, tell the jury what "immediate  20 suspension" means.  21 MR. PYSER: Object to form. Legal  22 conclusion.  23 THE WITNESS: I believe that "immediate  24 suspension" means an immediate suspension of the  25 DEA registration.</p>	<p style="text-align: right;">Page 81</p> <p>1 answer was and is no.  2 BY MR. PAPANTONIO:  3 Q. Well, if you knew it before you came in  4 here, when I asked you at the beginning of this  5 deposition, do you know whether or not Cardinal  6 pharmacies or customers, whether there's any  7 suspensions, what did you tell me?  8 MR. PYSER: Object to form. Asked and  9 answered.  10 THE WITNESS: You asked me was I aware of  11 any suspensions of Cardinal customers. And I  12 responded no, and I respond no again. This --  13 this --  14 BY MR. PAPANTONIO:  15 Q. But you knew about -- go ahead.  16 A. This is a suspension order, as it reads,  17 of Cardinal, not a Cardinal customer. So you asked  18 about customers, and I answered no.  19 Q. Okay. So this is not -- this is not just  20 the customer. This is the company itself that is  21 being suspended by the DEA for immediate suspension,  22 correct?  23 MR. PYSER: Object to the form.  24 BY MR. PAPANTONIO:  25 Q. The company itself, that you worked for?</p>

<p style="text-align: right;">Page 82</p> <p>1 MR. PYSER: Object to form.          2 BY MR. PAPANTONIO:          3 Q. Correct? Are you --          4 MR. PYSER: Object to form. Misstates          5 evidence.          6 MR. PAPANTONIO: Let me finish my question          7 before you -- I -- I get it. I get what you're          8 doing. But you're going to have to listen to          9 the question.          10 MR. PYSER: Well, I'm trying to get in          11 there before, so --          12 MR. PAPANTONIO: All right.          13 MR. PYSER: All right. Let me just ask --          14 give me a second to interject my objection.          15 That way it will be easier for you to finish          16 your question. Okay?          17 MR. PAPANTONIO: Yes.          18 MR. PYSER: I'm not trying to interrupt          19 you, Counsel.          20 MR. PAPANTONIO: Okay.          21 MR. PYSER: -- I'm just not sure where          22 your question's answering --          23 MR. PAPANTONIO: Well --          24 MR. PYSER: -- ending because you're          25 asking a series of them in each -- in each</p>	<p style="text-align: right;">Page 84</p> <p>1 Do you see that?          2 MR. PAPANTONIO: Underline "New Jersey."          3 THE WITNESS: Yes, I see that.          4 MR. PAPANTONIO: And then underline, if          5 you would, please, "order to show cause" and          6 "immediate suspension of registration."          7 BY MR. PAPANTONIO:          8 Q. And that's Swedesboro facility, right?          9 A. That's what it says, yes.          10 Q. So so far, we have a suspension of -- we          11 have suspension of the Auburn facility.          12 Have you ever been to the Auburn Cardinal          13 facility?          14 A. In Auburn, no.          15 Q. Have you ever been to the Lakeland          16 Cardinal facility that was suspended?          17 A. I have been to the Lakeland facility.          18 Q. Have you been to the Swedesboro facility          19 that was suspended?          20 A. I have been to the Swedesboro facility.          21 Q. Then -- okay, then the next one,          22 number 5 -- and by the way, those are -- those are          23 all different parts of the country. We're not just          24 talking about one area of the country, are we?          25 Here, we're talking about Washington</p>
<p style="text-align: right;">Page 83</p> <p>1 question.          2 MR. PAPANTONIO: Let me see if I can ask          3 this question pretty clear.          4 BY MR. PAPANTONIO:          5 Q. Immediate suspension of a registration to          6 Cardinal itself means Cardinal cannot sell narcotics          7 in Lakeland, Florida. Yes?          8 MR. PYSER: Object to form.          9 THE WITNESS: If the Lakeland, Florida,          10 facility has an immediate suspension order,          11 Lakeland, Florida, cannot sell or distribute          12 controlled substances.          13 BY MR. PAPANTONIO:          14 Q. And that's a Cardinal facility, correct?          15 According to this?          16 A. This facility is a Cardinal Health          17 facility.          18 Q. All right.          19 A. Or at least was at the time. I cannot          20 speak for now.          21 Q. Fair enough. Let's go on to number 4:          22 "On December 7th, 2007, the DEA, by its          23 administrator, Michele Leonhart, issued an order to          24 show cause and immediate suspension registration to          25 Cardinal with respect to its New Jersey facility."</p>	<p style="text-align: right;">Page 85</p> <p>1 state. We're talking about Florida. We're talking          2 about New Jersey. Those are different parts of the          3 country. I just want to be sure we're clear on that          4 as we go.          5 These are different Cardinal facilities in          6 different parts of the country, correct?          7 MR. PYSER: Object to form.          8 THE WITNESS: It's a facility in          9 Washington state and Lakeland, Florida, and          10 Swedesboro, New Jersey.          11 BY MR. PAPANTONIO:          12 Q. All across the U.S. I mean, you know          13 where Washington state is, right?          14 A. Yes.          15 Q. All right. Lakeland, Florida: You said          16 you've been there?          17 A. Yes.          18 Q. All right. It says: "On January 30,          19 2008, the DEA, by its deputy assistant, Joseph          20 T. Rannazzisi, issued an order to show cause to          21 Cardinal with respect to its distributor facility in          22 Stafford."          23 That's in Texas. All right? So we've          24 got --          25 A. Yes.</p>

<p style="text-align: right;">Page 86</p> <p>1 Q. -- so far we've got Auburn. We've got  2 Lakeland, Florida. We've got New Jersey, Swedesboro.  3 And now we've got another one at Stafford -- the  4 Stafford facility. That's in Texas.  5 Have you been there, too?  6 MR. PYSER: Object to form.  7 THE WITNESS: I have been to the Texas  8 facility.  9 BY MR. PAPANTONIO:  10 Q. And that's in January 2008. Let's go to  11 the next one, please.  12 "The orders" -- "The orders to show cause  13 referenced above alleged, among other things, that  14 Cardinal failed to maintain effective controls  15 against diversion of particular controlled substance  16 into other than legitimate medical, scientific, and  17 industrial channels as evidenced by sales to  18 customers of Cardinal."  19 Did you know that was going on,  20 Mr. Brantley? Did you know that your company was  21 failing to maintain effective controls --  22 MR. PAPANTONIO: Underline "effective  23 controls," please.  24 BY MR. PAPANTONIO:  25 Q. Your company was failing to maintain</p>	<p style="text-align: right;">Page 88</p> <p>1 describing didn't work in Washington, in Auburn. It  2 didn't work in Lakeland, Florida. It didn't work in  3 New Jersey, at Swedesboro. It didn't work in  4 Stafford facility in Texas -- so far. Now, that's  5 just the beginning.  6 But so far, you would agree, your system,  7 according to the DEA, failed to do its job, if we  8 just look at this first page of the document. Right?  9 MR. PYSER: Object to form.  10 BY MR. PAPANTONIO:  11 Q. Failed to do its job?  12 A. These are allegations.  13 Q. Well, sir, you pled to the allegations and  14 paid a fine -- did you know that? Did you know your  15 company actually paid a fine?  16 MR. PYSER: Object to form. Misstates  17 evidence.  18 THE WITNESS: I know that these were  19 allegations. I know that there was settlement.  20 I do not believe there was any acknowledgment of  21 anything. These were allegations from the DEA.  22 BY MR. PAPANTONIO:  23 Q. Okay. So you just paid up -- do you know  24 how much money you paid to the DEA? I'm just curious  25 whether you know how much money you paid to the DEA</p>
<p style="text-align: right;">Page 87</p> <p>1 effective controls of controlled substances.  2 Did you know, when you were working  3 there -- I'm not saying you did know. I'm just  4 asking, did you know that at all?  5 MR. PYSER: Object to form. And misstates  6 evidence.  7 BY MR. PAPANTONIO:  8 Q. Did you know that?  9 A. We had a program in place to identify and  10 report suspicious orders to the DEA, and we did.  11 Q. Okay. And you did, and whatever you were  12 reporting still wasn't adequate to protecting the  13 American public from narcotics, if we look at this  14 order, right?  15 MR. PYSER: Object to form.  16 BY MR. PAPANTONIO:  17 Q. True?  18 A. We had a system in place. We operate in  19 a -- in a closed supply chain. We had a system in  20 place to identify orders and report those orders to  21 the DEA.  22 Q. Let's see how well --  23 A. Report pharmacies to the DEA.  24 Q. Let's see how well it worked.  25 So far -- so far, your system that you're</p>	<p style="text-align: right;">Page 89</p> <p>1 because of the failure of your company to have a  2 controlled substance suspicious order system in  3 place.  4 Do you know how much you paid?  5 MR. PYSER: Object to form.  6 THE WITNESS: I do not recall how much the  7 company settled.  8 BY MR. PAPANTONIO:  9 Q. All right. Well, let's go up to the next  10 page, page 2.  11 A. But the company did not fail to have a  12 system in place. There was a system in place.  13 Q. The DEA disagreed with you, didn't they?  14 They disagree that you had a system in place. If we  15 look at just this part of the document, DEA did not  16 believe you had a system in place, according to this  17 document?  18 MR. PYSER: Object to form. Misstates  19 evidence. Calls for speculation.  20 THE WITNESS: This document did not say  21 that Cardinal Health did not have a program in  22 place.  23 BY MR. PAPANTONIO:  24 Q. Oh? Well, let's go to the next page.  25 A. Okay. Because the page that I read did</p>

<p style="text-align: right;">Page 90</p> <p>1 not say that --</p> <p>2 Q. Let's go to the next page, number 7.</p> <p>3 It says: "DEA also alleges that Cardinal</p> <p>4 failed to maintain effective controls against</p> <p>5 diversion . . ."</p> <p>6 Is that pretty clear to you? DEA says</p> <p>7 that "Cardinal failed to maintain effective control</p> <p>8 against diversion of controlled substances."</p> <p>9 You see that?</p> <p>10 MR. PYSER: Object to form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. You didn't -- you didn't -- you didn't --</p> <p>13 see that line before you just gave me that last</p> <p>14 answer, did you?</p> <p>15 A. I do see that line, and I repeat my</p> <p>16 previous answer.</p> <p>17 Q. They were wrong, just -- DEA is wrong</p> <p>18 here, huh?</p> <p>19 A. This does not say that Cardinal Health did</p> <p>20 not have a program in place.</p> <p>21 Q. Sir, they took your license away. They</p> <p>22 took your license away in Washington. Right? Yes?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. They took your license away in Washington?</p>	<p style="text-align: right;">Page 92</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Okay. And then if you look down, the next</p> <p>3 page, it goes on. I mean, the Jerry Steele Lane,</p> <p>4 Georgia, facility, the McDonough facility.</p> <p>5 Have you been there?</p> <p>6 A. Yes.</p> <p>7 Q. Where is that? You've been to Georgia;</p> <p>8 you've been to the facility itself, haven't you?</p> <p>9 A. Yes.</p> <p>10 Q. And that's a Cardinal facility, correct?</p> <p>11 A. It was at the time, yes.</p> <p>12 Q. And you were in charge of Georgia, just --</p> <p>13 that was part of your territory, wasn't it?</p> <p>14 A. What do you mean by "in charge of</p> <p>15 Georgia"? Do you mean --</p> <p>16 Q. Oversight.</p> <p>17 A. -- reviewing -- I -- I had no oversight of</p> <p>18 Georgia. My job was to review ingredient limit</p> <p>19 reports from all of the Cardinal facilities.</p> <p>20 Q. Right. And so every one of these things</p> <p>21 that we've been talking about, where the license has</p> <p>22 been suspended, you were in charge of reviewing</p> <p>23 reports, correct?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: I was one individual that</p>
<p style="text-align: right;">Page 91</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Correct?</p> <p>4 MR. PYSER: Object to form. Misstates</p> <p>5 evidence. Asked and answered.</p> <p>6 THE WITNESS: There was a -- there was an</p> <p>7 order to show cause and an immediate suspension</p> <p>8 of registration.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. They suspended your license in Washington</p> <p>11 to sell narcotics. They suspended your license in</p> <p>12 Lakeland to sell narcotics. They suspended your</p> <p>13 license in Swedesboro to sell narcotics. They</p> <p>14 suspended your license in Texas to sell narcotics.</p> <p>15 Correct?</p> <p>16 MR. PYSER: Object to form. Asked and</p> <p>17 answered.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Is that correct?</p> <p>20 A. There was --</p> <p>21 MR. PYSER: Object to form.</p> <p>22 THE WITNESS: There was an immediate</p> <p>23 suspension order issued for the facilities that</p> <p>24 you mentioned.</p> <p>25</p>	<p style="text-align: right;">Page 93</p> <p>1 did review those reports. Those reports were</p> <p>2 also submitted to the DEA from these particular</p> <p>3 distribution centers.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Well, you might be confused about that, so</p> <p>6 I'm going to let that one go.</p> <p>7 But let me ask you this --</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Strike that. Strike that.</p> <p>11 And let me ask you this: So we're on</p> <p>12 page -- we're on number 7 on page 2 of this document.</p> <p>13 Now, we've talked about all these other</p> <p>14 places, and now we're talking about McDonough</p> <p>15 facility. And you reviewed orders for McDonough</p> <p>16 facility, true?</p> <p>17 A. I reviewed ingredient limit reports --</p> <p>18 Q. And according to --</p> <p>19 A. -- for the McDonough facility.</p> <p>20 Q. -- the DEA, they say that "Cardinal failed</p> <p>21 to maintain effective controls against diversion of</p> <p>22 controlled substances at the following addresses."</p> <p>23 MR. PAPANTONIO: Underline "following</p> <p>24 addresses," please.</p> <p>25</p>

<p style="text-align: right;">Page 94</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. First one there is McDonough, right? You</p> <p>3 actually visited the place, right?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: That is the first facility</p> <p>6 listed.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. And then the next one is all the way out</p> <p>9 in California, Valencia facility, right?</p> <p>10 You visited that, true?</p> <p>11 A. I believe I have been to the -- to the</p> <p>12 Valencia facility.</p> <p>13 Q. And you reviewed reports coming from</p> <p>14 Valencia facility, correct?</p> <p>15 A. I did review ingredient limit reports for</p> <p>16 the Valencia facility.</p> <p>17 Q. And according to the DEA, the DEA is</p> <p>18 saying that Cardinal failed to maintain effective</p> <p>19 controls against diversion of controlled substances</p> <p>20 at Valencia facility, right?</p> <p>21 MR. PYSER: Object to form.</p> <p>22 THE WITNESS: This document alleges that</p> <p>23 Cardinal failed to maintain effective controls</p> <p>24 against diversion.</p> <p>25</p>	<p style="text-align: right;">Page 96</p> <p>1 You see that?</p> <p>2 A. I do see that.</p> <p>3 Q. "... parties desire to settle and</p> <p>4 resolve and hereby do settle and resolve all</p> <p>5 outstanding administrative claims and/or issues with</p> <p>6 respect to alleged failure of Cardinal" --</p> <p>7 MR. PAPANTONIO: Underline "failure of</p> <p>8 Cardinal" --</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. "... to detect and report suspicious</p> <p>11 orders and alleged failure of Cardinal to maintain</p> <p>12 adequate controls against the diversion of controlled</p> <p>13 substances on or prior to September 30, 2008."</p> <p>14 See that?</p> <p>15 A. I do see that.</p> <p>16 Q. All right. And then if you look down</p> <p>17 below that, you see where it says "covered conduct"?</p> <p>18 "For purposes of this agreement, covered</p> <p>19 conduct shall mean the following. The conduct</p> <p>20 alleged in the orders to show cause."</p> <p>21 See that?</p> <p>22 A. Is that under the paragraph "No admission</p> <p>23 or concession"?</p> <p>24 Q. See where it says "covered conduct"?</p> <p>25 A. Yes.</p>
<p style="text-align: right;">Page 95</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Okay. And -- and then the next one is the</p> <p>3 Denver facility in Colorado. That's a totally</p> <p>4 different facility; that's in Colorado. True?</p> <p>5 And you reviewed reports there, too,</p> <p>6 correct?</p> <p>7 A. I did review ingredient limit reports for</p> <p>8 the Denver, Colorado, facility.</p> <p>9 Q. All right. Let's go to -- let's go down</p> <p>10 to -- here it says "General" -- Stipulation</p> <p>11 agreement, General" -- specific questions I have for</p> <p>12 you.</p> <p>13 A. Same page?</p> <p>14 Q. Yes, sir, it's the same page.</p> <p>15 You see where it says "general," the word</p> <p>16 "general" there?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. It says: "Intentions of parties to</p> <p>19 effect settlement."</p> <p>20 And then it -- it goes -- says: "In order</p> <p>21 to avoid the uncertainty and the expense of</p> <p>22 litigation, in furtherance of the parties' belief</p> <p>23 that a settlement, this administration is in the</p> <p>24 public interest, parties desire to settle and resolve</p> <p>25 ..."</p>	<p style="text-align: right;">Page 97</p> <p>1 Q. "The conduct alleged in the orders to show</p> <p>2 cause," and then the -- go to the next page.</p> <p>3 It says: "The alleged failure of Cardinal</p> <p>4 to maintain adequate controls of controlled</p> <p>5 substances prior to 2008."</p> <p>6 That's when -- that's when you were in</p> <p>7 regulatory, prior to 2008, right?</p> <p>8 MR. PYSER: Object to form. And misstates</p> <p>9 evidence. Rule of completeness.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. You were there in regulatory in 2008?</p> <p>12 A. I was in quality and regulatory affairs</p> <p>13 from 2005 until some point -- either 2007, 2008. I</p> <p>14 don't recall the exact time frame.</p> <p>15 Q. And you were reviewing all of the reports</p> <p>16 for everything we've just covered -- Georgia,</p> <p>17 California, Florida, Colorado, Washington -- you were</p> <p>18 reporting -- you were the guy reporting -- reviewing</p> <p>19 reports, right?</p> <p>20 A. We were reviewing those reports for those</p> <p>21 facilities.</p> <p>22 Q. Says: "The alleged failure of Cardinal to</p> <p>23 maintain adequate controls against the diversion of</p> <p>24 controlled substances on or prior -- all -- at all</p> <p>25 distribution site facilities." Okay?</p>



<p style="text-align: right;">Page 98</p> <p>1 Let's -- let me slow -- let me slow down          2 here. This is -- we're on page 3 right now. Okay?          3 Are you on page 3?          4 A. Yes.          5 Q. Okay. At the very top of page 3, it says:          6 "The alleged failure of Cardinal to maintain adequate          7 controls against the diversion of controlled          8 substances prior -- on or prior to September 30th,          9 2008, at all" --          10 MR. PAPANTONIO: Would you underline "all          11 distribution facilities listed in Appendix A"?          12 Got that?          13 BY MR. PAPANTONIO:          14 Q. Now, remember what that says. We're          15 talking about the failure of Cardinal to maintain          16 adequate controls against the diversion of controlled          17 substance at all facilities that are listed in          18 Appendix A.          19 MR. PYSER: Object to form.          20 BY MR. PAPANTONIO:          21 Q. And let's look at Appendix A; see what it          22 has to say. Go to page 12, and then turn one more          23 page.          24 Now, I want to make sure these are all          25 facilities, sir, that you reviewed reports for.</p>	<p style="text-align: right;">Page 100</p> <p>1 Q. So if I wanted to find out about a          2 particular facility, say, in New York, one thing I          3 could look to is I could look to the registration          4 number, correct?          5 A. That registration number identifies the          6 DEA license, yes.          7 MR. PAPANTONIO: Underline that          8 registration number, please.          9 BY MR. PAPANTONIO:          10 Q. And then the next one, it says:          11 "Interstate Drive, Lakeland, Florida."          12 See that?          13 A. Yes.          14 Q. And then the next one is -- and these --          15 by the way, those two are Cardinal facilities, true?          16 A. Yes.          17 Q. And then the next one is Mississippi. We          18 hadn't talked about that, but that's a facility,          19 correct? That's a Cardinal facility?          20 A. At the time, I believe it was, yes.          21 Q. And then the next -- and by the way -- and          22 just so -- I want to be clear: You were also in          23 charge of reviewing reports coming out of Cardinal --          24 out of Madison, Mississippi?          25 A. I did review ingredient limit reports from</p>
<p style="text-align: right;">Page 99</p> <p>1 Start at the top, if you would, please.          2 "Cardinal facilities referenced in          3 paragraph 1 of this agreement."          4 That's just what we were looking at,          5 correct?          6 A. This is Appendix A to the agreement, yes.          7 Q. So this is Appendix A. And so in          8 Appendix A, it talks about New York operating under          9 DEA registration, correct?          10 A. Yes.          11 Q. And see where it gives a number there, it          12 even gives a DEA registration number?          13 A. Yes.          14 Q. Tell the jury how important that DEA          15 registration number is.          16 MR. PYSER: Object to the form.          17 THE WITNESS: The DEA registration number          18 is the license given to a registrant in order to          19 house and distribute controlled substances.          20 BY MR. PAPANTONIO:          21 Q. And it's way -- it's ways that DEA can          22 identify a particular facility, correct, by its -- by          23 its registration number?          24 A. That registration number is the license to          25 distribute controlled substances.</p>	<p style="text-align: right;">Page 101</p> <p>1 Madison, Mississippi.          2 Q. Registration RC0221236. Those -- those          3 registration numbers are -- are important, aren't          4 they? I mean, keeping up with the facility, the          5 registration number is what allows the facility to          6 do -- to sell narcotics, true?          7 MR. PYSER: Object to form.          8 THE WITNESS: That registration number is          9 the DEA license --          10 BY MR. PAPANTONIO:          11 Q. Okay. Yeah.          12 A. -- to distribute controlled substances.          13 Q. It's important, isn't it?          14 A. You cannot distribute controlled          15 substances without a DEA registration.          16 Q. Right. And then the next one is          17 La Vergne, Tennessee. Did I say that -- La Vergne?          18 That's Tennessee.          19 And you also reviewed -- you also reviewed          20 that, reports coming out of there?          21 A. I do not believe I reviewed reports for          22 La Vergne, Tennessee.          23 Q. Okay. Knoxville, Tennessee: How about          24 that?          25 A. Yes.</p>

Page 102

1 Q. McDonough, Georgia: You already told us  
 2 you did, right?  
 3 A. Yes.  
 4 Q. The next one is -- next one is number 7,  
 5 and that's in Ohio, right?  
 6 A. Findlay, Ohio, yes.  
 7 Q. And you reviewed reports there, true?  
 8 A. Yes.  
 9 Q. Yeah. And just to be clear, now, what  
 10 we're reviewing here, just so we don't lose sight of  
 11 what we're talking about, these are facilities that  
 12 the DEA said were not complying, weren't at the --  
 13 did not have adequate controls against -- for  
 14 controlled substance.  
 15 DEA said these facilities listed, that  
 16 we're going over right now, did not have controls,  
 17 true?  
 18 MR. PYSER: Object to form. Misstates  
 19 evidence.  
 20 BY MR. PAPANTONIO:  
 21 Q. Correct?  
 22 A. According to the document, DEA alleged --  
 23 Q. Yeah.  
 24 A. -- that the pharmacies listed in  
 25 Appendix -- or, I'm sorry, the registrants listed in

Page 103

1 Appendix A --  
 2 Q. And -- and these so far -- we've been  
 3 through all these, and there's only one facility that  
 4 you didn't review the reports for? So far?  
 5 A. So far.  
 6 Q. Okay. Let's go back to the list. And  
 7 what -- what number you want? 13. That's -- no, 8.  
 8 Groveport, Ohio: Did you review reports  
 9 for them?  
 10 A. If this is the NLC --  
 11 Q. Yeah.  
 12 A. -- I did not.  
 13 Q. Okay. Fair enough.  
 14 If you don't -- this is your time to tell  
 15 us what you did and didn't do, so -- feel free.  
 16 MR. PYSER: Object to form. Improper  
 17 speech.  
 18 BY MR. PAPANTONIO:  
 19 Q. Stafford, Texas: You did review reports  
 20 there, right?  
 21 A. Yes.  
 22 Q. Zanesville, Ohio: You reported -- you  
 23 reviewed reports there, right?  
 24 A. I do not believe I did reports for  
 25 Zanesville, Ohio. I believe that is a repackaging

Page 104

1 operation.  
 2 Q. Okay. How about Reno, Nevada?  
 3 A. I do not believe I reviewed reports for  
 4 Reno, Nevada.  
 5 Q. And then how about Massachusetts?  
 6 A. Are you referring to number 12 --  
 7 Q. Yeah.  
 8 A. -- Peabody, Massachusetts?  
 9 Q. Peabody, Massachusetts.  
 10 A. Yes.  
 11 Q. Okay. And again, these are -- this is an  
 12 appendix of places that the DEA said you were not  
 13 reporting the things that you were supposed to be  
 14 reporting to the DEA, correct?  
 15 MR. PYSER: Object to form. Misstates  
 16 evidence.  
 17 THE WITNESS: This is what the DEA alleged  
 18 of not having -- whatever the wording was. It  
 19 was not that you did not have a system in place,  
 20 but they alleged that -- can I go back and read  
 21 the --  
 22 BY MR. PAPANTONIO:  
 23 Q. Yeah. Go back and read it because I want  
 24 to make -- the next -- there it is: "The alleged  
 25 failure of Cardinal to maintain" --

Page 105

1 A. Yes. DEA alleged --  
 2 Q. -- "adequate controls against the  
 3 diversion of controlled substances."  
 4 And we can agree controlled substances are  
 5 narcotics, true?  
 6 A. A narcotic is a controlled substance.  
 7 Q. Yeah. And so every one of these  
 8 facilities we're talking about, we're talking about  
 9 Cardinal selling narcotics from those facilities,  
 10 correct?  
 11 A. Cardinal selling controlled substances  
 12 from those facilities, including narcotics, yes.  
 13 Q. And it says that Cardinal failed to  
 14 maintain adequate control -- just to catch up with  
 15 where we were -- correct?  
 16 MR. PYSER: Object to form. Misstates --  
 17 BY MR. PAPANTONIO:  
 18 Q. You failed to -- to maintain adequate  
 19 control?  
 20 MR. PYSER: Object to form.  
 21 THE WITNESS: DEA alleged --  
 22 BY MR. PAPANTONIO:  
 23 Q. Yeah.  
 24 A. -- failure to maintain adequate control.  
 25 Q. And then you all signed the document and

<p style="text-align: right;">Page 106</p> <p>1 paid the fine, didn't you?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Right?</p> <p>5 A. It was a settlement.</p> <p>6 Q. Yeah, right.</p> <p>7 A. Yes.</p> <p>8 Q. But you didn't just pay the money -- sir,</p> <p>9 did you have a vote in whether you paid the money or</p> <p>10 not?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 THE WITNESS: I didn't have a vote, no.</p> <p>13 But you left off the -- the "no admission or</p> <p>14 concession" paragraph. You --</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. No, no, we're --</p> <p>17 A. You skipped over that.</p> <p>18 Q. Well, you don't -- the jury can --</p> <p>19 A. You just asked, did we -- so . . .</p> <p>20 MR. PAPANTONIO: Hand me that, please.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. \$34 million, did you --</p> <p>23 MR. PAPANTONIO: No, I want one of those</p> <p>24 candies, please.</p> <p>25</p>	<p style="text-align: right;">Page 108</p> <p>1 Q. How about 40,000? Does that sound</p> <p>2 familiar to you? Did anybody ever tell you that you</p> <p>3 had 40,000 employees worldwide?</p> <p>4 A. I do not recall at the time how many</p> <p>5 employees --</p> <p>6 Q. Well, tell me --</p> <p>7 A. -- Cardinal had.</p> <p>8 Q. -- how many people were in charge of</p> <p>9 reviewing documents about diversion of controlled</p> <p>10 substance.</p> <p>11 A. You have to give me a time frame.</p> <p>12 Q. Any time. Just pick it.</p> <p>13 How about 2007? How many people were</p> <p>14 involved with reviewing the kind of things we're</p> <p>15 talking about, reviewing reports from this list of</p> <p>16 people -- this list of facilities, in 2007?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: Well --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Would you like a -- would you like a mint?</p> <p>21 They're pretty good.</p> <p>22 A. Not yet. No, thank you.</p> <p>23 Q. Okay. Go ahead.</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: There would have been an</p>
<p style="text-align: right;">Page 107</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. \$34 million, did you know your company</p> <p>3 paid \$34 million? Huh?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: I know now.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Does that seem like a -- that's pretty big</p> <p>8 fine, isn't it, \$34 million?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 THE WITNESS: It's -- well, big as</p> <p>11 compared to what?</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Well, you're -- well, that's a good</p> <p>14 question.</p> <p>15 Did you know that at the time they paid</p> <p>16 \$34 million, your company was rated a \$90 billion</p> <p>17 company? Cardinal was rated a \$90 billion company?</p> <p>18 Did you know that?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 THE WITNESS: At the time, I did not keep</p> <p>21 up with sales or revenue.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Do you know how many employees Cardinal</p> <p>24 had when you were working?</p> <p>25 A. I do not.</p>	<p style="text-align: right;">Page 109</p> <p>1 individual or individuals at the facilities who</p> <p>2 submitted the ingredient limit reports to the</p> <p>3 DEA, as well as -- I can't say a -- a certain</p> <p>4 number at the corporate level. Two or three.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Two or three. Two or three people at the</p> <p>7 corporate level. I think that's the number I had,</p> <p>8 and that's what I was going to ask you.</p> <p>9 It could have been two; it could have been</p> <p>10 three, correct?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Correct?</p> <p>14 A. Two or three individuals that actually</p> <p>15 reviewed the reports.</p> <p>16 Q. And you're selling narcotics all over the</p> <p>17 country -- Ohio, California, Florida, Texas, all over</p> <p>18 the country, Colorado -- right?</p> <p>19 MR. PYSER: Object -- object to form.</p> <p>20 THE WITNESS: There were distribution</p> <p>21 centers at several states, yes.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. And you've got 40 -- if I represented to</p> <p>24 you 40,000 employees working for the company, would</p> <p>25 you object to that, or would you just say, "I don't</p>

<p style="text-align: right;">Page 110</p> <p>1 know"?</p> <p>2 A. I would say I don't know. I . . .</p> <p>3 Q. But you do know there were only three --</p> <p>4 two or three people actually reviewing -- doing this</p> <p>5 work of reviewing these documents; you know that?</p> <p>6 A. That's not what I said. I said at the</p> <p>7 corporate office --</p> <p>8 Q. At the corporate office?</p> <p>9 A. -- and then there were individuals at the</p> <p>10 distribution centers who generated and submitted</p> <p>11 those reports to the DEA.</p> <p>12 Q. Well, the corporate office can shut things</p> <p>13 down immediately if they want to, can't they?</p> <p>14 Corporate office can shut a facility down immediately</p> <p>15 if they see that there's a problem, right?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Yes?</p> <p>19 A. I -- I don't know all of the authorities</p> <p>20 that a corporate office holds.</p> <p>21 Q. Go back to the list. Let's go ahead and</p> <p>22 finish up this list. We're on number 14 -- 13.</p> <p>23 Number 13, Wheeling, West Virginia. Right? That's</p> <p>24 on the list.</p> <p>25 Next is Auburn, Washington, on the list.</p>	<p style="text-align: right;">Page 112</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. At the corporate level?</p> <p>3 A. On the team --</p> <p>4 Q. Right?</p> <p>5 A. -- that I was a manager of --</p> <p>6 Q. Yeah.</p> <p>7 A. -- we reviewed the ingredient limit</p> <p>8 reports, yes.</p> <p>9 Q. And then we got, where did I -- Hudson,</p> <p>10 Wisconsin. Then we got Greensboro, North Carolina.</p> <p>11 We got Tolleson, Arizona. Denver, Colorado,</p> <p>12 Swedesboro, New Jersey. Roanoke, Texas. Charles,</p> <p>13 Missouri. Niagara Falls, New York.</p> <p>14 You see that?</p> <p>15 A. I do see that.</p> <p>16 Q. Now, that list that we just reviewed is a</p> <p>17 list that is in addition to -- in this document, in</p> <p>18 addition, they're saying that -- if you go back to</p> <p>19 page 1, just so we -- we remember what we're talking</p> <p>20 about here because that's a lot of -- that's a lot of</p> <p>21 different facilities.</p> <p>22 But if we go back to page 1, it says:</p> <p>23 "Cardinal is registered with DEA at 27 facilities."</p> <p>24 See that? And then it gives a list of the</p> <p>25 ones where they have actually -- been a suspension of</p>
<p style="text-align: right;">Page 111</p> <p>1 Next is Kansas City, Missouri, on the list.</p> <p>2 Valencia, California, on the list. Aurora, Illinois.</p> <p>3 Elk Grove, California.</p> <p>4 MR. PAPANTONIO: Go ahead and just</p> <p>5 highlight them, so the jury --</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Elk Grove, California. Hudson, Wisconsin.</p> <p>8 I'm just curious; now we've been about all</p> <p>9 over the country.</p> <p>10 Were you in charge of reviewing reports in</p> <p>11 Wisconsin, too?</p> <p>12 A. I reviewed ingredient limit reports for</p> <p>13 the Wisconsin facility.</p> <p>14 Q. And it would be you and maybe two other</p> <p>15 people?</p> <p>16 A. Yes.</p> <p>17 Q. You or two other people --</p> <p>18 A. At the corporate --</p> <p>19 Q. At the corporate level?</p> <p>20 A. -- level.</p> <p>21 Q. Yeah. You or two other people reviewing</p> <p>22 all this stuff?</p> <p>23 MR. PYSER: Object to form. Misstates</p> <p>24 testimony.</p> <p>25</p>	<p style="text-align: right;">Page 113</p> <p>1 registration, right underneath that. We talked about</p> <p>2 that. One, two, three, four, five -- see that?</p> <p>3 Right?</p> <p>4 And then we've got a list of -- number 7,</p> <p>5 if we go to the list on number 7, underneath that, it</p> <p>6 says: "These are facilities where Cardinal failed to</p> <p>7 maintain controls against diversion."</p> <p>8 See that? One, two, three -- all over the</p> <p>9 country?</p> <p>10 A. Which page are you on?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. I'm on page 2.</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Right?</p> <p>17 MR. PYSER: Object to form. Is there a</p> <p>18 question?</p> <p>19 THE WITNESS: What was your question?</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Yeah. My question is: In addition to</p> <p>22 those -- the first page, where we're talking about</p> <p>23 facilities actually losing their license, then we've</p> <p>24 got another set of -- of facilities that the DEA says</p> <p>25 these facilities failed to maintain effective</p>

<p style="text-align: right;">Page 114</p> <p>1 controls against diversion of controlled substances,          2 or narcotics. Right?          3 MR. PYSER: Object to form.          4 THE WITNESS: I see the DEA has written          5 that it alleges that Cardinal Health failed to          6 maintain effective controls against the          7 diversion of controlled substances.          8 BY MR. PAPANTONIO:          9 Q. And then we go to the appendix that we've          10 just been talking about -- what page? 12? 13?          11 Page 13.          12 And that gives us a list of facilities,          13 also Cardinal-owned facilities, Cardinal-owned          14 facilities that -- where the DEA is saying that you          15 failed to have an adequate program in those          16 facilities, too, right?          17 MR. PYSER: Object to form.          18 THE WITNESS: DEA alleged, yes.          19 BY MR. PAPANTONIO:          20 Q. Yeah, right. Well, let me show you          21 something. When is the first time you saw the death          22 map?          23 MR. PYSER: Object to form. Vague.          24 BY MR. PAPANTONIO:          25 Q. Have you seen -- have you seen the CDC</p>	<p style="text-align: right;">Page 116</p> <p>1 this -- you've been in this -- this business of          2 selling -- or been involved with the sale of opioids          3 for how many years total?          4 A. I have been in the pharmaceutical industry          5 since 2000.          6 Q. Okay. And nobody has shown you this death          7 map.          8 MR. PAPANTONIO: Could you put this up?          9 THE WITNESS: I do not recall seeing this          10 death map, or whatever this is.          11 MR. PYSER: Object to form.          12 BY MR. PAPANTONIO:          13 Q. Well, let me show it to you since this is          14 the first time you've seen it. That's page -- you'll          15 have it right in front of you. You can see it better          16 on the screen, though, the colors. I'm going to ask          17 you about the colors.          18 See those little red areas right there, up          19 on the screen? You might --          20 A. I do see red areas.          21 Q. Okay.          22 A. I can see it better on the --          23 Q. Okay. Wherever you can see it is fine          24 with me.          25 And then it's got brown -- it's got a</p>
<p style="text-align: right;">Page 115</p> <p>1 death map?          2 A. I'm not familiar with a death map, no.          3 Q. Did nobody tell you that as early as 1999,          4 that this company had access to a map -- your          5 company, Cardinal, early as 19- -- had access to a          6 map that showed the progression of death from opioid          7 overdoses between 1999 and 2016?          8 MR. PYSER: Object to form.          9 BY MR. PAPANTONIO:          10 Q. Anybody ever show you that?          11 A. I'm not familiar with the death map.          12 Q. You've never seen that? And you --          13 MS. MOORE: Cardinal-Brantley 5.          14 (Cardinal-Brantley 5 was marked for          15 identification.)          16 MR. PYSER: Object to form.          17 BY MR. PAPANTONIO:          18 Q. And just to be clear, you have worked with          19 Cardinal. You've worked with Kinray -- that's owned          20 by Cardinal, right? Just so the jury understands,          21 Kinray is owned by Cardinal?          22 A. Kinray is a division of Cardinal, yes.          23 Q. Right. And so you've worked with          24 Cardinal. You've worked with Kinray Cardinal, and          25 then you've worked with Purdue. You've been in</p>	<p style="text-align: right;">Page 117</p> <p>1 brown below that. You see -- you see the scale,          2 estimated age, death rate per hundred thousand          3 people?          4 A. I do see that, to the right.          5 Q. So you never knew that while you were          6 involved with the sale of opioids, that the CDC was          7 actually following to find out how many people were          8 dying from overdoses of opioids?          9 MR. PYSER: Object to form.          10 BY MR. PAPANTONIO:          11 Q. Right?          12 MR. PYSER: Object to form. Misstates          13 evidence.          14 BY MR. PAPANTONIO:          15 Q. You --          16 MR. PYSER: It's not what this document          17 shows.          18 BY MR. PAPANTONIO:          19 Q. You never knew that?          20 MR. PAPANTONIO: We're going to stand by          21 the question.          22 BY MR. PAPANTONIO:          23 Q. You never knew that, correct?          24 MR. PYSER: Object to form. That          25 misstates what this document is.</p>



<p style="text-align: right;">Page 118</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. You never knew that? You never knew --</p> <p>3 well, let's say it this way: You never even knew</p> <p>4 there was something called a "death map," did you?</p> <p>5 MR. PYSER: Object to form. There is no</p> <p>6 indication that this document is called a "death</p> <p>7 map." It's misleading by counsel.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Well, did you -- did you -- have you ever</p> <p>10 seen this map? You said "No, I've never seen" --</p> <p>11 okay.</p> <p>12 A. I don't recall seeing this.</p> <p>13 Q. Okay.</p> <p>14 MR. PAPANTONIO: Well, hey, do me a favor,</p> <p>15 would you, Evan, put 1999 on half the screen.</p> <p>16 And then put all the way up to 2016 right beside</p> <p>17 it.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. This might be fascinating for you.</p> <p>20 MR. PAPANTONIO: There you go, right</p> <p>21 there.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. So, 2016. Do you see that?</p> <p>24 A. I do.</p> <p>25 Q. You see it really well up on the screen.</p>	<p style="text-align: right;">Page 120</p> <p>1 MR. PYSER: And I'll make my objections,</p> <p>2 Counsel.</p> <p>3 MR. PAPANTONIO: You make your objections.</p> <p>4 MR. PYSER: You're making misleading</p> <p>5 statements about that.</p> <p>6 MR. PAPANTONIO: We'll let the jury decide</p> <p>7 whether it's misleading. The jury is going to</p> <p>8 see this.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Okay. So you see where it says "30," at</p> <p>11 the bottom, marked in brown?</p> <p>12 A. Yes.</p> <p>13 Q. Now, in 1999, tell me how many places you</p> <p>14 see brown.</p> <p>15 A. On the actual map?</p> <p>16 Q. Yeah.</p> <p>17 A. I can't tell if there's any brown.</p> <p>18 Q. I can't see it. I thought maybe you</p> <p>19 could.</p> <p>20 Okay. You go to --</p> <p>21 MR. PYSER: Object to form.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. You go to 2016. Can you see some brown</p> <p>24 there on 2016?</p> <p>25 A. I --</p>
<p style="text-align: right;">Page 119</p> <p>1 You see where it says "30 deaths per 100,000 people"?</p> <p>2 You see that? 30 deaths, in the brown. Correct?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 THE WITNESS: I see it on the right,</p> <p>5 the 30, at the bottom.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. 30 -- uh-huh. So between 1999, where this</p> <p>8 starts out, it doesn't have all that brown, does it?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Does it? Got a little bit of brown, but</p> <p>12 not a lot of brown, does it?</p> <p>13 MR. PYSER: Object to form. Counsel, it</p> <p>14 appears from the document that --</p> <p>15 MR. PAPANTONIO: Let's -- I don't want a</p> <p>16 speech. I'm going to -- I'm going to ask</p> <p>17 questions about the document without you leading</p> <p>18 this witness. It's very apparent what the</p> <p>19 document says.</p> <p>20 The document says while he was doing his</p> <p>21 job with Cardinal that people were dying all</p> <p>22 over the country. And I'm going to ask him</p> <p>23 about that.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Now, I want to ask you the question --</p>	<p style="text-align: right;">Page 121</p> <p>1 Q. How about that? Does that help you, if we</p> <p>2 blow it up?</p> <p>3 MR. PYSER: Object to form. And also</p> <p>4 object that the document before the witness is</p> <p>5 different in coloration than the document --</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, let's use the one on the -- let's</p> <p>8 use the one that's on the screen, so the jury can see</p> <p>9 it right along with you.</p> <p>10 You see some brown on that document?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 THE WITNESS: I see brown on the screen.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. It's all over the place, isn't it?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: I see brown on the screen.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. All right. Well, let me show you</p> <p>19 something else.</p> <p>20 And you understand that the brown</p> <p>21 represents 30 deaths per 100,000. The red represents</p> <p>22 28 to 29 deaths per 100,000. You see that? How --</p> <p>23 the progression of that?</p> <p>24 A. It says "The estimated age-adjusted death</p> <p>25 rate per 100,000."</p>

<p style="text-align: right;">Page 122</p> <p>1 Q. Okay. Good.</p> <p>2 So let me show you -- let's take a look</p> <p>3 at -- we've covered your distribution sites.</p> <p>4 MR. PAPANTONIO: Can you -- can you</p> <p>5 superimpose the distribution sites over the</p> <p>6 death map for him, please?</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Now first of all, before we get to the</p> <p>9 second, to the -- these -- take a look, and I want to</p> <p>10 make sure that all of those are -- are distribution</p> <p>11 sites that Cardinal had that were doing business.</p> <p>12 MR. PYSER: Object to form. Vague.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Is there something vague about that? That</p> <p>15 I asked you -- I'm interested.</p> <p>16 Is there something really vague about what</p> <p>17 I just asked you?</p> <p>18 A. The time frame is vague because --</p> <p>19 Q. Well --</p> <p>20 A. -- what time frame are you referring to?</p> <p>21 Q. Let's say -- let's say up to two</p> <p>22 thousand -- let's say 2008.</p> <p>23 A. At -- at 2008, did Cardinal Health have</p> <p>24 all of these facilities?</p> <p>25 Q. Yeah. How about 2013? Weren't you there</p>	<p style="text-align: right;">Page 124</p> <p>1 we?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: Zanesville was on the list,</p> <p>4 and I believe I mentioned that during the time</p> <p>5 frame when I was reviewing the reports from 2005</p> <p>6 to 2007-8 time frame, somewhere, that I do not</p> <p>7 recall Zanesville. I believe that's the</p> <p>8 repackaging operation.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. How about Findlay, Ohio?</p> <p>11 A. I believe that Findlay, Ohio, was there</p> <p>12 during that time frame.</p> <p>13 Q. Just go throughout the country. How about</p> <p>14 Syracuse, New York, up there in the right corner?</p> <p>15 A. Yes.</p> <p>16 Q. Niagara Falls, New York?</p> <p>17 A. I do not know with a certainty if Niagara</p> <p>18 Falls was there. I believe that's ParMed, which was</p> <p>19 an acquisition. And I don't -- I do not remember</p> <p>20 what year that company was acquired.</p> <p>21 Q. It's on the list, if you take a look at</p> <p>22 the list.</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. You want to take a look at the list?</p>
<p style="text-align: right;">Page 123</p> <p>1 in 2013?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: I can't say with a certainty</p> <p>4 whether all of the facilities were present in</p> <p>5 2008. There was an acquisition.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, the jury's heard about Swedesboro,</p> <p>8 right?</p> <p>9 A. Yes.</p> <p>10 Q. Jury's heard about Wheeling, West</p> <p>11 Virginia, right?</p> <p>12 A. You mentioned those.</p> <p>13 MR. PAPANTONIO: Did you -- can -- do you</p> <p>14 have a -- do we have a pointer? This is -- so I</p> <p>15 can get this -- I want to -- do you have a laser</p> <p>16 pointer? Or can you do it? Okay. Good.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Let's -- Swedesboro. I want to make sure</p> <p>19 we're not -- we're not mixing anything up. Take --</p> <p>20 Swedesboro, we talked about, right? Wheeling, West</p> <p>21 Virginia, right, talked about? Zanesville, Ohio?</p> <p>22 Now tell me when it -- stop me when I'm</p> <p>23 wrong about the fact that we've talked about these</p> <p>24 already in your testimony.</p> <p>25 Zanesville, Ohio, we talked about, didn't</p>	<p style="text-align: right;">Page 125</p> <p>1 A. It was on that list, but your question</p> <p>2 was, was I reviewing ingredient limit reports --</p> <p>3 Q. Okay.</p> <p>4 A. -- for them.</p> <p>5 Q. Well, let's --</p> <p>6 A. Was that there in 2008? And I cannot say</p> <p>7 with a certainty it was.</p> <p>8 Q. Fair enough. Fair enough.</p> <p>9 A. I don't recall the acquisition date.</p> <p>10 Q. Lakeland, Florida, we talked about, right?</p> <p>11 Stafford, Texas, we talked about, right?</p> <p>12 You're going to have to tell me yes or no.</p> <p>13 Yes?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 THE WITNESS: Well, you don't give me a</p> <p>16 chance to answer. You asked a question, you say</p> <p>17 "right." And then you keep going. So I'm</p> <p>18 thinking you're making a statement --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. No.</p> <p>21 A. -- as opposed to asking a question.</p> <p>22 Q. Am I right about Stafford, Texas, being</p> <p>23 something you -- a facility you actually reviewed?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: Yes.</p>

<p style="text-align: right;">Page 126</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Okay. And -- and Roanoke, Texas, is a</p> <p>3 facility you reviewed? Yes or no?</p> <p>4 A. Yes.</p> <p>5 Q. And Saint Charles, Missouri, correct?</p> <p>6 A. Correct, in that I reviewed it, yes.</p> <p>7 Q. And then all -- let's go all the way out</p> <p>8 to California. Valencia, California: You reviewed</p> <p>9 orders there, didn't you?</p> <p>10 A. I reviewed ingredient limit reports, yes.</p> <p>11 Q. And Elk Grove, California, you reviewed</p> <p>12 that?</p> <p>13 A. I reviewed ingredient limit reports, yes.</p> <p>14 Q. And Auburn, Washington, you reviewed that?</p> <p>15 A. I reviewed ingredient limit reports, yes.</p> <p>16 Q. Let me show you something now.</p> <p>17 MR. PAPANTONIO: Could you superimpose</p> <p>18 that distribution facility with the death map --</p> <p>19 with -- with the map that we've been -- that</p> <p>20 I've been calling "the death map." See what it</p> <p>21 looks like.</p> <p>22 MR. PYSER: Object to form. Object to --</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Have you ever seen --</p> <p>25 MR. PYSER: -- using this demonstrative.</p>	<p style="text-align: right;">Page 128</p> <p>1 number of people dying in Lakeland?</p> <p>2 Did anybody ever spend any time going over</p> <p>3 that with you?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: Again, when I was at the</p> <p>6 company, I do not recall seeing any numbers or</p> <p>7 graphs about, as you say, deaths across the</p> <p>8 country.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Why don't you tell me -- let's just --</p> <p>11 since we got it up there, you've got around -- let's</p> <p>12 say Denver -- Denver, Colorado.</p> <p>13 What -- what areas would Denver, Colorado,</p> <p>14 distribute to? They'd distribute right to that brown</p> <p>15 area, wouldn't they?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: I do not recall the</p> <p>18 distribution parameters or --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. You don't know where your company</p> <p>21 distributed? Is that -- you don't recall where your</p> <p>22 company distributed?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Is that what you're saying?</p>
<p style="text-align: right;">Page 127</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Have you ever seen this reduced to</p> <p>3 something that would -- that demonstrates the</p> <p>4 expansion of opioid deaths in America? Have you ever</p> <p>5 seen that prior to today?</p> <p>6 MR. PYSER: Object to form. And misstates</p> <p>7 evidence that the map makes that statement in</p> <p>8 any way, shape, or form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Have you ever seen anything, whether it's</p> <p>11 this map or anything, that showed you the expansion</p> <p>12 of death among people throughout the United States</p> <p>13 from opioids?</p> <p>14 MR. PYSER: Same --</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Anything?</p> <p>17 MR. PYSER: Same objections.</p> <p>18 THE WITNESS: I have not seen this. And I</p> <p>19 do not recall any document or graph of, as you</p> <p>20 state, deaths across the country.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. How about numbers? Anybody ever show you</p> <p>23 numbers, when you were working with the company,</p> <p>24 about people in Washington -- number -- this is the</p> <p>25 number of people dying in Washington; this is the</p>	<p style="text-align: right;">Page 129</p> <p>1 A. I can't say into what city and county each</p> <p>2 distribution center distributed into.</p> <p>3 Q. Well, can you tell me whether -- do you</p> <p>4 have any memory about Salt Lake City, Utah, whether</p> <p>5 it distributed in that area of brown?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 THE WITNESS: Again, I don't know exactly</p> <p>8 where every distribution center distributed</p> <p>9 drugs.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. And while you were an employee working,</p> <p>12 being paid by the company, through 2013, nobody even</p> <p>13 told you that there were agencies that were keeping</p> <p>14 out -- keeping up with the death of human beings</p> <p>15 relating to opioids.</p> <p>16 Is that a correct statement?</p> <p>17 MR. PYSER: Object to form. Misstates</p> <p>18 evidence.</p> <p>19 THE WITNESS: I do not recall any</p> <p>20 conversations, while an employee at Cardinal</p> <p>21 Health, regarding --</p> <p>22 MR. PAPANTONIO: Let's take --</p> <p>23 THE WITNESS: -- death by opioids.</p> <p>24 MR. PAPANTONIO: Let's take a ten-minute</p> <p>25 break.</p>

Page 130

1 VIDEOGRAPHER: Going off the record. The  
 2 time is 10:33.  
 3 (A recess transpired from 10:33 a.m. until  
 4 10:52 a.m.)  
 5 VIDEOGRAPHER: We're going back on the  
 6 record, beginning of media file number 2. Time  
 7 is 10:52.  
 8 BY MR. PAPANTONIO:  
 9 Q. Now, Mr. Brantley, we had a pending  
 10 question when you walked out about that map that we  
 11 were talking about.  
 12 First of all, you -- you haven't talked to  
 13 counsel about any of this testimony, right? You know  
 14 the rule on that. Did somebody tell you the rule on  
 15 that, that you're not permitted to talk to counsel  
 16 during the break about questions that are pending in  
 17 this deposition?  
 18 A. I did not speak to counsel --  
 19 Q. You didn't speak --  
 20 A. -- regarding questions pending in this  
 21 investigation.  
 22 Q. So there was no discussion about -- about  
 23 testimony here; is that -- is that what you're  
 24 telling us?  
 25 A. That is correct.

Page 131

1 Q. All right. We're going to try to take  
 2 breaks if we can. That was a little longer than we  
 3 typically do.  
 4 MR. PYSER: Object to form.  
 5 BY MR. PAPANTONIO:  
 6 Q. All right. So, sir, if we get back to the  
 7 document we've been -- that we have been reviewing.  
 8 We just got off the map, and we showed -- I showed  
 9 you where the distribution facilities were  
 10 superimposed on a map.  
 11 Do you recall that?  
 12 A. Yes.  
 13 Q. And you told me, I think earlier, that you  
 14 had never seen that map, right?  
 15 MR. PYSER: Object to form.  
 16 THE WITNESS: That's correct.  
 17 MR. PYSER: Object to form.  
 18 BY MR. PAPANTONIO:  
 19 Q. Okay. Now would you go to page 16, since  
 20 we're going to talk about some specifics about some  
 21 of this --  
 22 A. Are we on the map, or --  
 23 Q. Page 16 on -- on the document 4230.  
 24 Now, you understand, again, this is a  
 25 continuation of the document we've been talking

Page 132

1 about -- you see that -- in the matter of Cardinal  
 2 Health, right? You see that?  
 3 A. I see that.  
 4 Q. And that's November 28, 2007. You see  
 5 that date?  
 6 A. That is the stamp, November 28, 2007.  
 7 Q. So in addition to some of the other issues  
 8 we've been talking about -- earlier we talked  
 9 suspension. We talked about -- we talked about  
 10 facilities where the DEA didn't believe that there  
 11 was proper recording.  
 12 You recall those lists that we talked  
 13 about?  
 14 MR. PYSER: Object to form.  
 15 THE WITNESS: I do recall the list.  
 16 BY MR. PAPANTONIO:  
 17 Q. Okay. So on here, let's talk about some  
 18 other things.  
 19 It says: "Order to show cause and  
 20 immediate suspension of registration."  
 21 It says: "Notice is hereby given to  
 22 inform Cardinal Health of the immediate suspension of  
 23 drug enforcement -- DEA certificate registration."  
 24 And there it's -- if you look, it says:  
 25 "DEA certificate of registration is" -- and then it

Page 133

1 gives a number -- see, that's RW0191813 -- "is  
 2 assigned to Cardinal Health's Auburn, Washington,  
 3 distribution center."  
 4 That's another facility we haven't talked  
 5 about. You see that?  
 6 MR. PYSER: Object to form. Misstates  
 7 testimony.  
 8 THE WITNESS: I do see the sentence you  
 9 just read.  
 10 BY MR. PAPANTONIO:  
 11 Q. Okay. Now, correct me if I'm wrong, but  
 12 this is -- this is talking about the suspension of  
 13 the certificate of registration for Auburn,  
 14 Washington, correct?  
 15 A. This is a notice of immediate suspension.  
 16 Q. And then it says, under 2, it says:  
 17 "Respondent has failed to maintain effective controls  
 18 against diversion of a particular controlled  
 19 substance into other than legitimate medical,  
 20 scientific, and industrial channels in violation of  
 21 21 USC."  
 22 You see that?  
 23 MR. PYSER: Object to form.  
 24 BY MR. PAPANTONIO:  
 25 Q. Is that -- do you recall this incident

<p style="text-align: right;">Page 134</p> <p>1 where Auburn, Washington, all the way up there in --</p> <p>2 in Washington, that they had failed to maintain</p> <p>3 controls for diversion?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: To answer your first</p> <p>6 question, I do see the sentence.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Okay.</p> <p>9 A. And what was your second question again?</p> <p>10 Q. I just wanted to make -- were you involved</p> <p>11 with -- were you involved with checking orders for --</p> <p>12 for Auburn, Washington?</p> <p>13 A. I was reviewing ingredient limit reports</p> <p>14 for Auburn, Washington.</p> <p>15 Q. And you were at corporate headquarters,</p> <p>16 correct?</p> <p>17 A. I was at the corporate office.</p> <p>18 Q. Says: "Respondent's largest purchaser of</p> <p>19 combination hydrocodone products in 2007, Horen's</p> <p>20 Drug Incorporated, is a pharmacy engaged in a scheme</p> <p>21 to dispense controlled substances based on</p> <p>22 prescriptions that are issued for other than</p> <p>23 legitimate medical purposes by physicians acting</p> <p>24 outside the usual course of professional practice.</p> <p>25 This pharmacy dispenses excessive amounts of</p>	<p style="text-align: right;">Page 136</p> <p>1 document?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: According to this document,</p> <p>4 there was an immediate suspension of the</p> <p>5 registration for this facility.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. And they said: "This pharmacy dispensed</p> <p>8 excessive amounts of hydrocodone based on</p> <p>9 illegitimate" --</p> <p>10 MR. PAPANTONIO: Would you underline</p> <p>11 "illegitimate" -- oh, you already got it --</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. -- "illegitimate prescriptions originating</p> <p>14 from rogue Internet pharmacy websites."</p> <p>15 What is a "rogue Internet pharmacy</p> <p>16 website"?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: I would say that a rogue</p> <p>19 Internet pharmacy website is a website where an</p> <p>20 individual could log on, place an order for a</p> <p>21 drug, controlled substance, and have that order</p> <p>22 or have that drug shipped to that individual's</p> <p>23 house or place of business, what have you. And</p> <p>24 there may have been a phone consultation or --</p> <p>25 or something.</p>
<p style="text-align: right;">Page 135</p> <p>1 hydrocodone based on illegitimate prescriptions</p> <p>2 originating from rogue Internet pharmacy websites in</p> <p>3 violation of applicable federal and state law."</p> <p>4 Now, the question I have about that: What</p> <p>5 involvement did you have with -- with monitoring</p> <p>6 Internet pharmacies?</p> <p>7 MR. PYSER: Object to form. Misread the</p> <p>8 statement in the document.</p> <p>9 THE WITNESS: My involvement was to review</p> <p>10 the ingredient limit reports on a monthly basis,</p> <p>11 and conduct investigations of --</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Did you do that with web -- with Internet</p> <p>14 pharmacies?</p> <p>15 A. I did that with all of the customers that</p> <p>16 appeared on the ingredient limit reports.</p> <p>17 Q. And Internet pharmacy was one of them --</p> <p>18 Internet pharmacies, correct?</p> <p>19 A. Again, all customers that appeared on the</p> <p>20 ingredient limit report.</p> <p>21 Q. Yeah. Okay. And this -- apparently these</p> <p>22 people appeared -- because this -- this facility lost</p> <p>23 its registration to sell narcotics in Washington;</p> <p>24 this Cardinal facility, again, lost its registration</p> <p>25 to sell narcotics, correct, according to this</p>	<p style="text-align: right;">Page 137</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Without being -- okay. Let me break that</p> <p>3 down.</p> <p>4 A. So, to make it a --</p> <p>5 Q. First, let me ask the question. Okay,</p> <p>6 here it is: First of all, we agree Cardinal dealt</p> <p>7 with rogue Internet pharmacies, according to this</p> <p>8 document? They -- they were your customers?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 THE WITNESS: Cardinal had all types of</p> <p>11 pharmacy customers: Hospitals, VA, DOD, so</p> <p>12 forth.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Right. And so one of the things that you</p> <p>15 know that the rogue Cardinal -- that the rogue</p> <p>16 pharmacy would do is they would just ship narcotics</p> <p>17 all the way across the country without a doctor ever</p> <p>18 even reviewing whether the patient needed them, true?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Is that what you told me just a minute</p> <p>22 ago?</p> <p>23 A. I believe how a rogue Internet pharmacy</p> <p>24 operates is an individual owned -- owned a website,</p> <p>25 and that website was affiliated with pharmacies and</p>



Page 138

1 doctors across the country. An individual could log  
2 onto a computer and place an order for a prescription  
3 drug or a controlled substance. And I believe there  
4 was a phone consultation. There was a pharmacy  
5 shipment directly to the individual.  
6 Q. And you remember how many -- how many  
7 years you dealt directly with Horen's Drug Store  
8 there up in Washington that was a rogue Internet  
9 pharmacy? Do you remember how many years you did  
10 that --  
11 MR. PYSER: Object --  
12 BY MR. PAPANTONIO:  
13 Q. -- Cardinal did that?  
14 MR. PYSER: Object to form.  
15 THE WITNESS: Is your question how many  
16 years I dealt with Horen's Pharmacy? I never, I  
17 should say, dealt with Horen's Pharmacy. But  
18 from 2005 until -- whatever the time frame was  
19 in 2007 or '8, I reviewed the ingredient limit  
20 reports.  
21 BY MR. PAPANTONIO:  
22 Q. So you would have had to okay the shipment  
23 to Horen's Pharmacy, wouldn't you?  
24 MR. PYSER: Object to form.  
25

Page 139

1 BY MR. PAPANTONIO:  
2 Q. Eric Brantley would have had to okay it?  
3 A. That is not correct. I reviewed  
4 ingredient limit reports on a monthly basis.  
5 Q. Well, I mean, somebody had to --  
6 A. I did not okay a shipment.  
7 Q. Somebody had to ship it to Horen's  
8 Pharmacy. And in this document, they're saying  
9 Cardinal shipped narcotics to this rogue Internet  
10 pharmacy. That's what the document says, right?  
11 MR. PYSER: Object to form.  
12 THE WITNESS: The document says that there  
13 were shipments of controlled substances to this  
14 pharmacy.  
15 BY MR. PAPANTONIO:  
16 Q. And they called it a "rogue Internet  
17 pharmacy," didn't they?  
18 A. This document refers to it as a rogue  
19 Internet pharmacy.  
20 Q. And you're well aware of what the term  
21 "rogue Internet pharmacy" means, aren't you?  
22 A. I just stated --  
23 MR. PYSER: Object to form.  
24 THE WITNESS: I just stated what I thought  
25 a rogue Internet pharmacy was.

Page 140

1 BY MR. PAPANTONIO:  
2 Q. Fair enough.  
3 It says: "Despite substantial guidance  
4 provided to respondent by DEA regarding identifying  
5 rogue pharmacies such as Horen's Drug and despite the  
6 public information readily available to respondent"  
7 -- now, you understand "respondent" here is Cardinal;  
8 you know that, right?  
9 When you hear the word -- when we hear the  
10 word "respondent," we're talking about Cardinal,  
11 correct?  
12 A. I do understand that.  
13 Q. Okay. "And despite the public information  
14 readily available to respondent regarding Horen's  
15 Pharmacy Drugs' association with rogue Internet  
16 pharmacy websites, respondent" -- or Cardinal, right?  
17 Right? Cardinal? When we see the word "respondent,"  
18 we're talking about Cardinal?  
19 A. Cardinal is the respondent.  
20 Q. "Respondent repeatedly supplied Horen's  
21 Drug Store with excessive amounts of hydrocodone.  
22 Respondent distributed in excess of 600,000 dosage  
23 units of hydrocodone to Horen's Drug Store from 2007  
24 through -- through September -- excuse me, "March of  
25 2007 through September of 2007."

Page 141

1 Do you see that?  
2 MR. PYSER: Object to form.  
3 BY MR. PAPANTONIO:  
4 Q. Right?  
5 A. I do see that.  
6 Q. So here we have a rogue Internet pharmacy  
7 that Cardinal is shipping in excess of 600,000 dosage  
8 units of hydrocodone between March 2007 and  
9 September 2007 according to this document, correct?  
10 MR. PYSER: Object to form.  
11 THE WITNESS: The document does not say  
12 that Horen's Drug Store was a rogue Internet  
13 pharmacy. It says, "Horen's Drug Store's  
14 association with rogue Internet pharmacy  
15 website."  
16 BY MR. PAPANTONIO:  
17 Q. Oh, it's just associated with a rogue  
18 pharmacy? That's -- that's what you're saying here?  
19 A. I just wanted to clarify your statement.  
20 You stated that the document said that it was a  
21 rogue --  
22 Q. Yes.  
23 A. -- Internet pharmacy, and it indeed says  
24 it was associated with --  
25 Q. They just --

<p style="text-align: right;">Page 142</p> <p>1 A. -- a rogue Internet pharmacy.</p> <p>2 Q. They just did business with rogue</p> <p>3 pharmacies, which were illegal, correct?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 Argumentative.</p> <p>6 THE WITNESS: Whatever DEA meant by</p> <p>7 "association."</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Rogue pharmacies were illegal, correct?</p> <p>10 MR. PYSER: Object to form. Calls for a</p> <p>11 legal conclusion.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. They're illegal?</p> <p>14 A. Rogue pharmacies were rogue pharmacies. I</p> <p>15 believe the term "rogue" implies something.</p> <p>16 Q. Is "rogue" legal? Does that mean it's</p> <p>17 legal to you, when you hear the word "rogue"?</p> <p>18 MR. PYSER: Object to form. Legal</p> <p>19 conclusion.</p> <p>20 THE WITNESS: I don't know what -- what</p> <p>21 definition of "rogue" is implied here, but a</p> <p>22 rogue Internet pharmacy is what I explained it</p> <p>23 to be, what I thought it to be.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. So -- so Cardinal -- just so we can break</p>	<p style="text-align: right;">Page 144</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: According to this document,</p> <p>3 these numbers were shipped to Horen's.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. And it says: "Respondent" -- or Cardinal</p> <p>6 -- "Respondent, disregarding the clear indication</p> <p>7 that Horen's Drug Store was engaged in diversion of</p> <p>8 controlled substances, distributed unusually large</p> <p>9 amounts of hydrocodone to Horen's Drug Store."</p> <p>10 Now they're talking about your company</p> <p>11 distributed those kind of numbers, right?</p> <p>12 A. This document says that the respondent</p> <p>13 shipped those numbers to Horen's Drug Store.</p> <p>14 Q. Okay. Then it goes on to say -- the next</p> <p>15 paragraph, you see where it -- pick up where it says</p> <p>16 "Respondent has failed to maintain effective controls</p> <p>17 against diversion."</p> <p>18 You see that?</p> <p>19 A. I see where it says: "It is my</p> <p>20 preliminary finding that respondent has failed to</p> <p>21 maintain effective control" --</p> <p>22 Q. Right.</p> <p>23 A. -- yes.</p> <p>24 Q. You understand that was the final finding?</p> <p>25 Did you know that?</p>
<p style="text-align: right;">Page 143</p> <p>1 this down a little bit, Cardinal shipped 600,000</p> <p>2 dosage units to Horen's Drug Store between 2007</p> <p>3 and -- March 2007 to September 2007 -- and Horen's</p> <p>4 had an association with an illegal Internet pharmacy,</p> <p>5 correct?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 THE WITNESS: Horen's had an association</p> <p>8 with a rogue Internet pharmacy.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. And so it says -- goes on to say:</p> <p>11 "Including over 116,000 dosage units in July."</p> <p>12 See that? 116,000 dosage units in July,</p> <p>13 and over 120,000 -- 129,000 dosage units in August,</p> <p>14 and over 122,000 dosage units in September.</p> <p>15 Did these orders come across your desk?</p> <p>16 Did you review these documents, these kind of</p> <p>17 numbers?</p> <p>18 A. These numbers should have been on the</p> <p>19 ingredient limit report.</p> <p>20 Q. Yeah.</p> <p>21 A. Yes.</p> <p>22 Q. And they were shipped, weren't they?</p> <p>23 These -- these numbers were shipped? To the rogue --</p> <p>24 to Horen's, which was doing business with a rogue</p> <p>25 illegal pharmacy, correct?</p>	<p style="text-align: right;">Page 145</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Did you even remember this? Did you even</p> <p>4 remember shipping those kind of numbers to an</p> <p>5 Internet -- to an organization that was doing</p> <p>6 business with a rogue illegal Internet pharmacy?</p> <p>7 A. I believe you asked two or three</p> <p>8 questions. So --</p> <p>9 Q. Okay, break it down for --</p> <p>10 A. -- the first question was --</p> <p>11 Q. Break it down for -- answer it any way you</p> <p>12 want.</p> <p>13 A. It said something about a final. I can't</p> <p>14 speak to that. I can only say what it -- the</p> <p>15 paragraph that we are addressing here says: "It is</p> <p>16 my preliminary finding that the respondent has failed</p> <p>17 to maintain" -- so forth and so on.</p> <p>18 Q. And I asked you --</p> <p>19 A. So what was your second question? Sorry.</p> <p>20 Q. Did you remember that? Did you remember</p> <p>21 shipping those kinds of numbers to an -- to Horen's</p> <p>22 Drug Store, which was doing business with an illegal</p> <p>23 Internet pharmacy?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: I do not remember any -- any</p>

<p style="text-align: right;">Page 146</p> <p>1 numbers --</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Okay.</p> <p>4 A. -- shipped to customers during this time</p> <p>5 frame.</p> <p>6 Q. Well, the next paragraph says: "In view</p> <p>7 of the foregoing, and pursuant to 21 USC and 8824 is</p> <p>8 my preliminary findings that respondent" -- that's</p> <p>9 Cardinal, right? Correct? --</p> <p>10 A. Respondent is Cardinal.</p> <p>11 Q. -- "has failed to maintain effective</p> <p>12 controls against diversion, and continued</p> <p>13 registration of respondent would be otherwise</p> <p>14 inconsistent with public health and safety."</p> <p>15 Now, sir, how is diversion -- how does</p> <p>16 diversion, according to -- in your experience, doing</p> <p>17 this so many years, how does diversion create a</p> <p>18 public health problem?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Tell the jury.</p> <p>22 A. I'm sorry?</p> <p>23 Q. No, go ahead.</p> <p>24 A. Your question is, how is -- how does</p> <p>25 diversion --</p>	<p style="text-align: right;">Page 148</p> <p>1 supply chain --</p> <p>2 Q. Right.</p> <p>3 A. -- which we don't operate in. Our -- our</p> <p>4 supply chain is as I mentioned.</p> <p>5 Q. And it's illegal to operate in a -- it's</p> <p>6 illegal to operate within a realm of diversion,</p> <p>7 correct? You'd agree with that?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Yes?</p> <p>11 A. If there -- if there is an entity that</p> <p>12 operates outside of that chain, which Cardinal Health</p> <p>13 does not --</p> <p>14 Q. Well, there -- according to this, you did.</p> <p>15 Because Horen's was a drug store that was -- that was</p> <p>16 supplying an illegal rogue pharmacy, and Cardinal was</p> <p>17 the people that were supplying 600,000 dosage units</p> <p>18 to Horen's Drug Store.</p> <p>19 That's what this says, doesn't it?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. I mean, that's what this document says?</p> <p>23 A. The document says that -- that Cardinal</p> <p>24 shipped the -- the quantities that you mentioned</p> <p>25 earlier to Horen's Drug Store.</p>
<p style="text-align: right;">Page 147</p> <p>1 Q. How does diversion create a public health</p> <p>2 problem?</p> <p>3 A. In my opinion?</p> <p>4 Q. In your opinion.</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: Diversion could be the theft</p> <p>7 of drugs. Diversion is -- diversion happens</p> <p>8 when drugs leave the secure supply chain in</p> <p>9 which we operate in.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. That's a term, "secure supply chain."</p> <p>12 That's what -- that's what I was going to ask you</p> <p>13 about.</p> <p>14 A. So the -- the supply chain is, of course,</p> <p>15 the manufacturer manufactures a prescription drug,</p> <p>16 sells that drug to a wholesale distributor based on</p> <p>17 an order that the wholesale distributor places. That</p> <p>18 wholesale distributor places orders based on the</p> <p>19 pharmacies and the hospitals and the VA and the DOD</p> <p>20 and such that they serve. And those pharmacies place</p> <p>21 orders based on scripts that are run in from</p> <p>22 patients, written by doctors. So that is the supply</p> <p>23 chain.</p> <p>24 Q. Okay. And if everything --</p> <p>25 A. So diversion is going outside of that</p>	<p style="text-align: right;">Page 149</p> <p>1 But again, in that supply chain, from</p> <p>2 manufacturer to distributor to the pharmacy, all of</p> <p>3 these are licensed entities by the State as well as</p> <p>4 the DEA. That's the supply chain in which Cardinal</p> <p>5 operate -- operated and operates.</p> <p>6 Q. Right. And in this situation, Cardinal</p> <p>7 lost its license to operate because they weren't</p> <p>8 playing by the rules, correct?</p> <p>9 MR. PYSER: Object to form. Misstates --</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. They were suspended. The license was</p> <p>12 actually suspended because Cardinal was not playing</p> <p>13 by the rules of a supply chain?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Yes?</p> <p>17 MR. PYSER: Misstates evidence.</p> <p>18 THE WITNESS: The -- the registration for</p> <p>19 this facility was suspended. Not because</p> <p>20 Cardinal was not playing by the rules, because</p> <p>21 Cardinal operated within that chain. There was</p> <p>22 a player here, Horen's Drug Store, that was</p> <p>23 operating apparently outside of the chain by</p> <p>24 being associated with a rogue Internet pharmacy</p> <p>25 or rogue Internet pharmacy -- yeah, rogue</p>

<p style="text-align: right;">Page 150</p> <p>1 Internet pharmacy website.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Right. And it says -- right, look at B.</p> <p>4 You're answering the question, but here, look at B.</p> <p>5 "Despite substantial guidance provided to</p> <p>6 respondent" -- or that would be Cardinal -- "by DEA</p> <p>7 regarding identifying rogue pharmacies such as --</p> <p>8 such as Horen's Drug Store, and despite the public</p> <p>9 information readily available to respondent regarding</p> <p>10 Horen's Drug Store's association with rogue Internet</p> <p>11 pharmacies, respondent repeatedly supplied Horen's</p> <p>12 Drug Store with excessive amounts of hydrocodone."</p> <p>13 That's what that just said. Did I read</p> <p>14 that right?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Did I read that right?</p> <p>18 A. That is what the document says.</p> <p>19 Q. And you were the guy in corporate that was</p> <p>20 reviewing these orders, weren't you?</p> <p>21 A. I was an individual at the corporate</p> <p>22 office that was reviewing ingredient limit reports on</p> <p>23 a monthly basis.</p> <p>24 Q. And there were only two more of you,</p> <p>25 weren't there?</p>	<p style="text-align: right;">Page 152</p> <p>1 A. At the corporate level, I had the ability</p> <p>2 to identify customers based on the ingredient limit</p> <p>3 reports --</p> <p>4 Q. And you didn't do that with Horen's Drug?</p> <p>5 A. -- and make a recommendation to --</p> <p>6 Q. Excuse me. Go ahead.</p> <p>7 A. -- to discontinue sales to that particular</p> <p>8 customer.</p> <p>9 Q. And you didn't do that with Horen's Drug,</p> <p>10 did you?</p> <p>11 MR. PYSER: Object to form. And objection</p> <p>12 to that question as it was asked before.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. You didn't do that with Horen's Drug?</p> <p>15 A. I did not do what?</p> <p>16 Q. You didn't stop the flow? You don't shut</p> <p>17 Horen's Drug Store down, even though -- even though</p> <p>18 the DEA talked to you about rogue pharmacies such as</p> <p>19 Horen's Drug, you didn't shut them down, did you?</p> <p>20 A. Apparently, Horen's Drug Store was not</p> <p>21 shut down --</p> <p>22 Q. Yeah.</p> <p>23 A. -- prior to DEA taking action on Horen's</p> <p>24 Drug Store.</p> <p>25 Q. Well, let's see what it says. Look at C:</p>
<p style="text-align: right;">Page 151</p> <p>1 A. At the corporate level?</p> <p>2 Q. Yeah.</p> <p>3 A. As far as the team that I managed, yes.</p> <p>4 Q. And this is -- and these drugs are going</p> <p>5 out, these narcotic drugs are going out all over the</p> <p>6 country, aren't they? Yes?</p> <p>7 A. During --</p> <p>8 MR. PYSER: Object to form.</p> <p>9 THE WITNESS: During a certain time frame,</p> <p>10 during a certain time frame, there were two or</p> <p>11 three of us, from 2005 until, again, 2007-8 time</p> <p>12 frame.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. There were --</p> <p>15 A. And then there were others added. But</p> <p>16 during that time frame, yes, there were two or three.</p> <p>17 Q. At corporate level?</p> <p>18 A. At the corporate level.</p> <p>19 Q. At corporate level, you have the right to</p> <p>20 shut down anybody you want to at any time you want</p> <p>21 to, once you see excessive orders coming in.</p> <p>22 You have the right to do that, don't you?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. At corporate?</p>	<p style="text-align: right;">Page 153</p> <p>1 "Respondent, disregarding the clear indications that</p> <p>2 Horen's Drug Store was engaged in diversion of</p> <p>3 controlled substances, distributed unusually large</p> <p>4 amounts of hydrocodone to Horen's Drug Store."</p> <p>5 You see that?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 THE WITNESS: I do see that.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. That's C. And that would be -- that would</p> <p>10 come across your desk, right?</p> <p>11 A. What would come across my desk?</p> <p>12 Q. Orders would come across your desks. You</p> <p>13 would review orders?</p> <p>14 A. Ingredient limit reports would come</p> <p>15 across --</p> <p>16 Q. Yeah.</p> <p>17 A. -- my desk on a monthly basis.</p> <p>18 Q. Right. Exactly. And -- and then the next</p> <p>19 one says: "In view of the foregoing and pursuant to</p> <p>20 21 USC, it is my preliminary finding that respondent"</p> <p>21 -- that's Cardinal again -- "has failed to maintain</p> <p>22 effective controls against diversion, and that the</p> <p>23 continued registration of respondent would be</p> <p>24 otherwise inconsistent with public health and</p> <p>25 safety."</p>

<p style="text-align: right;">Page 154</p> <p>1 Now, is this the first time that you</p> <p>2 reviewed the fact that the DEA was shutting down</p> <p>3 Cardinal's ability to do business with Horen's Drug</p> <p>4 Store because it posed a public health and safety</p> <p>5 threat?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Did you know that, prior to coming here</p> <p>9 today?</p> <p>10 MR. PYSER: Object to form.</p> <p>11 THE WITNESS: Prior to coming here today,</p> <p>12 I was aware that DEA issued a show cause and an</p> <p>13 immediate suspension order for the Auburn</p> <p>14 distribution center.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. It says: "Moreover, it is my preliminary</p> <p>17 conclusion that respondent's continued</p> <p>18 registration while these proceedings are pending</p> <p>19 would constitute" -- let me read it -- "It is my" --</p> <p>20 let me just read it again.</p> <p>21 "Moreover, it is my preliminary conclusion</p> <p>22 that respondent's continued registration while these</p> <p>23 proceedings are pending would constitute an imminent</p> <p>24 danger to public health and safety."</p> <p>25 You see that?</p>	<p style="text-align: right;">Page 156</p> <p>1 health and safety? Can you recall right now how many</p> <p>2 times your company -- how many times your company was</p> <p>3 told that your company creates an imminent threat to</p> <p>4 public health and safety? You recall?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: Told by whom?</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. By the DEA or the Department of Justice.</p> <p>9 A. Are you referring to immediate suspension</p> <p>10 orders or --</p> <p>11 Q. Yeah.</p> <p>12 A. -- orders to show cause?</p> <p>13 Q. Yeah. Both.</p> <p>14 A. Well, according to this document, there</p> <p>15 were four.</p> <p>16 Q. Okay. And then we're going to -- that's</p> <p>17 just part -- that's part of the answer, but let me go</p> <p>18 ahead and ask it -- maybe I didn't ask the question</p> <p>19 right, in fairness to you. Go to page 20.</p> <p>20 You see where, page 20, it's talking:</p> <p>21 "Notice is hereby given to inform Cardinal Health of</p> <p>22 the immediate suspension of Drug Enforcement</p> <p>23 Administration certificate of registration," and this</p> <p>24 is Cardinal Health's Lakeland, Florida, distribution</p> <p>25 center. You see that?</p>
<p style="text-align: right;">Page 155</p> <p>1 How does -- how does -- how does diversion</p> <p>2 create an imminent threat, in your experience?</p> <p>3 What -- what examples can you give me of diversion</p> <p>4 creating an imminent threat?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: I believe that would be a</p> <p>7 question for the DEA regarding what they view to</p> <p>8 be an imminent threat.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. So you --</p> <p>11 A. That's a claim they made.</p> <p>12 Q. So at this point, you don't -- you don't</p> <p>13 have an opinion of how drugs cause an imminent threat</p> <p>14 to public health?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: In the case of this</p> <p>17 paragraph that we're reading --</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Yeah.</p> <p>20 A. -- I cannot speak to what DEA claims to be</p> <p>21 an -- I believe constitute an imminent danger to the</p> <p>22 public health and safety.</p> <p>23 Q. Okay. How many times have you seen your</p> <p>24 company, while you were there, being told that their</p> <p>25 conduct actually created an imminent threat to public</p>	<p style="text-align: right;">Page 157</p> <p>1 A. I do see that.</p> <p>2 Q. And then number 2, it says, down at the</p> <p>3 bottom: "Respondent has failed to maintain effective</p> <p>4 control against the diversion of particular</p> <p>5 controlled substances in other than legitimate</p> <p>6 medical, scientific, and industrial channels in</p> <p>7 violation of 21 USC."</p> <p>8 And they even give the dates, between</p> <p>9 August 2005 and October 2007.</p> <p>10 So in those years between -- here's my</p> <p>11 question: In those years between 2005 and 2007, your</p> <p>12 company failed to maintain effective controls against</p> <p>13 the diversion of narcotics; is that a correct</p> <p>14 statement? After you've just read that?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: That is what the DEA</p> <p>17 alleged.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. It said: "Respondent distributed over</p> <p>20 8 million dosage units of combination hydrocodone</p> <p>21 products to customers" -- and then -- follow me here,</p> <p>22 underline this -- "customers that it knew or should</p> <p>23 have known were diverting hydrocodone into other</p> <p>24 legitimate -- into other than legitimate medical or</p> <p>25 scientific industrial channels."</p>



<p style="text-align: right;">Page 158</p> <p>1 See that?</p> <p>2 A. I do see that.</p> <p>3 Q. Did you know that was going on while you</p> <p>4 were working with the company?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. That you were actually diverting</p> <p>8 hydrocodone into other than legitimate medical or</p> <p>9 scientific channels? Did you know that, when you</p> <p>10 were an employee with Cardinal?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 THE WITNESS: While I was an employee with</p> <p>13 Cardinal --</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Yes, sir.</p> <p>16 A. -- we reviewed ingredient limit reports</p> <p>17 and -- and submitted those reports to the DEA.</p> <p>18 Q. According to this report, it didn't work</p> <p>19 all that well, did it?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. You weren't succeeding in your mission to</p> <p>23 try to -- to do the things you said you were trying</p> <p>24 to do. It just wasn't working, was it?</p> <p>25 MR. PYSER: Same objections. And</p>	<p style="text-align: right;">Page 160</p> <p>1 Q. Remember CVS? Is that a large customer?</p> <p>2 A. If CVS was a customer, that's a large</p> <p>3 customer, being a chain, yes.</p> <p>4 Q. Yeah. And how about Walgreens? Do you</p> <p>5 remember Walgreens being a large customer?</p> <p>6 A. I don't remember if Walgreens was a</p> <p>7 customer or not.</p> <p>8 Q. Don't remember that?</p> <p>9 A. I don't remember if Walgreens was a</p> <p>10 customer.</p> <p>11 Q. Fair enough. But according to this,</p> <p>12 they're saying that your largest -- the largest</p> <p>13 purchasers of your -- of your narcotics engaged in a</p> <p>14 scheme.</p> <p>15 What does that word, "scheme" -- you</p> <p>16 understand what the word "scheme" means?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: I have a general idea of</p> <p>19 what a "scheme" is.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. Just so we're on the same sheet</p> <p>22 of --</p> <p>23 A. A -- a plan.</p> <p>24 Q. Yeah.</p> <p>25 A. Okay?</p>
<p style="text-align: right;">Page 159</p> <p>1 argumentative.</p> <p>2 THE WITNESS: According to what you've</p> <p>3 read on this first page, page 20, DEA has</p> <p>4 alleged that the respondent has failed to</p> <p>5 maintain effective controls.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Yeah. Let's go to the next page. 21.</p> <p>8 "Many of the respondent's largest</p> <p>9 purchases of combination hydrocodone products were</p> <p>10 pharmacies engaged in a scheme" -- see the word</p> <p>11 "scheme" there?</p> <p>12 A. I do see that word.</p> <p>13 Q. "... scheme to distribute controlled</p> <p>14 substances based on purported prescriptions that are</p> <p>15 issued for other than a legitimate medical purpose."</p> <p>16 Do you see that?</p> <p>17 A. I do see that.</p> <p>18 Q. "And by physicians acting outside the</p> <p>19 usual course of professional practice."</p> <p>20 Do you see that?</p> <p>21 A. I do see that.</p> <p>22 Q. So according to this, your -- who are your</p> <p>23 largest customers? Who do you remember your largest</p> <p>24 customers?</p> <p>25 A. I have no idea.</p>	<p style="text-align: right;">Page 161</p> <p>1 Q. A plan -- okay. Let's call it a "plan" --</p> <p>2 to distribute controlled substances, which are</p> <p>3 narcotics, right? "To distribute controlled</p> <p>4 substances based on purported prescriptions that are</p> <p>5 issued for other than legitimate medical purposes."</p> <p>6 MR. PYSER: Object to form.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. That's what that says, doesn't it?</p> <p>9 A. Well, to clarify, Schedule II controlled</p> <p>10 substances --</p> <p>11 Q. Well, you were working -- you were the</p> <p>12 person at -- in corporate, you and how many other</p> <p>13 people -- say, 2008, how many other people were in</p> <p>14 charge of doing all this review?</p> <p>15 MR. PYSER: Counsel, the witness did not</p> <p>16 get a chance to finish his answer. Please let</p> <p>17 him finish his answer --</p> <p>18 MR. PAPANTONIO: I'm sorry. I thought</p> <p>19 you --</p> <p>20 MR. PYSER: -- before you ask your next</p> <p>21 question.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Your lips had stopped moving. That's why</p> <p>24 I thought you had finished your answer. Go ahead.</p> <p>25 MR. PYSER: Counsel, that's inappropriate.</p>

<p style="text-align: right;">Page 162</p> <p>1 Let him finish his answer. We don't need your          2 commentary.          3 BY MR. PAPANTONIO:          4 Q. Go ahead.          5 MR. PAPANTONIO: I don't need your          6 objection, either. Just object as to form. If          7 I'm doing something wrong, put it on the record.          8 This man -- I'm giving this man every          9 opportunity he wants to answer his questions.          10 MR. PYSER: That's what I'm here for.          11 MR. PAPANTONIO: You're the guy          12 interrupting his ability to answer.          13 BY MR. PAPANTONIO:          14 Q. Now, sir, I want to ask -- let's take all          15 that away, and let me ask you this question again.          16 You were one of the three people involved          17 in reviewing documents that showed whether there were          18 any abnormalities in the orders that were being filed          19 for narcotics all over the country? Yeah?          20 MR. PYSER: Object to form.          21 And if you need to finish your last          22 answer, you can always go ahead.          23 THE WITNESS: During the time frame          24 between 2005 and either late 2007, early 2008 --          25 I don't recall -- I was one of the individuals,</p>	<p style="text-align: right;">Page 164</p> <p>1 controlled substances as reflected in the chart          2 below."          3 And then it says: "Respondent" --          4 Cardinal -- "knew or should have known that these          5 pharmacies were diverting hydrocodone into other than          6 legitimate medical, scientific, industrial channels."          7 That's what that says, doesn't it? You          8 see -- did I read that right?          9 First of all -- let's start there. Is          10 there anything you want to add to that paragraph?          11 A. That is -- that is how it reads.          12 Q. Okay. And then if we look at the chart          13 below, we then see in Florida, the average is less          14 than 8,400 dosage units hydrocodone a month, and then          15 it compares what Cardinal was actually sending to its          16 customers. See that?          17 MR. PYSER: Object to form.          18 BY MR. PAPANTONIO:          19 Q. Monthly average. Look at that -- look at          20 that area that says "Monthly Average." Read those          21 monthly average for MediPharm.          22 What does that say out next to -- under          23 "Monthly Average"? What does that say?          24 A. For MediPharm? 155,007.          25 Q. And for DRM, what does it say?</p>
<p style="text-align: right;">Page 163</p> <p>1 yes, that was reviewing ingredient limit reports          2 for --          3 BY MR. PAPANTONIO:          4 Q. And -- and this -- this document's talking          5 about 2007, aren't they? See it says --          6 A. I believe that was the -- the time frame,          7 yes.          8 Q. Yeah. And then it says: "Retail          9 pharmacies in Florida order an average of less than          10 8,000 dosage units of hydrocodone per month."          11 Did you know that? Do you remember that          12 now, that retail pharmacies -- those are people you          13 sold to, right?          14 MR. PYSER: Object to form.          15 THE WITNESS: Cardinal Health did sell to          16 retail pharmacies, yes.          17 BY MR. PAPANTONIO:          18 Q. "In Florida." You sold in Florida, right?          19 A. Yes, we sold them to the state of Florida.          20 Q. "... order an average of less than 8,400          21 dosage units of hydrocodone per month."          22 See that?          23 A. I do see that.          24 Q. It says: "Respondent distributed          25 hydrocodone to pharmacies engaged in the diversion of</p>	<p style="text-align: right;">Page 165</p> <p>1 A. 42,254.          2 Q. And let's look down to QR -- QRG. What          3 does it say?          4 A. 242,640.          5 Q. And let's look at United Prescriptions.          6 What does it say?          7 A. 287,025.          8 Q. And then if you look up to -- and those          9 are -- you understand those are Florida pharmacies,          10 right?          11 A. That's what this document states, yes.          12 Q. And so we compare those numbers to what          13 the DEA says is an average of less than 8,000 dosage          14 units. It's a pretty big difference, isn't it,          15 Mr. Brantley?          16 MR. PYSER: Object to form.          17 BY MR. PAPANTONIO:          18 Q. Pretty big difference?          19 MR. PYSER: Object to form.          20 THE WITNESS: There is a difference.          21 BY MR. PAPANTONIO:          22 Q. Yeah. 8,000 to 287,000, that's a pretty          23 big difference?          24 MR. PYSER: Object to form.          25</p>

Page 166

1 BY MR. PAPANTONIO:  
2 Q. Okay. You agree, that -- that's a big  
3 difference, right?  
4 A. It's a difference.  
5 Q. Yeah. All right. So you know that --  
6 that -- Reardon told you that the DEA had met with  
7 him and said that anything over 5,000 a month should  
8 be considered a suspicious order. Did you know that?  
9 MR. PYSER: Object to form.  
10 BY MR. PAPANTONIO:  
11 Q. Did you know that Reardon met with the  
12 DEA, and the DEA told Reardon, who was your boss,  
13 that anything over 5,000 orders, 5,000 units, should  
14 be considered a suspicious order?  
15 MR. PYSER: Object to form.  
16 BY MR. PAPANTONIO:  
17 Q. Correct?  
18 A. I do know that Steve had a meeting.  
19 Q. And -- and he didn't tell you that?  
20 A. And at some point, I believe that may have  
21 been discussed.  
22 Q. Okay. And you know the number was 5,000,  
23 correct?  
24 A. If that's what you say was said during the  
25 conversation, then . . .

Page 167

1 Q. I don't want you to take my word for it.  
2 I want to ask you. I'm asking you straight up.  
3 A. Well, please show me the documentation --  
4 Q. I'm going --  
5 A. -- so I can know --  
6 Q. I'm going to. --  
7 A. -- that it's accurate.  
8 Q. I'm trying to figure out what you remember  
9 and what you don't remember. A, you remember Reardon  
10 meeting with the DEA, don't you?  
11 A. I remember that happened. I don't  
12 remember the meeting.  
13 Q. And then you remember Reardon writing a  
14 letter -- or writing an e-mail that went to you and  
15 said that, we had a meeting and the number should not  
16 be above 5,000; you know that?  
17 MR. PYSER: Object to form.  
18 BY MR. PAPANTONIO:  
19 Q. Right?  
20 A. Again, I don't recall the meeting.  
21 Q. Yeah.  
22 MR. PAPANTONIO: Let me go ahead and show  
23 it to him. There's no -- show him 4781. Hold  
24 that other document you got there, hold that  
25 right where it is, because we're going to get

Page 168

1 back to it after we do this.  
2 MS. MOORE: Cardinal-Brantley 6.  
3 (Cardinal-Brantley 6 was marked for  
4 identification.)  
5 BY MR. PAPANTONIO:  
6 Q. See where it says "Steve Reardon" at the  
7 top?  
8 A. Yes.  
9 Q. Okay. And do you see where -- go to the  
10 second page.  
11 You see where it says "Pete Stoy," there,  
12 about a quarter down?  
13 A. Yes.  
14 Q. And then it says "Internet pharmacies";  
15 you see that?  
16 A. In the "Subject" line?  
17 Q. "Subject" line, right.  
18 A. I see that, yes.  
19 Q. And then it says -- it says, "Eric" -- is  
20 that you? Eric Brantley?  
21 A. I am Eric Brantley.  
22 Q. And you were the -- were you -- at this  
23 point, you were the person that was reviewing  
24 these -- these numbers that were coming across your  
25 desk for these pharmacies?

Page 169

1 A. This e-mail was sent August 2005.  
2 Q. Yeah.  
3 A. I was -- I was reviewing limit reports in  
4 2005.  
5 Q. And it's got your name on it, right?  
6 MR. PYSER: Object to form.  
7 BY MR. PAPANTONIO:  
8 Q. Correct? It has your -- and it says, this  
9 is from Eric -- from Steve Reardon, and it's -- you  
10 see your name in the people who -- who actually  
11 received this. "Eric Brantley"? See that?  
12 A. Are you referring to the e-mail at the  
13 bottom of page 2?  
14 Q. Yeah. Yeah.  
15 MR. PYSER: Just for the record, the video  
16 was displaying a different e-mail, which I think  
17 explains the confusion.  
18 BY MR. PAPANTONIO:  
19 Q. Well, let's be clear about it. We're  
20 looking at -- are we looking at 4781 right now?  
21 MR. PYSER: Counsel, just to be clear, the  
22 video before was showing --  
23 MR. PAPANTONIO: All right.  
24 MR. PYSER: -- the e-mail above, which  
25 has --

Page 170

1 MR. PAPANTONIO: All right.  
2 MR. PYSER: -- a different Eric on it.  
3 MR. PAPANTONIO: Are we on the right --  
4 we're on the right one.  
5 MR. PYSER: Now you're on the right spot.  
6 BY MR. PAPANTONIO:  
7 Q. Okay. It says -- you see where it says  
8 "Internet pharmacies"? "Subject, Internet  
9 pharmacies"?  
10 A. In the "Subject" line, yes.  
11 Q. Yeah. It says: "DEA has recently  
12 initiated investigations of Internet pharmacies who  
13 are purchasing excessive quantities of controlled  
14 substances, primarily phentermine and hydrocodone,  
15 and dispensing these controlled substances without a  
16 valid prescription."  
17 Do you see that?  
18 A. I do see that.  
19 Q. "In that there was not the required  
20 doctor-patient relationship."  
21 Now you understand that rogue pharmacies  
22 were just shipping this -- shipping narcotics  
23 throughout the country in situations where a doctor  
24 had not even reviewed or met with the patient? You  
25 know that, right?

Page 171

1 MR. PYSER: Object to form.  
2 THE WITNESS: I know that -- what a rogue  
3 Internet pharmacy did was ship product to  
4 customers based on a script from a doctor that  
5 may not have performed a physical examination.  
6 BY MR. PAPANTONIO:  
7 Q. And we know that Cardinal supplied rogue  
8 pharmacies like that, right?  
9 A. Cardinal shipped drugs to pharmacies in  
10 hospitals and VA and DOD and --  
11 Q. And rogue pharmacies?  
12 A. -- final dispensers.  
13 Q. Rogue pharmacies, too. Let's not forget  
14 that. You -- you want to add rogue pharmacies, that  
15 Cardinal shipped narcotics to rogue Internet  
16 pharmacies. We've already established that, right?  
17 MR. PYSER: Object to form, and asked and  
18 answered.  
19 BY MR. PAPANTONIO:  
20 Q. Am I right?  
21 MR. PYSER: Object to form.  
22 THE WITNESS: Are you referring to the  
23 pharmacies listed in the previous --  
24 BY MR. PAPANTONIO:  
25 Q. Yeah.

Page 172

1 A. -- document?  
2 Q. Yeah.  
3 A. Cardinal shipped controlled substances to  
4 the pharmacies listed in this --  
5 Q. I'm not going to --  
6 A. -- document.  
7 Q. I'm not going to rehash. The jury's heard  
8 it. DEA --  
9 MR. PYSER: Object to form.  
10 BY MR. PAPANTONIO:  
11 Q. It says -- it says: "DEA has recently  
12 initiated investigations of Internet pharmacies who  
13 are purchasing excessive quantities of controlled  
14 substances."  
15 And they were actually purchasing them  
16 from you, from your company, Cardinal, those  
17 excessive substances.  
18 MR. PYSER: Object to form.  
19 BY MR. PAPANTONIO:  
20 Q. Right? According to this?  
21 A. According to this document, Cardinal  
22 shipped controlled substances to the list of  
23 pharmacies in the previous document.  
24 Q. Okay. And it says: "And there was not  
25 the required doctor-patient relationship." Correct?

Page 173

1 A. Are we still -- are we reading the same  
2 e-mail?  
3 Q. Yeah.  
4 A. According to the e-mail, yes.  
5 Q. So somebody could just call up an Internet  
6 pharmacy, say, "Hey, I'd like 100 hydrocodone,"  
7 without ever seeing a doctor, and Cardinal would ship  
8 it, according to this?  
9 MR. PYSER: Object to form.  
10 BY MR. PAPANTONIO:  
11 Q. True?  
12 A. If someone called up a pharmacy and  
13 ordered hydrocodone, there would have been a  
14 prescription, and a pharmacy would have placed an  
15 order with Cardinal, and if it's one of these  
16 pharmacies listed, then Cardinal shipped to those  
17 pharmacies.  
18 Q. To rogue pharmacies?  
19 MR. PYSER: Object to form.  
20 BY MR. PAPANTONIO:  
21 Q. Correct?  
22 A. Cardinal -- Cardinal shipped to the  
23 pharmacies listed.  
24 Q. You don't like using the word "rogue." I  
25 get it. But they were --

<p style="text-align: right;">Page 174</p> <p>1 A. You --</p> <p>2 Q. -- considered -- they were --</p> <p>3 A. You --</p> <p>4 Q. -- qualified as rogue pharmacies?</p> <p>5 A. You have identified them as rogue</p> <p>6 pharmacies.</p> <p>7 Q. Okay. And the DEA --</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. -- did too, correct?</p> <p>11 A. And the DEA said that they were, I think,</p> <p>12 associated with rogue Internet --</p> <p>13 Q. Okay.</p> <p>14 A. -- websites.</p> <p>15 Q. Good enough.</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. It says: "As part of this ongoing</p> <p>19 initiative, the DEA has been meeting with drug</p> <p>20 distributors, including Cardinal" -- right? That's</p> <p>21 what it says -- "and soliciting their assistance in</p> <p>22 monitoring Internet pharmacy activities. As a result</p> <p>23 of these meetings, we have become aware that one</p> <p>24 wholesaler has recently ceased doing business with</p> <p>25 24 pharmacies located in Florida and Texas."</p>	<p style="text-align: right;">Page 176</p> <p>1 A. I don't recall a meeting.</p> <p>2 Q. You weren't there?</p> <p>3 MR. PYSER: Object.</p> <p>4 THE WITNESS: I don't recall --</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. A meeting?</p> <p>7 A. -- a particular meeting.</p> <p>8 Q. You recall getting this, though, don't</p> <p>9 you? This document you're looking at is sent to you,</p> <p>10 Eric Brantley?</p> <p>11 A. I don't remember my initial reading of his</p> <p>12 e-mail. I read this e-mail now. I don't recall back</p> <p>13 in 2000 --</p> <p>14 Q. '5?</p> <p>15 A. -- '5, receiving it.</p> <p>16 Q. Okay, but --</p> <p>17 A. That's not saying that I did not receive</p> <p>18 it. I don't recall.</p> <p>19 Q. Well, what was your job in 2005?</p> <p>20 A. As I've stated several times, my -- my job</p> <p>21 was to review ingredient limit reports, conduct</p> <p>22 investigations, and report those to the DEA.</p> <p>23 Q. And you knew that, in 2005, you should not</p> <p>24 ship an order that's in excess of 5,000 dosage units</p> <p>25 of hydrocodone a month? You knew that, didn't you?</p>
<p style="text-align: right;">Page 175</p> <p>1 But it wasn't your company that ceased</p> <p>2 doing business with those 24 companies, was it?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. You don't remember in 2005 where your</p> <p>6 company ceased doing business with 24 pharmacies,</p> <p>7 Florida or Texas, do you?</p> <p>8 A. We ceased doing business with several</p> <p>9 pharmacies, I believe, including the ones listed in</p> <p>10 this document.</p> <p>11 Q. Well, we're going to get to that. I'm</p> <p>12 going to -- we're going to talk about that, and I</p> <p>13 want to make sure you understand -- I want to be sure</p> <p>14 I understand -- you never knew that Reardon had been</p> <p>15 told that anything in excess of 5,000 dosage units</p> <p>16 should be considered suspicious order. You never</p> <p>17 knew that, did you?</p> <p>18 MR. PYSER: Object to form. Misstates</p> <p>19 evidence.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. We're going to read it in a minute, but --</p> <p>22 A. Steve went to a meeting, and there may be</p> <p>23 a -- a communication. I don't recall that meeting</p> <p>24 with Steve Reardon.</p> <p>25 Q. Okay. You weren't there, were you?</p>	<p style="text-align: right;">Page 177</p> <p>1 MR. PYSER: Object to form. Misstates</p> <p>2 evidence.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. I mean, you knew that there was a 5,000</p> <p>5 number out there when you were working in your job</p> <p>6 with Cardinal?</p> <p>7 MR. PYSER: Object to form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. True?</p> <p>10 A. I knew that I had to review the ingredient</p> <p>11 limit reports and report those after conducting</p> <p>12 investigations.</p> <p>13 Q. Well, it says: "Additionally, DEA has</p> <p>14 identified Colorado as the state that has an Internet</p> <p>15 pharmacy problem."</p> <p>16 Your -- part of your territory was</p> <p>17 Colorado, wasn't it?</p> <p>18 A. I did review ingredient limit reports for</p> <p>19 the Colorado facility.</p> <p>20 Q. It says: "Your excessive purchase reports</p> <p>21 should be reviewed to see if you have customers that</p> <p>22 are purchasing over 3,000 dosage units of phentermine</p> <p>23 or 5,000 dosage units of hydrocodone a month."</p> <p>24 You see that?</p> <p>25 A. I do see that.</p>



<p style="text-align: right;">Page 178</p> <p>1 Q. Now, if we go back to the -- go back to 2 that chart that we just talked about there. 3 You would agree that 155,000 is larger 4 than 5,000? I mean, pretty obvious, right? 5 A. Agreed. 6 Q. You would agree that 242,000 is certainly 7 bigger than 5,000, right? 8 A. Agreed. 9 Q. Go to the next page on 4230, please. 10 It says: "Respondent knew that pharmacies 11 generally order a wide variety of controlled 12 substances and other drug products with wholesale 13 distributors. Respondent also knew that orders that 14 deviate substantially from a normal pattern to a 15 suspicious -- were suspicious as the term 21 CFR --" 16 Now, I want to ask you, you understood 17 that one -- one thing you look at with the suspicious 18 order is the pattern of what the customer's ordering 19 changes, correct? 20 A. A suspicious order is identified as an 21 order of unusual size, frequency, or that deviates 22 substantially from a normal pattern. 23 Q. Right. So you would have been able to see 24 that an order pattern went from 5,000 dosage units a 25 month to 287,000 dosage units a month, correct?</p>	<p style="text-align: right;">Page 180</p> <p>1 THE WITNESS: Not only that -- if I may 2 continue to answer the question. 3 BY MR. PAPANTONIO: 4 Q. You can continue to say anything you want, 5 but -- 6 A. The -- the ingredient limit reports -- 7 reports were reported to the DEA every month -- 8 Q. And you -- 9 A. -- as required. 10 Q. And you continued to do business -- even 11 though you would report a suspicious order, you'd 12 continue doing business with people like Horen's 13 Pharmacy, wouldn't you? 14 MR. PYSER: Object to form. 15 BY MR. PAPANTONIO: 16 Q. Yes? 17 A. The pharmacies listed on the page before 18 me, page 21 of P423021, I believe these pharmacies 19 were -- Cardinal had discontinued business of 20 controlled substances and reported these pharmacies 21 to the DEA -- 22 Q. Well, we'll see what the -- 23 A. -- months -- 24 Q. Go ahead. 25 A. -- prior -- I think 12 to 18 months prior</p>
<p style="text-align: right;">Page 179</p> <p>1 MR. PYSER: Object to form. Calls for 2 speculation. 3 BY MR. PAPANTONIO: 4 Q. You would have been able to see that? 5 MR. PYSER: Object. 6 BY MR. PAPANTONIO: 7 Q. It comes across your desk, doesn't it? 8 MR. PYSER: Object to form. 9 THE WITNESS: I receive the ingredient 10 limit reports every month. And I review them. 11 And I will see quantities for the month. 12 BY MR. PAPANTONIO: 13 Q. Well, what if you saw 5,000 to -- 5,000 to 14 200 and -- hang on just a second -- 5,000 to 287,000? 15 Or -- yeah, 5,000 to 287,000? Would that look 16 suspicious to you? 17 A. This is one, I would have contacted the 18 pharmacy, I would have conducted an investigation, 19 and I would have reported that pharmacy to the DEA, 20 which was done -- 21 Q. Yeah, well, let's see -- 22 A. -- in the case of this pharmacy. 23 Q. -- if it was done. We're going to talk 24 about that in just a second. 25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 181</p> <p>1 to -- 2 Q. Yeah. So your testimony is that -- 3 A. -- this document. 4 Q. -- you thought that DEA found about -- 5 found out about this by you reporting it? Is that 6 your testimony here today? 7 A. My testimony is that we reported -- we 8 submitted to the DEA ingredient -- ingredient limit 9 reports -- 10 Q. Well, I want to be sure -- 11 A. -- with these customers -- 12 Q. I want to be sure about what -- 13 A. -- on a monthly basis, and that I 14 conducted investigations and reported these customers 15 to the DEA. 16 Q. So when the -- when the DEA says that we 17 discovered, the DEA found out about it, you're saying 18 that you actually are the ones reporting all this? 19 Is that your testimony here? 20 MR. PYSER: Object to form. 21 BY MR. PAPANTONIO: 22 Q. I want to be sure about that. 23 A. Where does it say that the DEA said that 24 they discovered? 25 Q. Listen to my question.</p>

<p style="text-align: right;">Page 182</p> <p>1 A. That was your question.</p> <p>2 Q. My question is: You understand that right</p> <p>3 now you're testifying that these -- these pharmacies</p> <p>4 were only put on the DEA's radar because you reported</p> <p>5 it? Is that your testimony?</p> <p>6 A. I never said --</p> <p>7 MR. PYSER: Object -- hold on. Object to</p> <p>8 form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. All right. Go ahead. I thought you said</p> <p>11 that. I want to be sure you didn't say that before</p> <p>12 we spend a lot of time here.</p> <p>13 A. I never said that.</p> <p>14 MR. PYSER: Object to form.</p> <p>15 MR. PAPANTONIO: Okay. All right.</p> <p>16 MR. PYSER: I'm going to object.</p> <p>17 THE WITNESS: What I said was --</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Go ahead.</p> <p>20 A. You asked me a question. What I said</p> <p>21 was --</p> <p>22 Q. Yeah.</p> <p>23 A. -- that on a monthly basis, we submitted</p> <p>24 ingredient limit reports to the DEA, and these --</p> <p>25 these customers would have been listed on those</p>	<p style="text-align: right;">Page 184</p> <p>1 THE WITNESS: What I say -- said, and what</p> <p>2 I say again, is that we submitted the ingredient</p> <p>3 limit reports to the DEA every month, and</p> <p>4 customers would have been on those reports. And</p> <p>5 if I had done an investigation of a customer and</p> <p>6 made the recommendation to discontinue shipment,</p> <p>7 we did that, and those pharmacies were reported</p> <p>8 to the DEA.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. And that's why the DEA is calling your</p> <p>11 conduct an imminent threat to public health? You</p> <p>12 understand that's what this is saying?</p> <p>13 A. I don't know why DEA made that --</p> <p>14 MR. PYSER: Object to form.</p> <p>15 THE WITNESS: -- allegation.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. So you're --</p> <p>18 MR. PYSER: Object to form on the</p> <p>19 question.</p> <p>20 And please let me interject --</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. So you're saying --</p> <p>23 MR. PYSER: -- before you answer.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. -- the DEA just got it all wrong; that you</p>
<p style="text-align: right;">Page 183</p> <p>1 ingredient limit reports.</p> <p>2 Q. And you continued shipping to them,</p> <p>3 though, didn't you? You didn't --</p> <p>4 A. And then I conducted investigations of</p> <p>5 these pharmacies, and we discontinued business with</p> <p>6 these pharmacies and reported those --</p> <p>7 Q. Yeah, and so --</p> <p>8 A. -- to the DEA.</p> <p>9 Q. So -- so your testimony, I want to be</p> <p>10 sure, is not -- this is not your testimony, that you</p> <p>11 reported this and then stopped shipping. Correct?</p> <p>12 You're saying you reported it and we</p> <p>13 stopped shipping? Is that -- is that your testimony</p> <p>14 here today?</p> <p>15 MR. PYSER: Object to form. Asked and</p> <p>16 answered.</p> <p>17 MR. PAPANTONIO: No, it's not.</p> <p>18 MR. PYSER: Misstates evidence.</p> <p>19 MR. PAPANTONIO: It's not been asked and</p> <p>20 answered. I want to be very clear on this.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Your testimony is that you would report to</p> <p>23 DEA, and you would stop shipping? Is that what you</p> <p>24 testified to?</p> <p>25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 185</p> <p>1 -- that your company was not an imminent threat to</p> <p>2 public health, that you didn't overship quantities of</p> <p>3 narcotics? That's your testimony here today; is that</p> <p>4 right?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Yes or no? It takes a yes-or-no answer</p> <p>8 before we move on here.</p> <p>9 A. My testimony, as I have said repeatedly,</p> <p>10 is that -- and these -- the case of these customers</p> <p>11 on this form, or customers you are referring to, they</p> <p>12 were on the ingredient limit reports, which were</p> <p>13 submitted to DEA on a monthly basis. And that if I</p> <p>14 had identified customers such as these, I conducted a</p> <p>15 -- an investigation. And those customers, if deemed</p> <p>16 necessary, we discontinued shipment of -- of</p> <p>17 controlled substances to those customers and reported</p> <p>18 those customers to Kyle Wright at the DEA.</p> <p>19 Q. And that's why they filed -- that's -- and</p> <p>20 that's why they fined you \$34 million, because you</p> <p>21 did it right? Is that your testimony?</p> <p>22 MR. PYSER: Object to form.</p> <p>23 MR. PAPANTONIO: Wait -- wait a second.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Your testimony --</p>

<p style="text-align: right;">Page 186</p> <p>1 MR. PYSER: I'm not going to wait a  2 second.  3 MR. PAPANTONIO: Wait, wait.  4 MR. PYSER: When you --  5 MR. PAPANTONIO: Let me finish my --  6 MR. PYSER: -- ask a question --  7 MR. PAPANTONIO: Let me finish my  8 question.  9 MR. PYSER: -- I'm going to interject an  10 objection.  11 MR. PAPANTONIO: Let me finish my  12 question, because --  13 MR. PYSER: You had asked a question  14 that --  15 MR. PAPANTONIO: I know you --  16 MR. PYSER: -- there's a question mark on  17 it --  18 MR. PAPANTONIO: -- want to preach to him  19 right now, and it's very obvious where he's  20 going.  21 MR. PYSER: When you ask a question and  22 there's a question mark on the transcript, I'm  23 going to interject --  24 MR. PAPANTONIO: Okay.  25 MR. PYSER: -- an objection at that point.</p>	<p style="text-align: right;">Page 188</p> <p>1 A. -- and we discontinued business with  2 customers and reported that to Kyle Wright --  3 Q. And they --  4 A. -- at the DEA.  5 Q. -- fined you 34 --  6 MR. PYSER: Counsel, Counsel, let him  7 finish his answer --  8 BY MR. PAPANTONIO:  9 Q. Are you finished?  10 MR. PYSER: -- and stop interjecting --  11 BY MR. PAPANTONIO:  12 Q. Are you finished?  13 MR. PYSER: -- in the middle of his  14 answer.  15 BY MR. PAPANTONIO:  16 Q. Are you finished?  17 A. I -- I am finished now that --  18 Q. I thought you were.  19 So, so -- so they fined you \$34 million  20 for doing things right? Is that your testimony?  21 MR. PYSER: Object to form.  22 BY MR. PAPANTONIO:  23 Q. Is that your testimony here today?  24 A. There were allegations made, and there was  25 a settlement.</p>
<p style="text-align: right;">Page 187</p> <p>1 MR. PAPANTONIO: Well, I'm going to ask  2 the question again.  3 BY MR. PAPANTONIO:  4 Q. Is it your testimony, sir, that it was  5 your -- that you reported all this bad conduct, and  6 that the DEA said that you were violating the law,  7 and you were fined \$34 million because you did things  8 right? Is that your testimony here, really?  9 MR. PYSER: Same objections. Object to  10 form.  11 BY MR. PAPANTONIO:  12 Q. I wonder, is that really your testimony  13 here today?  14 A. You've asked the same question several  15 times, so my answer does not change.  16 Q. Okay, good. Then --  17 A. I --  18 Q. -- what is your answer?  19 A. My answer is --  20 Q. Let me --  21 A. -- we submitted ingredient limit reports  22 to the DEA on a monthly basis --  23 Q. Great.  24 A. -- and that I conducted investigations --  25 Q. All right.</p>	<p style="text-align: right;">Page 189</p> <p>1 Q. Yeah. And so you're saying you paid --  2 you settled for \$34 million because your company was  3 doing things right? Is that your testimony?  4 MR. PYSER: Object to form. Asked and  5 answered, repeatedly.  6 BY MR. PAPANTONIO:  7 Q. Yes or no.  8 A. There were allegations made. There were  9 issues of -- there were issues of show cause made.  10 And there was at some point a settlement. That's all  11 I can speak to.  12 Q. Okay. That's right. That's all you can  13 speak to, isn't it?  14 MR. PYSER: Object --  15 BY MR. PAPANTONIO:  16 Q. That's all you can speak to in this  17 deposition, isn't it? What you just said?  18 MR. PYSER: Object to form.  19 Argumentative.  20 BY MR. PAPANTONIO:  21 Q. Right?  22 MR. PYSER: You're crossing the line,  23 Counsel.  24 BY MR. PAPANTONIO:  25 Q. That's all you can speak to? Yes?</p>

<p style="text-align: right;">Page 190</p> <p>1 A. I can answer the questions that you ask  2 me.  3 Q. Okay, well, let's -- let's see --  4 MR. PYSER: Object to form.  5 BY MR. PAPANTONIO:  6 Q. -- if you can answer this question. Go to  7 the next paragraph, D.  8 A. Which page are we on?  9 Q. I'm on -- still on page 22. It says: "On  10 September 2006, Eric Brantley, manager of quality and  11 regulatory affairs" -- that's you. See that?  12 A. I do see that.  13 Q. It says, it says that you, the respondent  14 "sent an e-mail to DEA" -- right? This is an e-mail  15 -- "E-commerce Section stating that respondent had  16 discontinued its sales of controlled substances to 13  17 Internet pharmacies."  18 That's what that said. Read it again and  19 make sure I got that right -- I'll read it again.  20 "On September 1st, Eric Brantley" --  21 that's you, sitting in the chair right there, right?  22 A. I am Eric Brantley.  23 Q. "... manager of quality and regulatory  24 affairs, sent an e-mail to DEA commerce section  25 stating the respondent had discontinued its sales of</p>	<p style="text-align: right;">Page 192</p> <p>1 we discontinued.  2 BY MR. PAPANTONIO:  3 Q. "September 1st, 2006, through  4 January 2007, Cardinal (respondent) distributed  5 393,000 dosage units of combination hydrocodone  6 products to RKR."  7 That's what it says, doesn't it?  8 MR. PYSER: Object to form.  9 THE WITNESS: That's how it reads.  10 MR. PAPANTONIO: Yeah, okay.  11 Let's take lunch. Just go ahead and take  12 lunch break. Get it done.  13 MR. PYSER: Let's -- let's keep going,  14 because --  15 MR. PAPANTONIO: Oh, I don't mind. I  16 mean, I just thought I'd give you --  17 THE WITNESS: I'm fine.  18 BY MR. PAPANTONIO:  19 Q. Okay. Well, I'm fine, too.  20 All right, here we go. Let's go ahead and  21 look at -- go ahead and --  22 MR. PAPANTONIO: Give me 4689, please.  23 THE WITNESS: Are we finished with this  24 document?  25</p>
<p style="text-align: right;">Page 191</p> <p>1 controlled substances to 13 suspected Internet  2 pharmacies. Included in respondent's report of  3 discontinued accounts was the -- was RKR Holdings,  4 RKR. On that same date" -- let me make sure -- lot  5 slow -- you know, I want to make sure we get this  6 right.  7 "On that same date, respondent distributed  8 200 doses -- dosage unit combination products RKR  9 from September 1st to -- 2006, January 2007,  10 respondent distributed 393,000 dosage units."  11 Now, I read that right, didn't I?  12 A. Yes.  13 Q. So you reported it, and you continued to  14 ship anyway. That was my question earlier, and you  15 didn't answer.  16 Does this paragraph answer that question  17 for you?  18 MR. PYSER: Object to form.  19 THE WITNESS: I reported RKR Pharmacy  20 along with several other pharmacies. And I  21 recall this pharmacy because there was an  22 acquisition of a company. I don't recall -- I  23 believe it was Dohmen -- and that acquisition,  24 that company was shipping to RKR as well. Once  25 I discovered it on the ingredient limit reports,</p>	<p style="text-align: right;">Page 193</p> <p>1 BY MR. PAPANTONIO:  2 Q. Not quite. You might keep it handy.  3 We'll probably go back to that.  4 MS. MOORE: This is Cardinal-Brantley 7.  5 (Cardinal-Brantley 7 was marked for  6 identification.)  7 BY MR. PAPANTONIO:  8 Q. Now, who was Hartman? Do you know who  9 that -- who Hartman is?  10 A. I'm familiar with the name Mark Hartman.  11 Q. How do you know him?  12 A. At some point, I believe in 2008, he  13 joined the QRA organization in some form. I think he  14 was a president or something. I don't remember  15 exactly.  16 Q. Okay. And did you ever see -- have you  17 seen this document prior to coming in here? He made  18 a -- Hartman made a presentation -- were you there  19 when he made his presentation?  20 A. I don't remember if I was there for the  21 presentation, and I don't remember this document.  22 Q. All right. Well, look at page 26.  23 A. 26.  24 Q. You see that one -- you see that one  25 statement, "The drug dealer is us"?</p>

<p style="text-align: right;">Page 194</p> <p>1 A. I do see that.</p> <p>2 Q. Do you know that Hartman represented to</p> <p>3 the folks there that Cardinal was part of being a --</p> <p>4 part of the drug dealer process?</p> <p>5 MR. PYSER: Object to form. Misstates</p> <p>6 evidence. There's a quote from a different</p> <p>7 person there.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. What does that say?</p> <p>10 MR. PYSER: That's outrageous, Counsel.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. What does that say? "The drug dealer is</p> <p>13 us." You see that?</p> <p>14 A. It says: "John Watson, National Drug</p> <p>15 Czar, February 2007."</p> <p>16 Q. Okay. And he showed this -- and he showed</p> <p>17 this to the employees there with -- with your</p> <p>18 company, Cardinal, correct?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 THE WITNESS: That's what you said.</p> <p>21 Again, I don't recall this -- this meeting or</p> <p>22 this presentation.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Did you ever meet Hartman and talk to him</p> <p>25 about whether -- what he meant about "The drug dealer</p>	<p style="text-align: right;">Page 196</p> <p>1 25 countries?</p> <p>2 A. I did not know that at the time.</p> <p>3 Q. So this is the first time -- that's 2008,</p> <p>4 isn't it? This is 2008 we're talking about?</p> <p>5 A. I don't know when this was drafted.</p> <p>6 Q. Well --</p> <p>7 A. Going back to the first slide, it says</p> <p>8 November 6th, 2008.</p> <p>9 Q. Okay. And so out of those 43,500</p> <p>10 employees, there were three employees that were in</p> <p>11 charge, in corporate, of reviewing orders that were</p> <p>12 being placed all the way from Washington state to</p> <p>13 Lakeland, Florida, correct?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. In 2008?</p> <p>17 A. From about 2005 to late 2007, early 2008.</p> <p>18 In November of 2008, there were more --</p> <p>19 Q. How many more?</p> <p>20 A. -- at the corporate level.</p> <p>21 Q. How many?</p> <p>22 A. I don't know the exact number, but there</p> <p>23 were --</p> <p>24 Q. Was it more than five?</p> <p>25 MR. PYSER: Counsel, let him finish his</p>
<p style="text-align: right;">Page 195</p> <p>1 is us"?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: I have met Mark Hartman, but</p> <p>4 we have not had a discussion about "The drug</p> <p>5 dealer is us" quote from John Watson, National</p> <p>6 Drug Czar.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Okay. And let's look at page 2, as we</p> <p>9 work our way to "The drug dealer is us" slide.</p> <p>10 You understand this is slides that were --</p> <p>11 that were prepared and shown to Cardinal employees.</p> <p>12 You understand that, right?</p> <p>13 MR. PYSER: Object to form. Misstates</p> <p>14 evidence.</p> <p>15 THE WITNESS: If you say that. I don't</p> <p>16 recall this presentation.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. All right. And then it says -- it talks</p> <p>19 about Cardinal. It says, "Number 19 on the</p> <p>20 Fortune 500." As far as being a Fortune 500 company,</p> <p>21 they were number 19.</p> <p>22 Did you know that?</p> <p>23 A. I know that now, from reading this slide.</p> <p>24 Q. And did you know that they had 43,500</p> <p>25 employees, more than 25 countries -- in more than</p>	<p style="text-align: right;">Page 197</p> <p>1 answer.</p> <p>2 THE WITNESS: There were more than five.</p> <p>3 A new VP came in. Couple directors. Again, I</p> <p>4 don't know the exact number, but it was more</p> <p>5 than ten, I would say.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. So they got 43,000 employees in the -- how</p> <p>8 many years were you operating with just three</p> <p>9 employees in quality control?</p> <p>10 MR. PYSER: Object to form. Misstates</p> <p>11 testimony.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. How many -- how many years were you</p> <p>14 working in quality control, where there were 43,000</p> <p>15 employees?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: 2005 to either late 2007 or</p> <p>18 early 2008. I don't recall the exact time</p> <p>19 frame.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. And you see the first paragraph says:</p> <p>22 "Cardinal Health is an 87 billion-dollar global</p> <p>23 company." See that?</p> <p>24 Did you -- is that the first time you've</p> <p>25 heard about how much money this company is --</p>



<p style="text-align: right;">Page 198</p> <p>1 considered a 87 billion-dollar global company?</p> <p>2 A. I do see that now.</p> <p>3 Q. And then it says, down here, second to the</p> <p>4 last, it says: "Currently, Cardinal Health is ranked</p> <p>5 number 19 on the Fortune 500."</p> <p>6 We've already talked about that, correct?</p> <p>7 MR. PYSER: Object to form. Asked and</p> <p>8 answered.</p> <p>9 THE WITNESS: I do see that.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Okay. And look at page 4.</p> <p>12 It says: "Supply chain integrity is a</p> <p>13 holistic approach to the supply chain."</p> <p>14 This is what -- you were trying to explain</p> <p>15 what the supply chain was, right?</p> <p>16 A. Yes.</p> <p>17 Q. Earlier?</p> <p>18 A. Well, from the manufacturer to the</p> <p>19 wholesale distributor to the final dispenser to the</p> <p>20 patient, based on a script from a doctor.</p> <p>21 Q. And if every part of it works right, then</p> <p>22 we don't have diversion, hopefully, correct?</p> <p>23 A. If every part of it works right, then from</p> <p>24 the manufacturer down to the person with the script,</p> <p>25 should get their drug.</p>	<p style="text-align: right;">Page 200</p> <p>1 this drug. 40 bars OxyContin, robotripping."</p> <p>2 Do you know what "robotripping" is?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 THE WITNESS: I do not.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. You never heard the term?</p> <p>7 A. I do not know what "robotripping" is.</p> <p>8 Q. And while you were working there, you</p> <p>9 didn't understand that -- that -- this concept that</p> <p>10 drugs were being abused by kids? Did you not -- did</p> <p>11 you not understand that when you were working there?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: I did not -- I do not recall</p> <p>14 this document, no.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Well, did you know that, though? Did you</p> <p>17 know that drugs is -- I mean, this goes all the way</p> <p>18 back, 2008 -- that drugs were being abused by kids?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 THE WITNESS: I believe certain drugs have</p> <p>21 been abused for a long time.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. And it said "Vics." Tell us what a "Vic"</p> <p>24 is.</p> <p>25 A. I don't know what a "Vic" is.</p>
<p style="text-align: right;">Page 199</p> <p>1 Those entities, manufacturers and</p> <p>2 wholesalers, operate within that security supply</p> <p>3 chain.</p> <p>4 Q. Okay. So in -- go to page 7, please. I</p> <p>5 just want to talk about what Mr. Hartman actually</p> <p>6 said to the people in that -- or showed the people</p> <p>7 in -- along with -- along with showing that "The drug</p> <p>8 dealer is us," he didn't say that, but he showed it</p> <p>9 to the audience, obviously, as part of his -- part of</p> <p>10 his -- if you look at this page 7. Let's go down</p> <p>11 this.</p> <p>12 Let's start with the issue of diversion.</p> <p>13 We have populated a couple of the boxes on our grid</p> <p>14 to represent the tremendous problem of rogue Internet</p> <p>15 drug sales.</p> <p>16 Isn't that what we've just been talking</p> <p>17 about, rogue Internet drug sales?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Didn't we just talk about drug Internet --</p> <p>21 A. We discussed that in a previous document.</p> <p>22 Q. Okay. Representing diversion for abuse,</p> <p>23 so our beautiful supply chain flow shows an obstacle.</p> <p>24 Here it is. "Drugs our kids are abusing. Vics,</p> <p>25 nearly 10 percent of our high school seniors abuse</p>	<p style="text-align: right;">Page 201</p> <p>1 Q. Do you know what "Vicodin" is?</p> <p>2 A. I do know what "Vicodin" is.</p> <p>3 Q. What is "Vicodin"?</p> <p>4 A. I believe it is a form of hydrocodone.</p> <p>5 Q. And your company sold that, correct?</p> <p>6 A. I believe --</p> <p>7 MR. PYSER: Object to form.</p> <p>8 THE WITNESS: I believe Cardinal Health</p> <p>9 did sell hydrocodone.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. You distributed Vicodin, didn't you?</p> <p>12 A. Cardinal Health did distribute</p> <p>13 hydrocodone.</p> <p>14 Q. And you don't know what "robotripping" is?</p> <p>15 A. I do not know what "robotripping" is.</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. And do you know what "Skittles" is, the</p> <p>19 term "Skittles," when we talk about -- within the</p> <p>20 drug use, what "Skittles" is?</p> <p>21 A. I only know Skittles as the candy.</p> <p>22 Q. That's what you think it is, is candy?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Correct?</p>

Page 202

1 MR. PYSER: Object to form.  
 2 BY MR. PAPANTONIO:  
 3 Q. You know -- you know Skittles as candy?  
 4 Is that what you're telling the jury?  
 5 A. There is --  
 6 MR. PYSER: Object to form.  
 7 THE WITNESS: -- Skittles and candy. I  
 8 mean, it's a brand of candy, Skittles.  
 9 BY MR. PAPANTONIO:  
 10 Q. Have you ever heard Skittles being  
 11 referred to when the discussion of drugs come up?  
 12 A. I don't recall Skittles.  
 13 Q. Never heard the term?  
 14 A. I don't recall.  
 15 MR. PYSER: Object to form.  
 16 THE WITNESS: I don't recall Skittles.  
 17 BY MR. PAPANTONIO:  
 18 Q. And you weren't at this -- you weren't at  
 19 the -- this presentation where he's talking about all  
 20 these issues, correct? We've established that?  
 21 MR. PYSER: Object to form. Asked and  
 22 answered.  
 23 BY MR. PAPANTONIO:  
 24 Q. Right?  
 25 A. I do not recall this presentation.

Page 203

1 Q. And then it says: "There is a website  
 2 dedicated to the use of Skittles that will calculate  
 3 by body weight the number of pills one must ingest to  
 4 reach different levels of abuse."  
 5 Did you know that as you were distributing  
 6 narcotics throughout the country, that there was a  
 7 website dedicated to the use of Skittles, that could  
 8 actually have somebody calculate how many drugs they  
 9 needed to -- to ingest? Did you know that?  
 10 MR. PYSER: Object to form.  
 11 THE WITNESS: I was not aware of a website  
 12 referring to Skittles and body weight of abuse  
 13 which is outside of the closed supply chain.  
 14 BY MR. PAPANTONIO:  
 15 Q. Okay. So the DEA -- next paragraph: "DEA  
 16 estimates that nearly 7 million Americans currently  
 17 abuse prescription drugs, up 80 percent from 2000."  
 18 See that?  
 19 A. I do see that.  
 20 Q. When did you start with the company?  
 21 A. When did I start with Cardinal Health?  
 22 Q. No, with Cardinal -- yeah. When did you  
 23 start with them? 2000, right?  
 24 A. I started with a company that was acquired  
 25 by Cardinal Health in 2002. I started with that

Page 204

1 company in 2000. January of 2000, I started with  
 2 Bentley Trading Company. And sometime in 2002, they  
 3 were acquired by Cardinal Health.  
 4 Q. So in 2000, you were working with  
 5 Cardinal, correct?  
 6 MR. PYSER: Object to form. Misstates  
 7 testimony.  
 8 BY MR. PAPANTONIO:  
 9 Q. Right?  
 10 A. In 2002 --  
 11 Q. Does that misstate your testimony, to say  
 12 that -- let me just phrase it another way.  
 13 A. Well, you asked the question, and --  
 14 Q. Well, let me ask -- let me rephrase the  
 15 question.  
 16 MR. PYSER: Let him finish the -- let him  
 17 finish the answer, Counsel.  
 18 BY MR. PAPANTONIO:  
 19 Q. You were working --  
 20 MR. PAPANTONIO: No. You objected. I'm  
 21 going to rephrase the question.  
 22 BY MR. PAPANTONIO:  
 23 Q. So you were working in the area of opioids  
 24 as early as 2000, weren't you?  
 25 MR. PYSER: Object to form.

Page 205

1 THE WITNESS: In 2000, I was working for  
 2 Bentley Trading Company, in the -- in the  
 3 distribution center.  
 4 BY MR. PAPANTONIO:  
 5 Q. Okay. In narcotics, correct?  
 6 MR. PYSER: Object to form.  
 7 THE WITNESS: There were controlled  
 8 substances present.  
 9 BY MR. PAPANTONIO:  
 10 Q. And so --  
 11 A. Excuse me.  
 12 Q. Yeah. Go ahead.  
 13 A. There was Schedule III through V  
 14 controlled substances present. There was no vault,  
 15 so there was no Schedule II --  
 16 Q. So the --  
 17 A. -- controlled substances.  
 18 Q. "The DEA estimates that nearly 7 million  
 19 Americans currently abuse prescription drugs, up  
 20 80 percent from 2000."  
 21 And we're talking -- this document is  
 22 2008, correct?  
 23 A. This document, according to the first  
 24 page, 2008.  
 25 Q. So between -- according to Hartman, who

Page 206

1 worked for Cardinal, he says between 2000 and 2008,  
2 that -- that there was -- that there -- the  
3 prescription abuse was up 80 percent. Right?  
4 MR. PYSER: Object to form.  
5 THE WITNESS: That's what's written on  
6 this page.  
7 BY MR. PAPANTONIO:  
8 Q. And during those years between 2005 and  
9 2008, you were one of the people at Cardinal that was  
10 actually determining how many -- how much drugs we  
11 can send out throughout the country?  
12 MR. PYSER: Object to form.  
13 BY MR. PAPANTONIO:  
14 Q. You were reviewing records? True?  
15 A. I was reviewing ingredient limit reports,  
16 yes.  
17 Q. And it says: "10 percent of high school  
18 seniors admit to abusing painkillers."  
19 See that?  
20 A. I do see that.  
21 Q. "Every day, 2,500 youths 12 to 17 abuse a  
22 prescription pain reliever for the first time."  
23 See that?  
24 A. I do see that.  
25 Q. So that was the environment that you were

Page 207

1 working in when you were making a decision about  
2 whether or not you should send drugs out to rogue  
3 pharmacies. Correct?  
4 MR. PYSER: Object to form. Vague as to  
5 time.  
6 THE WITNESS: Again, from 2005 to late  
7 2007 -- or early 2008; I'm not certain -- it was  
8 my job to review those ingredient limit reports,  
9 operating in that closed supply chain.  
10 BY MR. PAPANTONIO:  
11 Q. Okay. So what I'm getting at is, this was  
12 the environment that we just described. I don't want  
13 to go through it again, but we just described the  
14 environment that was existing with drug abuse during  
15 the time that you were choosing to sell drugs to  
16 rogue pharmacies that were operating on the Internet,  
17 correct?  
18 MR. PYSER: Object to form.  
19 THE WITNESS: I was an employee of  
20 Cardinal Health during the time frame of 2005 to  
21 late 2007, early 2008, doing that job. I was  
22 not -- I -- I did not have that role, I believe,  
23 in November of -- of 2008; but yes, I was  
24 employed with the company, doing that role, from  
25 2005 to early 2008.

Page 208

1 BY MR. PAPANTONIO:  
2 Q. And I'm asking you about the environment  
3 that you were working in. You're aware that that  
4 environment existed? The environment of drug abuse,  
5 certainly -- this is talking about children.  
6 But you were aware that this drug abuse  
7 environment and culture was existing during the time  
8 that you were shipping narcotic drugs to rogue  
9 Internet pharmacies? Yes or no?  
10 MR. PYSER: Object to form.  
11 THE WITNESS: There has been some form of  
12 drug abuse forever. Whether that drug is --  
13 BY MR. PAPANTONIO:  
14 Q. That doesn't answer my question. Listen  
15 to my question.  
16 A. What was -- well --  
17 Q. Would you -- no, no -- no, no --  
18 MR. PYSER: Let him finish the answer.  
19 MR. PAPANTONIO: No, I'm --  
20 BY MR. PAPANTONIO:  
21 Q. Okay. Can you answer --  
22 MR. PYSER: He was not --  
23 THE WITNESS: I believe your question  
24 was --  
25

Page 209

1 BY MR. PAPANTONIO:  
2 Q. Answer my question.  
3 A. Your -- your question was, was I employed  
4 doing my role that I've expressed during the time of  
5 drug abuse? And I said there has been drug abuse.  
6 And, yes, I was working for Cardinal Health during  
7 the time period from 2005 to early 2008 or '7 in that  
8 role where I was reviewing ingredient limit reports.  
9 Q. Okay.  
10 A. Was that your question?  
11 Q. Well, if that's your answer, I'll go with  
12 your answer right now because I know you want -- you  
13 want to say what you want to say, so you -- that's  
14 fine.  
15 MR. PAPANTONIO: Show him 4765.  
16 MR. PYSER: Object to form.  
17 Strike the commentary from counsel.  
18 BY MR. PAPANTONIO:  
19 Q. Yeah. We're going to read -- I'm going to  
20 read the question back in just a minute. I'm going  
21 to read your answer back with this document, okay,  
22 that we're about to look at.  
23 MR. PAPANTONIO: Show him this document,  
24 please.  
25 MS. MOORE: Cardinal-Brantley 8.

<p style="text-align: right;">Page 210</p> <p>1 (Cardinal-Brantley 8 was marked for  2 identification.)  3 BY MR. PAPANTONIO:  4 Q. You know what this is, don't you?  5 MR. PYSER: Object to form.  6 BY MR. PAPANTONIO:  7 Q. Do you know what this is?  8 A. At first glance, I do not.  9 Q. Take a minute and look at it, so I can --  10 I'm going to ask you some questions about this, and I  11 want to make sure you know what it is.  12 A. I see that the date is January 13 or 14th,  13 2005. And I was not in the role that we've been  14 speaking of since this morning during that time  15 frame.  16 Q. What were you doing in 2005?  17 A. I moved to the corporate office, I  18 believe, in May 2005. Prior to that, I was still  19 down in Texas, with the distribution center there.  20 Q. Okay. You did -- did you have a training  21 program in place when you left, for training people  22 in the field on how they should be involved with this  23 closed system that you talk about with narcotics?  24 Did you have a training system in place?  25 A. Did I have a training system in place when</p>	<p style="text-align: right;">Page 212</p> <p>1 A. I don't know what --  2 Q. Do you understand what --  3 A. I don't know what your --  4 Q. Well, let me show you.  5 A. -- version of standardized --  6 Q. I mean --  7 A. -- training is, but training -- training  8 was conducted. I myself conducted training --  9 Q. Oh, you did?  10 A. -- when I was at the company.  11 Q. You did. Okay. So let's look at page 15,  12 see what it says.  13 See the top, it says: "FY 05 current  14 state in estimated regulatory training cost."  15 It says: "No standardized training  16 process."  17 You see that?  18 MR. PYSER: Object to form. Vague as to  19 time.  20 BY MR. PAPANTONIO:  21 Q. Did I read that right? "No" -- did I read  22 that right? "No standardized training process"?  23 MR. PYSER: Object to form. Vague.  24 BY MR. PAPANTONIO:  25 Q. Right?</p>
<p style="text-align: right;">Page 211</p> <p>1 I left --  2 Q. Yeah.  3 A. -- Cardinal Health, the company --  4 Q. Yeah.  5 A. -- in 2013?  6 Q. Uh-huh.  7 A. There was a training system.  8 Q. Oh, there was? Standardized training  9 system was in place? Is that your testimony?  10 MR. PYSER: Object to form. Vague as to  11 time.  12 BY MR. PAPANTONIO:  13 Q. Was that your testimony, that there was a  14 training -- a training system in place to standard --  15 let's call it "standardized training system" -- in  16 place when you left the company?  17 MR. PYSER: Object --  18 BY MR. PAPANTONIO:  19 Q. Is that what you're telling the jury?  20 A. When I left --  21 MR. PYSER: Object to form.  22 THE WITNESS: When I left the company  23 in -- in 2013, training was conducted.  24 BY MR. PAPANTONIO:  25 Q. Standardized training?</p>	<p style="text-align: right;">Page 213</p> <p>1 A. That is what that statement says on the  2 slide.  3 Q. It says, underneath it: "Inconsistent  4 training across sites."  5 You see that?  6 MR. PYSER: Object to form.  7 THE WITNESS: I do see that on the slide.  8 BY MR. PAPANTONIO:  9 Q. And then if you go down to "Current  10 State," let's see where they land. It says: "Lack  11 of corporate sponsorship for training. Authority, if  12 there is any real accountability rests, if" -- I read  13 that -- let's -- let's start -- slow down.  14 "Lack of corporate sponsorship for  15 training authority, if there is any real  16 accountability, rests on individual sites in most  17 cases. In most cases, no repercussions for problems  18 in training, not showing up, not completing training"  19 -- see -- what does that say, "testing"?  20 It says: "Training process is nonexistent  21 in some sites."  22 You see that?  23 MR. PYSER: Object to form.  24 BY MR. PAPANTONIO:  25 Q. "Training process is nonexistent"?</p>

<p style="text-align: right;">Page 214</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Do you see that?</p> <p>4 A. I do see that.</p> <p>5 Q. Okay. And we're talking about people that</p> <p>6 are handling narcotics to be distributed throughout</p> <p>7 the country. Women, children. And there's no -- the</p> <p>8 training process is nonexistent in some sites.</p> <p>9 Right?</p> <p>10 MR. PYSER: Object to form. And</p> <p>11 argumentative. And vague as to time.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Correct? That's what this says?</p> <p>14 A. That's on this slide.</p> <p>15 Q. Right. And this is -- this is 2000 --</p> <p>16 this is 2005.</p> <p>17 Now go to the next -- go to the next line,</p> <p>18 right underneath, where it says: "Training process</p> <p>19 is nonexistent in some sites." It says: "References</p> <p>20 to insufficient training."</p> <p>21 And it even lays out the references that</p> <p>22 you can see where there's insufficient training.</p> <p>23 That's what that says, isn't it?</p> <p>24 MR. PYSER: Object to form.</p> <p>25</p>	<p style="text-align: right;">Page 216</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Did you tell me that?</p> <p>4 A. Yes. So this document is dated, again,</p> <p>5 January 13th, 14th, 2005.</p> <p>6 Q. Right.</p> <p>7 A. I joined -- I moved to corporate, I</p> <p>8 believe, middle of the year 2005, around May. And I</p> <p>9 myself conducted training. And when I left Cardinal</p> <p>10 Health in 2013, there was training.</p> <p>11 This document is dated January 13th of</p> <p>12 2005.</p> <p>13 Q. Okay, so you'd have been --</p> <p>14 A. I can't speak to prior to my time at the</p> <p>15 corporate office.</p> <p>16 Q. Okay. Let me get this right: When did</p> <p>17 Cardinal start selling narcotics across the</p> <p>18 United States? What year?</p> <p>19 MR. PYSER: Object to form. Asked and</p> <p>20 answered.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Was it 1999?</p> <p>23 A. I don't know when Cardinal started.</p> <p>24 Q. Well, we know they were selling in 2000,</p> <p>25 right? You know they were selling narcotics in 2000?</p>
<p style="text-align: right;">Page 215</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Right?</p> <p>3 A. It says that there are references to</p> <p>4 insufficient training.</p> <p>5 Q. Okay. And right -- right under -- see</p> <p>6 where it says "Numerous 483"?</p> <p>7 "References to insufficient training, one</p> <p>8 of root causes or symptom of causes, staff is not</p> <p>9 trained -- staff not trained."</p> <p>10 MR. PAPANTONIO: Underline "staff not</p> <p>11 trained."</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. See that?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. "Trainers not qualified."</p> <p>17 MR. PAPANTONIO: Underline that.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. And then it goes: "Training not provided</p> <p>20 in a timely manner."</p> <p>21 And then it goes: "No minimum training</p> <p>22 requirements."</p> <p>23 But didn't you just tell me that -- yeah,</p> <p>24 when you left -- when you were there, there was a</p> <p>25 training system involved?</p>	<p style="text-align: right;">Page 217</p> <p>1 A. Cardinal Health was distributing</p> <p>2 controlled substances in --</p> <p>3 Q. And now we're in 2005, and --</p> <p>4 MR. PYSER: Counsel, again, please let him</p> <p>5 finish his answer before you begin your next</p> <p>6 question.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. We're now in 2005. And there's no</p> <p>9 training, according to this.</p> <p>10 MR. PYSER: Object to form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Right? Isn't that what it says?</p> <p>13 MR. PYSER: Object to form. Calls for</p> <p>14 speculation. Misstates evidence.</p> <p>15 THE WITNESS: This slide states as you</p> <p>16 read, the references to insufficient training.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Okay.</p> <p>19 A. According to this slide.</p> <p>20 MR. PAPANTONIO: Let's take a lunch break</p> <p>21 now. We'll be back -- let's take 45 minutes.</p> <p>22 VIDEOGRAPHER: Going off record at 12:09.</p> <p>23 (Going off video record at 12:09 p.m.)</p> <p>24 (Off record discussion.)</p> <p>25 MR. PYSER: We're still on the record.</p>



<p style="text-align: right;">Page 218</p> <p>1 That's incorrect. There's no discussion about  2 any pending questions. I refer counsel to the  3 order on discovery and Track 1 cases 2006-2018.  4 Communications between a witness and his or her  5 counsel during a break taken with no question  6 pending shall not be the subject of inquiry.  7 Such conversations are subject to the  8 attorney-client and work product privileges.  9 MR. PAPANTONIO: No, they're not. There's  10 another part to it. But you -- you take  11 whatever avenue you want. You want to talk to  12 him, go ahead.  13 MR. PYSER: We will not discuss any  14 pending question, as the rules require.  15 MR. PAPANTONIO: There's about a dozen of  16 them pending right now.  17 MR. PYSER: So the record is clear, there  18 is no pending question. And to the extent there  19 is, I object to any pending question.  20 MS. MOORE: So Cardinal-Brantley 9 is  21 distribution center map. Cardinal-Brantley 10,  22 2016 death map. Cardinal-Brantley 11, 2016  23 death map and Cardinal distribution center map  24 combined.  25 (Cardinal-Brantley 9 was marked for</p>	<p style="text-align: right;">Page 220</p> <p>1 on this.  2 So it says: "Internal client perspective  3 of QRA." And that's -- okay, "Internal client  4 perspective of QRA."  5 And that's where you worked as -- in your  6 role at QRA. Correct?  7 A. Yes, from 2005 till --  8 MR. PAPANTONIO: Okay. Let's underline  9 the first thing it says, "QRA model."  10 BY MR. PAPANTONIO:  11 Q. See that?  12 A. Yes.  13 Q. This is when you were working in QRA,  14 correct?  15 A. What's the date there?  16 Q. Take a look at it. It is 2005.  17 A. Are we talking -- I was not in QRA in  18 January 2005, when this was --  19 Q. Okay.  20 A. -- presented.  21 Q. So -- so it says: "Number 1, quality is  22 not a mindset at Cardinal Health."  23 See that?  24 MR. PAPANTONIO: Underline that: "Quality  25 is not a mindset at Cardinal Health."</p>
<p style="text-align: right;">Page 219</p> <p>1 identification.)  2 (Cardinal-Brantley 10 was marked for  3 identification.)  4 (Cardinal-Brantley 11 was marked for  5 identification.)  6 (Off the stenographic record at  7 12:12 p.m.)  8 (Returning to video and stenographic  9 record at 1:17 p.m.)  10 VIDEOGRAPHER: We're going back on record.  11 Beginning of media file 3. Time is 1:17.  12 BY MR. PAPANTONIO:  13 Q. All right. Sir, when we -- Mr. Brantley,  14 when we broke up, we were talking about 4765. I  15 think it's in front of you right now.  16 Remember we talked about training?  17 A. Yes.  18 Q. Look at page 64. It's document 4765.  19 A. Did you say page 64?  20 Q. Page -- yeah. It's -- here it is.  21 4765.64. It may not be the page number, but --  22 A. Oh, okay.  23 Q. -- what I'm looking at, 4765.64.  24 A. I have it. Thank you.  25 Q. I think this is where we kind of left off</p>	<p style="text-align: right;">Page 221</p> <p>1 BY MR. PAPANTONIO:  2 Q. Then it says: "We are not proactive."  3 MR. PAPANTONIO: Underline "We are not  4 proactive."  5 BY MR. PAPANTONIO:  6 Q. And then it says: "This is not high  7 enough priority today."  8 See that? "This is not high enough  9 priority today."  10 MR. PAPANTONIO: Underline that.  11 BY MR. PAPANTONIO:  12 Q. Do you see these things I'm reading -- I'm  13 reading to you?  14 A. I do.  15 Q. Okay. Is this the first time you've seen  16 this?  17 A. It is.  18 Q. Did you know that quality, as late as  19 2005, was not a mindset at Cardinal Health?  20 MR. PYSER: Object to form.  21 BY MR. PAPANTONIO:  22 Q. Did you -- did you know that?  23 A. I did not know that. That is this  24 person's opinion.  25 Q. Do you know who the person is?</p>

<p style="text-align: right;">Page 222</p> <p>1 A. Please refresh my memory who wrote this.</p> <p>2 Q. We'll go back to it.</p> <p>3 A. Okay.</p> <p>4 Q. Okay. Then the second thing it says --</p> <p>5 did you know that in 2005, the -- the attitude was,</p> <p>6 "We are not proactive."</p> <p>7 You see that? "We are not proactive"?</p> <p>8 A. I do see that.</p> <p>9 Q. And this again is 2005. And just refresh</p> <p>10 your -- you're not sure when Cardinal started selling</p> <p>11 narcotics, whether it was 1999, 2000; you simply</p> <p>12 don't know. Correct?</p> <p>13 MR. PYSER: Object to form.</p> <p>14 THE WITNESS: I don't remember when --</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Okay.</p> <p>17 A. -- Cardinal Health was started.</p> <p>18 Q. And it says: "This is not high enough</p> <p>19 priority today."</p> <p>20 You see that? "This is not high enough</p> <p>21 priority today"?</p> <p>22 A. I see that.</p> <p>23 MR. PAPANTONIO: Would you flip up --</p> <p>24 would you go to that -- that map, what I'll call</p> <p>25 "the death map," and put it up on the screen,</p>	<p style="text-align: right;">Page 224</p> <p>1 2016. Do you see that?</p> <p>2 A. I can see that.</p> <p>3 Q. And then -- and then where we look at this</p> <p>4 where this is saying "This is not a high enough</p> <p>5 priority today," this is the number of people that</p> <p>6 are -- are up here on this map, it's showing the</p> <p>7 number of people affected by opioids, right?</p> <p>8 MR. PYSER: Object to form. Misstates</p> <p>9 evidence.</p> <p>10 THE WITNESS: I believe the map --</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. I mean, you see the map, don't you, 2005?</p> <p>13 A. Yeah. It's estimated age-adjusted death</p> <p>14 rate per 100,000, yes.</p> <p>15 Q. Right. And it says: "Quality is not a</p> <p>16 mindset at Cardinal Health."</p> <p>17 Then it goes on to say, "We're not</p> <p>18 proactive," and that "This is not a high enough</p> <p>19 priority today."</p> <p>20 And what I'm wondering, Mr. Brantley, is</p> <p>21 how many people have to die of -- of drug overdoses</p> <p>22 before it becomes a priority with Cardinal?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. How many people have to die?</p>
<p style="text-align: right;">Page 223</p> <p>1 2005. Just put it right next to this document,</p> <p>2 if you would, where it says "This is not high</p> <p>3 enough priority today." 2005.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. See, that's the map -- that's the map that</p> <p>6 the CDC -- where it says "Source, National Center for</p> <p>7 Health Statistics." See that?</p> <p>8 You know what CDC is, right?</p> <p>9 MR. PYSER: Object to form on the --</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Right?</p> <p>12 MR. PYSER: -- beginning part of that</p> <p>13 question. Misuse of the term "death map."</p> <p>14 THE WITNESS: I do know what CDC is.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. As a matter of fact, it even gives a -- it</p> <p>17 even gives a site, even gives you a website you can</p> <p>18 go to to find this.</p> <p>19 Did you have a computer in your office?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 THE WITNESS: I did have a computer.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Okay. And then it even gives citations,</p> <p>24 doesn't it? See down there? And it tells you where</p> <p>25 you can actually get the citations. 1999 through</p>	<p style="text-align: right;">Page 225</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: This statement is, as far</p> <p>3 as -- as far as quality, is someone's opinion.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Sir, this was -- this is a -- this is a</p> <p>6 Cardinal document. This was created by Cardinal. In</p> <p>7 the front of it says "Operation 1, Cardinal Health</p> <p>8 quality management."</p> <p>9 We're talking about quality management,</p> <p>10 right? Correct? That's what this document is,</p> <p>11 quality management?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. True? Look at the front page.</p> <p>15 A. It says "Quality."</p> <p>16 Q. Look at the front page. What does the</p> <p>17 front of the document say?</p> <p>18 A. "Operation 1. Cardinal Health quality</p> <p>19 management meeting."</p> <p>20 Q. And what were you? Weren't you a quality</p> <p>21 manager?</p> <p>22 MR. PYSER: Object to form.</p> <p>23 THE WITNESS: Not in January 2005, I was</p> <p>24 not.</p> <p>25</p>

<p style="text-align: right;">Page 226</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Right. Okay. So 2005, if we go back to</p> <p>3 that same page that says -- it says: "This is not --</p> <p>4 This is not a high enough priority," what I'm</p> <p>5 wondering is, what does it take, in Eric Brantley's</p> <p>6 mind, to say that -- what number of deaths make this</p> <p>7 a high enough priority to pay attention to?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Eric Brantley --</p> <p>11 A. Once again --</p> <p>12 Q. Eric Brantley. How many people have to</p> <p>13 die?</p> <p>14 A. Again I go back --</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: -- to the quality statement</p> <p>17 was, apparently, one individual's opinion.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Okay. We're going to -- we're going to</p> <p>20 talk about -- more about this document, but you don't</p> <p>21 even know who wrote that, do you?</p> <p>22 MR. PYSER: Object to form.</p> <p>23 THE WITNESS: I don't remember.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Okay. Because it's marked "Confidential"</p>	<p style="text-align: right;">Page 228</p> <p>1 Q. Right. And how about Tony Esposito? You</p> <p>2 knew Tony, didn't you?</p> <p>3 A. I don't recall Tony Esposito.</p> <p>4 Q. Well, did you know John Figalora?</p> <p>5 A. I don't think I've ever seen that name.</p> <p>6 Q. Kim Arnold?</p> <p>7 A. Again, I don't recall a Kim Arnold.</p> <p>8 Q. Well, these are -- you see where they're</p> <p>9 all listed, it says: "Operation 1, Cardinal Health,</p> <p>10 Audit and Compliance."</p> <p>11 You see that?</p> <p>12 A. I do.</p> <p>13 Q. And you were in quality compliance,</p> <p>14 weren't you? That was part of your role as quality</p> <p>15 compliance?</p> <p>16 A. Again, January 13th through 14th, 2005, I</p> <p>17 was not in that role.</p> <p>18 Q. Okay. And we know this -- let's say that</p> <p>19 Cardinal started selling these narcotics in the year</p> <p>20 2000. We're five years down the road here.</p> <p>21 You understand that? We're talking about</p> <p>22 2005 here.</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: I understand you're just</p> <p>25 saying from 2000 to 2005, yes.</p>
<p style="text-align: right;">Page 227</p> <p>1 on the bottom of it, but you've seen this before.</p> <p>2 True?</p> <p>3 A. I saw it when you gave it to me before</p> <p>4 lunch. That was my first time seeing it, that I</p> <p>5 recall.</p> <p>6 Q. Well, let's look at the next line. It</p> <p>7 says: "When financials are tight, quality suffers."</p> <p>8 Did you know that the quality of your</p> <p>9 quality management was dependent on your financial</p> <p>10 status as a company?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Did you know that? Somebody had made that</p> <p>14 determination?</p> <p>15 A. Again, this is someone's opinion, and I</p> <p>16 can't speak to someone's opinion.</p> <p>17 Q. Well, but did you -- had you ever talked</p> <p>18 to anybody about these things that are laid out in</p> <p>19 a -- in a team?</p> <p>20 Now, let me just ask you: Who was Gary</p> <p>21 Dech? Delch? Dolch, D-o-l-c-h. Who was Gary Dolch?</p> <p>22 A. Gary Dolch?</p> <p>23 Q. Yeah.</p> <p>24 A. I believe he was a VP or something like</p> <p>25 that in the quality regulatory affairs department.</p>	<p style="text-align: right;">Page 229</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Do you know what the death rate was for --</p> <p>3 how many human beings were dying every day from</p> <p>4 opioids, specifically opioid narcotics, from</p> <p>5 overdoses? Do you know that number?</p> <p>6 A. I do not know that number.</p> <p>7 Q. Has anybody ever told you that number that</p> <p>8 you can think of, and maybe you forgot?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 THE WITNESS: I do not recall anyone</p> <p>11 telling me that number, other than I think you</p> <p>12 may have discussed that prior to lunch on that</p> <p>13 chart.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. All right. Let's go back to point 64,</p> <p>16 that same document. You see where it says "People"?</p> <p>17 A. Yes.</p> <p>18 Q. It says: "Under resourced today."</p> <p>19 See that?</p> <p>20 A. Yes.</p> <p>21 Q. Says: "People we have are good, but they</p> <p>22 don't have enough bench strength."</p> <p>23 Do you know how many employees this</p> <p>24 company had in 2005?</p> <p>25 MR. PYSER: Object to form.</p>

Page 230

1 THE WITNESS: I do not.  
 2 BY MR. PAPANTONIO:  
 3 Q. Do you know how many billions of dollars  
 4 they were making in 2005?  
 5 MR. PYSER: Object to form.  
 6 THE WITNESS: I do not.  
 7 BY MR. PAPANTONIO:  
 8 Q. Do you know what the net worth of the  
 9 company was, in billions, in 2005?  
 10 MR. PYSER: Object to form.  
 11 THE WITNESS: I do not.  
 12 BY MR. PAPANTONIO:  
 13 Q. And then -- then next, it says: "Not  
 14 enough people."  
 15 You see that?  
 16 A. I do.  
 17 Q. And it says: "We need to upgrade, and we  
 18 need to deepen our talent."  
 19 Do you see that?  
 20 A. I do.  
 21 Q. And then you see where it says  
 22 "Processes"? It says: "Keep us out of trouble, but  
 23 not very proactive or innovative."  
 24 You see that?  
 25 A. I do.

Page 231

1 Q. "Not very proactive or innovative."  
 2 Did you ever remember a time when you were  
 3 with the company where there was just -- y'all were  
 4 running out of money, and you just didn't have enough  
 5 money to go around and pay for employees? Was there  
 6 ever a time like that that you recall?  
 7 MR. PYSER: Object to form.  
 8 THE WITNESS: Not that I recall.  
 9 BY MR. PAPANTONIO:  
 10 Q. Was there ever a time where -- where you  
 11 all were so worried about finances that you couldn't  
 12 hire extra people to do some of these jobs that  
 13 needed to be done to -- to prevent diversion? Do you  
 14 remember a time like that?  
 15 A. I do not recall a time.  
 16 Q. It says -- that first line -- "Not very  
 17 proactive. Not innovative."  
 18 And again, we're in 2005 at this point.  
 19 It says, "Site level measurements and incentives can  
 20 hinder investment in quality." See that?  
 21 A. I do.  
 22 Q. And then the last thing it says: "Limited  
 23 policy standardization."  
 24 Do you know what that means?  
 25 A. I do not.

Page 232

1 Q. Fair enough. All right.  
 2 MR. PAPANTONIO: Show him 4631. 4631.  
 3 MS. MOORE: Cardinal-Brantley 12.  
 4 (Cardinal-Brantley 12 was marked for  
 5 identification.)  
 6 BY MR. PAPANTONIO:  
 7 Q. And this is 2005. You see that?  
 8 A. I do.  
 9 Q. And were you there 5-12-2005?  
 10 A. I was an employee of Cardinal Health,  
 11 May 12th, 2005, yes.  
 12 Q. And then number 1, it says: "We three  
 13 wholesalers were asked by Greg Jones if we have  
 14 specific protocol to monitor possible drug diversion  
 15 outside of ARCOS activity with Internet pharmacies or  
 16 wholesale accounts."  
 17 You see that? "Greg Jones asked if we  
 18 have specific protocols to monitor."  
 19 You see that?  
 20 A. I do see that.  
 21 Q. "To monitor diversion."  
 22 You see that?  
 23 MR. PYSER: Object to form.  
 24 THE WITNESS: I do see that.  
 25

Page 233

1 BY MR. PAPANTONIO:  
 2 Q. And then it says: "To my knowledge, we do  
 3 not."  
 4 Do you see that?  
 5 A. I do see that.  
 6 Q. And then under -- underneath that, it  
 7 says: "If a distributor or Internet pharmacy  
 8 customer is properly licensed and a legal entity to  
 9 purchase from us, we typically do not monitor what  
 10 they purchase or track who they sell to."  
 11 You see that?  
 12 A. I do.  
 13 Q. So according to that, I mean, you could  
 14 have an Internet company that is buying drugs over  
 15 the Internet.  
 16 They could be -- they could be a drug  
 17 cartel, for all you know, right, according to that?  
 18 MR. PYSER: Object to form.  
 19 BY MR. PAPANTONIO:  
 20 Q. They could be a drug cartel, couldn't  
 21 they?  
 22 MR. PYSER: Same objection.  
 23 THE WITNESS: Again, I go back -- I read  
 24 what this says, but ingredient limit reports  
 25 were submitted to the DEA.

<p style="text-align: right;">Page 234</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. That's not my question. Listen to my</p> <p>3 question very well.</p> <p>4 A. Your -- your question was if they --</p> <p>5 Q. If we -- if we buy what was just stated --</p> <p>6 by -- who --</p> <p>7 MR. PAPANTONIO: Carol, let me have that</p> <p>8 document again.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. If we -- if we agree with what was just</p> <p>11 stated by Steve Reardon, who is -- who was your</p> <p>12 supervisor, correct?</p> <p>13 A. What are we agreeing to?</p> <p>14 Q. Hang on. Let -- let me finish my</p> <p>15 question.</p> <p>16 A. Well, you asked a question --</p> <p>17 Q. No, I haven't asked a question.</p> <p>18 A. Okay.</p> <p>19 Q. If we agree what Steve Reardon says, that</p> <p>20 "To my knowledge, we don't have a monitoring system,</p> <p>21 and we typically don't monitor -- monitor or track</p> <p>22 Internet sales," you don't know where the drugs are</p> <p>23 going, do you?</p> <p>24 MR. PYSER: Object to form. That's</p> <p>25 blatantly misleading. This is not an e-mail</p>	<p style="text-align: right;">Page 236</p> <p>1 Internet pharmacies."</p> <p>2 That's what it says, doesn't it?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 THE WITNESS: That is what Mark says. I</p> <p>5 don't agree with that.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Well, okay.</p> <p>8 A. Who is Mark Mitchell? Vice president,</p> <p>9 health system sales?</p> <p>10 Q. Yeah, who is Steve Reardon? Steve Reardon</p> <p>11 did your job, didn't he?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. He was your boss, correct?</p> <p>15 A. Steve Reardon was my boss.</p> <p>16 Q. And he's on a document that says: "You</p> <p>17 know what? We typically don't monitor Internet</p> <p>18 sales."</p> <p>19 That's what it says, doesn't it?</p> <p>20 A. It does say that.</p> <p>21 MR. PYSER: Objection.</p> <p>22 THE WITNESS: Steve did not draft that</p> <p>23 document.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. And you understand --</p>
<p style="text-align: right;">Page 235</p> <p>1 from Steve Reardon.</p> <p>2 MR. PAPANTONIO: It's got Steve Reardon's</p> <p>3 name on it -- you're right.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. It's got Steve Reardon's name on it,</p> <p>6 right?</p> <p>7 A. I was just going to ask, where did you</p> <p>8 read that, because --</p> <p>9 Q. It's got --</p> <p>10 A. -- I don't remember reading that.</p> <p>11 Q. -- Steve Reardon's name.</p> <p>12 I did misstate it, didn't I?</p> <p>13 It says -- it says "Mark Mitchell" -- who</p> <p>14 you know, correct?</p> <p>15 A. No.</p> <p>16 Q. You don't know Mark?</p> <p>17 A. No.</p> <p>18 Q. It says "To Steve Reardon."</p> <p>19 Do you see "Reardon," right there?</p> <p>20 A. I do.</p> <p>21 Q. And he was your boss, correct?</p> <p>22 A. Yes.</p> <p>23 Q. And if we believe what is being said here,</p> <p>24 let's -- actually, by Mark Mitchell, it says: "To my</p> <p>25 knowledge, we don't have a monitoring system for</p>	<p style="text-align: right;">Page 237</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. -- if you are not monitoring sales, this</p> <p>4 stuff could be going all over the country, to drug</p> <p>5 cartels, for all we know, right?</p> <p>6 MR. PYSER: Object.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. If that's true, it could be going to drug</p> <p>9 cartels. Yes?</p> <p>10 A. You started your question with, "If you</p> <p>11 don't monitor sales."</p> <p>12 Q. Yes.</p> <p>13 A. And again I state, we were submitting</p> <p>14 ingredient limit reports to DEA on a monthly basis.</p> <p>15 Q. That's not my question. If we don't have</p> <p>16 a way -- your company, Cardinal -- doesn't have a way</p> <p>17 to monitor Internet sales, for all you know,</p> <p>18 Mr. Brantley, those sales could be going to drug</p> <p>19 cartels all over the country: Yes or no?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 And also an objection to the prior</p> <p>22 question. I didn't want to disrupt --</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Yes or no?</p> <p>25 MR. PYSER: -- the questioner.</p>



<p style="text-align: right;">Page 238</p> <p>1 THE WITNESS: Again, you asked a question,  2 if we do not have this.  3 BY MR. PAPANTONIO:  4 Q. Right. If you don't --  5 A. We did have this. So that's my answer to  6 the question.  7 Q. Not according to this document, you don't.  8 A. This -- this document is not from Steve  9 Reardon. It's from Mark Mitchell and health system  10 sales, who I do not know.  11 Q. Sales. He's in the business of sales,  12 right?  13 MR. PYSER: Object to form.  14 THE WITNESS: He's in --  15 BY MR. PAPANTONIO:  16 Q. He's selling?  17 A. He's in sales; he's not in QRA.  18 Q. That doesn't make -- he's in sales, and he  19 works for the company, gets a paycheck from your  20 company, doesn't he?  21 MR. PYSER: Object to form.  22 BY MR. PAPANTONIO:  23 Q. Yes or no?  24 A. At this -- time of this e-mail, I'm to  25 assume that he was an employee of the company, yes.</p>	<p style="text-align: right;">Page 240</p> <p>1 conducted at the pharmaceutical distribution facility  2 in Birmingham, Alabama."  3 That was an area that you were responsible  4 for, correct?  5 A. By "responsible," if you mean did I review  6 ingredient limit reports --  7 Q. Right.  8 A. -- if it was a Cardinal Health  9 distribution center, yes.  10 Q. Okay. And it says: "From June 26th to  11 June 29th, 2006, a regulatory compliance review was  12 conducted at the pharmaceutical distribution Dohman  13 facility in Birmingham."  14 You're familiar with that facility, right?  15 A. No. So -- this is probably why. So if  16 this was a Dohmen facility --  17 Q. Yeah.  18 A. -- which is -- which is what you said,  19 I --  20 Q. Well, tell the jury who a Dohmen facility  21 is. We haven't talked about that. Who are they?  22 A. Again --  23 MR. PYSER: Counsel, please let him finish  24 his answer.  25 THE WITNESS: -- there was an acquisition</p>
<p style="text-align: right;">Page 239</p> <p>1 Q. All right. All right, so let's talk about  2 444. 44 -- 4444. How about that? Take a look at  3 4444.  4 Right now, what I'm doing as you look at  5 this, I'm going through the systems that you had in  6 place while you were there. Okay?  7 MS. MOORE: Cardinal-Brantley 13.  8 (Cardinal-Brantley 13 was marked for  9 identification.)  10 THE WITNESS: Okay.  11 BY MR. PAPANTONIO:  12 Q. I'm asking you questions about the systems  13 that they had in place -- that you had in place. So  14 as we go, take a look at this document, 4444.  15 Have you seen this document?  16 It's got your name on it; that's why I was  17 wondering.  18 A. I don't recall seeing it, but if it was  19 sent to me --  20 Q. Yeah, it was sent to you.  21 A. -- back in 2006 --  22 Q. Right.  23 A. -- I'm sure I saw it at the time.  24 Q. It says: "Attached find the report  25 detailing the findings of the compliance assessment</p>	<p style="text-align: right;">Page 241</p> <p>1 at some point. We discussed it earlier with, I  2 believe, the RKR, and you asked about sales --  3 BY MR. PAPANTONIO:  4 Q. Right.  5 A. -- and I told you that there was an  6 acquisition and a Dohmen.  7 Q. Uh-huh.  8 A. So if this was a Dohmen facility -- which  9 is why -- I'm very -- I'm not very familiar with the  10 Birmingham, Alabama, location. It may have been a  11 Dohmen facility. You read that somewhere. I may not  12 have had responsibility --  13 Q. It's got your name --  14 A. -- for reviewing reports for Dohmen.  15 Q. It's got your name on it, doesn't it?  16 A. The -- the e-mail was sent to me, yes,  17 but --  18 Q. Yeah. And when you got -- so you got the  19 e-mail.  20 You don't remember getting the e-mail,  21 right?  22 A. That is correct.  23 Q. And then if you look at page 4, you see  24 where it says "Significant issues"?  25 A. Yes.</p>

<p style="text-align: right;">Page 242</p> <p>1 Q. See where it says "DEA" -- it says: "DEA  2 theft loss reports are not submitted to DEA within  3 7 days of discovery."  4 And you know that they were supposed to  5 be, right?  6 MR. PYSER: Object to form.  7 THE WITNESS: DEA, theft loss reports.  8 Would that be a 106?  9 BY MR. PAPANTONIO:  10 Q. Uh-huh. You know they're supposed to be  11 reported, correct? Within 7 days?  12 Yes or no? Do you know?  13 A. Sir, I'm -- I'm trying to remember the  14 regulation. You asked me a question.  15 Q. Okay.  16 A. So I do know that the 106s must be filed  17 within a certain time of discovery. I don't remember  18 the time frame.  19 If it says 7 days here, I'm going with  20 what it says here. I know that it needs to be filed  21 within X amount of days of discovery. I just don't  22 remember the exact time frame.  23 Q. And why is that so important, that you  24 report theft from your facilities? Tell the jury why  25 that's so important.</p>	<p style="text-align: right;">Page 244</p> <p>1 BY MR. PAPANTONIO:  2 Q. You see where it says --  3 MR. PYSER: -- to answer the question.  4 BY MR. PAPANTONIO:  5 Q. -- "There is no system to determine  6 excessive or suspicious ordering"?  7 Did you see that? That's right up  8 underneath. It says -- in plain words: "There is no  9 system to determine excessive or suspicious ordering  10 by customers of controlled substance products."  11 You see that?  12 A. I do see that.  13 Q. And you know there's supposed to be,  14 correct? There's supposed to be a system to  15 determine excessive or suspicious orders by a  16 customer?  17 MR. PYSER: Object to form.  18 BY MR. PAPANTONIO:  19 Q. True?  20 A. 21CFR states that a registrant should have  21 a system in place to detect and report suspicious  22 orders.  23 Q. And this says there is no system.  24 That's what it says, doesn't it? There is  25 no system; there is no system to determine suspicious</p>
<p style="text-align: right;">Page 243</p> <p>1 A. We report theft and loss from distribution  2 centers so that the DEA is aware that there has been  3 a theft or a loss at the facility.  4 Q. Then it goes: "Customers were receiving  5 scheduled product they were not entitled to receive  6 due to their DEA registrations are not being reviewed  7 and set up correctly in the computer system."  8 Is that something you were in charge of?  9 MR. PYSER: Object to form.  10 THE WITNESS: No, I was not in charge of  11 that.  12 And -- and I would just like to ask, was  13 this a Dohmen facility, or what was this --  14 BY MR. PAPANTONIO:  15 Q. The document's going to speak for itself.  16 I don't think it's -- we're not just talking about  17 Dohmen. If you take a look at it, you'll see that,  18 but . . .  19 A. Okay.  20 Q. So it says --  21 A. No, I was not responsible for that.  22 Q. Okay. It says "There is" --  23 MR. PYSER: Feel free to -- feel free to  24 review the document as long as you need in  25 order --</p>	<p style="text-align: right;">Page 245</p> <p>1 ordering. That's what this says, correct?  2 A. So if -- if --  3 Q. Well, first of all, answer my question.  4 There is -- according to this document,  5 there is no system to determine suspicious ordering,  6 according to that line.  7 That's what it says, right?  8 A. According to that line --  9 MR. PYSER: Object to -- object to form.  10 You've got to let him answer the question.  11 MR. PAPANTONIO: No, I'm going to -- I'm  12 going to ask a question, and he's going to  13 answer the question. If you want to give  14 speeches, that's your opportunity to do -- it's  15 called a redirect; you can do that. Feel free  16 to do it.  17 MR. PYSER: Counsel, you asked him a  18 question --  19 MR. PAPANTONIO: I'm going to move on.  20 MR. PYSER: -- "So that's what that says,  21 correct?" He began to answer, and you asked a  22 different question.  23 BY MR. PAPANTONIO:  24 Q. Is that what that says? Correct? Am I  25 right that this says, "There is no system to</p>

<p style="text-align: right;">Page 246</p> <p>1 determine excessive or suspicious ordering"? Yes or 2 no? Does it say that? 3 MR. PYSER: Object to form. 4 THE WITNESS: That is what this says. And 5 if you are going to ask me questions about this 6 document, I would like to read it to see if it 7 is indeed Dohmen. 8 BY MR. PAPANTONIO: 9 Q. Fine. Go off the clock, because we're not 10 going to take time -- 11 MR. PYSER: No, we're going to stay on the 12 record -- 13 BY MR. PAPANTONIO: 14 Q. -- to read it on the record. 15 MR. PAPANTONIO: No, we're not. But we 16 stay on the record -- 17 MR. PYSER: He's going to read it if he 18 needs to read it. 19 THE WITNESS: I want to read this document 20 to see if it -- 21 MR. PAPANTONIO: You can read it, but it's 22 not going to be on our time, friend; okay? It's 23 not going to be on our time. 24 THE WITNESS: I just want to read the 25 document.</p>	<p style="text-align: right;">Page 248</p> <p>1 A. You're asking me questions -- 2 Q. Nobody from the company showed you -- not 3 your lawyer, but nobody from the company showed you 4 this document before you came in here, where it says, 5 "There is no system to determine suspicious 6 ordering," nobody showed that to you prior to me 7 showing it to you right now, correct? 8 MR. PYSER: Object to form. 9 BY MR. PAPANTONIO: 10 Q. Yes or no? 11 A. That is correct. 12 So I'm going to read the document if 13 you're going to continue asking me questions about 14 the document. 15 Q. Only thing I'm asking you is one page. If 16 your attorney wants to ask you questions after that, 17 he can do it, but I'm asking the questions I want to 18 ask. That's my right to do it. That's how this 19 works. 20 A. And it's my right to read the document, I 21 believe. 22 Q. You're right. And you haven't read the 23 document. Take a minute -- if you want to take -- 24 and we're going to just go off the record -- 25 A. Okay.</p>
<p style="text-align: right;">Page 247</p> <p>1 MR. PAPANTONIO: Just keep up with the 2 time on this. 3 BY MR. PAPANTONIO: 4 Q. We're not going to go on our time for you 5 to read the document. 6 How many hours did you prepare for this 7 deposition? 8 A. This is my first time seeing this 9 document -- 10 Q. How many -- 11 A. -- and you're asking me questions -- you 12 asked me that earlier, and I said I did not know, and 13 that's my same answer -- 14 Q. Was it more than 12? 15 A. More than 12 what? 16 Q. Hours. 17 A. Probably -- yes. 18 Q. Was it two days? 19 A. Meaning -- meaning 48 hours? No. 20 Q. Was it three days? 21 A. Meaning 72 hours? No. 22 Q. How many hours was it? 23 A. Again, I don't know. But I did not review 24 this document. You're -- 25 Q. Right.</p>	<p style="text-align: right;">Page 249</p> <p>1 Q. -- so we don't spend our time doing 2 something you haven't done before you came here 3 today. 4 A. Okay. 5 Q. Okay? 6 MR. PAPANTONIO: Give me a time. 7 THE WITNESS: How much time do I have? Am 8 I limited? Do I have ten minutes, do I have -- 9 BY MR. PAPANTONIO: 10 Q. You -- you have -- 11 A. -- five hours? 12 Q. -- as much time as you want, because right 13 now we're going off the record -- 14 A. Okay. 15 Q. -- and I'm going to get the time back 16 anyway. 17 A. Okay. Sounds good. 18 VIDEOGRAPHER: Going off record. Time 19 is 1:43. 20 (Off the video record at 1:43 p.m.) 21 MR. PAPANTONIO: Keep the camera rolling. 22 No, I want the judge to see this. 23 MR. PYSER: Counsel -- 24 MR. PAPANTONIO: No, I have the right to 25 do it. I want the camera rolling, because I'm</p>

Page 250

1 going to bring this up to special counsel. And  
2 we're going to take the depo again if --  
3 MR. PYSER: If you're going to keep the  
4 camera rolling, we're on the record. You can  
5 have it on the record or off the record.  
6 MR. PAPANTONIO: We're off the record with  
7 the camera rolling.  
8 MR. PYSER: You can be on the record or  
9 off the record, but you can't be off the record  
10 with the camera on.  
11 MR. PAPANTONIO: We're going to have the  
12 camera on, and we're going to be off the record,  
13 then, because we're wasting time because you  
14 don't have this witness prepared. That's your  
15 job. They meet with witnesses and they talk  
16 with them about documents.  
17 MR. PYSER: Counselor, you're showing him  
18 a document from 12 years ago.  
19 MR. PAPANTONIO: Right.  
20 THE WITNESS: I've read what I needed.  
21 MR. PAPANTONIO: You can. Okay. Good.  
22 VIDEOGRAPHER: All right. Stand by to go  
23 back on.  
24 MR. PYSER: I will say for the record that  
25 the time taken, because counsel wanted him to

Page 251

1 review a record should count against his own  
2 time.  
3 BY MR. PAPANTONIO:  
4 Q. Okay. Upon review --  
5 VIDEOGRAPHER: We're going back on the  
6 video record. The time is 1:44.  
7 (Back on the video record at 1:44 p.m.)  
8 BY MR. PAPANTONIO:  
9 Q. Upon review of purchase and sales, DEA  
10 forms, you -- what -- tell me what DEA Form 222 is.  
11 A. A DEA Form 222 is a form that's in  
12 triplicate of a brown, a green, and a blue, that is  
13 used for the sale and distribution of Schedule II  
14 controlled substances.  
15 Q. And according to this, it had customer  
16 data missing. Correct?  
17 A. I'm sorry, I just -- I lost my page.  
18 Q. So it says --  
19 A. What page are we on?  
20 Q. We're on page -- what's that page number?  
21 I don't know what page you're on. Hang  
22 on. What is it -- 4. Page 4.  
23 See where it says: "Upon review of  
24 purchase and sales, DEA form 222, several errors were  
25 found, including data was missing."

Page 252

1 You don't want data missing on a --  
2 something that's a 222, do you? That's not a good  
3 thing, is it?  
4 MR. PYSER: Object to form.  
5 THE WITNESS: Based on this statement, I  
6 don't know what data was missing.  
7 BY MR. PAPANTONIO:  
8 Q. Then it says: "Controlled substance  
9 returns to vendors are shipped without proof of  
10 delivery."  
11 You understand that? "Controlled  
12 substance returns to vendors are shipped without  
13 proof of delivery."  
14 See that?  
15 A. I do see that.  
16 Q. That would be improper, wouldn't it?  
17 MR. PYSER: Object to form.  
18 THE WITNESS: I don't know if I fully  
19 understand what that means.  
20 BY MR. PAPANTONIO:  
21 Q. Okay. Fair enough.  
22 "Destruction and theft losses of ARCOS  
23 reportable items are not being consistently reported  
24 to ARCOS."  
25 Tell the jury what "ARCOS" is. They've

Page 253

1 heard about it by this time in the trial, but tell  
2 them what your -- you describe ARCOS for them.  
3 A. ARCOS is an automated reporting tool for  
4 Schedule II controlled substances. It tracks the  
5 transactions of those drugs from receipt to sale. It  
6 tracks -- basically -- basically that's it. It  
7 tracks the movement of Schedule II ARCOS  
8 reportable -- ARCOS reportable controlled substances.  
9 Q. Go to the next page, point 5, very next  
10 page.  
11 See where it says "DEA," about halfway  
12 down the page?  
13 A. Yes.  
14 Q. It says: "DEA quarterly exception report  
15 is not used to verify customers' licensure is still  
16 active."  
17 See that?  
18 A. I do.  
19 Q. What is "a customers' licensure"?  
20 A. The license. If the -- either the State  
21 license or the DEA license; I don't know which one  
22 this statement is referring to.  
23 Q. So according to this, there's no report  
24 used to verify a customer's license is even active,  
25 correct?

<p style="text-align: right;">Page 254</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: According to this, a</p> <p>3 quarterly exception report is not used.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Yeah. Well, tell -- what's a quarterly</p> <p>6 exception -- what is that report?</p> <p>7 A. I really don't know. There are various</p> <p>8 ways to identify or to verify a DEA registration.</p> <p>9 I'm not sure what the exception report, the quarterly</p> <p>10 exception report is.</p> <p>11 Q. Fair enough. Look at page 7. Point 7.</p> <p>12 You see where it says down here,</p> <p>13 "Controlled substance order filing"?</p> <p>14 A. Yes.</p> <p>15 Q. "There is no system in place" -- "There is</p> <p>16 no system in place to determine excessive purchasing</p> <p>17 of controlled substance products."</p> <p>18 Do you see that?</p> <p>19 A. I do see that.</p> <p>20 Q. And that is improper, not to have a system</p> <p>21 to determine excessive purchasing? That's improper,</p> <p>22 isn't it?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: The regulation states,</p> <p>25 21 CFR 1301.74(b), that a system must be in</p>	<p style="text-align: right;">Page 256</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Why are they important?</p> <p>3 A. Which report are we referring to?</p> <p>4 Q. Any type of inventory report.</p> <p>5 Why are inventory reports important?</p> <p>6 A. Well, the biannual inventory is required</p> <p>7 by the CFR.</p> <p>8 Q. Right.</p> <p>9 A. Yes.</p> <p>10 Q. And tell the jury what that is.</p> <p>11 A. What what is?</p> <p>12 Q. Biannual.</p> <p>13 A. It's an annual -- it's a report taken</p> <p>14 every two years.</p> <p>15 Q. And it's to keep up with the drugs that</p> <p>16 are supposed to have been moving through the hands of</p> <p>17 Cardinal, correct?</p> <p>18 A. It's an inventory of all the drugs from</p> <p>19 the cage vault.</p> <p>20 MR. PAPANTONIO: All right. Let's go</p> <p>21 1165. Show him 1165.</p> <p>22 MS. MOORE: This will be</p> <p>23 Cardinal-Brantley 14.</p> <p>24 ( Cardinal-Brantley 14 was marked for</p> <p>25 identification.)</p>
<p style="text-align: right;">Page 255</p> <p>1 place to identify and report suspicious orders.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. And if you'll go to -- tell us, first of</p> <p>4 all, what is a "periodic controlled substance</p> <p>5 inventory"? What is that, "periodic controlled</p> <p>6 substance inventory"?</p> <p>7 A. A periodic control substance inventory?</p> <p>8 Q. Uh-huh.</p> <p>9 A. There are several inventories taken of</p> <p>10 controlled substances, so I don't know what this is</p> <p>11 referring to.</p> <p>12 But there is a daily movement count; any</p> <p>13 controlled substance that had a movement the previous</p> <p>14 day is counted in the cage and vault. There is an</p> <p>15 inventory taken at -- I think the end of the month</p> <p>16 for certain substances. You have your ARCOS report.</p> <p>17 Inventory, you have your biannual, biannual</p> <p>18 inventory.</p> <p>19 So there are several inventories. I don't</p> <p>20 know what this one is exactly referring to.</p> <p>21 Q. Tell the jury why these inventory reports</p> <p>22 are important.</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: Well -- well, I --</p> <p>25</p>	<p style="text-align: right;">Page 257</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. You've seen this, haven't you?</p> <p>3 A. This is a McKesson document.</p> <p>4 Q. Right. Have you seen this?</p> <p>5 A. No, I have not.</p> <p>6 Q. Do you understand that the same</p> <p>7 presentation was made to Cardinal? Did you know</p> <p>8 that?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. From the DEA?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: Again, I've never seen this</p> <p>14 document.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Well, I'll show you --</p> <p>17 A. And it's a McKesson document.</p> <p>18 Q. Well, okay. Did you know that Purdue --</p> <p>19 you're working for Purdue right now, right?</p> <p>20 A. Correct.</p> <p>21 Q. And you know they were fined \$635 million</p> <p>22 in 2007? You knew that, right?</p> <p>23 MR. LAFATA: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. They were fined \$635 million in 2007?</p>



<p style="text-align: right;">Page 258</p> <p>1 MR. PYSER: Object to form.</p> <p>2 MR. LAFATA: Object to form.</p> <p>3 THE WITNESS: I don't know --</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Right?</p> <p>6 A. -- the exact amount. I -- there was some</p> <p>7 type of fine or settlement at some point.</p> <p>8 Q. Well, you know that they were criminally</p> <p>9 indicted? You know that?</p> <p>10 MR. LAFATA: Object to form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Before you went to work with them, you</p> <p>13 knew that, didn't you?</p> <p>14 A. I did not know that.</p> <p>15 MR. LAFATA: Same objection.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Is that the first time you've heard that?</p> <p>18 The people you've been -- how many -- how many years</p> <p>19 you been working with Purdue?</p> <p>20 A. Since February 2017.</p> <p>21 Q. Okay. So -- so I'm just telling you this</p> <p>22 for the first time, that the company you went to work</p> <p>23 for was criminally investigated, was fined</p> <p>24 \$635 million; that's the first time you've heard</p> <p>25 that?</p>	<p style="text-align: right;">Page 260</p> <p>1 A. I was aware of the settlement, penalty,</p> <p>2 whatever it was.</p> <p>3 Q. Did you -- were you aware of the fact</p> <p>4 that -- that Purdue was accused of phoneying --</p> <p>5 phoneying up research to make it look like the</p> <p>6 product they were making was not addictive? Did you</p> <p>7 know that --</p> <p>8 MR. LAFATA: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. -- before you went to work with this</p> <p>11 company, Purdue?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: Again, I did not know the</p> <p>14 details of the proceedings back then.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Go ahead.</p> <p>17 A. I was aware of a monetary settlement or</p> <p>18 fine or whatever it was, but I was not aware of the</p> <p>19 details of the settlement. So I can't speak to that.</p> <p>20 Q. All right. Well, we're going to go back</p> <p>21 to that, but I just want to know what you knew prior</p> <p>22 to coming in here.</p> <p>23 Did you know that in 2000, the year 2000,</p> <p>24 the GAO -- excuse me -- yeah, GAO had determined that</p> <p>25 Purdue was making up lies about the safety of their</p>
<p style="text-align: right;">Page 259</p> <p>1 MR. LAFATA: Object to form.</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: I do not know the details of</p> <p>4 that settlement, or whatever that was.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Is that important to you, that you went to</p> <p>7 work with a company that had actually been criminally</p> <p>8 investigated by the Department of Justice?</p> <p>9 MR. PYSER: Object.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Does that bother you at all, that you're</p> <p>12 working for a company that's selling narcotics all</p> <p>13 across the country, and they've been criminally</p> <p>14 investigated by the Department of Justice? Does that</p> <p>15 concern you at all, as we sit here?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: With the scope of the --</p> <p>18 whatever it is that you're referring to, that</p> <p>19 settlement or whatever it is -- again, I don't</p> <p>20 know all the details.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Right.</p> <p>23 A. So to put it into the full context, I</p> <p>24 can't answer that. I -- I'm employed by Purdue.</p> <p>25 Q. But you knew this --</p>	<p style="text-align: right;">Page 261</p> <p>1 product? Did you know that?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Prior to coming in here today, before you</p> <p>5 went to work for them?</p> <p>6 MR. PYSER: Object to form.</p> <p>7 THE WITNESS: Again, I don't know all of</p> <p>8 the details about the proceedings from the</p> <p>9 settlement, fine, whatever it was.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Well, Mr. Brantley, is it important that</p> <p>12 you know about the background of a company before you</p> <p>13 go to work with them? Is that important to you, Eric</p> <p>14 Brantley, as we sit here today?</p> <p>15 A. Again --</p> <p>16 MR. LAFATA: Object to form. Asked and</p> <p>17 answered.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Is that important?</p> <p>20 A. Again, I knew of some amount of a</p> <p>21 settlement, fine, whichever it was; did not know all</p> <p>22 the details. I have read some. And that's what I</p> <p>23 know, and that's what I can speak to.</p> <p>24 I do not -- to this day, I do not know all</p> <p>25 of the details of whatever happened with the</p>

Page 262

1 settlement or the fine or the case.  
 2 Q. So it doesn't -- it doesn't matter to you,  
 3 right? It doesn't matter to, Eric Brantley, that --  
 4 what Purdue did? That just doesn't matter to you,  
 5 does it?  
 6 MR. LAFATA: Same objection.  
 7 THE WITNESS: Again, I was aware of an  
 8 amount of money that was paid for a fine,  
 9 settlement, back then. I don't remember the  
 10 year, but I was aware of it.  
 11 BY MR. PAPANTONIO:  
 12 Q. And you know what they did? Can you tell  
 13 the jury what they did, as far as what your -- what  
 14 was in your head when you said, "Yeah, I'm going to  
 15 go to work with this company"?  
 16 What was in your head when --  
 17 A. I did not know what they did.  
 18 Q. You still today, you don't -- you still  
 19 don't know what they did?  
 20 A. To this day, I have not read the details  
 21 of the settlement.  
 22 Just because I'm an employee of the  
 23 company does not mean I know everything that happened  
 24 as -- as far as a settlement or a fine or whatever  
 25 the case was.

Page 263

1 Q. But you have a choice where you want to go  
 2 to work, don't you? I mean, you can choose what  
 3 company you want to go to work for, correct?  
 4 A. Yes.  
 5 Q. And you made the choice, with the  
 6 information you had about Purdue, that you're going  
 7 to work with them --  
 8 MR. PYSER: Object --  
 9 BY MR. PAPANTONIO:  
 10 Q. -- true?  
 11 MR. PYSER: Object to form.  
 12 THE WITNESS: I am a current employee of  
 13 Purdue.  
 14 BY MR. PAPANTONIO:  
 15 Q. Okay. We'll come back to that.  
 16 Let's go to -- let's go to page -- do you  
 17 have the document?  
 18 A. Are we still in the McKesson document?  
 19 Q. Yeah. Yeah, yeah. Go to page -- go to  
 20 point 15 in that document.  
 21 MS. CHARLES: I object to using a McKesson  
 22 confidential document. You have not asked  
 23 permission to use the document with this  
 24 witness. You only asked permission to use it on  
 25 Friday, with a further note that he is a Purdue

Page 264

1 employee, and you have not asked to use that for  
 2 this deposition.  
 3 BY MR. PAPANTONIO:  
 4 Q. All right. Go to page -- go to point 15,  
 5 please.  
 6 A. Okay.  
 7 Q. Now, you see this list that's up there.  
 8 You see this document -- see this list? Have you  
 9 ever seen that list before?  
 10 A. Again, this is a McKesson document, so I  
 11 would not have seen it.  
 12 Q. Well, how about -- how about I'm getting  
 13 ready to show it to you in a Cardinal document?  
 14 Now, do you see --  
 15 MR. PYSER: Object to form.  
 16 BY MR. PAPANTONIO:  
 17 Q. You see where it says "DEA" --  
 18 MR. PYSER: Strike counsel's speech.  
 19 BY MR. PAPANTONIO:  
 20 Q. You see where it says "DEA numbers"?  
 21 A. I do.  
 22 Q. And you're going to love this.  
 23 What is the DEA number again?  
 24 MR. PYSER: Object to form.  
 25

Page 265

1 BY MR. PAPANTONIO:  
 2 Q. Let me ask you: What is the DEA number?  
 3 A. That's the DEA registration.  
 4 Q. Right. And what -- in -- why is that  
 5 important, that DEA number?  
 6 A. That's the registration to distribute  
 7 controlled substances.  
 8 Q. Right. And a person that wants to find  
 9 out about one of these registrants, they can actually  
 10 track them down with the DEA number, can't they?  
 11 A. What do you mean by "track them down"?  
 12 Q. They can find out everything they want to  
 13 about any of these people through a DEA number, can't  
 14 they?  
 15 MR. PYSER: Object to form.  
 16 THE WITNESS: No. The DEA number only  
 17 tells you their address and their -- the type of  
 18 registration, whether they're a distributor or a  
 19 pharmacy. It tells you their location.  
 20 BY MR. PAPANTONIO:  
 21 Q. But that's -- that's important  
 22 information, isn't it? I mean --  
 23 A. I mean, it --  
 24 Q. It's important information, is what I'm  
 25 asking.

<p style="text-align: right;">Page 266</p> <p>1 A. It tells you the name, address of the</p> <p>2 registrant, and the type of registration: Are they</p> <p>3 engaged as a distributor or a pharmacy or a doctor?</p> <p>4 That's what the DEA number tells you.</p> <p>5 Q. Right. And the name of the pharmacy</p> <p>6 certainly is important if you want to find out what</p> <p>7 transactions took place with the name of the</p> <p>8 pharmacy, with the pharmacy, right? It's important?</p> <p>9 The name of a pharmacy -- see how it's got the name</p> <p>10 right there?</p> <p>11 A. The name of the pharmacy is a part of the</p> <p>12 DEA registration.</p> <p>13 Q. And that's important, isn't it?</p> <p>14 MR. PYSER: Object to form. Vague.</p> <p>15 THE WITNESS: I don't know what you're</p> <p>16 asking.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Well, let me show you what I'm asking.</p> <p>19 A. Okay.</p> <p>20 Q. Do you know that you're -- do you know --</p> <p>21 and I'm wondering whether you did this or had</p> <p>22 anything to do with it.</p> <p>23 MR. PAPANTONIO: Show him document 4831,</p> <p>24 please. Put these side by side. Would you,</p> <p>25 please. This is page -- show him the document</p>	<p style="text-align: right;">Page 268</p> <p>1 Q. It says -- it will say "P1" -- actually,</p> <p>2 you know what's even better than that --</p> <p>3 A. Oh, is that the --</p> <p>4 Q. You see where --</p> <p>5 A. At the top?</p> <p>6 Q. You see right here, it's got 176 on it?</p> <p>7 Go to the page that says 176.</p> <p>8 You got it?</p> <p>9 A. Is it the same, this one, the screen?</p> <p>10 Q. Yes, sir. It's the same one up on the</p> <p>11 screen.</p> <p>12 A. I'll view it on the screen --</p> <p>13 Q. Okay.</p> <p>14 A. -- because I can't find it.</p> <p>15 MR. PYSER: You can take your time and</p> <p>16 look at the document, if you want to look at the</p> <p>17 document and review it.</p> <p>18 THE WITNESS: This numbering system, I'm</p> <p>19 not seeing a point something. And I'm trying</p> <p>20 to --</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Well, maybe counsel can help you with it.</p> <p>23 That's what -- that's what they're here for, is to</p> <p>24 help you with this, so -- It's got a 176 --</p> <p>25 A. Ah, wait a minute.</p>
<p style="text-align: right;">Page 267</p> <p>1 first.</p> <p>2 MS. MOORE: Cardinal-Brantley 15.</p> <p>3 (Cardinal-Brantley 15 was marked for</p> <p>4 identification.)</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Page -- go to page 175. What it will be,</p> <p>7 Mr. Brantley, you see down here in the corner, it</p> <p>8 will have a point 175 on it: Point 175.</p> <p>9 MR. PAPANTONIO: Can I have one of those</p> <p>10 candies, please?</p> <p>11 THE WITNESS: Can I take the clip off?</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Yes, sir, you can take a clip off.</p> <p>14 A. I'm sorry, point 175?</p> <p>15 Q. Right. 175.</p> <p>16 A. Is it going to be this number -- this</p> <p>17 number?</p> <p>18 Q. Here's what it's going to look like. See</p> <p>19 up there on the screen? That's what it's going to</p> <p>20 look like, the one to the right.</p> <p>21 A. I don't see a point number at the bottom</p> <p>22 of the page.</p> <p>23 Q. You don't have a point 175? Bottom</p> <p>24 right-hand corner?</p> <p>25 A. Is it a CAH MDL number?</p>	<p style="text-align: right;">Page 269</p> <p>1 Q. You got it?</p> <p>2 A. No, I thought that was it. 122 . . .</p> <p>3 Q. Bottom left-hand corner, it will have</p> <p>4 a 176.</p> <p>5 A. Okay. Now I see your --</p> <p>6 Q. There we go.</p> <p>7 A. -- system here.</p> <p>8 I believe it's 175.</p> <p>9 Q. Okay. 175.</p> <p>10 A. Yes.</p> <p>11 Q. Okay. So you got 175 in front of you,</p> <p>12 right?</p> <p>13 A. Yes.</p> <p>14 Q. Now, you notice the difference between the</p> <p>15 document that appears on the left side of the screen</p> <p>16 and the document that appears on the right side of</p> <p>17 the screen? See that?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 THE WITNESS: I'm going to look at it</p> <p>20 here.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Yeah, go ahead and look --</p> <p>23 A. I have glasses on, but that doesn't --</p> <p>24 still doesn't allow me to see --</p> <p>25 Q. Yeah, look at -- that's fine. But you see</p>

<p style="text-align: right;">Page 270</p> <p>1 the difference between what appears on the document</p> <p>2 you're looking at and the document that McKesson sent</p> <p>3 us? See that?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: I see the two documents.</p> <p>6 Again, what am I looking for?</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Let me -- let me ask you a question about</p> <p>9 it.</p> <p>10 Were you responsible for removing -- were</p> <p>11 you responsible for removing all those DEA numbers</p> <p>12 and the names of the pharmacy that don't appear on</p> <p>13 the Cardinal document?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. It's pretty important, because we're going</p> <p>17 to ask for sanctions on this. Okay?</p> <p>18 A. Was I responsible for removing --</p> <p>19 Q. Just so you understand -- yes, sir.</p> <p>20 A. No.</p> <p>21 Q. Do you -- do you understand that on the</p> <p>22 Cardinal document, all of the -- all of the -- the</p> <p>23 names of the pharmacy -- see that? They're not --</p> <p>24 they're not there, are they?</p> <p>25 MR. PYSER: Counsel, you just made a</p>	<p style="text-align: right;">Page 272</p> <p>1 Mr. Brantley of --</p> <p>2 MR. PAPANTONIO: We'll -- we'll take --</p> <p>3 MR. PYSER: -- something that's</p> <p>4 sanctionable?</p> <p>5 MR. PAPANTONIO: We'll take this up with</p> <p>6 Mr. -- this is not about Mr. Brantley's problem,</p> <p>7 unless he did it.</p> <p>8 I suspect a lawyer did that that works</p> <p>9 somewhere for your organization. So we're going</p> <p>10 to find out.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Did you have anything to do with removing</p> <p>13 the numbers, the DEA numbers, on the -- in the</p> <p>14 document on the right?</p> <p>15 MR. PYSER: Object --</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. Did -- did Eric Brantley have anything to</p> <p>18 do with that?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Yes or no?</p> <p>22 A. No.</p> <p>23 Q. Did Eric Brantley have anything to do with</p> <p>24 removing the names of the pharmacies there on the</p> <p>25 right side of the document?</p>
<p style="text-align: right;">Page 271</p> <p>1 threat of sanctions. I'd like to understand the</p> <p>2 basis for your threat of sanctions.</p> <p>3 MR. PAPANTONIO: I won't --</p> <p>4 MR. PYSER: If you're doing it -- if</p> <p>5 you're doing it to intimidate the witness, it's</p> <p>6 highly improper.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Then take sanctions out of it. That's not</p> <p>9 between me -- that's between me and the lawyers.</p> <p>10 But you understand that somebody left off</p> <p>11 the numbers of the pharmacies on the one on the right</p> <p>12 hand, and they left the names of the pharmacies on</p> <p>13 the one on the right hand.</p> <p>14 Do you see that?</p> <p>15 MR. PYSER: Counsel, are you accusing DEA</p> <p>16 of sanctions? Because this is a DEA</p> <p>17 presentation --</p> <p>18 MR. PAPANTONIO: No, I'm --</p> <p>19 MR. PYSER: -- from 2013.</p> <p>20 MR. PAPANTONIO: I'm accusing your -- I'm</p> <p>21 accusing your company of removing it before we</p> <p>22 got it. That's what I'm accusing it of.</p> <p>23 MR. PYSER: Okay. And on --</p> <p>24 MR. PAPANTONIO: So -- so --</p> <p>25 MR. PYSER: -- what basis are you accusing</p>	<p style="text-align: right;">Page 273</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: No.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Eric Brantley?</p> <p>5 Huh?</p> <p>6 A. No.</p> <p>7 Q. And you would agree, those -- that -- that</p> <p>8 number and the name of that pharmacy tells you a lot,</p> <p>9 doesn't it? If you want information about whether</p> <p>10 there was any kind of misconduct by the pharmacy, you</p> <p>11 got to know who they are, right?</p> <p>12 MR. PYSER: Object to form. Asked and</p> <p>13 answered.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. True?</p> <p>16 A. It identifies the name and the DEA</p> <p>17 registration of the registrant.</p> <p>18 Q. Okay. Now, the next document --</p> <p>19 MR. PAPANTONIO: What number is this?</p> <p>20 MS. MOORE: Internet pharmacy.</p> <p>21 MR. PAPANTONIO: Yeah. Internet -- there</p> <p>22 we go. Go to the next one, please. All right.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. Now, you see these are all -- these --</p> <p>25 these are Internet pharmacies. You see that?</p>

Page 274

1 MR. PYSER: Counsel, if you're going to  
2 ask him questions about an exhibit, can you show  
3 him the document, please?  
4 MR. PAPANTONIO: These are Internet  
5 pharmacies. Yeah, I thought we did. Go  
6 ahead --  
7 MR. PYSER: You have not given the witness  
8 that exhibit.  
9 MR. PAPANTONIO: Yeah.  
10 Here, take mine. Take mine. I'll use the  
11 board up here.  
12 (Cardinal-Brantley 16 was marked for  
13 identification.)  
14 BY MR. PAPANTONIO:  
15 Q. You see the -- where it's all highlighted  
16 in red?  
17 MR. PYSER: Feel free to review this  
18 exhibit. It doesn't have a Bates number on it.  
19 It's unclear what it is.  
20 MR. PAPANTONIO: Where is it?  
21 MS. MOORE: It's this.  
22 MR. PAPANTONIO: Oh, this is an exhibit.  
23 This is a demonstrative exhibit. Okay.  
24 BY MR. PAPANTONIO:  
25 Q. Now, do you see where it's all highlighted

Page 275

1 in red?  
2 MR. PYSER: Object to form.  
3 THE WITNESS: I do see red highlights.  
4 BY MR. PAPANTONIO:  
5 Q. Those are pharmacies, sir.  
6 Out of that entire list -- how many are  
7 there? 34? 34, right?  
8 A. This list does have 34 --  
9 Q. Would --  
10 A. -- entities.  
11 Q. Would you count for the jury how many are  
12 highlighted in red.  
13 A. I count 21.  
14 Q. Do you -- is there anybody in there with  
15 those red that are not Cardinal customers, as far as  
16 you know?  
17 MR. PYSER: Object to form.  
18 THE WITNESS: Is there anyone highlighted  
19 in red --  
20 BY MR. PAPANTONIO:  
21 Q. That are not Cardinal customers.  
22 A. -- that is not a Cardinal customer?  
23 Q. Yeah.  
24 MR. PYSER: Object to form.  
25 THE WITNESS: Are you saying that was not

Page 276

1 a Cardinal customer in 2006?  
2 BY MR. PAPANTONIO:  
3 Q. Uh-huh.  
4 MR. PYSER: Object to form.  
5 THE WITNESS: I don't remember. I -- I  
6 can't remember all the names of pharmacies.  
7 BY MR. PAPANTONIO:  
8 Q. Well, look at MediPharm.  
9 You see that, "MediPharm" up there,  
10 MediPharm? Isn't that number 1?  
11 A. MediPharm, yes.  
12 Q. Do you know that you -- that we went --  
13 went through this already, but you remember the  
14 document that I showed you, 4230, point 21, where we  
15 found out that MediPharm had a monthly average in  
16 sales of 155,000 opioids? You remember that? This  
17 thing right here?  
18 A. I do remember seeing that sheet.  
19 Q. Okay. And do you -- can you go down the  
20 list and tell us how many of those -- how many of  
21 those that you can recall right now that you did  
22 business with?  
23 AccuMed: Do you remember them?  
24 A. No.  
25 Q. New Care: Don't remember them, huh?

Page 277

1 MR. PYSER: Object to form.  
2 THE WITNESS: New Care rings a bell.  
3 BY MR. PAPANTONIO:  
4 Q. Okay. So you just don't -- it's been a  
5 long time --  
6 A. I remember some, and I don't remember  
7 others. It's been a number of years.  
8 Q. All right. Fair enough.  
9 We're going to attach that to the  
10 deposition, so hold that -- hold that thing with the  
11 red -- with the red there.  
12 All right. What else have you got here?  
13 Stand by.  
14 MR. PYSER: Counsel, I'm going to note for  
15 the record the -- again, raising objection to  
16 the improper threat of sanctions.  
17 Had counsel done just a little bit of  
18 research, they would have seen that this  
19 document is available on a public website, with  
20 a .gov address, listed exactly as it's shown,  
21 with no pharmacies or DEA numbers listed.  
22 MR. PAPANTONIO: Right, because Cardinal  
23 removed them, and that's what we're going to  
24 take out. It doesn't have anything to do with  
25 Mr. Brantley.



Page 278

1 MR. PYSER: That allegation is ridiculous.  
 2 And the fact that you raised it with  
 3 Mr. Brantley --  
 4 MR. PAPANTONIO: We'll -- we'll -- we'll  
 5 see.  
 6 MR. PYSER: -- rather than raising it with  
 7 counsel, if you actually have a real concern --  
 8 MR. PAPANTONIO: We'll -- that's what --  
 9 that's what --  
 10 MR. PYSER: -- is absolutely improper.  
 11 MR. PAPANTONIO: That's what hearings are  
 12 for. Okay?  
 13 MR. PYSER: So you're -- you're more than  
 14 welcome to use the public website where this  
 15 document is available --  
 16 MR. PAPANTONIO: Right. Right.  
 17 MR. PYSER: -- without accusing Cardinal  
 18 or Mr. Brantley of removing information.  
 19 MR. PAPANTONIO: That's for another day.  
 20 Mr. Brantley hasn't been accused of anything.  
 21 BY MR. PAPANTONIO:  
 22 Q. You didn't do anything wrong, Mr.  
 23 Brantley.  
 24 You had nothing to do with that document,  
 25 did you? Either one of those documents. You had

Page 279

1 nothing to do with it?  
 2 A. I have not seen those documents.  
 3 Q. Okay. So that's clear.  
 4 MR. PAPANTONIO: Carol?  
 5 BY MR. PAPANTONIO:  
 6 Q. Sir, what we -- tell me, I asked you  
 7 earlier whether or not you know Mike Williams, and  
 8 you said -- I think you said you didn't know who he  
 9 was.  
 10 A. That name does not ring a bell.  
 11 Q. Okay. Now, so you have -- have you seen  
 12 this document, 4453?  
 13 She's going to get it for you right now.  
 14 A. Okay.  
 15 MS. MOORE: Cardinal-Brantley 17.  
 16 (Cardinal-Brantley 17 was marked for  
 17 identification.)  
 18 MR. PAPANTONIO: Do you have a way of  
 19 marking the section there? If you can mark a  
 20 section of the video? We've got -- we've got it  
 21 covered, that last section that we just did. We  
 22 got it.  
 23 BY MR. PAPANTONIO:  
 24 Q. Okay. So 4453. You see that?  
 25 A. I do.

Page 280

1 Q. Monday, October 2005. Results from an  
 2 internal quality audit.  
 3 Remember, we talked about the need to  
 4 audit and -- talked about that earlier?  
 5 A. About audits?  
 6 Q. Yeah.  
 7 A. Okay.  
 8 Q. Okay. So Mike Williams -- it says: "DEA  
 9 on site background information, package is not  
 10 update."  
 11 It says: "The alarm system has not been  
 12 tested by the alarm company."  
 13 You see that?  
 14 "CCTV equipment is not working properly."  
 15 Do you see that?  
 16 A. I do.  
 17 Q. Do you realize -- anybody tell you that  
 18 Mike Williams was accused of actually stealing and  
 19 reselling opioids from the facility where he was in  
 20 charge of security?  
 21 MR. PYSER: Object to form.  
 22 BY MR. PAPANTONIO:  
 23 Q. Had anybody told you that prior to coming  
 24 in here today?  
 25 MR. PYSER: Object to form.

Page 281

1 THE WITNESS: I -- I don't recall that,  
 2 no.  
 3 BY MR. PAPANTONIO:  
 4 Q. And if -- certainly if you've got the guy  
 5 in charge of security that's actually stealing  
 6 product and selling it on the street, that would be  
 7 called diversion, wouldn't it?  
 8 MR. PYSER: Object to form.  
 9 THE WITNESS: That would be called theft.  
 10 BY MR. PAPANTONIO:  
 11 Q. Would be called theft.  
 12 And do you understand -- since you don't  
 13 know Mike, take a look at 4485. Let's -- let's  
 14 introduce you to Mike Williams.  
 15 You would agree that theft of -- theft  
 16 from a facility that is supposed to be locked down  
 17 and protected actually promotes diversion, doesn't  
 18 it?  
 19 MS. MOORE: Cardinal-Brantley 18.  
 20 (Cardinal-Brantley 18 was marked for  
 21 identification.)  
 22 THE WITNESS: I'm sorry --  
 23 BY MR. PAPANTONIO:  
 24 Q. Yeah, you would agree that --  
 25 A. -- what's your question?

Page 282

1 Q. -- a facility that's supposed to be locked  
 2 down and the product protected, if it's being sold  
 3 from the facility by the guy in charge, the head guy  
 4 at security, that actually promotes diversion,  
 5 doesn't it?  
 6 MR. PYSER: Object to form.  
 7 THE WITNESS: That's theft.  
 8 BY MR. PAPANTONIO:  
 9 Q. Right. Right. That's theft, and that's  
 10 wrong.  
 11 And you should have systems in place that  
 12 prevent that, correct?  
 13 A. And there are and were systems in place.  
 14 Q. There were systems in place? Let's read  
 15 this document.  
 16 It says: "The police showed up at 7 p.m.  
 17 tonight asking to talk to a supervisor. I asked both  
 18 officers to hide their badges and leave their guns  
 19 outside so that our folks would not freak out seeing  
 20 police seizing property. I also gave them some old  
 21 Cardinal badges that they wore so folks would think  
 22 they were part of the audit team or something like  
 23 that. The two other officers stayed in the  
 24 conference room with Althea and interviewed Jeff from  
 25 maintenance."

Page 283

1 Are you familiar with any of this?  
 2 A. No.  
 3 Q. This is the first time you've ever heard  
 4 this before?  
 5 MR. PYSER: Object to form.  
 6 THE WITNESS: Yes. I do not recall any of  
 7 this.  
 8 BY MR. PAPANTONIO:  
 9 Q. Okay. And you don't have any idea how  
 10 long Mike was involved with security? Head man at  
 11 security of this facility? You don't have any idea?  
 12 A. Again, I had not heard of Mike.  
 13 Q. And you don't know how many incidents like  
 14 this, where there's theft from the -- from the  
 15 facility by employees where drugs are taken from the  
 16 vault and sold on the street? You don't have any  
 17 idea how many times that occurred with Cardinal, do  
 18 you?  
 19 MR. PYSER: Object to form.  
 20 THE WITNESS: I do not know.  
 21 BY MR. PAPANTONIO:  
 22 Q. And as a matter of fact, one reason you're  
 23 given a license to sell the product is because it's  
 24 your responsibility -- Cardinal's responsibility --  
 25 to make sure the product is not diverted by way of

Page 284

1 theft, correct?  
 2 MR. PYSER: Object to form.  
 3 THE WITNESS: One of the responsibilities  
 4 is to have systems in place for security of  
 5 controlled substances.  
 6 BY MR. PAPANTONIO:  
 7 Q. And if you violate this -- if you -- if  
 8 you violate that, you're actually violating the  
 9 right -- well, you're violating the -- the standard  
 10 for how you ought to engage in business, aren't you?  
 11 MR. PYSER: Object to form.  
 12 THE WITNESS: This is referring to an  
 13 individual. And again --  
 14 BY MR. PAPANTONIO:  
 15 Q. Right.  
 16 A. -- I don't know what this individual did.  
 17 I don't know the details --  
 18 Q. Right.  
 19 A. -- and so forth.  
 20 Q. Oh, I believe. I believe it.  
 21 But you don't know how many times this  
 22 occurred. Let's -- let's read it.  
 23 You don't have any -- any idea how many  
 24 times this kind of thing occurred to your facilities  
 25 from Washington to Lakeland, do you?

Page 285

1 MR. PYSER: Object --  
 2 BY MR. PAPANTONIO:  
 3 Q. You have no idea?  
 4 MR. PYSER: Object to form.  
 5 BY MR. PAPANTONIO:  
 6 Q. Right?  
 7 A. I do not know.  
 8 Q. Okay.  
 9 It says -- see where it says: "They  
 10 recovered from Mike pills for Xanax and OxyContin."  
 11 I'm reading right here, you see there  
 12 "They recovered" --  
 13 A. I do see that.  
 14 Q. "They recovered from Mike pills for Xanax  
 15 and OxyContin, 40 milligrams."  
 16 That's pretty strong, isn't it,  
 17 40 milligrams?  
 18 MR. PYSER: Object to form.  
 19 THE WITNESS: What is? Oxycodone --  
 20 BY MR. PAPANTONIO:  
 21 Q. Yeah.  
 22 A. -- 40 milligrams?  
 23 Q. That's pretty strong, isn't it?  
 24 A. I couldn't speak to the strength. There  
 25 are several strengths of oxycodone.

<p style="text-align: right;">Page 286</p> <p>1 Q. "They suspect from the transcripts of  2 their chat log that Mike has done this in the past.  3 This time, his motivation was not money. He was  4 supposedly exchanging pills for sex."  5 And that's the first time you've heard  6 that story? That's the first thing I want to ask:  7 First time you heard that story?  8 MR. PYSER: Object to form.  9 THE WITNESS: Yes.  10 BY MR. PAPANTONIO:  11 Q. And as we sit here, you're not able to  12 tell me how many times this very thing occurred  13 throughout the country, are you?  14 MR. PYSER: Object to form. Calls for  15 speculation.  16 THE WITNESS: I do not know.  17 BY MR. PAPANTONIO:  18 Q. But you are able to tell me that the  19 responsibility, once they found out that Mike  20 Williams was stealing pills and selling them for sex,  21 what was the responsibility of Cardinal once they  22 found that out? Tell the jury.  23 MR. PYSER: Object to form.  24 THE WITNESS: The CFR states that a theft  25 and loss report or a 106 needs to be filed</p>	<p style="text-align: right;">Page 288</p> <p>1 BY MR. PAPANTONIO:  2 Q. December 18, 2007.  3 A. Yes.  4 Q. You were still working with the company  5 then, weren't you?  6 A. Yes.  7 Q. It says: "Cardinal Health gets another  8 controlled substance suspension."  9 See that?  10 A. Yes.  11 Q. It says: "Dow Jones News Service."  12 And then it says: "Drug wholesaler  13 Cardinal Health has notified customers that the U.S.  14 Drug Enforcement Administration suspended the  15 company's license to distribute controlled substance  16 from a third distribution center."  17 See that?  18 A. Yes.  19 Q. Do you remember this incident?  20 A. I do not.  21 Q. Well, you see where there's a -- there's  22 actually a -- a document -- if you look at the third  23 page, there's actually a news article that's attached  24 to the e-mail. And it says: "Cardinal Health gets  25 another controlled substance suspension."</p>
<p style="text-align: right;">Page 287</p> <p>1 within X number of days of discovery.  2 BY MR. PAPANTONIO:  3 Q. Didn't we establish -- I think we  4 established it was -- it was 7 days, right?  5 A. I believe that's what our earlier document  6 said, 7 days.  7 Q. All right.  8 MR. PAPANTONIO: Show him a -- document  9 4999, please.  10 BY MR. PAPANTONIO:  11 Q. And before we go to that, I just want to  12 be sure: Nobody's talked to you about how many times  13 this occurred throughout the country, over what  14 period of time?  15 A. That is correct.  16 Q. Okay.  17 MS. MOORE: Cardinal-Brantley 19.  18 (Cardinal-Brantley 19 was marked for  19 identification.)  20 BY MR. PAPANTONIO:  21 Q. 4999, see where it says, "2007"?  22 MR. PYSER: 4999?  23 MR. PAPANTONIO: 4999.  24 THE WITNESS: Yes.  25</p>	<p style="text-align: right;">Page 289</p> <p>1 See that?  2 It says: "Drug wholesaler Cardinal Health  3 Incorporated has notified customers that U.S. Drug  4 Enforcement Administration suspended the company's  5 license to distribute controlled substances from a  6 third distributor center."  7 See that?  8 A. Yes.  9 Q. Did you know about this?  10 A. Are these the same three that were listed  11 in the earlier document that you showed me with the  12 settlement agreement?  13 Q. Some of them are different. That's why  14 we're going to go through them.  15 MR. PYSER: Object to form.  16 BY MR. PAPANTONIO:  17 Q. It says: "In all three cases the DEA  18 cited problems with the center's distribution of the  19 narcotic pain reliever hydrocodone, known commonly as  20 Vicodin, a Cardinal spokesman said. The suspensions  21 prohibit the distribution of any controlled  22 substances from the three centers, the spokesman  23 said. Cardinal, based in Dublin, Ohio, wrote to  24 customers of its Swedesboro, New Jersey,  25 pharmaceutical distribution center last week that the</p>

Page 290

1 DEA would suspend the license to distribute  
 2 controlled substances from the facility  
 3 December 13th, 2007."  
 4 Were you working with the company  
 5 December 13, 2007?  
 6 MR. PYSER: Object to form.  
 7 THE WITNESS: Yes.  
 8 BY MR. PAPANTONIO:  
 9 Q. "Cardinal didn't issue a news release  
 10 about the latest suspension, which followed its  
 11 recent announcements that the DEA was suspending its  
 12 license to distribute controlled substances from its  
 13 centers in Auburn, Washington and Lakeland, Florida."  
 14 You see that?  
 15 A. Yes.  
 16 Q. And you knew about the suspensions. We've  
 17 already talked about them, in Auburn, Washington, and  
 18 Lakeland, Florida, correct?  
 19 A. Yes. With the earlier document.  
 20 Q. Right. It says: "The company operates  
 21 25 pharmaceutical distribution centers."  
 22 And the jury has already seen a picture of  
 23 those -- of those distribution centers, correct?  
 24 A. I believe an earlier document said 27.  
 25 Q. 27; it did. This says 25.

Page 291

1 A. Yes.  
 2 Q. "The DEA, in an order to Cardinal  
 3 suspending the Auburn license, said the company had  
 4 failed to maintain effective controls against the  
 5 diversion of a particular controlled substance,  
 6 citing the sale of hydrocodone to a pharmacy that  
 7 allegedly dispensed excessive amounts of drug based  
 8 on illegitimate Internet prescriptions."  
 9 Now, were you asked to get involved in  
 10 this investigation at all? Did anybody from the DEA  
 11 call you and say, "We need your help as far as this  
 12 investigation's concerned"?  
 13 MR. PYSER: Object to form.  
 14 THE WITNESS: What investigation are you  
 15 referring to? Because these -- these three are  
 16 the same that we discussed prior to lunch.  
 17 Right?  
 18 BY MR. PAPANTONIO:  
 19 Q. Okay. What -- what I'm asking you,  
 20 were -- listen to my question.  
 21 Were you asked to get involved in this at  
 22 all, as far as an investigation? Were you asked to  
 23 comment or interviewed or any involvement in this  
 24 investigation that we're talking about right here?  
 25 A. From the DEA?

Page 292

1 Q. Yes, sir.  
 2 MR. PYSER: Object to form.  
 3 THE WITNESS: In regards to the Lakeland  
 4 facility, I had conversations with the Lakeland  
 5 DEA office as I made the recommendation to  
 6 discontinue business to certain pharmacies. And  
 7 those were reported to the DEA.  
 8 BY MR. PAPANTONIO:  
 9 Q. Okay.  
 10 A. And I remember there was an e-mail  
 11 communication with -- I cannot remember her name, but  
 12 she was, I believe, the supervisor for the Florida  
 13 office.  
 14 Q. It says -- okay. It says: "In spite of a  
 15 DEA warning about rogue Internet pharmacies,  
 16 Cardinal's Auburn branch distributed nearly  
 17 18 million dosage units of hydrocodone to retail  
 18 pharmacies in the first nine months of this year."  
 19 Now, do you remember that, that your  
 20 company distributed 18 million doses of hydrocodone  
 21 after the DEA had warned you about rogue Internet  
 22 pharmacies? Do you remember that?  
 23 MR. PYSER: Object to form.  
 24 THE WITNESS: I don't remember how many  
 25 dosage units of a drug was distributed.

Page 293

1 BY MR. PAPANTONIO:  
 2 Q. Okay. Let's see about the next line, see  
 3 if you remember anything about that.  
 4 "In spite of the DEA warning about rogue  
 5 Internet pharmacies, Cardinal's Auburn branch  
 6 distributed nearly 18 million doses of -- dosage  
 7 units of hydrocodone to retail pharmacies in the  
 8 first nine months of this year, including 605,000  
 9 units to Burlington Drug Store, which received a  
 10 suspension of its DEA certificate of registration."  
 11 You see that?  
 12 A. I do.  
 13 Q. Now, Burlington -- you're familiar with  
 14 Burlington, too, aren't you?  
 15 MR. PAPANTONIO: Underline Burlington,  
 16 please?  
 17 THE WITNESS: I believe that's the one we  
 18 discussed earlier in an earlier document.  
 19 BY MR. PAPANTONIO:  
 20 Q. Well, let's go on here. Where is  
 21 Burlington? Tell -- tell me where Burlington is.  
 22 Where -- where is the location of Burlington? Is  
 23 it --  
 24 A. I believe it was -- it was serviced by the  
 25 Auburn facility. So I want to assume that it was in

<p style="text-align: right;">Page 294</p> <p>1 Washington state.</p> <p>2 Q. Was that within the purview of your job,</p> <p>3 to take care of looking at -- at orders coming from</p> <p>4 Washington state?</p> <p>5 A. I did review ingredient limit reports for</p> <p>6 the Auburn facility.</p> <p>7 Q. Okay. You have 1941 in front of you. Go</p> <p>8 ahead and take a minute and find 1941. 1941.</p> <p>9 A. Is that in this document?</p> <p>10 Q. Yes, sir. It's 1941. 1941.</p> <p>11 A. Where would that number be?</p> <p>12 Q. That's going to be probably right on the</p> <p>13 left-hand --</p> <p>14 A. Are we still talking about this document?</p> <p>15 Q. No, sir. We're going to a different</p> <p>16 document. We're going to 1941.</p> <p>17 A. Is that one that I already have?</p> <p>18 Q. Yes.</p> <p>19 A. Okay.</p> <p>20 Q. It will be your third -- about your third</p> <p>21 exhibit there.</p> <p>22 A. Give me --</p> <p>23 Q. I told you that we'd come back to it.</p> <p>24 A. You said 1941?</p> <p>25 Q. 1941, right.</p>	<p style="text-align: right;">Page 296</p> <p>1 to.</p> <p>2 A. Referring to "upside," I don't know what</p> <p>3 that means.</p> <p>4 Q. Well, there's a benefit in -- there's a</p> <p>5 benefit in reporting what you're supposed to,</p> <p>6 following the law, reporting to the DEA, correct?</p> <p>7 MR. PYSER: Object to form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. I mean, that's a good thing, isn't it?</p> <p>10 A. I cannot provide an opinion on what Bill</p> <p>11 Mahoney from McKesson said.</p> <p>12 Q. I don't want -- I don't want you to. I</p> <p>13 want to ask you.</p> <p>14 When you were working in quality</p> <p>15 regulatory, there was an upside to actually telling</p> <p>16 the truth about suspicious orders to the DEA: Yes or</p> <p>17 no?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 Counsel, if you're asking a question,</p> <p>20 that's fine; but then take down the document you</p> <p>21 say that you're not asking him about.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Yes or no?</p> <p>24 A. And again, 21 CFR 1301.74(b) states that</p> <p>25 the registrant shall design a system to identify and</p>
<p style="text-align: right;">Page 295</p> <p>1 A. Ah.</p> <p>2 Q. You got it?</p> <p>3 A. It's a pretty nice stack here.</p> <p>4 MS. CHARLES: I'm repeating my earlier</p> <p>5 objection about using this document.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. So you see the first page on that</p> <p>8 document, it says: "Perhaps the most surprising</p> <p>9 revelation was Steve Reardon and Gilberto Quintero</p> <p>10 saying Cardinal does not report suspicious orders to</p> <p>11 DEA."</p> <p>12 And then it says: "No upside."</p> <p>13 You see that?</p> <p>14 A. Yes.</p> <p>15 Q. What is the "upside"? This says: "No</p> <p>16 upside to reporting to DEA."</p> <p>17 Why don't you tell us what you think is</p> <p>18 the upside to reporting to the DEA?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 THE WITNESS: I cannot speak to what Bill</p> <p>21 Mahoney --</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Right.</p> <p>24 A. -- said.</p> <p>25 Q. I don't want you -- no, I don't want you</p>	<p style="text-align: right;">Page 297</p> <p>1 report suspicious orders.</p> <p>2 Q. Right. And if you don't --</p> <p>3 A. I can't speak to an upside or a downside.</p> <p>4 There's the regulation, and you comply with the</p> <p>5 regulation.</p> <p>6 Q. Well, the downside is you're breaking the</p> <p>7 law if you don't, true?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. That's a downside. When you are breaking</p> <p>11 the law, that's a downside, wouldn't you say?</p> <p>12 A. Again, "upside" and "downside" is a --</p> <p>13 seems like a figure of speech that I can't speak to.</p> <p>14 Q. Okay.</p> <p>15 A. I can tell you what the regulation is.</p> <p>16 Q. Yeah. Let's go to to the second page.</p> <p>17 Bottom paragraph.</p> <p>18 "Later had dinner with the group.</p> <p>19 Interesting gossip came from Reardon and Quintero,</p> <p>20 who relate that Cardinal is not reporting suspicious</p> <p>21 orders to DEA on the advice of outside counsel. We</p> <p>22 don't get any credit for doing it."</p> <p>23 You see that? "We don't get any credit</p> <p>24 for doing it."</p> <p>25 Now, you didn't say that, did you?</p>



<p style="text-align: right;">Page 298</p> <p>1 MR. PYSER: Objection.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. "We don't get any credit for reporting</p> <p>4 suspicious orders to DEA."</p> <p>5 MR. PAPANTONIO: Underline that: "We</p> <p>6 don't get any credit for doing it."</p> <p>7 MR. PYSER: Object to form.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. See that?</p> <p>10 A. I do see that.</p> <p>11 Q. And then it says -- goes on and says:</p> <p>12 "There is no upside."</p> <p>13 MR. PYSER: Object to form.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Do you see that? Those aren't your words,</p> <p>16 because you would never use "upside" and "downside,"</p> <p>17 is what you told us.</p> <p>18 MR. PYSER: Object to form.</p> <p>19 THE WITNESS: That's a terminology I -- I</p> <p>20 can't speak to "upside," "downside."</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. "There's no upside."</p> <p>23 A. I did not --</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: That's not a statement that</p>	<p style="text-align: right;">Page 300</p> <p>1 Q. Okay, let's talk about it. All right.</p> <p>2 Let's see here.</p> <p>3 "State reaches agreement with Cardinal on</p> <p>4 drug trading issues."</p> <p>5 You see that?</p> <p>6 A. Yes.</p> <p>7 Q. It says: "Attorney General Spitzer today</p> <p>8 announced an agreement with Cardinal to improve</p> <p>9 safety and security practice in trading of</p> <p>10 prescription pharmaceutical among wholesalers."</p> <p>11 And you were aware of this investigation,</p> <p>12 right?</p> <p>13 A. Yes.</p> <p>14 Q. Okay.</p> <p>15 "An investigation by the Attorney</p> <p>16 General's Office into trading pharmaceuticals on the</p> <p>17 secondary market determined that certain trading</p> <p>18 practices by wholesalers had the potential to</p> <p>19 compromise the security and the safety of national</p> <p>20 drug distribution."</p> <p>21 Tell the jury what a "secondary market"</p> <p>22 is.</p> <p>23 A. A secondary wholesaler would be a -- I</p> <p>24 guess an alternate-source vendor; a -- I don't really</p> <p>25 know what the exact definition of a secondary</p>
<p style="text-align: right;">Page 299</p> <p>1 I made.</p> <p>2 MR. PAPANTONIO: All right. So what we're</p> <p>3 going to do is we're going to -- these guys have</p> <p>4 got some questions here. I'm going to see if</p> <p>5 I'm done. Let's take ten minutes and do some</p> <p>6 housekeeping to see if we can move on. Okay?</p> <p>7 VIDEOGRAPHER: Off the record. The time</p> <p>8 is 2:27.</p> <p>9 (A recess transpired from 2:27 p.m. until</p> <p>10 2:42 p.m.)</p> <p>11 VIDEOGRAPHER: Going back on the record.</p> <p>12 Beginning of media file number 5. Time is 2:42.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Sir, a little artwork here.</p> <p>15 MR. PAPANTONIO: Show him 4575, please.</p> <p>16 MS. MOORE: Brantley 20.</p> <p>17 (Cardinal-Brantley 20 was marked for</p> <p>18 identification.)</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Take a look at that, sir.</p> <p>21 Have you ever seen that document?</p> <p>22 A. This -- is this a news release?</p> <p>23 Q. Uh-huh. Have you ever seen it?</p> <p>24 A. I don't recall seeing this news release,</p> <p>25 no.</p>	<p style="text-align: right;">Page 301</p> <p>1 wholesaler would be, but it would be, I guess, a</p> <p>2 smaller -- I don't know the exact definition.</p> <p>3 Q. That's okay. I mean, you're not</p> <p>4 expected --</p> <p>5 A. A nonauthorized distributor.</p> <p>6 Q. Yeah, that's okay.</p> <p>7 It said: "Cardinal, based in Dublin,</p> <p>8 ranked 19th on the Fortune 500 list of America's</p> <p>9 corporation -- largest corporation, is one of the</p> <p>10 three primary distributors."</p> <p>11 Now, tell me who the three primary</p> <p>12 distributors are, from your -- from your memory.</p> <p>13 A. The -- the big three would be Cardinal</p> <p>14 Health, AmerisourceBergen, and McKesson.</p> <p>15 Q. And they had special licenses to be able</p> <p>16 to sell narcotics, correct? McKesson, Cardinal, and</p> <p>17 ABC?</p> <p>18 A. It takes a DEA registration with</p> <p>19 Schedule II on it.</p> <p>20 Q. Not everybody can sell narcotics, correct?</p> <p>21 A. It takes a DEA registration with</p> <p>22 Schedule II, yeah.</p> <p>23 Q. Right. And you have to -- to get that,</p> <p>24 you have to make certain promises that you're going</p> <p>25 to do certain things in line with what the DEA</p>

<p style="text-align: right;">Page 302</p> <p>1 requires, true?</p> <p>2 A. You have to apply for an application with</p> <p>3 the DEA. I'm not familiar with what's all on the</p> <p>4 application, but you do have to apply with the DEA</p> <p>5 for that license.</p> <p>6 Q. It says: "Cardinal has agreed to adopt a</p> <p>7 set of wholesale safe product practices to establish</p> <p>8 a new standard for safe trading pharmaceuticals and</p> <p>9 point the way forward for an industry that is vital</p> <p>10 to the health of Americans."</p> <p>11 You see that?</p> <p>12 A. Yes.</p> <p>13 Q. Do you remember what the -- do you</p> <p>14 remember what your promise was about going forward</p> <p>15 and establishing these new standards? Remember what</p> <p>16 your promise was, back in 2005?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: If you're referring -- if</p> <p>19 you're referring to the wholesaler safe product</p> <p>20 practices --</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Yeah.</p> <p>23 A. -- this was around buying and selling</p> <p>24 prescription pharmaceuticals from another wholesaler,</p> <p>25 or pharmaceutical trading. And it was all around</p>	<p style="text-align: right;">Page 304</p> <p>1 with buying from those vendors to take advantage of</p> <p>2 higher available profit margins."</p> <p>3 Did you know that that was going on when</p> <p>4 you were there?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. At Cardinal? That you were actually</p> <p>8 buying from alternative sources so you could take</p> <p>9 advantage of a higher profit margin? Did you know</p> <p>10 that?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 THE WITNESS: I knew that we were buying</p> <p>13 from other wholesalers, from alternate --</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. You had no --</p> <p>16 A. -- source wholesalers.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Go ahead.</p> <p>19 A. No, that's it.</p> <p>20 Q. Yeah. So you had no idea that it was</p> <p>21 going to make higher profit margins by doing that?</p> <p>22 Is that what you're telling us?</p> <p>23 A. I never got into the profit or sale or</p> <p>24 pricing.</p> <p>25 Q. "Cardinal also sold pharmaceuticals to</p>
<p style="text-align: right;">Page 303</p> <p>1 pedigree.</p> <p>2 Q. It was around what? Pedigree?</p> <p>3 A. Pedigree.</p> <p>4 Q. Tell the jury what "pedigree" is.</p> <p>5 A. So what a pedigree is is basically</p> <p>6 tracking a -- a pharmaceutical drug back to an</p> <p>7 authorized distributor. And what an authorized</p> <p>8 distributor is, or was at this time, was if you had</p> <p>9 made two transactions with a -- with a manufacturer</p> <p>10 within 24 months, per PDMA regulations, you were</p> <p>11 considered an authorized distributor.</p> <p>12 So that pedigree tracked all of the</p> <p>13 movement from the drug back to an authorized</p> <p>14 distributor. Okay? And that pedigree had to be</p> <p>15 passed.</p> <p>16 So the wholesale safe product practices</p> <p>17 were -- and again, I'm trying to go by memory -- was</p> <p>18 something that we had the customer sign, stating that</p> <p>19 they would only purchase -- you know, I don't</p> <p>20 remember the exact wording, but it was around passing</p> <p>21 pedigree, and it was around authorized distributors.</p> <p>22 Q. Okay. And look at the last paragraph.</p> <p>23 "The investigation determined that</p> <p>24 Cardinal purchased drugs from certain</p> <p>25 alternate-source vendors despite risks associated</p>	<p style="text-align: right;">Page 305</p> <p>1 certain customers, even in the the face of evidence</p> <p>2 that those customers may have been illegally</p> <p>3 diverting the drugs outside of their intended</p> <p>4 channels of distribution." Correct?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: That is what it says.</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Did you know that that was going on?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 THE WITNESS: Did I know what, exactly?</p> <p>11 I'm sorry.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Well, did you know that the investigation</p> <p>14 had determined that Cardinal purchase drugs from</p> <p>15 alternative sources, could take advantage of the --</p> <p>16 the higher profits -- you said you didn't know about</p> <p>17 that, correct?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 THE WITNESS: Correct.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. You didn't know that?</p> <p>22 A. I don't know the pricing.</p> <p>23 Q. And you didn't know that Cardinal also</p> <p>24 sold pharmaceuticals to certain customers, even in</p> <p>25 the face of evidence that those customers may have</p>

<p style="text-align: right;">Page 306</p> <p>1 been illegally diverting drugs outside their intended          2 channels of distribution?          3 MR. PAPANTONIO: Where is my document on          4 this? That's not it.          5 BY MR. PAPANTONIO:          6 Q. Did you know that?          7 A. This is referring to price diversion.          8 Q. I understand.          9 Did you know about this?          10 MR. PYSER: Object to form.          11 THE WITNESS: I knew that there were --          12 there were purchases made from alternate-source          13 wholesalers.          14 BY MR. PAPANTONIO:          15 Q. Okay.          16 A. That there was trading amongst          17 wholesalers.          18 Q. And this was taking place in New York,          19 correct?          20 MR. PYSER: Object to form.          21 BY MR. PAPANTONIO:          22 Q. Or all -- actually taking place all over          23 the country, true?          24 MR. PYSER: Object to form.          25 THE WITNESS: There was a facility when I</p>	<p style="text-align: right;">Page 308</p> <p>1 that process of buying these drugs from that          2 secondary source and selling them all over the --          3 were being sold all over the country? You know that,          4 don't you?          5 MR. PYSER: Object to form.          6 THE WITNESS: They were sold into several          7 states, yes.          8 BY MR. PAPANTONIO:          9 Q. Okay. That's all I wanted.          10 Okay. So would you go to page 4 of this          11 document.          12 You see where that says -- this says, at          13 the top: "Attorney General of the State of New York          14 Medicaid Fraud Control Unit and Health Care Bureau in          15 the matter of Cardinal Health incorporated."          16 And this was during a time that you were          17 working for the company in 2005, correct?          18 A. Yes.          19 Q. Says: "Assurance of discontinuance          20 pursuant to executive law 6315." See that?          21 A. Yes.          22 Q. Now, let me see what it is you assured --          23 well, not you, but your company assured the Attorney          24 General of New York that you were going to do.          25 Number -- you see page -- point 5? It's</p>
<p style="text-align: right;">Page 307</p> <p>1 started in Texas that was the trading company.          2 BY MR. PAPANTONIO:          3 Q. Right. And you knew that this -- this          4 practice was taking place all over the country, did          5 you not? Did you not know that?          6 MR. PYSER: Object to form.          7 THE WITNESS: This practice was taking          8 place in Texas.          9 BY MR. PAPANTONIO:          10 Q. Okay.          11 A. At the Texas facility. That was the          12 facility that bought and sold the product from other          13 wholesalers.          14 Q. Did it happen in other states besides          15 Texas?          16 MR. PYSER: Object to form.          17 BY MR. PAPANTONIO:          18 Q. This is New York Attorney General here.          19 A. The trading company was based in Texas.          20 That is the facility that purchased drugs from other          21 wholesalers and then distributed drugs to other          22 wholesalers in Texas. That's where the facility was          23 located.          24 Q. All right. I understand where the          25 facility is located, but you understand that that --</p>	<p style="text-align: right;">Page 309</p> <p>1 the next page. It says: "Cardinal is one of the          2 three primary distributors of pharmaceuticals in the          3 United States. Up until it ended the practice in          4 2005, Cardinal, like other national full-line          5 distributors, bought and sold drugs in the secondary          6 market, buying from and selling to wholesale known as          7 alternative vendors."          8 So there was -- you know, did you know          9 whether McKesson was doing that?          10 MR. PYSER: Object to form.          11 THE WITNESS: I only knew what -- what          12 Cardinal Health was doing.          13 BY MR. PAPANTONIO:          14 Q. Okay. It says the -- it says: "As one          15 Cardinal employee wrote in a 2001 e-mail to          16 colleagues worried about the risk of ASV market, 'The          17 firm must understand the need to not kill the goose,          18 ASV, who is laying the golden eggs.' Through its          19 conduct, Cardinal has violated executive law 63(12)."          20 Are you familiar with that? 63(12)?          21 MR. PYSER: Object to form.          22 THE WITNESS: I cannot cite 63(12) at this          23 moment.          24 BY MR. PAPANTONIO:          25 Q. And do you know the employee who wrote in</p>

<p style="text-align: right;">Page 310</p> <p>1 2001 e-mail that they were worried about the risks of          2 the alternative-source market possibly killing the          3 golden -- killing the goose who is laying the golden          4 eggs? Did you know the employee who said that?          5 MR. PYSER: Object to form.          6 THE WITNESS: No.          7 BY MR. PAPANTONIO:          8 Q. I'm sorry. Did you -- did you answer          9 that?          10 A. No, I do not know who said that.          11 Q. Okay.          12 Go down to paragraph 5. It says: "Unique          13 opportunities. In 2003, internal Cardinal e-mail is          14 a compliance officer, one executive addressed the          15 issue of smaller vendors which provided unique          16 opportunities to Cardinal. Although the          17 acknowledging that the vendors are high risk, the          18 writer wrote that since we need the margin from these          19 high risk vendors, we will continue to buy from          20 them."          21 What is -- when you talk about a high-risk          22 vendor, tell me what that means to you, as somebody          23 in quality control?          24 A. A high-risk vendor -- again, this is going          25 back to price diversion and the secondary market. So</p>	<p style="text-align: right;">Page 312</p> <p>1 See where it says H -- 11, excuse me.          2 That's 11 down there. See that 11? It says          3 "Cardinal" --          4 A. Page 7?          5 Q. Yes. Page 7. Point 7.          6 A. Oh, point 7. I'm looking at the page          7 number on the bottom.          8 Q. Point 7.          9 "Cardinal repeatedly sold pharmaceuticals          10 to customers that it knew or should have known were          11 diverting pharmaceuticals."          12 Were you one of the people at Cardinal          13 that knew that?          14 MR. PYSER: Object to form.          15 THE WITNESS: I was an employee at          16 Cardinal Health prior to March 2005.          17 BY MR. PAPANTONIO:          18 Q. Okay. But did you know -- did you ever          19 learn that Cardinal had repeatedly sold          20 pharmaceuticals to customers that it knew or should          21 have known were diverting pharmaceuticals? Did you          22 know that?          23 MR. PYSER: Object to form.          24 THE WITNESS: No, I --          25</p>
<p style="text-align: right;">Page 311</p> <p>1 depending on who you ask, a -- an alternate-source          2 vendor, according to this document, they're stating          3 that they -- some of them could have been high risk.          4 MR. PYSER: Object to form of the last          5 question.          6 BY MR. PAPANTONIO:          7 Q. And so you're -- you're dealing with a          8 high-risk vendor that is actually dealing with          9 narcotics, correct? I mean -- if we accept what that          10 says, you're dealing with narcotics. That's the          11 first thing you can agree with, right?          12 MR. PYSER: Object to form.          13 THE WITNESS: I actually don't remember if          14 Schedule II controlled substances were traded at          15 Trading Company.          16 BY MR. PAPANTONIO:          17 Q. Let's read on, then. Okay?          18 A. Okay.          19 Q. It says our -- "One employee in 2002 wrote          20 an e-mail discussing a newspaper article" --          21 A. Are you on another page? I'm sorry.          22 Q. Yes, sir. I'm on point 6 there.          23 A. Okay.          24 Q. Well, actually, you know what? Get          25 through this a little quicker. Go to page 7.</p>	<p style="text-align: right;">Page 313</p> <p>1 BY MR. PAPANTONIO:          2 Q. First time you saw that?          3 A. It is not the first time I have seen          4 the --          5 Q. Okay.          6 A. -- actual -- whatever this form is called.          7 Q. It says: "Prior to 2005, Cardinal made          8 numerous sales of pharmaceuticals to Nevada -- to a          9 Nevada company which purported to be a closed-door          10 pharmacy that served only nursing homes."          11 Then it says: "In a routine pattern, the          12 Nevada company placed two orders at the same time.          13 One was for products likely to be needed by its          14 stated patient population or nursing home residents,          15 typically in quantities of 1s or 2s, as would be          16 expected for its needs. The other was for much          17 higher quantities, included products unlikely to be          18 needed by nursing home residents. Despite this          19 pattern, Cardinal continued to fill the company's          20 dual orders as described."          21 Did you ever -- were you aware of this          22 pattern that was taking place in nursing homes in          23 Nevada?          24 MR. PYSER: Object to form.          25</p>

<p style="text-align: right;">Page 314</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. This pattern of distribution?</p> <p>3 A. No.</p> <p>4 Q. The dual -- you understand what this is</p> <p>5 saying there: A dual pattern to distribution? You</p> <p>6 never did that, I take it, Mr. Brantley? I have no</p> <p>7 information that you did; I want to make sure you</p> <p>8 didn't.</p> <p>9 A. No.</p> <p>10 MR. PYSER: Object to form.</p> <p>11 Give me a moment to get the objection in.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. It says: "Similarly, starting</p> <p>14 January 2003, Cardinal was alerted to its customers</p> <p>15 of the Carrington network of closed-door pharmacies</p> <p>16 were diverting drugs."</p> <p>17 Again, then it goes down -- I -- are you</p> <p>18 familiar with the Carrington story, where they were</p> <p>19 diverting drugs? Was that something that came across</p> <p>20 your desk?</p> <p>21 MR. PYSER: Object to form.</p> <p>22 THE WITNESS: I don't remember it. But</p> <p>23 it's not my first time hearing --</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Uh-huh?</p>	<p style="text-align: right;">Page 316</p> <p>1 THE WITNESS: There was a system in place?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Well, there was a system in place at the</p> <p>5 time this was occurring, where you were actually --</p> <p>6 where you were actually buying secondary market?</p> <p>7 You're saying you had a system in place --</p> <p>8 MR. PYSER: Object --</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. -- to protect from diversion? Is that</p> <p>11 your testimony?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: I was answering your</p> <p>14 question, after the settlement, was there a -- a</p> <p>15 system in place, and I say that there was a</p> <p>16 system in place.</p> <p>17 MR. PAPANTONIO: Okay. Show him 4961,</p> <p>18 please.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Now, that was New York we were talking</p> <p>21 about, right? That was New York Attorney General we</p> <p>22 just got finished talking about, right?</p> <p>23 A. This is from the New York Attorney</p> <p>24 General, yes.</p> <p>25 Q. Okay. Now, this is 4961.</p>
<p style="text-align: right;">Page 315</p> <p>1 A. It's not my first time hearing of</p> <p>2 Carrington, but I don't remember.</p> <p>3 Q. Well, tell me what you know about</p> <p>4 Carrington.</p> <p>5 A. I don't remember the details at all. I</p> <p>6 just -- the name sounds familiar.</p> <p>7 Q. Okay.</p> <p>8 So after this, your company made a promise</p> <p>9 that you were going to put together an anti-diversion</p> <p>10 system for your company, didn't you?</p> <p>11 I understand this is 2005. Right?</p> <p>12 A. Does it state that in here?</p> <p>13 Q. I'm just asking you: Do you know whether</p> <p>14 they did or didn't?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: Again, you're going back to</p> <p>17 a time frame and you're asking me, did we put a</p> <p>18 system in place. I don't understand your</p> <p>19 question.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Well, did you put a system in place</p> <p>22 after -- after the Attorney General told you you were</p> <p>23 doing things wrong? Did you correct the problem? Or</p> <p>24 do you know?</p> <p>25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 317</p> <p>1 MS. MOORE: Brantley 21.</p> <p>2 (Cardinal-Brantley 21 was marked for</p> <p>3 identification.)</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Now, this is -- this is about Purdue, who</p> <p>6 you're working with now.</p> <p>7 And I wanted to ask you what you --</p> <p>8 remember, I was asking you what you knew about Purdue</p> <p>9 prior to the time you took the job?</p> <p>10 A. Yes.</p> <p>11 Q. And it says: "John L. Brown, the United</p> <p>12 States Attorney for the Western District of Virginia</p> <p>13 and Virginia Attorney General announced today that</p> <p>14 the Purdue Frederick Company, along with its</p> <p>15 president, chief legal officer, and former chief</p> <p>16 medical officer, have pleaded guilty to charges of</p> <p>17 misbranding Purdue's addictive and highly abusable</p> <p>18 drug, OxyContin."</p> <p>19 Is that the first time that you've seen</p> <p>20 those words, where they actually had to plead guilty</p> <p>21 to misbranding highly addictive and abusable drug</p> <p>22 OxyContin?</p> <p>23 MR. LAFATA: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Have you ever seen that before?</p>



<p style="text-align: right;">Page 318</p> <p>1 MR. LAFATA: Same objection.</p> <p>2 THE WITNESS: Again, like I stated</p> <p>3 earlier, I did not review detailed documents of</p> <p>4 this proceeding, settlement, whatever it was.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Well, would that have impacted your</p> <p>7 decision to go to work for them, if you knew that</p> <p>8 they had pleaded guilty to a criminal charge of</p> <p>9 misbranding addictive abusable drug OxyContin, would</p> <p>10 that have affected Eric Brantley's decision to go to</p> <p>11 work for these people?</p> <p>12 MR. LAFATA: Object to form.</p> <p>13 THE WITNESS: Well, again, I'd have to</p> <p>14 know in the full context. But to my knowledge,</p> <p>15 oxycodone and OxyContin comes in a bottle with a</p> <p>16 "C II" on it, which means it's a Schedule II</p> <p>17 controlled substance. And that's issued by the</p> <p>18 DEA. So --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Well, let me -- let's see what this says.</p> <p>21 A. So it's known that it's a Schedule II</p> <p>22 drug, and it contains oxycodone.</p> <p>23 And the fact that it's Schedule II means</p> <p>24 that it is prone to --</p> <p>25 Q. So you don't know what they did, do you?</p>	<p style="text-align: right;">Page 320</p> <p>1 article online from -- from Google or something.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Would you have --</p> <p>4 A. Excuse me.</p> <p>5 But I did not know the details of --</p> <p>6 Q. Would you have gone to work for them if</p> <p>7 you found out that the Purdue Frederick Company and</p> <p>8 three executives admitted that Purdue fraudulently</p> <p>9 marketed OxyContin by falsely claiming that OxyContin</p> <p>10 was less addictive, less subject to abuse, and less</p> <p>11 likely to cause withdrawal symptoms than other</p> <p>12 medications? If somebody had told you that the day</p> <p>13 you said, "I'm going to work for this company," would</p> <p>14 you have gone to work for them anyway?</p> <p>15 MR. LAFATA: Object to form.</p> <p>16 THE WITNESS: Again, with my knowledge of</p> <p>17 controlled substances, knowing that it is a</p> <p>18 Schedule II controlled substance, and the API is</p> <p>19 oxycodone, and the fact that it is a Schedule II</p> <p>20 controlled substance, that means that it is</p> <p>21 prone to abuse or addiction.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. And you --</p> <p>24 A. So knowing that, it's a Schedule II</p> <p>25 controlled substance.</p>
<p style="text-align: right;">Page 319</p> <p>1 You don't know what this company that you decided to</p> <p>2 go to work for -- when did you go to work for them?</p> <p>3 A. February 2017.</p> <p>4 MR. LAFATA: Object to form.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Well, you see, what I'm trying to figure</p> <p>7 out, Mr. Brantley, is we've been sitting here</p> <p>8 questioning you about -- about your company Cardinal,</p> <p>9 which you worked for, right?</p> <p>10 In a second, I'm going to ask you about</p> <p>11 Kinray, who you worked for.</p> <p>12 And I'm wondering how you make a decision,</p> <p>13 because -- how you make a decision on what company</p> <p>14 you're going to go for and not go to work for.</p> <p>15 MR. LAFATA: Object.</p> <p>16 BY MR. PAPANTONIO:</p> <p>17 Q. So -- so here's what I'm asking -- let me</p> <p>18 ask you this question: Did you know that Purdue and</p> <p>19 the three executives will pay a total of</p> <p>20 \$634 million? Did you know that, after they pleaded</p> <p>21 guilty to a criminal offense? Did you know that?</p> <p>22 MR. LAFATA: Object to form.</p> <p>23 THE WITNESS: Again, prior to going to</p> <p>24 work for Purdue, I did not know all of the</p> <p>25 details. I have read a couple sentences from an</p>	<p style="text-align: right;">Page 321</p> <p>1 Q. Well, how the about the fraud part? You</p> <p>2 understand, these people admitted fraud in the way</p> <p>3 they marketed? You didn't know that before I just</p> <p>4 showed it to you, did you?</p> <p>5 MR. LAFATA: Object to form.</p> <p>6 THE WITNESS: I -- I understand that the</p> <p>7 bottle has a "C II" on it, which means it is a</p> <p>8 Schedule II controlled substance, which means it</p> <p>9 is --</p> <p>10 Q. Sir, you know --</p> <p>11 A. So if the bottle had not had a Schedule II</p> <p>12 on it, I may be able to answer that question. But</p> <p>13 the fact that the bottle has a "C II" on it means</p> <p>14 that it is a Schedule II controlled substance.</p> <p>15 Q. Let me ask again.</p> <p>16 Three executives for the company admitted</p> <p>17 and pled guilty to a felony fraud in the way they</p> <p>18 represented their -- their product, and that's okay</p> <p>19 with you.</p> <p>20 Is that -- is that what you're telling me?</p> <p>21 MR. LAFATA: Object to form.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. That's okay?</p> <p>24 MR. LAFATA: Asked and answered, over and</p> <p>25 over. Object to form.</p>

<p style="text-align: right;">Page 322</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Mr. Brantley?</p> <p>3 A. I was not an employee of Purdue at the</p> <p>4 time. And I go back to saying that if the bottle --</p> <p>5 if the three executives were referring to a</p> <p>6 controlled substance where the bottle had a "C II" on</p> <p>7 it, meaning that it is a Schedule II controlled</p> <p>8 substance, knowledge of a controlled substance that</p> <p>9 the industry has --</p> <p>10 Q. Okay. And I guess go to page --</p> <p>11 A. -- I have that knowledge, and that's my</p> <p>12 answer to that question.</p> <p>13 Q. Okay. Go to point 2. Go to the next</p> <p>14 page.</p> <p>15 You see about halfway down, it says: "The</p> <p>16 Purdue Frederick Company pleaded guilty to felony</p> <p>17 misbranding of OxyContin with the intent to defraud</p> <p>18 and mislead."</p> <p>19 And you're saying you would have gone to</p> <p>20 work with a company even though you knew that; is</p> <p>21 that what you're saying?</p> <p>22 MR. LAFATA: Objection. Asked and</p> <p>23 answered, about six times now.</p> <p>24 MR. PAPANTONIO: No, this is a new one.</p> <p>25 This -- this is --</p>	<p style="text-align: right;">Page 324</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Is that what you're telling us?</p> <p>3 MR. LAFATA: Same objection.</p> <p>4 THE WITNESS: I'm stating, again, I don't</p> <p>5 know what the misbranding was or so forth, but</p> <p>6 the brand, the label had a "C" with a Roman</p> <p>7 numeral Schedule II, which meant it was a</p> <p>8 Schedule II controlled substance, and the active</p> <p>9 ingredient is oxycodone.</p> <p>10 So the fact that it is a Schedule II</p> <p>11 controlled substance means it is prone --</p> <p>12 Q. If they lied about --</p> <p>13 MR. LAFATA: Mr. Brantley, you can finish</p> <p>14 your answer.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. Go ahead.</p> <p>17 A. Prone to abuse and addiction. So --</p> <p>18 Q. Right.</p> <p>19 A. You can't get around the "C" with a Roman</p> <p>20 numeral II on it. That means --</p> <p>21 Q. Right.</p> <p>22 A. -- this is a Schedule II drug --</p> <p>23 Q. Right.</p> <p>24 A. -- that's prone to abuse and addiction.</p> <p>25 Q. And if they lied about it, that's</p>
<p style="text-align: right;">Page 323</p> <p>1 MR. LAFATA: Objection. Asked and</p> <p>2 answered.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Let me ask you --</p> <p>5 A. Again, the bottle of OxyContin has a "C"</p> <p>6 with a Roman numeral II on it, which means it is a</p> <p>7 Schedule II controlled substance issued by the DEA,</p> <p>8 which means, as a Schedule II drug containing</p> <p>9 oxycodone --</p> <p>10 Q. Highly addictive?</p> <p>11 A. -- it is prone to abuse.</p> <p>12 Q. It's highly addictive, right? Highly</p> <p>13 addictive?</p> <p>14 A. The fact that a controlled substance has a</p> <p>15 "Schedule II" on it means that the DEA is saying --</p> <p>16 has claimed that it is prone to addiction.</p> <p>17 Q. And you didn't -- and you knew, then, I</p> <p>18 take it, that -- what you're telling me, you knew</p> <p>19 then that the executives to Purdue, they actually</p> <p>20 pleaded guilty to a felony, misbranding OxyContin,</p> <p>21 where they misbranded OxyContin with an intent to</p> <p>22 defraud and mislead; you're saying you knew that when</p> <p>23 you decided, "I'm going to go to work with this</p> <p>24 stellar company, Purdue"?</p> <p>25 MR. LAFATA: Object to form.</p>	<p style="text-align: right;">Page 325</p> <p>1 something you're proud of? If they lied about the</p> <p>2 addictive nature, is that something you're proud of?</p> <p>3 MR. LAFATA: Objection. Badgering.</p> <p>4 THE WITNESS: Are you saying that they</p> <p>5 lied that it was a Schedule II controlled</p> <p>6 substance?</p> <p>7 BY MR. PAPANTONIO:</p> <p>8 Q. Yeah. Yeah.</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Do you -- are you proud of the fact that</p> <p>12 you went from Cardinal, and you went to Kinray, and</p> <p>13 now you're with Purdue, with a company where the</p> <p>14 executives had to plead guilty to committing fraud</p> <p>15 and misleading the public about the addictive nature</p> <p>16 of their drug? Does that make you proud to be with</p> <p>17 that company?</p> <p>18 MR. LAFATA: Object to form.</p> <p>19 THE WITNESS: To answer your first</p> <p>20 question, because you asked about two or three</p> <p>21 in that sentence --</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. No.</p> <p>24 MR. LAFATA: The witness --</p> <p>25 MR. PAPANTONIO: No, no. No, no, no, no,</p>

<p style="text-align: right;">Page 326</p> <p>1 no.</p> <p>2 MR. LAFATA: Mr. Brantley, you can finish</p> <p>3 your answer.</p> <p>4 MR. PAPANTONIO: No, no, no. Read the</p> <p>5 question --</p> <p>6 MR. LAFATA: You will not interrupt his --</p> <p>7 MR. PAPANTONIO: I will interrupt his</p> <p>8 answer --</p> <p>9 MR. LAFATA: Mr. Brantley, you may finish</p> <p>10 your answer to that question by counsel.</p> <p>11 THE WITNESS: The -- the first --</p> <p>12 MR. PAPANTONIO: Whoa, whoa, whoa, whoa,</p> <p>13 whoa.</p> <p>14 MR. LAFATA: Mr. Brantley, there's a</p> <p>15 question on the table.</p> <p>16 MR. PAPANTONIO: There is not a question</p> <p>17 on the table.</p> <p>18 MR. LAFATA: You can finish your answer.</p> <p>19 MR. PAPANTONIO: There's not a question on</p> <p>20 -- read --</p> <p>21 MR. LAFATA: You can finish the answer --</p> <p>22 MR. PAPANTONIO: Read the question back,</p> <p>23 Madam Court -- the question I asked him, I want</p> <p>24 read back in the record, before --</p> <p>25 MR. LAFATA: No. You've interrupted the</p>	<p style="text-align: right;">Page 328</p> <p>1 before counsel interrupted you. That's the</p> <p>2 proper --</p> <p>3 THE WITNESS: The -- the first part of the</p> <p>4 question was --</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Yeah.</p> <p>7 A. -- about executives lying.</p> <p>8 Q. Right. They lied.</p> <p>9 A. And I said, are you stating that they lied</p> <p>10 about the fact that it was a Schedule II controlled</p> <p>11 substance?</p> <p>12 Q. The answer is yes.</p> <p>13 A. And you said yes.</p> <p>14 Q. Yes.</p> <p>15 A. So I don't know how you can lie about the</p> <p>16 fact that something is a Schedule II controlled</p> <p>17 substance when it's printed on every bottle.</p> <p>18 Q. What would they tell you --</p> <p>19 A. That's my -- that's my answer to the first</p> <p>20 part of your question.</p> <p>21 So if you can please repeat the second and</p> <p>22 third part of that question.</p> <p>23 Q. Okay. Second part is: What were they</p> <p>24 telling the American public about the addictive</p> <p>25 nature of their drugs?</p>
<p style="text-align: right;">Page 327</p> <p>1 witness.</p> <p>2 Mr. Brantley, you may answer the</p> <p>3 question --</p> <p>4 MR. PAPANTONIO: Read the question --</p> <p>5 MR. LAFATA: -- you're in the middle of</p> <p>6 answering --</p> <p>7 MR. PAPANTONIO: No. You're -- it's not</p> <p>8 going to happen. Hush. It's not going to</p> <p>9 happen. Okay?</p> <p>10 So read the question back.</p> <p>11 MR. LAFATA: Mr. Brantley, you may</p> <p>12 continue with the answer you were giving</p> <p>13 before --</p> <p>14 MR. PAPANTONIO: You may not, until the</p> <p>15 question is read to you.</p> <p>16 Madam Court Reporter, read the question</p> <p>17 back to him that I asked.</p> <p>18 MR. PYSER: Mr. Brantley, you can finish</p> <p>19 your answer. And if they want the question read</p> <p>20 back after that, they can go ahead all they</p> <p>21 want. But he can't interrupt your answer.</p> <p>22 MR. PAPANTONIO: Do you remember the</p> <p>23 question?</p> <p>24 MR. LAFATA: Mr. Brantley, you can answer</p> <p>25 the question you were in the middle of answering</p>	<p style="text-align: right;">Page 329</p> <p>1 Do you know the answer to that, since</p> <p>2 you're going to give me all these answers?</p> <p>3 A. I can't speak to --</p> <p>4 Q. The company that you're working for right</p> <p>5 now, who pled guilty a felony for fraud and</p> <p>6 misleading -- misleading statements about their</p> <p>7 product, can you please tell us what your company,</p> <p>8 that you're so proud of, was telling the American</p> <p>9 public?</p> <p>10 MR. LAFATA: Object to form.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. What -- what is it? What were they</p> <p>13 telling the American public?</p> <p>14 MR. LAFATA: Same objection.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. This is your chance.</p> <p>17 MR. LAFATA: Same objection.</p> <p>18 THE WITNESS: I have no idea what was</p> <p>19 being said to the public.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. You have no idea. That's what I was</p> <p>22 trying to get at. So the attorney down here is</p> <p>23 objecting to what you -- he wants you to answer your</p> <p>24 question.</p> <p>25 But truthfully -- I'll ask it this way:</p>

Page 330

1 You have no idea what Purdue was doing to lie to the  
 2 American public, to commit fraud to the American  
 3 public, and to get fined for a \$600,000 felony  
 4 criminal event.  
 5 You don't know the answer to that, do you?  
 6 MR. LAFATA: Object to the colloquy.  
 7 Object to the form.  
 8 THE WITNESS: I do not know the details of  
 9 the proceedings, what was said and what was not  
 10 said.  
 11 BY MR. PAPANTONIO:  
 12 Q. Okay.  
 13 A. Again, the only thing I know is that  
 14 OxyContin is oxycodone, and it comes in a bottle with  
 15 a "C II" on it, which means it's a Schedule II  
 16 controlled substance issued by the DEA, which means  
 17 it is prone to addiction.  
 18 Q. We'll have the opportunity to talk about  
 19 this again at another deposition, okay? Because I'm  
 20 going to move on.  
 21 MR. LAFATA: Object to the colloquy.  
 22 BY MR. PAPANTONIO:  
 23 Q. It says -- you read the -- you read the  
 24 next-to-the-last paragraph here: "The falsification  
 25 of drug product information is very serious breach of

Page 331

1 the public trust."  
 2 You agree with that?  
 3 A. Again, I don't know the details of what  
 4 was said and what was not said.  
 5 Q. Well, I'm just asking, do you agree with  
 6 it?  
 7 MR. LAFATA: Objection. Asked and  
 8 answered.  
 9 BY MR. PAPANTONIO:  
 10 Q. That -- do you agree with the statement  
 11 that the falsification of drug product information is  
 12 very serious breach of the public trust?  
 13 A. I would need to know the definition of  
 14 "drug product information." That's a very broad  
 15 term. It could be a lot of information -- like part  
 16 of the information is, is it a Schedule II drug? And  
 17 if it is, what does that mean?  
 18 Q. Well, we know this much, don't we: They  
 19 were prosecuted for it. You know that, don't you?  
 20 MR. LAFATA: Object to form.  
 21 BY MR. PAPANTONIO:  
 22 Q. You know that, don't you? They were --  
 23 A. I know according to this document, you've  
 24 mentioned a number, 600-or-so million dollars that  
 25 was paid. So --

Page 332

1 Q. Sir, I didn't say that. I said that three  
 2 executives pled guilty to felonies.  
 3 You knew that when you signed up with  
 4 Purdue, didn't you?  
 5 A. Earlier, you threw out a number. You said  
 6 it was 600-and-some million. You just said that you  
 7 did not say that, but you said it earlier.  
 8 So what was the second part to your  
 9 question, after you made that statement?  
 10 Q. The second part is: You knew when you  
 11 signed up with this company that you were taking a  
 12 paycheck from a company that had pled guilty to fraud  
 13 and misleading the public about the dangers of  
 14 addiction with their product? You knew that when you  
 15 signed on to this company? You knew that?  
 16 MR. LAFATA: Objection to form.  
 17 THE WITNESS: When I signed on at Purdue,  
 18 I was aware of a proceeding where there was a  
 19 settlement or fine, or whatever it was, of  
 20 600-some million, or something like that. Yes.  
 21 I was aware of --  
 22 BY MR. PAPANTONIO:  
 23 Q. And that didn't bother you, signing up  
 24 with that? Didn't bother you, did it?  
 25 MR. LAFATA: Object to form. Asked and

Page 333

1 answered.  
 2 THE WITNESS: Again, having knowledge of  
 3 what OxyContin is, it's oxycodone that comes in  
 4 a bottle with a "C" with a Roman numeral II, so  
 5 it's a Schedule II controlled substance.  
 6 BY MR. PAPANTONIO:  
 7 Q. Well, Mr. Brantley, you understand why I'm  
 8 asking this question, don't you? Because you've been  
 9 sitting here --  
 10 A. I --  
 11 Q. -- all day -- wait a second.  
 12 You've been sitting here all day  
 13 testifying about the conduct of Cardinal.  
 14 Can we agree to that, that you've been in  
 15 that chair all day testifying about the conduct of  
 16 Cardinal. True?  
 17 MR. LAFATA: Object to form. Compound.  
 18 MR. PYSER: Object to form.  
 19 THE WITNESS: I would ask that you ask one  
 20 question at a time, because you're asking two or  
 21 three questions --  
 22 BY MR. PAPANTONIO:  
 23 Q. No, no --  
 24 A. -- and then when I try to answer you --  
 25 Q. That's one question.

Page 334

1 A. -- you --  
2 Q. It's one question.  
3 A. -- you don't let me.  
4 Q. You've been sitting here all day long  
5 testifying about the conduct of Cardinal. Yes or no?  
6 MR. PYSER: Object to form.  
7 THE WITNESS: I've been sitting here  
8 answering questions about documents that you've  
9 shown me and graphs and e-mails, and I've been  
10 answering those questions.  
11 BY MR. PAPANTONIO:  
12 Q. And then I asked you about the new company  
13 you're with, Purdue, who is a felon, pled felony  
14 charges, and you said that you were willing to work  
15 with them. True?  
16 MR. LAFATA: Object to form.  
17 BY MR. PAPANTONIO:  
18 Q. That's what you said; you were willing to  
19 work with Purdue.  
20 A. Again, you showed me a document, and I  
21 said that the knowledge I had was about the  
22 settlement or the fine or whatever it was, and that I  
23 took a job at Purdue Pharma.  
24 Q. Okay. And then you did the -- and you  
25 knew another company that you worked for -- just so

Page 335

1 we can get Eric Brantley's view of the world --  
2 another company that you worked for was called  
3 Kinray, correct?  
4 MR. PYSER: Object to form. Harassing the  
5 witness.  
6 BY MR. PAPANTONIO:  
7 Q. Is that correct? You worked for Kinray,  
8 true?  
9 A. Yes.  
10 MR. PYSER: Object.  
11 BY MR. PAPANTONIO:  
12 Q. Tell the jury what years you worked for  
13 Kinray before you went to work with Purdue. Tell us  
14 what years those were.  
15 A. I am trying to remember the exact years.  
16 I know I left Kinray -- I left Kinray -- I want to  
17 say October 2013.  
18 Q. Right?  
19 A. And I was there for I believe two years.  
20 So I would have started in 2011, from '11 to 2013, is  
21 what I am remembering.  
22 Q. And you know that Kinray was -- was fined  
23 \$10 million for their conduct in the way they  
24 distributed narcotics? You know that as you sit here  
25 today, don't you?

Page 336

1 MR. PYSER: Object to form.  
2 THE WITNESS: I read that somewhere, yes.  
3 BY MR. PAPANTONIO:  
4 Q. You said you read it somewhere?  
5 A. Yes.  
6 Q. Where do you think you read it?  
7 MR. PYSER: Object to form.  
8 THE WITNESS: I don't know. Probably  
9 Google.  
10 BY MR. PAPANTONIO:  
11 Q. And you know --  
12 A. I don't recall if I was an employee at  
13 that time of the settlement or proceeding, whatever  
14 it was.  
15 Q. All right. So I want to ask you --  
16 MR. PAPANTONIO: Could I get the -- could  
17 I get the Elmo, please?  
18 BY MR. PAPANTONIO:  
19 Q. I want to talk to you a little bit about  
20 Pleasantville.  
21 You know where Pleasantville is, sir?  
22 MR. PYSER: Counsel, if you're marking --  
23 MR. PAPANTONIO: I'm going to mark it and  
24 offer it. I'll do it at the right time. Okay?  
25

Page 337

1 BY MR. PAPANTONIO:  
2 Q. Do you know where Pleasantville is?  
3 A. I do not.  
4 Q. Okay. Do you know where -- have you --  
5 have you worked West Virginia?  
6 A. Have I worked in West Virginia?  
7 Q. Uh-huh.  
8 A. I have never worked in West Virginia.  
9 Q. Have you reviewed -- have you reviewed  
10 sales and distribution in the state of West Virginia?  
11 A. During the 2005 to late 2007 or early 2008  
12 time frame, I was responsible for viewing ingredient  
13 limited reports, which would have included --  
14 Q. Now, the --  
15 A. -- the Wheeling, West Virginia, facility.  
16 Q. Right. Okay. So if -- let's just make up  
17 some facts, and I want to ask you what you know.  
18 You -- well, first of all, you know that  
19 there was a city in West Virginia where there was a  
20 population -- I'm going to call it "Pleasantville."  
21 You know what the real name is, don't you?  
22 A. I do not.  
23 MR. PYSER: Object to form.  
24 BY MR. PAPANTONIO:  
25 Q. That doesn't surprise me.



<p style="text-align: right;">Page 338</p> <p>1 MR. PYSER: Object to form. Move to          2 strike counsel's --          3 BY MR. PAPANTONIO:          4 Q. You know there was a city in -- you know          5 there was a city in West Virginia where there were          6 400 people, and there were 6 million pills sold to          7 those 400 people, and your company was involved in          8 selling 6 million pills to 400 people.          9 Did you -- have you ever heard that          10 before?          11 MR. PYSER: Object to form.          12 MR. PAPANTONIO: Name of the town?          13 I'm asking you, Michael. Kermit?          14 THE WITNESS: I have not heard of Kermit.          15 BY MR. PAPANTONIO:          16 Q. Do you know what Kermit is? Have you ever          17 heard of Kermit?          18 MR. PYSER: Object to form.          19 BY MR. PAPANTONIO:          20 Q. Huh?          21 A. I have not heard of Kermit.          22 Q. Have you ever heard of Mount Gay?          23 A. I have not heard of Mount Gay.          24 Q. But you're the person who cleared orders          25 for West Virginia; you're one of the people that did</p>	<p style="text-align: right;">Page 340</p> <p>1 evidence.          2 BY MR. PAPANTONIO:          3 Q. Tell me how that happened?          4 A. I cannot state how 400 people -- are you          5 suggesting that 6 million pills were shipped to          6 400 people?          7 Q. Yeah.          8 MR. PYSER: Object to form.          9 BY MR. PAPANTONIO:          10 Q. Is that the first you've heard that, that          11 6 million pills were shipped to 400 people? That          12 surprises you, doesn't it?          13 MR. PYSER: Object to form. Misstates          14 evidence.          15 BY MR. PAPANTONIO:          16 Q. Doesn't it?          17 A. I have not heard it.          18 Q. The first time you've heard it is me          19 telling you about it, right?          20 MR. PYSER: Object to form.          21 THE WITNESS: That is correct.          22 BY MR. PAPANTONIO:          23 Q. And in these days that you prepared to          24 come here to testify, nobody even shared that with          25 you, had they?</p>
<p style="text-align: right;">Page 339</p> <p>1 that, right?          2 A. I reviewed --          3 MR. PYSER: Object to form.          4 THE WITNESS: I reviewed ingredient limit          5 reports that included --          6 BY MR. PAPANTONIO:          7 Q. And nobody --          8 A. -- the Wheeling, West Virginia, facility.          9 Q. Okay. Nobody told you that there was a          10 town called Kermit -- let's call it -- let's call it          11 Kermit, not Pleasantville.          12 There's a town called Kermit, with          13 400 people, and 6 million pills were pumped into the          14 city of Kermit.          15 You didn't know that, prior to me telling          16 you that right now?          17 MR. PYSER: Object to form.          18 BY MR. PAPANTONIO:          19 Q. Yes or no?          20 A. I did not know that.          21 Q. Okay. Now, tell me, how would -- you've          22 been doing this a long time. Tell me how 400 people          23 would absorb 6 million pills over a period of two          24 years?          25 MR. PYSER: Object to form. Misstates</p>	<p style="text-align: right;">Page 341</p> <p>1 MR. PYSER: Object.          2 BY MR. PAPANTONIO:          3 Q. That 400 people, a city of 400 people,          4 that there were 6 million pills pumped into that          5 city. Right?          6 MR. PYSER: Object to form.          7 And I counsel the witness not to answer          8 any questions about his conversations with          9 counsel.          10 BY MR. PAPANTONIO:          11 Q. You didn't know --          12 MR. PYSER: That's privileged, and counsel          13 knows that it's privileged.          14 BY MR. PAPANTONIO:          15 Q. Oh, did counsel tell you that?          16 MR. PYSER: Counsel --          17 BY MR. PAPANTONIO:          18 Q. Nobody -- nobody told you that, did they,          19 prior to coming here?          20 MR. PYSER: Object to form.          21 BY MR. PAPANTONIO:          22 Q. Let me ask the question again:          23 Did anybody from the company tell you that          24 there was a city, there were 400 people that had          25 6 million pills pumped into it over a period of two</p>

<p style="text-align: right;">Page 342</p> <p>1 years?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 BY MR. PAPANTONIO:</p> <p>4 Q. Anybody tell you that?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: No one from the company told</p> <p>7 me that.</p> <p>8 BY MR. PAPANTONIO:</p> <p>9 Q. Well, does that sound like too many pills</p> <p>10 to you?</p> <p>11 MR. PYSER: Object to form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. In all your experience working for Purdue</p> <p>14 and then working for Kinray and working for Cardinal,</p> <p>15 does that sound like too many pills being pumped into</p> <p>16 an area of 400 people?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. Two years?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 THE WITNESS: So, not knowing the context,</p> <p>22 earlier you stated that 6 million pills were</p> <p>23 shipped to 400 people.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Right?</p>	<p style="text-align: right;">Page 344</p> <p>1 lived in these various areas, right? Salespeople?</p> <p>2 True?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Yes?</p> <p>6 A. I'm not familiar where the salespeople</p> <p>7 lived.</p> <p>8 Q. Well, did the salespeople --</p> <p>9 A. But they were salespeople.</p> <p>10 Q. They were salespeople, and they lived in</p> <p>11 cities all over the country, correct?</p> <p>12 MR. PYSER: Object to form. Whose</p> <p>13 salespeople?</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Yes or no? Cardinal had salespeople --</p> <p>16 you know what I'm talking about. Cardinal had</p> <p>17 salespeople that lived in these cities all over the</p> <p>18 country.</p> <p>19 Did you know that, prior to coming here</p> <p>20 today?</p> <p>21 MR. PYSER: Object to form.</p> <p>22 THE WITNESS: Cardinal has salespeople</p> <p>23 that lived in the various cities.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. Yeah. And you've actually seen pictures,</p>
<p style="text-align: right;">Page 343</p> <p>1 A. And I asked, were they shipped to</p> <p>2 400 people? Then you later stated they were shipped</p> <p>3 to a town with residents of --</p> <p>4 Q. Kermit.</p> <p>5 A. -- of 400 people.</p> <p>6 Q. Right.</p> <p>7 A. So in the whole context, was it only the</p> <p>8 400 people that consumed the 6 million pills, or were</p> <p>9 there people coming in from other towns or states? I</p> <p>10 don't know the context, so I can't answer the</p> <p>11 question.</p> <p>12 Q. Nobody showed it to you, did they?</p> <p>13 How about -- let me ask you this.</p> <p>14 MR. PYSER: Object to the form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. How about if we just have 3 million pills,</p> <p>17 3 million pills shipped to Kermit over a period of</p> <p>18 two years, with 400 people.</p> <p>19 That's too many pills, isn't it?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 THE WITNESS: My answer does not change.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. All right. I believe that.</p> <p>24 Now, you understand -- you traveled to</p> <p>25 these areas, and they had salespeople that actually</p>	<p style="text-align: right;">Page 345</p> <p>1 haven't you, of pill mills where people are actually</p> <p>2 lined up around the pill mill to be able to get their</p> <p>3 pill.</p> <p>4 Have you ever seen pictures like that --</p> <p>5 MR. PYSER: Object to form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. -- throughout the country?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 THE WITNESS: Yes.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. Yeah. And as a matter of fact, the</p> <p>12 salesperson that lives in a city where there's a pill</p> <p>13 mill has the ability to see the pill mill, right? I</p> <p>14 mean, they drive by the pill mills; that's the way</p> <p>15 it's set up. Right?</p> <p>16 MR. PYSER: Object to form. Calls for</p> <p>17 speculation.</p> <p>18 THE WITNESS: I can't answer to where they</p> <p>19 drive to.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Okay. So your testimony is you don't know</p> <p>22 whether a salesperson living in a city where there's</p> <p>23 pill mills with people lined up around them, you</p> <p>24 don't know whether they would see that or not?</p> <p>25 That's your testimony, correct?</p>

<p style="text-align: right;">Page 346</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: My testimony -- my testimony</p> <p>3 is that I cannot answer to where a particular</p> <p>4 salesperson would drive.</p> <p>5 BY MR. PAPANTONIO:</p> <p>6 Q. Well, do you know cities all over the</p> <p>7 country where salespeople live, they would have</p> <p>8 newspaper reports -- you ever seen newspaper reports</p> <p>9 about overdoses in cities all over the country? You</p> <p>10 ever see even one? Did anybody send you even one</p> <p>11 article talking about people dying from overdoses</p> <p>12 because of the product that your company was selling?</p> <p>13 MR. PYSER: Object to form.</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. Did they ever do that?</p> <p>16 A. No one has sent me an article.</p> <p>17 Q. Have you seen any articles about your</p> <p>18 company selling products that were killing people by</p> <p>19 overdoses?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Yes or no?</p> <p>23 MR. PYSER: Vague.</p> <p>24 THE WITNESS: Which company are we</p> <p>25 referring to?</p>	<p style="text-align: right;">Page 348</p> <p>1 A. I don't know what the definition -- what</p> <p>2 the definition is of "plenty," but I have seen</p> <p>3 articles over the last --</p> <p>4 Q. Okay. If you had a city like -- let's</p> <p>5 say --</p> <p>6 A. -- couple years.</p> <p>7 MR. PYSER: Sir, were you done with your</p> <p>8 answer?</p> <p>9 THE WITNESS: Yeah. I was just saying</p> <p>10 that I have seen articles over the last couple</p> <p>11 of years.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. If you have a city like Kermit, sir,</p> <p>14 and it's -- let's say 3 million pills are coming into</p> <p>15 Kermit.</p> <p>16 If 400 people can't absorb those pills,</p> <p>17 where do the pills go?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Do you -- have you analyzed that at all?</p> <p>21 When you were in quality control, did you ever</p> <p>22 analyze -- if I'm shipping 3 million pills into a</p> <p>23 city of 400 people, where did all the rest of the</p> <p>24 pills go?</p> <p>25 MR. PYSER: Object to form.</p>
<p style="text-align: right;">Page 347</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Cardinal.</p> <p>3 A. Have I seen articles?</p> <p>4 Q. Yeah.</p> <p>5 A. Can you ask the question again, so I know</p> <p>6 the --</p> <p>7 Q. Yeah. Have you seen articles that state</p> <p>8 that people were dying of overdoses relating to the</p> <p>9 sale of opioids? Let's -- let's start there.</p> <p>10 A. I've seen articles about people dying from</p> <p>11 the abuse of opioids.</p> <p>12 Q. And when did you start seeing those first</p> <p>13 articles?</p> <p>14 A. I don't recall when I first started seeing</p> <p>15 the articles. They were over the last several years.</p> <p>16 Q. Saw them in newspaper reports, I take it?</p> <p>17 True?</p> <p>18 A. I don't know if it was a newspaper report</p> <p>19 or CNN or the TV or the Internet.</p> <p>20 Q. But you -- you saw plenty -- would it be</p> <p>21 fair to say you saw plenty of articles where people</p> <p>22 were dying from drug overdoses related to opioids?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. True?</p>	<p style="text-align: right;">Page 349</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. You ever even thought about that prior to</p> <p>3 coming in here today?</p> <p>4 A. So which -- which question would you like</p> <p>5 me to answer?</p> <p>6 Q. Have you ever thought about what happens</p> <p>7 when 3 million pills are shipped into a city of</p> <p>8 400 people, what happens to the other pills if</p> <p>9 they're not absorbed by those 400 people?</p> <p>10 MR. PYSER: Object to form.</p> <p>11 THE WITNESS: I cannot speak to exactly</p> <p>12 where pills go. But again, not knowing the</p> <p>13 context of -- I think you mentioned Kermit -- I</p> <p>14 don't know if there are surrounding counties,</p> <p>15 surrounding cities, if people came into -- I</p> <p>16 don't know if it's rural area, if it's an urban</p> <p>17 industrial area; have people traveled from a</p> <p>18 neighboring county or city to come to it?</p> <p>19 Again, I don't know the context of --</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Right.</p> <p>22 A. -- Kermit.</p> <p>23 Q. So that tells me a lot. Tells me a lot,</p> <p>24 because what you're saying is you're the guy that's</p> <p>25 signing off on all of these drugs to be shipped all</p>

<p style="text-align: right;">Page 350</p> <p>1 over the country, and you never even visited the  2 cities that you were shipping drugs to.  3 A. I reviewed ingredient limit reports on a  4 monthly basis, and I submitted those reports, and  5 those reports were submitted to the DEA. I conducted  6 investigations as necessary and reported those  7 pharmacies to the DEA. I review ingredient limit  8 reports.  9 Q. Did you go to Kermit?  10 MR. PYSER: Object -- object to form on  11 the prior question. I didn't want to --  12 BY MR. PAPANTONIO:  13 Q. Did you go to Kermit?  14 MR. PYSER: -- interrupt the question.  15 Object to form again.  16 BY MR. PAPANTONIO:  17 Q. Did you visit Kermit?  18 MR. PYSER: Object to form.  19 THE WITNESS: I have not visited Kermit,  20 to my knowledge.  21 BY MR. PAPANTONIO:  22 Q. Did you visit Mount Gay --  23 MR. PYSER: Object to form.  24 BY MR. PAPANTONIO:  25 Q. -- West Virginia?</p>	<p style="text-align: right;">Page 352</p> <p>1 there was a connection between South Florida and all  2 the way up to Maine, where people would pick up  3 drugs, opioids, and sell them all along the way? You  4 ever heard that before?  5 MR. PYSER: Object to form.  6 BY MR. PAPANTONIO:  7 Q. First time you've ever heard of an Oxy  8 Express?  9 MR. PYSER: Object to form.  10 THE WITNESS: Again, I have not heard the  11 term "Oxy Express."  12 BY MR. PAPANTONIO:  13 Q. What term is a term that describes what I  14 just said?  15 A. I've not heard the term "Oxy Express."  16 Q. And you've --  17 A. You just explained a -- a scenario.  18 Q. And you've worked with Cardinal, and  19 you've worked with Kinray, and now you're there with  20 Purdue, and you've never heard of an Oxy Express; is  21 that your testimony?  22 MR. PYSER: Object to form.  23 BY MR. PAPANTONIO:  24 Q. Yes?  25 MR. PYSER: Asked and answered.</p>
<p style="text-align: right;">Page 351</p> <p>1 A. I have not been to Mount Gay, West  2 Virginia, to my knowledge.  3 Q. So you wouldn't know whether 3 million  4 pills were being shipped into a population of 400 or  5 not, would you? You have no idea? True?  6 MR. PYSER: Object to form.  7 THE WITNESS: I know nothing of Mount Gay  8 or Kermit.  9 BY MR. PAPANTONIO:  10 Q. But nevertheless, you were the person that  11 was permitting -- you were signing off on orders in  12 places like West Virginia, weren't you?  13 MR. PYSER: Object to form. Misstates  14 evidence.  15 BY MR. PAPANTONIO:  16 Q. Correct?  17 A. I was reviewing ingredient limit reports  18 on a monthly basis.  19 Q. Right. Now, tell us, tell the jury what  20 the "Oxy Express" is. Oxy Express.  21 A. I don't know what the Oxy Express is.  22 Q. You've never heard the term "Oxy Express"?  23 Is that -- is that your testimony today, really?  24 A. I don't know what Oxy Express is.  25 Q. Okay. Did you know that there was --</p>	<p style="text-align: right;">Page 353</p> <p>1 THE WITNESS: I have worked for Cardinal,  2 Kinray, and as you said, now Purdue. I'm not  3 familiar with the term "Oxy Express."  4 BY MR. PAPANTONIO:  5 Q. Oh, Endo: You worked for Endo, too,  6 didn't you?  7 A. I did work for QualiTest Pharmaceuticals.  8 Q. Okay, I missed Endo.  9 So you've worked for -- you worked for  10 Cardinal, you worked for Endo, you worked for Kinray,  11 you worked for Purdue, and not one time have you ever  12 heard the term "Oxy Express"; is that your testimony  13 here today?  14 MR. PYSER: Object to form.  15 MS. VANNI: Objection.  16 THE WITNESS: Again, I have not heard the  17 term "Oxy Express."  18 BY MR. PAPANTONIO:  19 Q. So, sir, if you got a town, you got a town  20 of 400 people, let's say just -- let's say just two  21 million pills are coming in there, a million a year.  22 Take it down to 2 million.  23 And if the 400 people, the children and  24 the mommas and the daddies, they can't absorb  25 those -- those 2 million pills, where do the other</p>

<p style="text-align: right;">Page 354</p> <p>1 pills go?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: My answer does not change</p> <p>4 from the other two or three times you asked the</p> <p>5 question.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Have you ever heard of the term "glut"?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Have you ever heard the term "glut"</p> <p>11 before?</p> <p>12 A. I have not heard the term "glut."</p> <p>13 Q. Well, what -- do you understand what the</p> <p>14 term "glut" means? I?</p> <p>15 A. I do not know what "glut" means.</p> <p>16 What does "glut" mean?</p> <p>17 Q. Well, you -- I'm not going to answer that</p> <p>18 for you. I just want to know, you've been at this --</p> <p>19 how many years have you just described that you've</p> <p>20 been in the -- in the opioid business, and you never</p> <p>21 heard the term "glut"?</p> <p>22 MR. PYSER: Object to form.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. A glut of opioids in small towns; you've</p> <p>25 never heard that term?</p>	<p style="text-align: right;">Page 356</p> <p>1 West Virginia.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Yeah. Do --</p> <p>4 A. But I do not know where in West Virginia</p> <p>5 Mount Gay is.</p> <p>6 Q. But you were a person that signed off on</p> <p>7 order requests in West Virginia, weren't you? You</p> <p>8 were one of the three people that did that, right?</p> <p>9 A. You say "signed off on order requests" --</p> <p>10 I'm sorry.</p> <p>11 MR. PYSER: Object to form.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Or review?</p> <p>14 A. You say "signed off on order requests." I</p> <p>15 review ingredient limit reports on a monthly basis.</p> <p>16 Q. Right. Okay. And you did that for West</p> <p>17 Virginia, right?</p> <p>18 A. I did that for the facility located in</p> <p>19 Wheeling, West Virginia.</p> <p>20 Q. All right. And you knew that -- that</p> <p>21 there was a town -- you didn't know, I take it, that</p> <p>22 there was a town called Mount Gay, where a population</p> <p>23 of 1,700 people lived, never even heard that?</p> <p>24 MR. PYSER: Object to form.</p> <p>25</p>
<p style="text-align: right;">Page 355</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: To answer your -- one of two</p> <p>3 or three questions --</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. Yeah.</p> <p>6 A. -- the first one is, I've been in the</p> <p>7 industry since January 2000.</p> <p>8 Q. Okay.</p> <p>9 A. And I have not heard the term "glut."</p> <p>10 Q. Have you ever seen a -- you have the --</p> <p>11 have you ever seen anything like I'm -- let's put it</p> <p>12 up on the screen.</p> <p>13 MR. PYSER: Object to form.</p> <p>14 And, Counsel, are you going to be marking</p> <p>15 those as exhibits?</p> <p>16 MR. PAPANTONIO: Oh, yeah. Yeah, I would</p> <p>17 not dream of not putting my artwork in there.</p> <p>18 Hold it right there.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Let's go to Mount Gay, population</p> <p>21 1,700 people.</p> <p>22 Do you know where Mount Gay is, sir?</p> <p>23 MR. PYSER: Object to form. Asked and</p> <p>24 answered.</p> <p>25 THE WITNESS: Again, I do not -- it's in</p>	<p style="text-align: right;">Page 357</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. True?</p> <p>3 A. Again, up until a few minutes ago when you</p> <p>4 mentioned Mount Gay, I've never heard of Mount Gay.</p> <p>5 Q. All right. Let's see what -- do you have</p> <p>6 any -- so right now, you couldn't tell me how many</p> <p>7 pills were sold in Mount Gay, as we sit here, right?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 THE WITNESS: That is correct.</p> <p>10 BY MR. PAPANTONIO:</p> <p>11 Q. And you've been in this business -- you</p> <p>12 worked for Cardinal for -- I'm sorry, how many years</p> <p>13 total? Cardinal?</p> <p>14 A. I started with a company, January of 2000,</p> <p>15 that was acquired by Cardinal in 2002. And I left</p> <p>16 Cardinal in 2013.</p> <p>17 Q. And you've never heard of the term "glut,"</p> <p>18 right?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 BY MR. PAPANTONIO:</p> <p>21 Q. Never heard that?</p> <p>22 A. I've never heard the term "glut."</p> <p>23 Q. And you've never head of the term "Oxy</p> <p>24 Express"; is that correct?</p> <p>25 MR. PYSER: Object to form.</p>



<p style="text-align: right;">Page 358</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Yes or no?</p> <p>3 A. I'm giving my lawyer a chance to see if he</p> <p>4 wants to speak.</p> <p>5 Q. Yes or no? You've never --</p> <p>6 A. I've never --</p> <p>7 MR. PYSER: Counsel -- object to form.</p> <p>8 You've got to give me a chance to enter --</p> <p>9 intersperse an objection if needed, and you've</p> <p>10 got to give the witness a chance to answer your</p> <p>11 question before you ask your next question.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. Yes or no: You've never heard of the term</p> <p>14 "Oxy Express"?</p> <p>15 Easy. Yes or no?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: Again, again, I have not</p> <p>18 heard the term "Oxy Express."</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Have you ever seen a depiction of what</p> <p>21 happens with pills when a town like Mount Gay is</p> <p>22 getting millions of pills and then understanding</p> <p>23 where those millions of pills went if they weren't</p> <p>24 absorbed in a town like Mount Gay? Have you ever</p> <p>25 heard an analysis of that?</p>	<p style="text-align: right;">Page 360</p> <p>1 MR. PAPANTONIO: David, you want to --</p> <p>2 or --</p> <p>3 MR. FULLER: You want to take a quick</p> <p>4 break?</p> <p>5 MR. PAPANTONIO: Yeah, let's take a break.</p> <p>6 VIDEOGRAPHER: We're going off the record.</p> <p>7 The time is 3:31.</p> <p>8 (A recess transpired from 3:31 p.m. until</p> <p>9 3:44 p.m.)</p> <p>10 (Cardinal-Brantley 22 was marked for</p> <p>11 identification.)</p> <p>12 (Cardinal-Brantley 23 was marked for</p> <p>13 identification.)</p> <p>14 VIDEOGRAPHER: We're going back on the</p> <p>15 record. Beginning of media unit file number 6.</p> <p>16 The time is 3:44.</p> <p>17 EXAMINATION</p> <p>18 BY MR. FULLER:</p> <p>19 Q. Mr. Brantley, you've been speaking with</p> <p>20 Mr. Papantonio for quite some time. I wanted just to</p> <p>21 follow up on a few things and cover a few new areas;</p> <p>22 I'm going to try not to repeat anything. Okay?</p> <p>23 A. Okay.</p> <p>24 Q. So the two or three people that also</p> <p>25 filled your role from '05 to '07, who were they?</p>
<p style="text-align: right;">Page 359</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Dealing with the -- dealing with the term</p> <p>4 "Oxy Express"?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Have you ever heard of it?</p> <p>8 A. Again, I've not heard the term "Oxy</p> <p>9 Express."</p> <p>10 MR. PAPANTONIO: Play this thing. Just go</p> <p>11 ahead and play it.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. So we got a town of 1,700 people. They</p> <p>14 can't absorb the pills. So you didn't even know</p> <p>15 there was something called an Oxy Express that</p> <p>16 actually drove through Mount Gay and distributed</p> <p>17 those pills along the Eastern Seaboard; nobody had</p> <p>18 ever told you that prior to coming in here today,</p> <p>19 right?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Huh?</p> <p>23 A. Again, I have not heard the term "Oxy</p> <p>24 Express."</p> <p>25 Q. Fair enough. I believe that. All right.</p>	<p style="text-align: right;">Page 361</p> <p>1 A. Tim Dunham.</p> <p>2 Q. Okay.</p> <p>3 A. And Nick Rausch.</p> <p>4 Q. Okay. And you were talking with</p> <p>5 Mr. Papantonio about the memorandum agreement from</p> <p>6 2007, 2008, correct? I think it's 4230.</p> <p>7 A. Is that in this stack?</p> <p>8 Q. Yeah, it's Exhibit Number 4.</p> <p>9 A. Is there a number at the top, a PI number?</p> <p>10 Q. 4230, if that helps you.</p> <p>11 Not that one. Keep going.</p> <p>12 A. Here it is.</p> <p>13 Q. There you go.</p> <p>14 I think you testified earlier, Cardinal</p> <p>15 entered into -- Cardinal Health entered into this</p> <p>16 memorandum agreement; is that right?</p> <p>17 A. Yes.</p> <p>18 Q. And you were there during this time frame.</p> <p>19 This is the time frame where a bunch of facilities</p> <p>20 lost their license, had their license suspended,</p> <p>21 correct?</p> <p>22 A. Yes.</p> <p>23 Q. And Cardinal made certain obligations or</p> <p>24 took on certain obligations as part of this</p> <p>25 agreement; isn't that true?</p>

<p style="text-align: right;">Page 362</p> <p>1 A. If they're listed in here somewhere.</p> <p>2 Q. Sure. I think they start on page 3.</p> <p>3 "Terms and conditions, obligations of Cardinal."</p> <p>4 Do you see that?</p> <p>5 A. Yes.</p> <p>6 Q. And if you turn to page 4 and go to F --</p> <p>7 see Section F there?</p> <p>8 A. Yes.</p> <p>9 Q. And you're aware, are you not, that</p> <p>10 Cardinal, through Section F, agreed to do an 18-month</p> <p>11 lookback and review its shipments to current</p> <p>12 customers for -- let's see: "Oxycodone, hydrocodone,</p> <p>13 alprazolam, phentermine, retail and physician</p> <p>14 customers for the 18 months immediately preceding the</p> <p>15 execution of this agreement, and identify any</p> <p>16 customers who purchased those same drugs that</p> <p>17 exceeded thresholds."</p> <p>18 Do you see that there?</p> <p>19 A. I do.</p> <p>20 Q. And you are therefore aware that Cardinal</p> <p>21 took on this obligation and completed this</p> <p>22 obligation.</p> <p>23 Did you have any role in that?</p> <p>24 A. What time frame are we talking -- are we</p> <p>25 talking --</p>	<p style="text-align: right;">Page 364</p> <p>1 out yet.</p> <p>2 A. Oh.</p> <p>3 Q. I apologize.</p> <p>4 MR. FULLER: Bates number 4722, and it's</p> <p>5 Exhibit Number -- what's the exhibit number at</p> <p>6 the bottom?</p> <p>7 MS. JAMISON: 24.</p> <p>8 MR. FULLER: 24. Oh, the sticker?</p> <p>9 THE WITNESS: 024.</p> <p>10 MR. FULLER: Got it.</p> <p>11 (Cardinal-Brantley 24 was marked for</p> <p>12 identification.)</p> <p>13 BY MR. FULLER:</p> <p>14 Q. This will be Plaintiffs' Exhibit</p> <p>15 Number 24.</p> <p>16 And you see this e-mail, it starts off</p> <p>17 from Mr. Kurtz, Bob Kurtz:</p> <p>18 Do you know who Bob Kurtz is?</p> <p>19 A. I do not. I think I've heard that name</p> <p>20 before, but I don't remember who he was.</p> <p>21 Q. Operations manager down in Lakeland,</p> <p>22 Florida; does that sound familiar?</p> <p>23 A. Again, I've heard the name before, but --</p> <p>24 Q. Fair enough.</p> <p>25 A. -- that still does not put it into</p>
<p style="text-align: right;">Page 363</p> <p>1 Q. The agreement was entered in the end of</p> <p>2 2008.</p> <p>3 A. So that would be -- no, I was no longer in</p> <p>4 the role I was in when I was speaking -- speaking</p> <p>5 earlier.</p> <p>6 Q. Where were you at this point?</p> <p>7 A. I was still at Cardinal Health, but</p> <p>8 sometime in 2008, I moved over to where I was solely</p> <p>9 doing the price diversion.</p> <p>10 Q. Okay.</p> <p>11 A. Monitoring and investigations.</p> <p>12 Q. Fair enough.</p> <p>13 And you mentioned --</p> <p>14 MR. FULLER: Let's roll to 4722 and talk</p> <p>15 again just briefly about the Lakeland facility.</p> <p>16 BY MR. FULLER:</p> <p>17 Q. You mentioned several times that the</p> <p>18 system that was in place was this reviewing</p> <p>19 ingredient limit reports, correct, is what you would</p> <p>20 do?</p> <p>21 A. Yes.</p> <p>22 Q. And you did that manually; is that right?</p> <p>23 A. Yes.</p> <p>24 I'm sorry, you said 4722?</p> <p>25 Q. I'm sorry. Yeah, I didn't even pass it</p>	<p style="text-align: right;">Page 365</p> <p>1 context.</p> <p>2 Q. And he's sending it to Rafael Varela; do</p> <p>3 you know Mr. Varela?</p> <p>4 A. I have heard that name as well.</p> <p>5 Q. If you scan down a little bit lower on the</p> <p>6 e-mail, Mr. Varela is the compliance and QA manager</p> <p>7 for Cardinal Health, Lakeland, Florida.</p> <p>8 Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. Okay. And it starts off -- now let's go</p> <p>11 through the time frame. I apologize. December 5th,</p> <p>12 2007.</p> <p>13 MR. FULLER: Up at the top, Evan. There</p> <p>14 you go.</p> <p>15 BY MR. FULLER:</p> <p>16 Q. December 5th, 2007. It's right about the</p> <p>17 time that these immediate suspension orders are</p> <p>18 coming out, correct?</p> <p>19 A. I don't remember the dates.</p> <p>20 November 28th, 2007, was -- seems like to be the</p> <p>21 first one, yes.</p> <p>22 Q. Okay. So right about that time, and this</p> <p>23 e-mail is in response, because it says "More</p> <p>24 information on DEA suspension."</p> <p>25 Do you see that there?</p>

<p style="text-align: right;">Page 366</p> <p>1 A. Yes.</p> <p>2 Q. And then it says: "Just some thoughts on</p> <p>3 Auburn, Washington, incident that concern me."</p> <p>4 It says -- and if we skip down to the next</p> <p>5 paragraph: "The manual process we perform now with</p> <p>6 the discovery of suspected excessive purchases being</p> <p>7 left up to the keyer notifying myself or the picker,</p> <p>8 double-checker, QCer questioning the amount being</p> <p>9 processed seems to leave ample opportunity for</p> <p>10 failure."</p> <p>11 MR. FULLER: And Evan, if you could</p> <p>12 underline that.</p> <p>13 BY MR. FULLER:</p> <p>14 Q. "Ample opportunity for failure." It's</p> <p>15 clearly a concern being voiced by the people in</p> <p>16 Lakeland, right?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: This is a concern being</p> <p>19 stated by Bob Kurtz.</p> <p>20 BY MR. FULLER:</p> <p>21 Q. And if you look back at 4230, what's the</p> <p>22 date of the immediate suspension order for Lakeland?</p> <p>23 Go to page 20. 4230, 20.</p> <p>24 MR. FULLER: You don't need to go, Evan;</p> <p>25 just --</p>	<p style="text-align: right;">Page 368</p> <p>1 sending off, and then you had pickers and checkers</p> <p>2 looking for excessive orders in the building, right?</p> <p>3 A. Yes. That report was a computer-generated</p> <p>4 report.</p> <p>5 Q. Right. But there was no red flags that</p> <p>6 got flagged, correct?</p> <p>7 MR. PYSER: Object to form.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. None?</p> <p>10 A. Every -- every entity that appeared on</p> <p>11 that ingredient limit report had reached the</p> <p>12 threshold requirement.</p> <p>13 Q. Exceeded the threshold, correct?</p> <p>14 A. Exceeded the threshold for -- reached or</p> <p>15 exceeded the threshold for that substance.</p> <p>16 Q. And those reports came out well after</p> <p>17 those products were shipped, after the pills were out</p> <p>18 on the street, right?</p> <p>19 MR. PYSER: Object to form.</p> <p>20 THE WITNESS: Those were monthly reports.</p> <p>21 BY MR. FULLER:</p> <p>22 Q. And the report came out after the pills</p> <p>23 were already on the street, didn't they?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: The report was generated</p>
<p style="text-align: right;">Page 367</p> <p>1 MR. PYSER: Is it -- on this first page,</p> <p>2 is it December 5th?</p> <p>3 BY MR. FULLER:</p> <p>4 Q. Yes?</p> <p>5 A. 2007?</p> <p>6 Q. There you go.</p> <p>7 A. Okay.</p> <p>8 Q. Same day that e-mail is sent, isn't it?</p> <p>9 A. December 5th, 2007. December 5th, 2007.</p> <p>10 Yes.</p> <p>11 Q. They say: "A system-generated flag would</p> <p>12 be a more complete, thorough method for</p> <p>13 determining" -- or excuse me -- "of determining</p> <p>14 spikes or excessive quantities than we are currently</p> <p>15 performing."</p> <p>16 Did I read that correctly?</p> <p>17 A. Yes.</p> <p>18 Q. And during that time frame, there was no</p> <p>19 automated system for generating flags, was there?</p> <p>20 MR. PYSER: Object to form.</p> <p>21 THE WITNESS: To my knowledge, the system</p> <p>22 was reviewing the ingredient limit reports that</p> <p>23 I was doing then.</p> <p>24 BY MR. FULLER:</p> <p>25 Q. You had the monthly reports that you were</p>	<p style="text-align: right;">Page 369</p> <p>1 after the shipments had shipped.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. It says: "As you know, I've investigated</p> <p>4 many accounts, tracked their ordering history and</p> <p>5 reached out for guidance and directions. But without</p> <p>6 someone bringing a suspected excessive quantity order</p> <p>7 to our attention, many, many more could be going out</p> <p>8 the door under our noses."</p> <p>9 And as Mr. Papantonio showed you earlier,</p> <p>10 that was the problem. All the pills were going out</p> <p>11 the door; no one was stopping them, wasn't it?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: Well, the cage vault</p> <p>14 personnel did have the ability to identify and</p> <p>15 order at time of picking and report that order.</p> <p>16 BY MR. FULLER:</p> <p>17 Q. Well, in order to do that, they would have</p> <p>18 to know what they're picking.</p> <p>19 You would agree with that, wouldn't you?</p> <p>20 A. Based on their knowledge.</p> <p>21 Q. They would have to to know what they're</p> <p>22 picking to be able to --</p> <p>23 A. They would have to know what's in front of</p> <p>24 them, what they are picking.</p> <p>25 Q. Absolutely.</p>

<p style="text-align: right;">Page 370</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. And if they don't, they can't do their</p> <p>4 job, can they?</p> <p>5 MR. PYSER: Object to form.</p> <p>6 THE WITNESS: If they don't know what</p> <p>7 they're picking?</p> <p>8 BY MR. FULLER:</p> <p>9 Q. Absolutely.</p> <p>10 A. If they don't know what they're picking,</p> <p>11 are you saying they can't do their job? They can</p> <p>12 still pick and ship orders, right?</p> <p>13 Q. They can pick and ship orders, but they</p> <p>14 can't pick out the excessive orders, right?</p> <p>15 MR. PYSER: Object to form.</p> <p>16 THE WITNESS: If they don't know what</p> <p>17 they're picking -- I'm just trying to</p> <p>18 understand. If they don't know what they're</p> <p>19 picking, they can --</p> <p>20 BY MR. FULLER:</p> <p>21 Q. If they don't know it's a Control II, or</p> <p>22 what type of product it is that they're picking, they</p> <p>23 can't do their job to bring it to someone's</p> <p>24 attention, can they?</p> <p>25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 372</p> <p>1 but portions of Ohio as well, correct?</p> <p>2 A. I don't remember. I know that -- I'm sure</p> <p>3 they service West Virginia. It's possible they could</p> <p>4 have serviced -- I just don't remember.</p> <p>5 Q. Well, let's see what Mr. Baranski had to</p> <p>6 say about the picker's knowledge on what they were</p> <p>7 picking. Okay? He would be the one to ask, you</p> <p>8 would agree, correct?</p> <p>9 MR. PYSER: Objection.</p> <p>10 BY MR. FULLER:</p> <p>11 Q. He's the director of operations for that</p> <p>12 facility?</p> <p>13 MR. PYSER: Object to form. Vague as to</p> <p>14 time frame.</p> <p>15 THE WITNESS: I can't say that he would be</p> <p>16 the one to ask, I mean, at that level, but --</p> <p>17 BY MR. FULLER:</p> <p>18 Q. He's the one that runs the building,</p> <p>19 right?</p> <p>20 A. He has oversight of the -- he's the</p> <p>21 director of operations of the facility.</p> <p>22 Q. He's the head honcho, as far as that</p> <p>23 building, correct?</p> <p>24 A. He is the highest-ranking person at that</p> <p>25 facility.</p>
<p style="text-align: right;">Page 371</p> <p>1 THE WITNESS: Well, if you don't know what</p> <p>2 you're picking, then you can't identify it, yes,</p> <p>3 true.</p> <p>4 BY MR. FULLER:</p> <p>5 Q. Fair enough.</p> <p>6 And then it says, "I wonder, could a</p> <p>7 similar situation happen in Lakeland and management</p> <p>8 be questioned why wasn't this discovered?"</p> <p>9 Do you see that there?</p> <p>10 A. Yes.</p> <p>11 Q. It happens the same day the immediate</p> <p>12 suspension order is issued for Lakeland, doesn't it?</p> <p>13 MR. PYSER: Object to form.</p> <p>14 THE WITNESS: Yes, we did verify that the</p> <p>15 two dates match the December 5th, yes.</p> <p>16 BY MR. FULLER:</p> <p>17 Q. Pickers and checkers.</p> <p>18 Do you know Mr. Baranski?</p> <p>19 A. I do not.</p> <p>20 Q. He was the director of operations -- is</p> <p>21 the director of operations for the Wheeling facility.</p> <p>22 You know the Wheeling distribution center in West</p> <p>23 Virginia?</p> <p>24 A. I'm familiar with the Wheeling facility.</p> <p>25 Q. That also serviced not only West Virginia</p>	<p style="text-align: right;">Page 373</p> <p>1 Q. Fair enough.</p> <p>2 MR. FULLER: Go ahead.</p> <p>3 (Whereupon a portion of a video played.)</p> <p>4 "Q Now, when we're going to pick up</p> <p>5 the product -- and let's deal with the</p> <p>6 controls.</p> <p>7 "A Sure.</p> <p>8 "Q If you have -- and I guess this</p> <p>9 depends on how you get the order. If</p> <p>10 I'm going to pick up the same substances</p> <p>11 both in a brand name and in a generic,</p> <p>12 how do I know which to grab, if I'm the</p> <p>13 picker?</p> <p>14 "A The unit tells them what</p> <p>15 location to go to.</p> <p>16 "Q And would the order have</p> <p>17 specified whether it was picking up a</p> <p>18 generic -- you know, something made by a</p> <p>19 particular manufacturer versus a</p> <p>20 generic?</p> <p>21 "A We teach our people to pick from</p> <p>22 location to tote. I don't even care if</p> <p>23 they know the product. I want them to</p> <p>24 know location to tote.</p> <p>25 MR. PYSER: Object to form on the use of</p>

<p style="text-align: right;">Page 374</p> <p>1 the video, and the time frame.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. So according to Mr. Baranski, they're</p> <p>4 picking by location only. He doesn't even care if</p> <p>5 they know the product. Right? That's what he</p> <p>6 testified to, correct?</p> <p>7 A. He stated that he doesn't care whether</p> <p>8 they know the product. That does not mean that the</p> <p>9 person picking does not know what the product is. He</p> <p>10 expressed his opinion.</p> <p>11 Q. Sure. And according to him, the one over</p> <p>12 the Wheeling distribution center, he doesn't even</p> <p>13 care if they know the product: Pick from location to</p> <p>14 tote.</p> <p>15 That's what he testified to, correct?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: That is the statement that</p> <p>18 he made.</p> <p>19 BY MR. FULLER:</p> <p>20 Q. Okay. Now, we looked at that MOU just for</p> <p>21 a second. Are you aware whether Cardinal did do an</p> <p>22 18-month lookback over its distributions?</p> <p>23 A. I don't know.</p> <p>24 Q. Fair enough. Let's go to 4923.</p> <p>25 MR. FULLER: Go ahead and pass them.</p>	<p style="text-align: right;">Page 376</p> <p>1 Q. And you see the spike in pills from 1996</p> <p>2 to 2008? The dosage units going into Cuyahoga</p> <p>3 County?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: I do see an increase.</p> <p>6 BY MR. FULLER:</p> <p>7 Q. And in fact, if you do the math, it's over</p> <p>8 1,000 percent increase from 1996 to 2008?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 BY MR. FULLER:</p> <p>11 Q. Are you aware of anything in Cuyahoga</p> <p>12 County that would have caused this increase in pain?</p> <p>13 MR. PYSER: Object to form.</p> <p>14 BY MR. FULLER:</p> <p>15 Q. Any epidemic going on during that time</p> <p>16 frame?</p> <p>17 MR. PYSER: Object to form.</p> <p>18 THE WITNESS: I'm not familiar with</p> <p>19 Cuyahoga.</p> <p>20 Q. Do you know where Cuyahoga County is?</p> <p>21 A. I do not.</p> <p>22 Q. It's Cleveland, Ohio.</p> <p>23 A. Okay.</p> <p>24 Q. If we go to page 3 of the document.</p> <p>25 A. That was page 3. You mean the third page?</p>
<p style="text-align: right;">Page 375</p> <p>1 (Cardinal-Brantley 25 was marked for</p> <p>2 identification.)</p> <p>3 BY MR. FULLER:</p> <p>4 Q. Now, what you have in front of you is a</p> <p>5 chart of Cardinal distributions.</p> <p>6 Oh, and I apologize; for the record, it is</p> <p>7 Plaintiffs' Exhibit Number 29 -- 25. This is</p> <p>8 Cardinal's distributions into Cuyahoga County for</p> <p>9 hydrocodone and oxycodone.</p> <p>10 Do you see that there, at the top?</p> <p>11 MR. PYSER: Just for the record, we've got</p> <p>12 a black-and-white version that the witness has,</p> <p>13 and a color copy up on the screen.</p> <p>14 MR. FULLER: Yeah, you do.</p> <p>15 Q. Do you see that?</p> <p>16 A. Yes, I do see that at the top.</p> <p>17 Q. Okay. And you see during the time frame</p> <p>18 that you have been with Cardinal -- and let's go all</p> <p>19 the way back to '96. You're aware that 1996 is when</p> <p>20 OxyContin came onto the market, correct?</p> <p>21 A. I do not remember when OxyContin came onto</p> <p>22 the market.</p> <p>23 Q. Okay. I'll represent to you it's around</p> <p>24 1996.</p> <p>25 A. Okay.</p>	<p style="text-align: right;">Page 377</p> <p>1 Q. Yeah, the third page.</p> <p>2 A. It says.</p> <p>3 Q. I apologize; it's point 3, at the top.</p> <p>4 A. Okay. Oh. Gotcha.</p> <p>5 Q. This is the same information for Summit</p> <p>6 County, which is Akron, Ohio.</p> <p>7 You see the same spike from 1996 up to</p> <p>8 2008 as well, correct?</p> <p>9 A. There is an increase.</p> <p>10 Q. And during this time frame, Cardinal was</p> <p>11 aware -- well, let me back up.</p> <p>12 In the anti-diversion group, the QRA</p> <p>13 department, did you ever pull numbers like this to</p> <p>14 look at the history and pattern of your customer</p> <p>15 sales?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 A. When I was doing my role from 2005 to</p> <p>18 early '8 or late '7, whichever it was, I did not --</p> <p>19 excuse me. I did not pull such reports.</p> <p>20 Q. So you're not aware of anybody in the</p> <p>21 diversion department, at least to your knowledge that</p> <p>22 pulled such reports, correct?</p> <p>23 MR. PYSER: Object to form.</p> <p>24 THE WITNESS: I can't speak for what</p> <p>25 others did. I can only speak for what I did.</p>



<p style="text-align: right;">Page 378</p> <p>1 Q. And my question is: To your knowledge, no  2 one pulled any type of reports of this nature,  3 correct?  4 A. To my knowledge, I don't know if they did  5 or not.  6 Q. Okay. Now, you see the spike, and you see  7 the color on the overhead. And as it represents at  8 the bottom, it's oxycodone and hydrocodone.  9 Do you see that there?  10 A. Yes.  11 Q. Okay. And other than -- other than the --  12 strike that.  13 Let's move on to the pill comparison.  14 Actually, hold on one second, Evan. You're aware,  15 are you not, that in the government -- let me ask it  16 differently.  17 You know that during the time frame that  18 you were at Cardinal, certain areas of the country  19 were having more of a problem with opioid abuse than  20 others, correct?  21 MR. PYSER: Object to form.  22 THE WITNESS: I actually learned that  23 after I left the company. Again, that was more  24 through media than anything else. And that  25 was . . .</p>	<p style="text-align: right;">Page 380</p> <p>1 A. Okay. Do you mean point 14 at the top?  2 Q. Yes, sir. I'm sorry.  3 A. I was thinking 14 at the bottom. Okay.  4 Q. Force of habit. By the time you get used  5 to it, we'll be done.  6 See the last full paragraph with the last  7 paragraph on the page: "Media reports of OxyContin  8 abuse and diversion began to surface in 2000. The  9 reports first appeared in rural areas of some states,  10 generally in the Appalachian regions, and continued  11 to spread in other rural areas in large cities in  12 several states. Rural communities in Maine,  13 Kentucky, Ohio, Pennsylvania, Virginia, and West  14 Virginia were reportedly being devastated by the  15 abuse and diversion of OxyContin."  16 Is that the first time you're seeing this?  17 A. This is my first time seeing this  18 document, yes.  19 Q. We can agree, can we not, that Cardinal  20 should have been aware of this, being that they were  21 a distributor of a dangerous substance during this  22 time frame, correct?  23 MR. PYSER: Object to form.  24 THE WITNESS: Are you saying that Cardinal  25 should have been aware of this document? I -- I</p>
<p style="text-align: right;">Page 379</p> <p>1 BY MR. FULLER:  2 Q. Let's go to 1087.  3 Do you know what the GAO is? Government  4 Accounting Office?  5 A. I'm not familiar with the office. I've  6 heard the term "GAO."  7 Q. You've heard the acronym before, correct?  8 A. Yes.  9 (Cardinal-Brantley 26 was marked for  10 identification.)  11 MR. FULLER: This will be Plaintiffs'  12 Number 26.  13 BY MR. FULLER:  14 Q. You see this document? "OxyContin abuse  15 and diversion, and the effects to address the  16 problem. Prescription drugs."  17 And what is the date indicated on this  18 document, Mr. Brantley?  19 A. December 2003.  20 Q. Okay. And this is shortly after you came  21 to Cardinal, but you're still in Texas, right?  22 A. In 2003 I was still in Texas, correct.  23 Q. If you'll turn to page 14. And let's see  24 what the government report says about who is having  25 problems with OxyContin, at least during this time.</p>	<p style="text-align: right;">Page 381</p> <p>1 can't speak to that.  2 BY MR. FULLER:  3 Q. So even though they're distributing  4 OxyContin, oxycodone, hydrocodone, across the  5 country, when the government does a massive  6 investigation and report based on those  7 distributions, your opinion is Cardinal doesn't  8 necessarily need to be aware of it, correct?  9 MR. PYSER: Object to form.  10 THE WITNESS: That's not what I said.  11 What I said is I don't know who would have read  12 the GAO report. I -- again --  13 BY MR. FULLER:  14 Q. Can we at least agree they should have  15 read it?  16 A. I've heard of GAO, but I -- I don't know  17 who would have -- I don't know what this is. I don't  18 know if this is a financial document. It says it's  19 from the General Accounting Office. Does that mean  20 it went to someone in accounting or finance? I can't  21 speak to that.  22 Q. Can we at least agree that they should  23 have been aware of it?  24 MR. PYSER: Object to form.  25</p>

<p style="text-align: right;">Page 382</p> <p>1 BY MR. FULLER:</p> <p>2 Q. Cardinal should have been aware of this</p> <p>3 report?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: I can't agree that someone</p> <p>6 should have read a document that came from the</p> <p>7 General Accounting Office.</p> <p>8 BY MR. FULLER:</p> <p>9 Q. Fair enough.</p> <p>10 And here it indicates several states that</p> <p>11 are being more impacted. Ohio and West Virginia are</p> <p>12 two of them, aren't they?</p> <p>13 A. According to this paragraph.</p> <p>14 Q. Well, let's look and see what's going on,</p> <p>15 even shortly after this time frame, with the</p> <p>16 distribution of OxyContin.</p> <p>17 MR. FULLER: Let's go to the PowerPoint</p> <p>18 presentation, Evan.</p> <p>19 BY MR. FULLER:</p> <p>20 Q. Now, here we're going to look at first,</p> <p>21 Mr. Brantley, is comparison between Illinois and</p> <p>22 Ohio, two neighboring states, correct?</p> <p>23 Is that right, Mr. Brantley?</p> <p>24 A. Yes.</p> <p>25 Q. Similar in size, I'll represent to you,</p>	<p style="text-align: right;">Page 384</p> <p>1 Q. You think that may be the only</p> <p>2 explanation, correct?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 BY MR. FULLER:</p> <p>5 Q. You don't know?</p> <p>6 A. I don't know. That's just the first thing</p> <p>7 that came to mind when you asked the question.</p> <p>8 Q. Fair enough. How many customers do we</p> <p>9 have in the respective state compared to Ohio, right?</p> <p>10 MR. PYSER: Object to form.</p> <p>11 BY MR. FULLER:</p> <p>12 Q. And then what is everybody else</p> <p>13 distributing to the respective states, correct?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 THE WITNESS: I don't know who the primary</p> <p>16 supplier is for the customers in Illinois. I</p> <p>17 don't know what chains and --</p> <p>18 BY MR. FULLER:</p> <p>19 Q. Let's keep going through the slide, and</p> <p>20 we'll get to that, okay?</p> <p>21 A. Okay.</p> <p>22 MR. FULLER: Let's go to 2007, Evan.</p> <p>23 MR. PYSER: Counsel, do you have this as</p> <p>24 an exhibit?</p> <p>25 MR. FULLER: I don't have a printout, but</p>
<p style="text-align: right;">Page 383</p> <p>1 and you'll see, similar in population. And this is</p> <p>2 just Cardinal distributions from 2006 through 2014.</p> <p>3 All right?</p> <p>4 A. Okay.</p> <p>5 MR. FULLER: So let's see the first slide,</p> <p>6 Evan.</p> <p>7 BY MR. FULLER:</p> <p>8 Q. So 2006, in Illinois, we have 4.9 million</p> <p>9 pills of oxycodone distributed. In Ohio, we have</p> <p>10 67 million oxycodone pills distributed.</p> <p>11 Does that cause you any concern?</p> <p>12 MR. PYSER: Object to form.</p> <p>13 THE WITNESS: I don't know the context.</p> <p>14 Where -- was Cardinal the primary supplier for</p> <p>15 pharmacies in Ohio, and it was not the primary</p> <p>16 supplier of pharmacies in Illinois?</p> <p>17 BY MR. FULLER:</p> <p>18 Q. That could be one explanation, right?</p> <p>19 A. I don't know the -- you put numbers on the</p> <p>20 screen, but I don't know the context of the customer</p> <p>21 base in those states.</p> <p>22 Q. Fair point. That could be one</p> <p>23 explanation, right?</p> <p>24 A. I would say that's probably an</p> <p>25 explanation.</p>	<p style="text-align: right;">Page 385</p> <p>1 I'll get you one. It's not a problem.</p> <p>2 BY MR. FULLER:</p> <p>3 Q. So in 2007, 5.9 million into Illinois and</p> <p>4 72-plus million into Ohio, still.</p> <p>5 Cause you any concern?</p> <p>6 A. Again, I have my same response. I don't</p> <p>7 know the customer base.</p> <p>8 Q. Right.</p> <p>9 A. I don't know if there's a large chain in</p> <p>10 Ohio that's serviced by Cardinal and a large chain in</p> <p>11 Illinois that's serviced by another wholesaler.</p> <p>12 Q. Well, this time -- during this time frame,</p> <p>13 you were servicing CVS; you know that, right?</p> <p>14 2006-7, you're there reviewing ingredient limit</p> <p>15 reports?</p> <p>16 A. Of course I don't recall all back then,</p> <p>17 but I -- I know that CVS is a Cardinal customer.</p> <p>18 Q. Big customer. Nationwide company.</p> <p>19 Correct?</p> <p>20 A. CVS is a -- a large chain.</p> <p>21 Q. Absolutely.</p> <p>22 MR. FULLER: Let's keep going, Evan.</p> <p>23 BY MR. FULLER:</p> <p>24 Q. 2008, 6.3, 75 million. Still a huge</p> <p>25 disparity.</p>

<p style="text-align: right;">Page 386</p> <p>1 We can at least agree on that, correct?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: There is a difference</p> <p>4 between 75 million and 6 million, yes.</p> <p>5 BY MR. FULLER:</p> <p>6 Q. It's about 11-time difference, over</p> <p>7 11-time -- 12-time difference, isn't it?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 THE WITNESS: If you did the math that</p> <p>10 fast in your head, I will accept that it's</p> <p>11 12 times.</p> <p>12 BY MR. FULLER:</p> <p>13 Q. I will give you my pen if you want to</p> <p>14 write it out.</p> <p>15 A. I have a calculator.</p> <p>16 Q. So let's keep going.</p> <p>17 2009, 6.884. 2010, 7.6 to 94 million.</p> <p>18 2011, 8.9, 96 million. 2012, 10 million to</p> <p>19 100 million.</p> <p>20 Now, we can both do the math on that,</p> <p>21 Mr. Brantley, right: 10 times --</p> <p>22 A. That was a little easier.</p> <p>23 Q. -- the amount of pills?</p> <p>24 MR. PYSER: Object to form.</p> <p>25</p>	<p style="text-align: right;">Page 388</p> <p>1 isn't it?</p> <p>2 MR. PYSER: Object to form.</p> <p>3 THE WITNESS: For the overall customers,</p> <p>4 without knowing the details, whether there was a</p> <p>5 large chain or a hospital or a VA --</p> <p>6 BY MR. FULLER:</p> <p>7 Q. Well, let me ask: At least during the --</p> <p>8 the first few years when this disparity is going on,</p> <p>9 did anybody that you're aware of at Cardinal pull</p> <p>10 this information and look and say, "Hey, look, we</p> <p>11 know there's an outbreak of a problem in Appalachian</p> <p>12 areas; let's compare them to like states and see</p> <p>13 what's going on"?</p> <p>14 You don't have any knowledge of that</p> <p>15 happening at Cardinal Health, do you?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: I don't know whether that</p> <p>18 was done or not by --</p> <p>19 BY MR. FULLER:</p> <p>20 Q. At least nobody informed you if they did,</p> <p>21 did they?</p> <p>22 A. I was not aware.</p> <p>23 Q. No one said, "Hey, when you're reviewing</p> <p>24 your ingredient limit reports, pay particular</p> <p>25 attention to Ohio, West Virginia"; you were never</p>
<p style="text-align: right;">Page 387</p> <p>1 BY MR. FULLER:</p> <p>2 Q. But 10 times the amount of pills into</p> <p>3 Illinois by Cardinal compared to Ohio, right?</p> <p>4 MR. PYSER: Object to form.</p> <p>5 THE WITNESS: That's what that graph</p> <p>6 states.</p> <p>7 BY MR. FULLER:</p> <p>8 Q. 2013, 2014.</p> <p>9 MR. FULLER: Let's go to the next slide,</p> <p>10 Evan.</p> <p>11 BY MR. FULLER:</p> <p>12 Q. So this is the number of customers.</p> <p>13 1,716 Cardinal customers in Illinois; 1,744 Cardinal</p> <p>14 customers in Ohio.</p> <p>15 Very close, isn't it?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 THE WITNESS: Just based on those numbers,</p> <p>18 but that doesn't tell how many were chains, how</p> <p>19 many were hospitals, how many was DOD, how many</p> <p>20 was VA.</p> <p>21 BY MR. FULLER:</p> <p>22 Q. Sure.</p> <p>23 A. That's just customers, so I -- I don't</p> <p>24 know --</p> <p>25 Q. But very close in the number of customers,</p>	<p style="text-align: right;">Page 389</p> <p>1 told that, were you?</p> <p>2 A. When I review ingredient limit reports, I</p> <p>3 reviewed them the same.</p> <p>4 Q. So again --</p> <p>5 A. I reviewed the reports.</p> <p>6 Q. My -- my question, though, is, no one came</p> <p>7 to you and said, "Hey, pay particular attention to</p> <p>8 West Virginia and Ohio," did they?</p> <p>9 MR. PYSER: Object to form. Asked and</p> <p>10 answered.</p> <p>11 THE WITNESS: I do not recall anyone</p> <p>12 coming to me, but I looked at all of the</p> <p>13 ingredient limit reports all the same.</p> <p>14 BY MR. FULLER:</p> <p>15 Q. Fair enough.</p> <p>16 MR. FULLER: Keep going, Evan.</p> <p>17 BY MR. FULLER:</p> <p>18 Q. So this lays out the population. There's</p> <p>19 a million more people in Illinois than Ohio, but Ohio</p> <p>20 got over 10 times the number of pills.</p> <p>21 You see that?</p> <p>22 A. I do see that chart, yes.</p> <p>23 Q. Can we at least agree that this deserves</p> <p>24 some looking into as to why the disparity?</p> <p>25 MR. PYSER: Object to form.</p>

<p style="text-align: right;">Page 390</p> <p>1 BY MR. FULLER: 2 Q. Would you agree with that? 3 A. This states -- pills that Cardinal 4 shipped? Is this -- is this just Cardinal? 5 Q. Yes, sir. 6 A. So again, I go back to my earlier 7 statement as far as not knowing what type of 8 registrants -- 9 Q. Fair enough. 10 A. -- Cardinal was shipping into in the two 11 states, because that makes a -- 12 Q. Sure. 13 A. -- a difference. 14 Q. You can't tell by the raw numbers, right? 15 A. Correct. I -- I can't tell if it's a 16 chain or if it's a hospital -- 17 Q. But we at least need to do an 18 investigation to find out why; can we agree with 19 that? 20 MR. PYSER: Object to form. 21 THE WITNESS: Again, you first need to 22 know -- 23 BY MR. FULLER: 24 Q. You have to do your investigation to know. 25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 392</p> <p>1 that information to do that comparison, did they? 2 MR. PYSER: Object to form. 3 THE WITNESS: Again, like I stated 4 earlier, I don't know. 5 BY MR. FULLER: 6 Q. At least you're not aware of it if they 7 did, correct? 8 MR. PYSER: Same objection. 9 THE WITNESS: I don't know. I'm not aware 10 if they did or not. 11 BY MR. FULLER: 12 Q. Fair enough. 13 MR. PAPANTONIO: Let's go to the next 14 slide, Evan. 15 BY MR. FULLER: 16 Q. So this is distributions from all 17 distributors. One of the questions you had earlier, 18 right, were we primary versus someone else? Were we 19 primary in Ohio versus someone else being primary in 20 Illinois? One of the concerns you voiced earlier, 21 right? 22 A. Right. 23 Q. And this shows that even going back to 24 2006, 29 million pills into Illinois, that's all 25 distributors; and 170 million going into a very</p>
<p style="text-align: right;">Page 391</p> <p>1 BY MR. FULLER: 2 Q. Is there a reason for this? 3 A. I'd have to know if these are chains, if 4 these are retail, if these are hospitals. I mean, 5 you have to have the complete picture or the proper 6 context before I can answer the question. 7 Again, I don't know what the customers 8 were. I don't know if they were retail independents 9 in one state and chains in another state, or 10 hospitals, or . . . 11 Q. And unless we pull the information, we're 12 not going to know. 13 We can agree with that, right? 14 MR. PYSER: Object to form. 15 THE WITNESS: Unless you can show me the 16 information that says, you know, how many chains 17 were in Ohio versus Illinois, and hospitals and 18 pharmacy -- I mean DOD, VA, so forth. 19 BY MR. FULLER: 20 Q. And as far as you're aware, Cardinal never 21 pulled that information to do that comparison, did 22 they? 23 MR. PYSER: Object to form. 24 BY MR. FULLER: 25 Q. When you were there, they never pulled</p>	<p style="text-align: right;">Page 393</p> <p>1 similar state of Ohio, from all distributors. And 2 this is just oxycodone. 3 And then we see in 2007, 30 and 190; and 4 it -- it keeps going with a huge disparity. That's 5 what the information shows, correct? 6 MR. PYSER: Object to form. 7 THE WITNESS: The information shows there 8 is a difference between the two states in 9 shipments. 10 BY MR. FULLER: 11 Q. Now, let me ask you: There at Cardinal, 12 did anybody come to you, made you aware of any huge 13 epidemic of pain in the state of Ohio during this 14 time frame? 15 MR. PYSER: Object to form. 16 THE WITNESS: During that time frame, I 17 was not made aware of any -- as you say, 18 epidemic of pain. 19 BY MR. FULLER: 20 Q. Okay. 21 MR. FULLER: Let's go to the next slide, 22 Evan. 23 BY MR. FULLER: 24 Q. So during this same time span in Illinois, 25 which has a million more people than the state of</p>

Page 394

1 Ohio, you have 351 million pills compared to  
2 2.1 billion pills in the state of Ohio.  
3 MR. FULLER: Next slide, Evan.  
4 BY MR. FULLER:  
5 Q. Six times the number of pills into the  
6 state of Ohio compared to Illinois.  
7 Do you see that there?  
8 MR. PYSER: Object to form.  
9 THE WITNESS: That slide says that  
10 Illinois received 351 million pills and Ohio  
11 received 2.1.  
12 BY MR. FULLER:  
13 Q. 2.1 billion --  
14 A. Oh.  
15 Q. -- is what it's supposed to say.  
16 A. So it was a misprint. Okay. Now -- okay.  
17 Q. He changed it quick.  
18 So let me ask the question again.  
19 2.1 billion pills into the state of Ohio, and  
20 12.8 billion pills -- excuse me. 351 million pills  
21 in the state of Illinois.  
22 MR. PYSER: Object to form.  
23 THE WITNESS: That's what the slide  
24 states.  
25

Page 395

1 BY MR. FULLER:  
2 Q. And do you have any knowledge as to why --  
3 strike that.  
4 We can agree that that is a huge  
5 disparity, right?  
6 MR. PYSER: Object to form.  
7 THE WITNESS: That is a difference. And I  
8 don't know why doctors wrote more scripts in  
9 Ohio versus Illinois.  
10 BY MR. FULLER:  
11 Q. But we do know who shipped more pills to  
12 Ohio versus Illinois, don't we?  
13 MR. PYSER: Object to form.  
14 BY MR. FULLER:  
15 Q. We saw the numbers coming out of Cardinal.  
16 And Cardinal, as you stated earlier, is providing  
17 pills to pharmacy, and have a regulatory obligation  
18 to look for suspicious activity, don't they,  
19 suspicious orders? Correct?  
20 MR. PYSER: Object to form.  
21 THE WITNESS: According to the CFR, they  
22 have an obligation to identify and report  
23 suspicious orders.  
24 BY MR. FULLER:  
25 Q. And as you mentioned earlier, they need to

Page 396

1 use the information they have to do so, don't they?  
2 Correct?  
3 THE WITNESS: Yes. And as I stated, we  
4 used -- I used ingredient limit reports, and  
5 they are also used at the division -- they were  
6 distributed to the DEA from the distribution  
7 centers.  
8 BY MR. FULLER:  
9 Q. And the other part of that system is we  
10 had pickers and checkers trying to flag excessive  
11 orders, as we saw in Lakeland, which didn't work out  
12 very well for Lakeland as well, correct?  
13 MR. PYSER: Object to form.  
14 THE WITNESS: The -- the pickers and  
15 checkers were in addition to the ingredient  
16 limit reports that were submitted to the DEA,  
17 and -- and in addition to the review that I was  
18 doing and submitting to the DEA.  
19 BY MR. FULLER:  
20 Q. Right. And you, as you testified earlier,  
21 you reported customers to the DEA, not suspicious  
22 orders, correct?  
23 A. I reported customers.  
24 Q. Fair enough.  
25 MR. FULLER: I don't have anything

Page 397

1 further.  
2 VIDEOGRAPHER: Going off record. Time  
3 is 4:19.  
4 (A recess transpired from 4:19 p.m. until  
5 4:25 p.m.)  
6 VIDEOGRAPHER: We're going back on record,  
7 the beginning of media file number 7. The time  
8 is 4:25.  
9 EXAMINATION  
10 BY MR. BUCHANAN:  
11 Q. Mr. Brantley, good afternoon.  
12 A. Good afternoon.  
13 Q. My name is Dave Buchanan, and I have a few  
14 other questions for you. I want to kind of move  
15 through a different period of time.  
16 MR. BUCHANAN: Evan, could we -- could we  
17 go to the -- the CDC document? I don't know the  
18 exhibit number in the deposition, but it's  
19 P1.324.3.  
20 BY MR. BUCHANAN:  
21 Q. You recall looking at this with  
22 Mr. Papantonio earlier?  
23 A. Yes.  
24 Q. Okay. And you have it in your stack there  
25 as well, if that's easier; I don't know what's best



<p style="text-align: right;">Page 398</p> <p>1 for you. But I just wanted to orient ourselves.</p> <p>2       So as I understand it, sir, you first got</p> <p>3 involved at least with companies involved in the</p> <p>4 opioid and narcotics business in around 2001; is that</p> <p>5 right?</p> <p>6       A. I started with Bentley Trading January of</p> <p>7 2000.</p> <p>8       Q. Okay.</p> <p>9       A. And that company was acquired, 2002, by</p> <p>10 Cardinal Health.</p> <p>11       Q. And on the screen, we have got this</p> <p>12 period -- this is 2001.</p> <p>13       That would have been during your period</p> <p>14 with Cardinal or Billy Trading; is that right?</p> <p>15       A. With Bentley Trading, yes.</p> <p>16       Q. Bentley; thank you.</p> <p>17       MR. BUCHANAN: Let's go forward to 2006.</p> <p>18 All right. Thank you.</p> <p>19 BY MR. BUCHANAN:</p> <p>20       Q. So this would have been a period of time</p> <p>21 when you were with Cardinal still, right?</p> <p>22       A. Yes.</p> <p>23       Q. And this would have been a point in time</p> <p>24 when you had some role or involvement in connection</p> <p>25 with suspicious orders, or at least monitoring and</p>	<p style="text-align: right;">Page 400</p> <p>1 on the screen, as it's changing over time, you see</p> <p>2 blue starting to fade, white starting to pop, brown,</p> <p>3 red, orange, yellow, indicating greater age-adjusted</p> <p>4 death rates per 100,000 people.</p> <p>5       Do you see that, sir, as we've been</p> <p>6 looking at these?</p> <p>7       MS. VANNI: Objection.</p> <p>8       THE WITNESS: I am seeing the transition</p> <p>9 of color.</p> <p>10 BY MR. BUCHANAN:</p> <p>11       Q. Okay. Okay. And did you stay in a</p> <p>12 suspicious-order monitoring function in some way in</p> <p>13 2009, '10, '11?</p> <p>14       MS. VANNI: Objection to the form.</p> <p>15       THE WITNESS: No. 2009, '10 and '11 --</p> <p>16 2009, I moved to the McDonough, Georgia,</p> <p>17 facility, and I was the compliance officer for</p> <p>18 the McDonough, Georgia, facility until 2011,</p> <p>19 until they closed the facility in 2011. That's</p> <p>20 when I went to Kinray in New York, and I</p> <p>21 commuted back and forth.</p> <p>22       During both times I served in the capacity</p> <p>23 as compliance officer, not in suspicious order</p> <p>24 monitoring.</p> <p>25</p>
<p style="text-align: right;">Page 399</p> <p>1 reporting functions from a regulatory perspective,</p> <p>2 fair?</p> <p>3       MR. PYSER: Same objections to the use of</p> <p>4 this document.</p> <p>5       THE WITNESS: 2006, yes.</p> <p>6 BY MR. BUCHANAN:</p> <p>7       Q. Okay.</p> <p>8       MR. BUCHANAN: And can we scroll forward</p> <p>9 to 2007.</p> <p>10 BY MR. BUCHANAN:</p> <p>11       Q. As I understand, you were still in that</p> <p>12 function in 2007; is that right?</p> <p>13       MS. VANNI: Object to the form.</p> <p>14       THE WITNESS: 2007, yes.</p> <p>15 BY MR. BUCHANAN:</p> <p>16       Q. And did you stay in that function as well</p> <p>17 in 2008?</p> <p>18       MS. VANNI: Same. Objection. Form.</p> <p>19       THE WITNESS: I'm not clear whether it was</p> <p>20 late 2007 or early 2008 time frame where I</p> <p>21 started the transition.</p> <p>22       MR. BUCHANAN: Evan, could you scoot it</p> <p>23 forward to 2008.</p> <p>24 BY MR. BUCHANAN:</p> <p>25       Q. All right. We see -- and you see the map</p>	<p style="text-align: right;">Page 401</p> <p>1 BY MR. BUCHANAN:</p> <p>2       Q. And "compliance officer," as that term was</p> <p>3 being used in that 2009, '10, '11 period of time,</p> <p>4 didn't include any responsibility or role or function</p> <p>5 for suspicious order monitoring?</p> <p>6       A. My only responsibility in that regard</p> <p>7 would have been doing site visits, surveillance</p> <p>8 visits, type thing, and then reporting back to the</p> <p>9 corporate department that handled it.</p> <p>10       MR. BUCHANAN: Could we go forward, Evan,</p> <p>11 2009; let's just see how it looks.</p> <p>12 BY MR. BUCHANAN:</p> <p>13       Q. Getting better or getting worse, sir?</p> <p>14       MS. VANNI: Objection.</p> <p>15       THE WITNESS: Pardon me?</p> <p>16 BY MR. BUCHANAN:</p> <p>17       Q. Getting better, getting worse?</p> <p>18       MS. VANNI: Same objection.</p> <p>19       THE WITNESS: The -- by the color</p> <p>20 transitioning?</p> <p>21 BY MR. BUCHANAN:</p> <p>22       Q. Yeah.</p> <p>23       A. It's about the same.</p> <p>24       MR. BUCHANAN: Next slide, please.</p> <p>25</p>

<p style="text-align: right;">Page 402</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Getting better or getting worse during</p> <p>3 2010?</p> <p>4 MS. VANNI: Objection.</p> <p>5 THE WITNESS: 2010's still looking about</p> <p>6 the same.</p> <p>7 MR. BUCHANAN: Okay. Let's fast forward,</p> <p>8 2012, sir.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. You -- I think in 2012 you joined</p> <p>11 QualiTest; is that right?</p> <p>12 A. No. Late 2013. I believe October 2013 is</p> <p>13 when I joined QualiTest.</p> <p>14 Q. Thank you. Thank you.</p> <p>15 So 2012, we'd agree, you got more red, you</p> <p>16 got more orange, you got more yellow, more white --</p> <p>17 MS. VANNI: Objection.</p> <p>18 BY MR. BUCHANAN:</p> <p>19 Q. -- than you had in 2007, 2008, when you</p> <p>20 were fulfilling that suspicious order monitoring</p> <p>21 role?</p> <p>22 MS. VANNI: Objection.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. True?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 404</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. About 70 percent of which were controlled</p> <p>3 substances, right?</p> <p>4 MS. VANNI: Object to the form.</p> <p>5 THE WITNESS: I don't know.</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Okay. You didn't have an appreciation,</p> <p>8 sir, that the company -- the vast majority of the</p> <p>9 company's business was in fact scheduled drugs?</p> <p>10 MS. VANNI: Object to form.</p> <p>11 THE WITNESS: You asked did I know was it</p> <p>12 70 percent, and I said no, I did not know that</p> <p>13 it was 70 percent.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. Okay. Fair enough.</p> <p>16 Did you have an appreciation, sir, that</p> <p>17 the vast majority -- or the majority of the company's</p> <p>18 sales were for scheduled drugs?</p> <p>19 MS. VANNI: Object to form.</p> <p>20 THE WITNESS: There was a -- I can't -- I</p> <p>21 don't know for sure, but that sounds about</p> <p>22 right. It was -- controlled substances was a</p> <p>23 large part of the business, yes.</p> <p>24 BY MR. BUCHANAN:</p> <p>25 Q. Okay. And so let's -- let's orient</p>
<p style="text-align: right;">Page 403</p> <p>1 Q. Okay.</p> <p>2 MR. BUCHANAN: Let's go to 2013.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. This, now, would be your first year with</p> <p>5 QualiTest; is that right?</p> <p>6 MS. VANNI: Objection to form.</p> <p>7 THE WITNESS: I believe October 2013.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Okay. And you'd agree, sir, that</p> <p>10 certainly this map is showing an increasing rate of</p> <p>11 death on an age-adjusted rate basis as compared to</p> <p>12 2001 when we first looked at the chart with</p> <p>13 Mr. Papantonio, true?</p> <p>14 MS. VANNI: Object to the form.</p> <p>15 THE WITNESS: Based on this scale, yes,</p> <p>16 the chart shows a color difference.</p> <p>17 BY MR. BUCHANAN:</p> <p>18 Q. Okay. When you were at QualiTest, sir,</p> <p>19 QualiTest was a manufacturer of opioids and</p> <p>20 narcotics. Fair?</p> <p>21 MS. VANNI: Object to the form.</p> <p>22 THE WITNESS: They were a manufacturer of</p> <p>23 prescription drugs, including controlled</p> <p>24 substances, including narcotics.</p> <p>25</p>	<p style="text-align: right;">Page 405</p> <p>1 ourselves, I guess, in terms of where QualiTest is in</p> <p>2 the picture. QualiTest is a generic manufacture of</p> <p>3 drugs, true?</p> <p>4 MS. VANNI: Objection. Form.</p> <p>5 THE WITNESS: Yes.</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Okay. They operated through a couple --</p> <p>8 couple of different companies; you remember Vintage</p> <p>9 Pharmaceuticals? You remember that name?</p> <p>10 A. Vintage Pharmaceuticals, yes.</p> <p>11 Q. Okay. They were one of the registrant</p> <p>12 holders doing business as QualiTest, true?</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 THE WITNESS: Yes, I -- I believe that</p> <p>15 Vintage was one of the DEA registration.</p> <p>16 BY MR. BUCHANAN:</p> <p>17 Q. Okay. And I guess -- let's talk about</p> <p>18 that DEA registration.</p> <p>19 As I understand this, I mean, you can't</p> <p>20 just decide, legally, that you'd like to distribute</p> <p>21 or make or sell narcotics, scheduled narcotics,</p> <p>22 without having a registration, true?</p> <p>23 MS. VANNI: Object to the form.</p> <p>24 THE WITNESS: A DEA registration is</p> <p>25 required to handle controlled substances.</p>

<p style="text-align: right;">Page 406</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Okay. And as part of that registration</p> <p>3 process, I mean, a manufacturer, a distributor, a</p> <p>4 pharmacy, they're making a promise, right?</p> <p>5 MS. VANNI: Object to the form.</p> <p>6 THE WITNESS: I don't know the details of</p> <p>7 acquiring a -- a registration. You fill out an</p> <p>8 application and -- and so forth, and pay the</p> <p>9 fee, and a registration is issued.</p> <p>10 BY MR. BUCHANAN:</p> <p>11 Q. It's a closed system, designed to be,</p> <p>12 right?</p> <p>13 A. It is -- it is designed to be a closed</p> <p>14 system.</p> <p>15 Q. When it's not a closed system, then we</p> <p>16 have drugs, controlled drugs, leaking out of the</p> <p>17 system, creating the risk of diversion, abuse,</p> <p>18 addiction, and injury. Fair?</p> <p>19 MS. VANNI: Objection to form.</p> <p>20 THE WITNESS: It is a closed system, like</p> <p>21 I stated earlier, from the manufacturer to the</p> <p>22 distributor to the pharmacy to the patient,</p> <p>23 based on a script that he or she received from</p> <p>24 the doctor. That is the system. So when it</p> <p>25 goes outside of that system, that's not the</p>	<p style="text-align: right;">Page 408</p> <p>1 prevent diversion, true?</p> <p>2 MS. VANNI: Object to the form.</p> <p>3 THE WITNESS: That is part of the --</p> <p>4 that's part of the regulation, yes.</p> <p>5 BY MR. BUCHANAN:</p> <p>6 Q. That's part of the public trust?</p> <p>7 MS. VANNI: Object to the form.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. You ask -- "you" being a manufacturer or</p> <p>10 "you" being a distributor who wishes to distribute a</p> <p>11 controlled substance -- asks for a registration so</p> <p>12 that they can distribute controlled substances;</p> <p>13 that's the ask of the government, right?</p> <p>14 MS. VANNI: Object to the form.</p> <p>15 THE WITNESS: One asks for a registration</p> <p>16 so that they can either manufacture and/or</p> <p>17 distribute controlled substances.</p> <p>18 BY MR. BUCHANAN:</p> <p>19 Q. And in return, you commit to maintain</p> <p>20 effective controls to prevent diversion. Fair?</p> <p>21 MS. VANNI: Object to the form.</p> <p>22 THE WITNESS: That is what the regulation</p> <p>23 states, and that is what registrants are held</p> <p>24 to.</p> <p>25</p>
<p style="text-align: right;">Page 407</p> <p>1 system that the manufacturers and distributors</p> <p>2 operate in.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. And so when you get that registration, or</p> <p>5 when you apply for it, apply to the government, say,</p> <p>6 "I'd like to be a registrant; I'd like to be a</p> <p>7 distributor," you're promising that "We're going to</p> <p>8 maintain effective controls to prevent diversion,"</p> <p>9 right?</p> <p>10 MS. VANNI: Object to the form.</p> <p>11 THE WITNESS: What comes with obtaining a</p> <p>12 DEA registration is compliance with the Code of</p> <p>13 Federal Regulations that govern controlled</p> <p>14 substances.</p> <p>15 BY MR. BUCHANAN:</p> <p>16 Q. Well, that's a statute, right?</p> <p>17 A. The statute, and --</p> <p>18 Q. Yeah.</p> <p>19 A. -- the Controlled Substances Act, and --</p> <p>20 yes, 21 CFR, I believe 1300 to the end is what</p> <p>21 governs controlled substances.</p> <p>22 Q. Staying with the the Controlled Substances</p> <p>23 Act, staying with the statute, staying with the</p> <p>24 federal law, you'd agree, sir, that a registrant, a</p> <p>25 distributor, has to maintain effective controls to</p>	<p style="text-align: right;">Page 409</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. That's what the statute states, right?</p> <p>3 A. That's what -- the statute.</p> <p>4 Q. Okay. And so we'd agree at the point in</p> <p>5 time, sir, in 2013 -- when did you first get</p> <p>6 approached -- or did you get approached about joining</p> <p>7 QualiTest? How did that come about, sir?</p> <p>8 MS. VANNI: Object to the form.</p> <p>9 THE WITNESS: I believe it was indeed a</p> <p>10 job search engine. I was looking for a job,</p> <p>11 simply because the commute from Atlanta to</p> <p>12 La Guardia -- La Guardia is horrible, and I did</p> <p>13 that for a year and a half, commuting. I just</p> <p>14 couldn't do it anymore, so I started looking for</p> <p>15 another job.</p> <p>16 So I believe the job search was on the</p> <p>17 Internet; maybe Indeed or Monster, or whatever</p> <p>18 the thing was at the time. I don't remember.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. So was it before or after you interviewed</p> <p>21 for the job that you learned that QualiTest had</p> <p>22 problems with their suspicious-orders monitoring</p> <p>23 system?</p> <p>24 MS. VANNI: Object to the form.</p> <p>25 THE WITNESS: I never knew that QualiTest</p>

<p style="text-align: right;">Page 410</p> <p>1 had problems with their suspicious order  2 monitoring system.  3 BY MR. BUCHANAN:  4 Q. Not until you got there?  5 MS. VANNI: Object to the form.  6 THE WITNESS: When I got there, I wasn't  7 aware of any problems with the suspicious order  8 monitoring system.  9 BY MR. BUCHANAN:  10 Q. Oh. Okay. We'll talk about that.  11 At the point in time when you were  12 interviewing with QualiTest, or about the time when  13 you joined, were you aware that the company was  14 selling billions of oxycodone pills on a yearly or  15 biyearly basis?  16 MS. VANNI: Object to the form.  17 THE WITNESS: I was not aware of the  18 quantity or sales of controlled substances by  19 the company.  20 BY MR. BUCHANAN:  21 Q. Were you aware that the DEA had a sitdown  22 with them --  23 MR. PAPANTONIO: Object to the form.  24 BY MR. BUCHANAN:  25 Q. -- and said, "You're not doing what you</p>	<p style="text-align: right;">Page 412</p> <p>1 suspicious-order monitoring system the company was  2 employing?  3 MS. VANNI: Same objection.  4 THE WITNESS: After my employment, I did  5 have a meeting, and I was told that there was a  6 meeting with DEA.  7 BY MR. BUCHANAN:  8 Q. The meeting, right?  9 MS. VANNI: Objection.  10 THE WITNESS: I don't know what "the  11 meeting" means, but there was a meeting with the  12 DEA.  13 BY MR. BUCHANAN:  14 Q. Isn't that how you referred to it in your  15 presentation, sir, "the meeting"?  16 MS. VANNI: Object to the form.  17 THE WITNESS: I don't recall.  18 BY MR. BUCHANAN:  19 Q. Okay. Well, I mean, let's talk about  20 QualiTest in the scheme of narcotics and opioids.  21 MR. BUCHANAN: Can I have, please, 575.  22 And what's our next in order for the deposition?  23 BY MR. BUCHANAN:  24 Q. Sir, I'm going to pass you Exhibit 27 to  25 your deposition.</p>
<p style="text-align: right;">Page 411</p> <p>1 need to do with regard to your suspicious order  2 monitoring"?  3 Were you aware of that, sir?  4 MS. VANNI: Object to the form.  5 THE WITNESS: What time frame are you  6 asking was I aware of it?  7 BY MR. BUCHANAN:  8 Q. Would be March 2013.  9 A. No, I mean what time frame are you asking  10 was I aware of a meeting with DEA?  11 Q. I guess at the point in time before you  12 joined.  13 A. Was it prior to my employment? No, I was  14 not aware.  15 Q. Okay. Because before you joined, in fact,  16 the company had a little sitdown with the DEA, and  17 DEA expressed concern with what the company was doing  18 with regard to its monitoring of orders. Fair?  19 MS. VANNI: Object to the form.  20 THE WITNESS: I was not aware of any  21 sitdown prior to my employment with QualiTest.  22 BY MR. BUCHANAN:  23 Q. After you joined the company, sir, did you  24 subsequently learn that the company had a sitdown  25 with the DEA where the DEA expressed concern with the</p>	<p style="text-align: right;">Page 413</p> <p>1 (Cardinal-Brantley 27 was marked for  2 identification.)  3 MR. BUCHANAN: Can you pull it up, please,  4 Evan, while we're getting copies distributed.  5 BY MR. BUCHANAN:  6 Q. And I'll wait until you get one before I  7 ask you questions. Here you go. Here you are.  8 MR. BUCHANAN: Counsel, there's a couple  9 coming over for you.  10 BY MR. BUCHANAN:  11 Q. Sir, these are charts of -- that were  12 shown to the company at a meeting with the DEA in  13 March of 2013. I direct your attention, please,  14 to -- I want to use the page numbers in the top  15 right, those little dot numbers; just dot 3, to get  16 it rolling.  17 First of all, have you seen these before?  18 A. I did see these, I believe, in a binder.  19 Q. Yeah. We -- we don't actually get them in  20 a binder when they come to us in litigation, but  21 hopefully you recognize this as something you saw  22 while you were at QualiTest.  23 A. Yes, that's what I mean. I -- I believe I  24 saw them in a binder when I was there at QualiTest.  25 Q. Okay. So just to set the scene, as you</p>

<p style="text-align: right;">Page 414</p> <p>1 understand this, sir, the DEA sat down with the 2 company in 2013, March of 2013, and identified a 3 number of concerns with regard to the company's 4 suspicious order practices. True? 5 MS. VANNI: Objection to form. 6 THE WITNESS: If that says that in here -- 7 I haven't read it yet; these are just graphs. 8 BY MR. BUCHANAN: 9 Q. Do you have that recollection, sir? 10 MS. VANNI: Objection. 11 BY MR. BUCHANAN: 12 Q. Do you have that recollection or 13 understanding from your time at QualiTest that the 14 DEA sat down, presented charts -- these charts -- had 15 a discussion with the company where they raised 16 concerns with the company's practices as it related 17 to suspicious orders? 18 MS. VANNI: Object to form. 19 THE WITNESS: I do remember sitting down 20 and seeing the charts, and I do remember there 21 was a conversation that they had met with DEA. 22 I don't remember what the findings were or the 23 details from that conversation. 24 BY MR. BUCHANAN: 25 Q. Okay. And so this comes from the DEA's</p>	<p style="text-align: right;">Page 416</p> <p>1 BY MR. BUCHANAN: 2 Q. I think you said you saw it, right? 3 During your employment with the company, sir? 4 A. Well, the question is -- the date is 5 March 6th, 2013, and during my employment, I did see, 6 again, a binder with these graphs in it. 7 Q. Oh, good. I just want to make sure we 8 were still on the same page. 9 102 million pills. And this is -- this is 10 just one -- one tablet strength, and for one pill 11 bottle format, correct? 12 MS. VANNI: Object to the form. 13 BY MR. BUCHANAN: 14 Q. Oxycodone, 15 milligrams; you see that, 15 right? Right there, sir? 16 A. Yes, oxycodone, 15 milligrams. 17 Q. Okay. And between the two, what's that, 18 200 million pills? 19 MS. VANNI: Object to the form. 20 THE WITNESS: Yes. 21 BY MR. BUCHANAN: 22 Q. 200 million pills. One dosage, one bottle 23 size, and one year; is that right? 24 MS. VANNI: Object to the form. 25</p>
<p style="text-align: right;">Page 415</p> <p>1 assembly of data across manufacturers and the 2 information they captured. We're on point 3. 3 And you see the first two columns on the 4 left, sir? Not really columns; like I said, the 5 vertical bars. Vintage Pharmaceuticals and Generics 6 Bidco, LLC. 7 Do you see those two? 8 A. Yes. 9 Q. Now you recognize those companies, sir, as 10 QualiTest affiliates that were in the business of 11 making narcotics? 12 MS. VANNI: Objection. 13 THE WITNESS: I remember seeing Vintage 14 Pharmaceuticals and Generic Bidco. 15 BY MR. BUCHANAN: 16 Q. Okay. So this is showing, sir, if I've 17 got it right, that -- and follow along with me here. 18 We have got 102 million pills. 19 And what's the period of time, sir? 20 Vintage Pharmaceuticals, 102 million pills they're 21 making? What year is that? 22 MS. VANNI: Object to the use of this 23 document, to the extent it predates his 24 employment with the company. 25</p>	<p style="text-align: right;">Page 417</p> <p>1 BY MR. BUCHANAN: 2 Q. Is that what this shows, sir? 3 A. According to this form -- 4 MS. VANNI: Same objection. 5 THE WITNESS: -- yes, 200 million pills. 6 BY MR. BUCHANAN: 7 Q. All right. Let's -- let's move forward. 8 I guess I should -- I probably didn't set 9 this chart up right. We'll do -- and we said -- and 10 I'm -- we're doing some rounding here, sir, just 11 because I think we're -- we're close enough if we're 12 within a million or so, but 200 million pills in 13 2011. Fair? 14 MS. VANNI: Objection. 15 THE WITNESS: Yes. 16 BY MR. BUCHANAN: 17 Q. Okay. Could you scroll forward with me, 18 sir, to -- let's see -- point 10. Two pages down. 19 Again we see that Vintage Pharmaceuticals 20 and Generics Bidco. You see that? First two columns 21 on the left? 22 A. Yes. 23 Q. What's that up to, roughly? 250? 24 250 million? 25 MS. VANNI: Object to the form.</p>



Page 418

1 THE WITNESS: Yes, about -- about 250.  
 2 BY MR. BUCHANAN:  
 3 Q. All right. 250 million pills. And that's  
 4 2012, right?  
 5 A. Yes.  
 6 Q. Okay. So you went from 200 million oxy,  
 7 15 milligrams, in that one bottle size, to  
 8 250 million over that year. Is that right?  
 9 MS. VANNI: Object to form.  
 10 THE WITNESS: This year was 2012. I don't  
 11 remember what the other year was, but . . .  
 12 BY MR. BUCHANAN:  
 13 Q. Okay.  
 14 MR. BUCHANAN: And can I just have the  
 15 Elmo real quick, Evan.  
 16 BY MR. BUCHANAN:  
 17 Q. So-- I just want to make sure we don't get  
 18 too far down; we're kind of keeping track, right?  
 19 A. Okay.  
 20 Q. Those are -- those numbers track, we've  
 21 been talking about?  
 22 MS. VANNI: Object to the form.  
 23 BY MR. BUCHANAN:  
 24 Q. Oxy, 15 milligrams, 100-count bottles,  
 25 200 million in 2011, 250 million in 2012, right?

Page 419

1 MS. VANNI: Same objection.  
 2 THE WITNESS: Yes.  
 3 BY MR. BUCHANAN:  
 4 Q. Okay. Oxycodone was a drug of abuse,  
 5 true?  
 6 MS. VANNI: Objection.  
 7 THE WITNESS: Oxycodone is a Schedule II  
 8 controlled substance. As a Schedule II, it's  
 9 prone to abuse.  
 10 BY MR. BUCHANAN:  
 11 Q. Okay. And also prone to diversion; you  
 12 knew that, right, sir?  
 13 MS. VANNI: Objection.  
 14 THE WITNESS: By being a Schedule II drug,  
 15 that means it's prone to abuse and diversion.  
 16 BY MR. BUCHANAN:  
 17 Q. Okay.  
 18 MR. BUCHANAN: Let's see if we can get to  
 19 -- scroll forward a little bit.  
 20 BY MR. BUCHANAN:  
 21 Q. The company also sold oxy, 15 milligrams,  
 22 in 500-count containers; isn't that right?  
 23 MS. VANNI: Object to the form.  
 24 BY MR. BUCHANAN:  
 25 Q. If you go to page 18.

Page 420

1 A. Okay.  
 2 Q. Sorry. Been a few years.  
 3 All right. Now we're back on 2011.  
 4 Oxy, 15-milligram, 500-count bottles; see  
 5 those?  
 6 A. Yes.  
 7 Q. And I guess you sold less of this  
 8 particular bottle size, right, sir?  
 9 MS. VANNI: Objection.  
 10 BY MR. BUCHANAN:  
 11 Q. That -- what's that, about 13 million?  
 12 Does that sound right?  
 13 A. Yes.  
 14 Q. All right. Let's move on to point 24.  
 15 Okay. This looks like -- what, about  
 16 23 million pills sold in 2012?  
 17 MS. VANNI: Objection.  
 18 BY MR. BUCHANAN:  
 19 Q. Of this oxy 15 in the 500-bottle count,  
 20 right?  
 21 MS. VANNI: Same objection.  
 22 THE WITNESS: Yes.  
 23 BY MR. BUCHANAN:  
 24 Q. Okay.  
 25 MR. BUCHANAN: Can I just flip back to the

Page 421

1 Elmo real quick, Evan.  
 2 BY MR. BUCHANAN:  
 3 Q. All right. I guess just in -- in these  
 4 two bottle counts, sizes, sir, you're up to a half a  
 5 billion pills in two years at QualiTest for oxy 15s,  
 6 right?  
 7 MS. VANNI: Object to the form.  
 8 THE WITNESS: 270. 213.  
 9 BY MR. BUCHANAN:  
 10 Q. I'm sorry, for two years, yeah, 200.  
 11 That's 450 -- I'm sorry, sir. What is that?  
 12 About --  
 13 A. About 490.  
 14 Q. 490. Getting close?  
 15 A. Yes.  
 16 Q. All right. Let's -- there was another  
 17 dosage strength of oxycodone that the company made  
 18 and sold, right?  
 19 A. I believe so. I'd have to see the data.  
 20 Q. All right. Let's see what that looks  
 21 like.  
 22 MR. BUCHANAN: Could I please have --  
 23 let's go to page point 30, Evan.  
 24 MS. VANNI: I'm sorry, what page?  
 25 MR. BUCHANAN: Point 30. Top right

<p style="text-align: right;">Page 422</p> <p>1 corner.</p> <p>2 MS. VANNI: Thank you.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. All right. And is this showing, sir,</p> <p>5 the -- the pill counts manufactured and sold by the</p> <p>6 two QualiTest entities in 2011 for the oxy</p> <p>7 30-milligram dosage strength?</p> <p>8 MS. VANNI: Object to the form.</p> <p>9 THE WITNESS: Yes.</p> <p>10 BY MR. BUCHANAN:</p> <p>11 Q. And what do you have, about 182 million</p> <p>12 pills for 2011?</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. Does that look right to you, sir?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. All right.</p> <p>18 MR. BUCHANAN: Let's go to 2012. Page</p> <p>19 point 43. All right.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Page point 43, two left columns. That's</p> <p>22 reflecting the production there for the other two</p> <p>23 QualiTest facilities, Generics Bidco and Vintage</p> <p>24 Pharmaceuticals. Oxy, 30 milligrams, again in the</p> <p>25 100-count bottle.</p>	<p style="text-align: right;">Page 424</p> <p>1 Let's see -- oxy -- I'm sorry, Oxy,</p> <p>2 30 milligrams, and 500 count.</p> <p>3 MR. BUCHANAN: All right. Can we go to</p> <p>4 point 50.</p> <p>5 BY MR. BUCHANAN:</p> <p>6 Q. And I think that's showing -- what, about</p> <p>7 20 million pills, sir, in those two columns, if you</p> <p>8 add them up? Oxycodone, 30-milligram, 500s. Okay?</p> <p>9 A. Yes.</p> <p>10 Q. All right. Moving on to point 54, let's</p> <p>11 look at the 2012 numbers.</p> <p>12 Is that 46 million?</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. 46 million dosage units, sir?</p> <p>16 A. Yes. Yes.</p> <p>17 Q. Okay. Close to a billion oxy, sir, in two</p> <p>18 years, two dosage strengths?</p> <p>19 Is that what you have?</p> <p>20 MS. VANNI: Objection.</p> <p>21 THE WITNESS: Give or take, yeah, close to</p> <p>22 a billion.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. A billion pills. Oxycodone, highly</p> <p>25 abused, highly diverted. True, sir?</p>
<p style="text-align: right;">Page 423</p> <p>1 And -- looks like you're growing the</p> <p>2 market, huh?</p> <p>3 MS. VANNI: Object to the form.</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. What are we up to, 280 million?</p> <p>6 MS. VANNI: Object to the form.</p> <p>7 THE WITNESS: Yes.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Probably a little low with the 280, but</p> <p>10 that's good enough for our purposes; two hundred</p> <p>11 and --</p> <p>12 MS. VANNI: Object to the colloquy.</p> <p>13 MR. BUCHANAN: Okay, I'll be more precise.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. 285 million: Does that sound closer to</p> <p>16 you, sir?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. Wow. Picked up 100 million pills</p> <p>19 you sold between 2011, 2012.</p> <p>20 All right, we're following each other,</p> <p>21 right, sir? My -- my writing is not the best, but</p> <p>22 does that correlate with your memory of your</p> <p>23 testimony?</p> <p>24 A. Yes.</p> <p>25 Q. Okay. Let's move on.</p>	<p style="text-align: right;">Page 425</p> <p>1 MS. VANNI: Objection.</p> <p>2 THE WITNESS: I can't speak if it's highly</p> <p>3 abused or highly diverted. It is definitely</p> <p>4 prone to abuse and diversion.</p> <p>5 BY MR. BUCHANAN:</p> <p>6 Q. Okay. And the company made other schedule</p> <p>7 drugs, right?</p> <p>8 A. Yes.</p> <p>9 Q. Hydrocodone was a popular one the company</p> <p>10 sold?</p> <p>11 MS. VANNI: Object to the form.</p> <p>12 THE WITNESS: The company sold</p> <p>13 hydrocodone.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. And you know that hydrocodone was</p> <p>16 ultimately a Schedule II; was that 2013, '14?</p> <p>17 A. It was up-scheduled, I believe, October of</p> <p>18 one of those years.</p> <p>19 Q. Okay. And another drug that was prone to</p> <p>20 abuse, true?</p> <p>21 MS. VANNI: Object to the form.</p> <p>22 THE WITNESS: Yes.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. And diversion?</p> <p>25 MS. VANNI: Same objection.</p>

<p style="text-align: right;">Page 426</p> <p>1 THE WITNESS: Yes.</p> <p>2 BY MR. BUCHANAN:</p> <p>3 Q. Another one you made billions of tablets</p> <p>4 of, right?</p> <p>5 MS. VANNI: Objection.</p> <p>6 THE WITNESS: I'd have to see the charts</p> <p>7 to know how many tablets we made.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Okay. Just -- let me just take you to</p> <p>10 one, and -- we're going to have to build this one out</p> <p>11 for this one, too, but -- can you go to point 59.</p> <p>12 These are, again, the two QualiTest</p> <p>13 facilities there on the bottom left: Vintage and</p> <p>14 Generics Bidco.</p> <p>15 Do you see that?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. And I won't build the full chart</p> <p>18 out, sir, but it's -- what's that, 262 million dosage</p> <p>19 units of the hydrocodone 10s combined with</p> <p>20 acetaminophen?</p> <p>21 A. Yes.</p> <p>22 Q. And that's just in the hundred-count</p> <p>23 bottle, right?</p> <p>24 MS. VANNI: Object to the form.</p> <p>25 THE WITNESS: Yes.</p>	<p style="text-align: right;">Page 428</p> <p>1 going to move along. If the jury would like to look</p> <p>2 at it, I'm sure they'll have the chance.</p> <p>3 All right, sir. So we can agree it's a</p> <p>4 closed system -- supposed to be a closed system,</p> <p>5 right?</p> <p>6 MS. VANNI: Object to the form.</p> <p>7 THE WITNESS: Yes.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. And your promise as a registrant is that</p> <p>10 you -- you, the registrant -- are going to ensure and</p> <p>11 create effective controls to prevent diversion,</p> <p>12 right?</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 THE WITNESS: That we're going to have</p> <p>15 systems in place to help prevent diversion, to</p> <p>16 identify and prevent diversion.</p> <p>17 BY MR. BUCHANAN:</p> <p>18 Q. Well, I mean, you're getting fuzzy on the</p> <p>19 statute with me, sir.</p> <p>20 We talked about the statute earlier,</p> <p>21 right?</p> <p>22 MS. VANNI: Objection.</p> <p>23 THE WITNESS: Yes. And the statute states</p> <p>24 that the registrant shall implement a system to</p> <p>25 identify and notify DEA of potential -- of</p>
<p style="text-align: right;">Page 427</p> <p>1 MR. BUCHANAN: Could we go to point 67.</p> <p>2 BY MR. BUCHANAN:</p> <p>3 Q. Looks like, sir, in 2012, you guys are up</p> <p>4 to 560 million dosage units. 560 million dosage</p> <p>5 units of hydrocodone 10, acetaminophens, in the</p> <p>6 100-count bottle, in one year.</p> <p>7 Do I have that correct, sir?</p> <p>8 MS. VANNI: Object to the form.</p> <p>9 THE WITNESS: Yes.</p> <p>10 BY MR. BUCHANAN:</p> <p>11 Q. You wouldn't fuss with me, sir, in saying</p> <p>12 that just based on your experience with one year and</p> <p>13 one dosage and one combination, that you sold</p> <p>14 billions in hydrocodone in 2011 and 2012, would you,</p> <p>15 sir?</p> <p>16 MS. VANNI: Object to the form.</p> <p>17 THE WITNESS: I can't attest to the</p> <p>18 billions, but I'm sure there was -- just from</p> <p>19 what I've looked at so far, a billion, at least.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Yeah, and that was just --</p> <p>22 A. Yeah.</p> <p>23 Q. That was just for one, right?</p> <p>24 There's other pages in here, and I've got</p> <p>25 a limited window of time, so I'm going to -- I'm</p>	<p style="text-align: right;">Page 429</p> <p>1 suspicious orders.</p> <p>2 BY MR. BUCHANAN:</p> <p>3 Q. "A registrant shall have effective</p> <p>4 controls to prevent diversion."</p> <p>5 Does that language sound familiar to you,</p> <p>6 sir?</p> <p>7 A. I was referring to 21 CFR 1301.74(b).</p> <p>8 Q. And I'm referring you to the statute in</p> <p>9 the Controlled Substances Act, sir. It's a statute</p> <p>10 you're familiar with; you cited it in your</p> <p>11 PowerPoints, right?</p> <p>12 MS. VANNI: Object to the form.</p> <p>13 THE WITNESS: I may have put it in the</p> <p>14 PowerPoints over time, yes.</p> <p>15 BY MR. BUCHANAN:</p> <p>16 Q. Right. And a registrant shall maintain</p> <p>17 effective controls against -- to prevent diversion.</p> <p>18 That's what the statute says, right?</p> <p>19 MS. VANNI: Object to the form.</p> <p>20 THE WITNESS: Yes.</p> <p>21 BY MR. BUCHANAN:</p> <p>22 Q. As a manufacturer, sir, pumping out</p> <p>23 billions of pills with hydrocodone, oxycodone, would</p> <p>24 you agree, sir, that the company has a</p> <p>25 responsibility, as a reasonable company, to prevent</p>

Page 430

1 diversion?

2 VIDEOGRAPHER: Object to the form.

3 THE WITNESS: According to the statute and

4 the regulation that we both discussed, that's a

5 responsibility of a registrant.

6 MR. BUCHANAN: Even separate from that,

7 sir, this is dangerous stuff. True?

8 MS. VANNI: Object to the form.

9 THE WITNESS: The two drugs that you

10 mentioned are Schedule II controlled substances,

11 which means, as you know, they are prone to

12 abuse and diversion.

13 BY MR. BUCHANAN:

14 Q. Okay. And I said "dangerous."

15 Would you agree with me?

16 MS. VANNI: Objection. Form.

17 THE WITNESS: These are drugs that are

18 prescribed by a doctor and dispensed by a

19 pharmacy and consumed. So your definition of

20 "dangerous" is your definition, but they are a

21 prescription drug that are prescribed by doctors

22 and dispensed by pharmacies and so forth.

23 BY MR. BUCHANAN:

24 Q. Well, we looked at the chart, sir, and we

25 looked at overdose deaths. You see that? Remember,

Page 431

1 we went through from 2000 -- I think we picked it up

2 at 2006?

3 A. Yes, this chart.

4 Q. You looked at that, right?

5 A. Yes.

6 Q. You saw the death rate climb as the years

7 went along?

8 MS. VANNI: Objection.

9 THE WITNESS: I did see the change in

10 colors over the -- from 2001 to -- I think you

11 went up to '13 or something.

12 BY MR. BUCHANAN:

13 Q. Right. So this stuff, oxycodone,

14 hydrocodone, is dangerous; can we agree?

15 MS. VANNI: Objection.

16 THE WITNESS: I would say that the abuse

17 of these drugs could be dangerous.

18 BY MR. BUCHANAN:

19 Q. Right. A reasonable manufacturer, sir,

20 implements systems to prevent diversion, true?

21 MS. VANNI: Object to the form.

22 THE WITNESS: Manufacturers implement

23 systems to identify diversion.

24 BY MR. BUCHANAN:

25 Q. A reasonable one does that, right?

Page 432

1 MS. VANNI: Object to the form.

2 BY MR. BUCHANAN:

3 Q. Should do that.

4 A. A manufacturer that has a DEA

5 registration, per the statute and the -- the

6 regulation that we've gone over, is to identify -- is

7 to have a system in place to identify and report

8 suspicious orders.

9 BY MR. BUCHANAN:

10 Q. I'm just saying as a -- as a member of the

11 public -- and I'm -- I'm using a company as a

12 member -- as a member of the public in this country,

13 selling something that is addictive, that can lead to

14 overdoses, that can tear up families, that can tear

15 up communities, that can kill people, would you

16 agree, sir, even if the DEA didn't say anything more,

17 if you were going to pump out 2 billion pills, you

18 better take care in your distribution of this product

19 to make sure the usage is contained as designed?

20 MS. VANNI: Object to the form.

21 BY MR. BUCHANAN:

22 Q. Can we agree on that?

23 MS. VANNI: Objection.

24 THE WITNESS: I will say that a

25 manufacturer, per the regulation, should operate

Page 433

1 in a closed-door system and design a system to

2 identify and report suspicious orders.

3 BY MR. BUCHANAN:

4 Q. You see, sir -- would you agree, sir, that

5 when these products that you made billions of tablet

6 of in 2011 and 2012, when they leave legitimate

7 channels they've been manufactured to support,

8 heart-wrenching consequences can occur; would you

9 agree with me on that?

10 MS. VANNI: Object to the form.

11 THE WITNESS: The abuse of controlled

12 substances is sad.

13 BY MR. BUCHANAN:

14 Q. Would you agree, sir, as a responsible

15 corporate citizen, you got to do as much as you can

16 do to prevent drug abuse and diversion in the

17 communities?

18 Would you agree to that, sir?

19 MS. VANNI: Object to the form.

20 BY MR. BUCHANAN:

21 Q. As a responsible corporate citizen?

22 A. Again, I go back to the governing statute

23 and regulation --

24 Q. Okay.

25 A. -- of having a secure supply chain and

<p style="text-align: right;">Page 434</p> <p>1 designing a system to identify and report suspicious  2 orders.  3 MR. BUCHANAN: Let's get 594 for the  4 witness and counsel.  5 And what's the next in order, Scott? 28?  6 Okay.  7 BY MR. BUCHANAN:  8 Q. This is going to be Exhibit 28 to your  9 deposition, sir.  10 (Cardinal-Brantley 28 was marked for  11 identification.)  12 BY MR. BUCHANAN:  13 Q. This is kind of fresh after your arrival  14 at the company, sir. This is, I believe,  15 October 2013.  16 I'm sorry, there's an e-mail, and then  17 behind the e-mail, there's a letter. I'm going to be  18 spending my time with the letter. You're free to  19 peruse the cover page if you'd like.  20 It's an October 18, 2013, letter. "Dear  21 Valued Customer."  22 You see that, sir?  23 A. Yes.  24 Q. "A large percentage of QualiTest products  25 are categorized as controlled substances or listed</p>	<p style="text-align: right;">Page 436</p> <p>1 You'd agree with that statement; true,  2 sir?  3 A. Yes. As a controlled substance, they are  4 prone to abuse and diversion.  5 Q. "And as a result, these products have  6 become highly desirable and to those seeking to abuse  7 or divert for profit."  8 See that?  9 A. I do.  10 Q. Okay. You had that knowledge in 2013,  11 sir?  12 MS. VANNI: Object to the form.  13 THE WITNESS: Again, as a Schedule II  14 or III controlled substance, they are prone to  15 abuse and addiction.  16 BY MR. BUCHANAN:  17 Q. I'm just -- I'm not asking you to reframe  18 it or give me something else; I just want to make  19 sure you had that knowledge.  20 You agree with that?  21 A. I can only go back to the regulation.  22 Q. Well, this doesn't relate to the  23 regulation, sir. This is just a fact: "Certain  24 QualiTest products have become highly desirable to  25 seeking to abuse or divert for profit."</p>
<p style="text-align: right;">Page 435</p> <p>1 chemicals that are regulated by the Drug Enforcement  2 Administration."  3 Sir, do you see that?  4 A. Yes.  5 Q. That's what you wrote in the letter, and  6 that's consistent with your memory, right?  7 MS. VANNI: Objection to the  8 characterization of him writing the letter.  9 THE WITNESS: This letter was signed by  10 Tracey Hernandez.  11 BY MR. BUCHANAN:  12 Q. Oh, I see. And -- and are you not cc'd on  13 this, sir?  14 A. I'm listed at the bottom as a DE  15 Compliance Department contact.  16 BY MR. BUCHANAN:  17 Q. Okay. You are a DE Compliance Department  18 contact on this letter that went out to your  19 customers on October 18, 2013, correct, sir?  20 MS. VANNI: Object to the form.  21 THE WITNESS: Yes.  22 BY MR. BUCHANAN:  23 Q. Okay. Continuing the first paragraph, it  24 says, "These products, while necessary for patients,  25 can be targets for abuse and diversion."</p>	<p style="text-align: right;">Page 437</p> <p>1 Do you agree or disagree, sir?  2 A. That is the definition of a Schedule II  3 controlled substance.  4 Q. I'm not asking whether it's a definition,  5 sir. I'm asking you factually.  6 This is just an event?  7 A. Factually, it is a Schedule II --  8 factually, it is a Schedule II controlled substance,  9 and as a Schedule II controlled substance, they are  10 prone to abuse and diversion.  11 Q. Okay.  12 "When our products leave legitimate  13 channels they have been manufactured to support,  14 heart-wrenching consequences often occur."  15 See that, sir?  16 A. I do.  17 Q. Next in this letter to your valued  18 customers, sir, it's written response -- "As  19 responsible corporate citizens, individuals, parents,  20 friends, caregivers, relatives, and acquaintances, we  21 need to do as much as we can do to prevent drug abuse  22 and diversion in our communities."  23 Did I read that correctly, sir?  24 MS. VANNI: Object to the colloquy in the  25 beginning.</p>



<p style="text-align: right;">Page 438</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Did I read that correctly?</p> <p>3 A. Yes.</p> <p>4 Q. Thank you.</p> <p>5 It states: "Each company and individual</p> <p>6 in the supply chain has that responsibility."</p> <p>7 Did I read that correctly, sir?</p> <p>8 A. Yes.</p> <p>9 Q. "To put adequate controls in place to</p> <p>10 discourage and prevent the diversion of prescription</p> <p>11 products for uses other than those for which they</p> <p>12 were originally intended."</p> <p>13 Did I read that correctly, sir?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. And the context around this letter,</p> <p>16 sir, is that you had a visit with the DEA down in</p> <p>17 Washington in the spring of 2013, right?</p> <p>18 MS. VANNI: Object to the form.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. I'm sorry, your QualiTest -- I'd say</p> <p>21 co-employees, once you joined, but Ms. Hernandez and</p> <p>22 others had a meeting with the DEA in the spring of</p> <p>23 2013, right?</p> <p>24 A. There was a meeting with the DEA.</p> <p>25 Q. Okay. And you were scheduled to go back</p>	<p style="text-align: right;">Page 440</p> <p>1 diligence efforts when fulfilling orders to provide</p> <p>2 greater assurance that our products are purchased by</p> <p>3 appropriate patients for prescribed uses."</p> <p>4 Is that right?</p> <p>5 A. That's what it says.</p> <p>6 Q. Okay. That's something reasonable for a</p> <p>7 company to do, right?</p> <p>8 MS. VANNI: Object to the form.</p> <p>9 THE WITNESS: It's always good to make</p> <p>10 enhancements.</p> <p>11 BY MR. BUCHANAN:</p> <p>12 Q. Well, it's always good to do whatever you</p> <p>13 can do to make something that's really dangerous less</p> <p>14 dangerous; would you agree with me, sir?</p> <p>15 MS. VANNI: Objection.</p> <p>16 THE WITNESS: It's always good to enhance</p> <p>17 any program.</p> <p>18 BY MR. BUCHANAN:</p> <p>19 Q. Right. And what you're talking about here</p> <p>20 is products that have become highly desirable to</p> <p>21 those seeking to abuse or divert for profit, right?</p> <p>22 A. I believe that was stated in the letter.</p> <p>23 Q. Okay. And then you're talking about</p> <p>24 changes that are going to be implemented, right, as a</p> <p>25 responsible corporate citizen, right?</p>
<p style="text-align: right;">Page 439</p> <p>1 and see the DEA again in October of 2013 and show how</p> <p>2 you shored up your systems, right?</p> <p>3 MS. VANNI: Object to the form.</p> <p>4 THE WITNESS: I don't know if -- if there</p> <p>5 was another meeting in October 2013.</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Okay. All right.</p> <p>8 It states what you're going to do here at</p> <p>9 the bottom. You're making changes that may impact</p> <p>10 your customers when placing orders, right? Changes?</p> <p>11 A. Are you on the same page?</p> <p>12 Q. I am. Second paragraph -- third</p> <p>13 paragraph, sir: "Some of these changes may impact</p> <p>14 you in placing orders with us in the future," just to</p> <p>15 orient you, sir:</p> <p>16 You see that?</p> <p>17 I'm going to read the --</p> <p>18 A. "QualiTest would like to make you aware of</p> <p>19 some changes that we are making." Okay, yes.</p> <p>20 Q. Okay. So QualiTest was making changes,</p> <p>21 right?</p> <p>22 MS. VANNI: Object to the form.</p> <p>23 THE WITNESS: Yes.</p> <p>24 BY MR. BUCHANAN:</p> <p>25 Q. Okay. "QualiTest is enhancing its due</p>	<p style="text-align: right;">Page 441</p> <p>1 MS. VANNI: Object to the form.</p> <p>2 THE WITNESS: This letter is about the</p> <p>3 changes that would be implemented.</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. Okay. And you're just telling your</p> <p>6 customers that, right? So they're not surprised when</p> <p>7 all of a sudden, if -- you know their orders start</p> <p>8 getting canceled, right?</p> <p>9 MS. VANNI: Object to the form.</p> <p>10 THE WITNESS: Just telling the customers</p> <p>11 about the changes.</p> <p>12 BY MR. BUCHANAN:</p> <p>13 Q. Okay. You say, "As a result, you may</p> <p>14 receive more frequent inquiries from QualiTest</p> <p>15 regarding your own suspicious monitoring efforts."</p> <p>16 Let's pause on that.</p> <p>17 So what you did when you implemented this</p> <p>18 change is you started asking your customers, these</p> <p>19 people -- well, withdrawn.</p> <p>20 QualiTest is a manufacturer, true?</p> <p>21 A. Yes.</p> <p>22 Q. Also had a distributor registration, true?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And so -- but when QualiTest is</p> <p>25 selling to folks like Cardinal, your prior employer,</p>

Page 442

1 they're a middleman, right? They're not -- they're  
 2 not dispensing the drug to patients, right?  
 3 A. Who's a middleman? QualiTest?  
 4 Q. Cardinal, wholesalers -- wholesalers,  
 5 distributors -- they're middlemen?  
 6 A. Your question wasn't clear. So you're  
 7 asking me whether Cardinal is a middleman or whether  
 8 QualiTest is a middleman?  
 9 Q. If it wasn't clear, I apologize, sir.  
 10 What I was saying is, QualiTest was making pills,  
 11 right?  
 12 A. QualiTest is the manufacturer of --  
 13 Q. We saw, you know, billions of scheduled  
 14 drugs being made in 2011 and 2012 alone, true?  
 15 MS. VANNI: Objection.  
 16 THE WITNESS: Yes, according to the -- the  
 17 graphs that we --  
 18 BY MR. BUCHANAN:  
 19 Q. Okay.  
 20 A. -- reviewed earlier.  
 21 Q. And then QualiTest is going to put those  
 22 in the hands of -- sometimes directly with retail  
 23 pharmacies, but mostly through distributors, right?  
 24 MS. VANNI: Object to the form.  
 25 THE WITNESS: Yes.

Page 443

1 BY MR. BUCHANAN:  
 2 Q. Right. And the distributors are then  
 3 going to route these things to their ultimate home, a  
 4 pharmacy, where they could be dispensed if they're  
 5 not diverted, right?  
 6 A. Right. They were selling to the final  
 7 dispensers: Pharmacies, hospitals, and so forth.  
 8 Q. So one of the things you're going to do is  
 9 you're going to start asking if they have suspicious  
 10 order monitoring processes, right? Going to start  
 11 knowing your customer, right?  
 12 MS. VANNI: Object to the form.  
 13 THE WITNESS: By the phrase start, I can't  
 14 speak to what was done prior to my arrival. So  
 15 to say that something is going to start with  
 16 this letter, again, I can't speak to what was  
 17 done prior to October 2013, when I arrived.  
 18 BY MR. BUCHANAN:  
 19 Q. Okay. But you were going to be asking  
 20 your customers for their suspicious-order monitoring  
 21 protocols, right?  
 22 A. That is a question on the attached  
 23 questionnaire.  
 24 Q. Yeah. I mean, that's -- that's what's  
 25 listed as a change, right? Some things are going to

Page 444

1 change, and that's one of the things you list as a  
 2 change, right?  
 3 MS. VANNI: Object to the form.  
 4 THE WITNESS: Show me the exact statement  
 5 so I can know exactly what it says, please. I  
 6 got lost in here.  
 7 BY MR. BUCHANAN:  
 8 Q. Okay.  
 9 A. Where, exactly --  
 10 Q. Beginning of the paragraph, it says "going  
 11 to be making some changes"; do you see that?  
 12 A. No, I mean to the question that you asked  
 13 about specifically what was going to change.  
 14 Q. Okay. "As a result, you may receive more  
 15 frequent inquiries from QualiTest regarding your own  
 16 suspicious-order monitoring efforts, the quantity of  
 17 the product you are ordering from us, or the customer  
 18 service."  
 19 Do you see that, sir?  
 20 A. Yes, "you may receive more frequent  
 21 inquiries," which means --  
 22 Q. My question to you, sir, is do you see  
 23 that?  
 24 A. Yes, it is, which means that they were --  
 25 Q. No, no. No, no, sir.

Page 445

1 A. -- prior to --  
 2 MS. VANNI: Let him finish.  
 3 BY MR. BUCHANAN:  
 4 Q. My question is: Do you see it?  
 5 A. I see it.  
 6 MR. FULLER: You'll have an opportunity to  
 7 do a direct examination --  
 8 MS. VANNI: No, let him answer  
 9 his question.  
 10 THE WITNESS: I was answering your  
 11 previous question.  
 12 MR. BUCHANAN: No, no, no. That's not how  
 13 it works. An examination -- an examination here  
 14 is supposed to proceed as it would in court. A  
 15 witness would not be permitted to do that in  
 16 court.  
 17 MS. VANNI: He's allowed to answer his --  
 18 your question.  
 19 MR. BUCHANAN: That's not an answer. The  
 20 answer was -- did it -- do you see that, sir?  
 21 MS. VANNI: It may not be an answer you  
 22 like --  
 23 MR. BUCHANAN: No, that's not --  
 24 MS. VANNI: -- that's an answer.  
 25 MR. BUCHANAN: Okay. We'll move along.

<p style="text-align: right;">Page 446</p> <p>1 It's not a matter of whether I like it or not, 2 sir. I just like responsive answers to my 3 questions. 4 MS. VANNI: Move to strike the colloquy. 5 BY MR. BUCHANAN: 6 Q. All right. You're also going to start 7 doing due diligence visits. 8 You see that, sir? 9 MS. VANNI: Object to the form. 10 THE WITNESS: I'm trying to read where it 11 says that. 12 BY MR. BUCHANAN: 13 Q. Did you do due diligence visits while you 14 were at QualiTest, sir? 15 A. Yes. 16 Q. Okay. This is -- what's the date of this 17 -- October 18th, 2013. So this is -- what, two 18 weeks, two and a half weeks after you joined the 19 company? 20 A. I don't remember my exact start date. I 21 believe it was October 2013. I don't remember when. 22 Q. Do you remember sharing with your 23 colleagues, sir, your vision for QualiTest's 24 suspicious order monitoring system? 25 MS. VANNI: Object to the form.</p>	<p style="text-align: right;">Page 448</p> <p>1 BY MR. BUCHANAN: 2 Q. Thank you. I appreciate the 3 clarification. I'll withdraw that question. 4 There was a meeting with DEA, March of 5 2013, during which suspicious order monitoring was 6 discussed? 7 MS. VANNI: Object to the form. 8 THE WITNESS: I believe that's what we 9 reviewed. 10 BY MR. BUCHANAN: 11 Q. There was a follow-up six months later, 12 right? 13 MS. VANNI: Objection. 14 Q. In October of 2013, with the DEA? 15 A. I believe that's what you stated. 16 Q. Okay. And you joined the company in 17 September 2013, right? 18 MS. VANNI: Objection. 19 THE WITNESS: I don't recall if it was 20 September or October 2013. 21 BY MR. BUCHANAN: 22 Q. Okay. 23 A. Somewhere around that time frame. 24 MR. BUCHANAN: Can we pass the witness 58, 25 please -- 583. Excuse me.</p>
<p style="text-align: right;">Page 447</p> <p>1 THE WITNESS: Are you referring to a 2 training? Are you referring to a PowerPoint? 3 Are you referring to -- a conversation? 4 BY MR. BUCHANAN: 5 Q. I'm referring to your vision for it. 6 MS. VANNI: Object to the form. 7 THE WITNESS: What was your original 8 question? 9 BY MR. BUCHANAN: 10 Q. Do you recall sharing, sir, with your 11 colleagues, your vision for their suspicious order 12 monitoring system? 13 MS. VANNI: Same objection. 14 THE WITNESS: Again, on several occasions 15 I've had meetings with colleagues regarding 16 the -- the system. So, yes, I remember sharing. 17 BY MR. BUCHANAN: 18 Q. Okay. And so this arises, as we said, 19 there was a -- there's this meeting with the FDA in 20 March of 2013. There's a further meeting with FDA in 21 October of 2013. You step in September of 2013. 22 True? 23 MS. VANNI: Objection. 24 THE WITNESS: Do you mean DEA? You stated 25 "FDA."</p>	<p style="text-align: right;">Page 449</p> <p>1 BY MR. BUCHANAN: 2 Q. This is an e-mail, sir -- and I'll -- I'll 3 wait before I get into the meat of it -- from 4 yourself to yourself, Monday, October 7, 2013. 5 I'll represent to you, sir, I've seen 6 reference that you started on September 30. 7 Does that refresh your recollection? I 8 mean, it's your testimony; I'm just asking if that 9 helps you remember. 10 A. If you have seen something that stated I 11 started September 30th, I accept that. 12 Q. Okay. So we're looking now at -- 13 MR. BUCHANAN: What was the exhibit we 14 identified? 29? This is Brantley 29. 15 (Cardinal-Brantley 29 was marked for 16 identification.) 17 BY MR. BUCHANAN: 18 Q. "Below is a high-level outline of my 19 vision for our SOM program." 20 Do you see that, sir? 21 A. Yes. 22 Q. Okay. You talk about implementing new 23 account setup criteria, correct? 24 A. Yes. 25 Q. Do you recall, sir, the implementation of</p>

Page 450

1 questionnaires now for new accounts as part of the  
2 setup process and the verification process of  
3 QualiTest in this fall of 2013 time?  
4 MS. VANNI: Object to form.  
5 THE WITNESS: I did draft questionnaires.  
6 I believe one was attached to the previous  
7 document.  
8 BY MR. BUCHANAN:  
9 Q. Okay. So the letter that we just looked  
10 at, the one from October, was that 18th? You're  
11 saying you did the questionnaire that was attached to  
12 that?  
13 A. This looks like a draft of the  
14 questionnaire that I did, yes.  
15 Q. Okay. Well, it's -- it's attached to a  
16 signed letter, right?  
17 MS. VANNI: Object to the form.  
18 BY MR. BUCHANAN:  
19 Q. I'm just confirming, sir, that --  
20 that's -- that's the one that went with it, right?  
21 A. It's -- it's stapled to this letter, yes.  
22 Q. Okay. And that's something you prepared  
23 once you got to QualiTest, right?  
24 A. This questionnaire is one that I -- it  
25 looks like one that I prepared.

Page 451

1 Q. Okay. Getting back now to the -- what  
2 exhibit are we on, Scott? 29?  
3 It's a high-level outline of your vision  
4 for the SOM program, right?  
5 A. I'm sorry. I was on the wrong page.  
6 Yes.  
7 MS. VANNI: Object to the form.  
8 BY MR. BUCHANAN:  
9 Q. Okay. And basically there's going to be a  
10 vetting process in connection with new accounts now,  
11 right?  
12 MS. VANNI: Objection.  
13 THE WITNESS: There would be a vetting  
14 process. You say "now." I don't -- again, I  
15 can't speak to what was done prior to me.  
16 BY MR. BUCHANAN:  
17 Q. Okay. Well, if we go down here, third,  
18 fourth bullet, we see: "The DEA compliance team will  
19 verify DEA numbers, verify information on the  
20 questionnaire, including license verification among  
21 other things, conduct Internet research on the  
22 company ownership and pick, including disciplinary  
23 history."  
24 Did I read that correctly, sir?  
25 A. Yes.

Page 452

1 Q. That's something that's reasonable for a  
2 company to do, is trade in billions of pills of  
3 narcotics, true?  
4 MS. VANNI: Objection.  
5 THE WITNESS: That is part of the program  
6 that I was rolling out as part of the  
7 questionnaire, Know Your Customer, which is not  
8 in 21 CFR 1301.74(b).  
9 BY MR. BUCHANAN:  
10 Q. Okay. So that's something that's  
11 reasonable for a company who is trading in billions  
12 of pills of narcotics to do, correct?  
13 MS. VANNI: Object to the form.  
14 THE WITNESS: That is something over and  
15 above what the regulations stated, that we did.  
16 BY MR. BUCHANAN:  
17 Q. I'm not asking you that, sir. I'm asking  
18 you whether it was reasonable for you to do that:  
19 Yes or no?  
20 A. It is something that we did.  
21 Q. Okay. Was it unreasonable to do that?  
22 A. You state reasonable --  
23 MS. VANNI: Objection.  
24 THE WITNESS: -- unreasonable; I'm stating  
25 a fact. It was something that we did.

Page 453

1 BY MR. BUCHANAN:  
2 Q. Okay, it was something --  
3 A. It's a fact.  
4 Q. -- that a responsible company would do,  
5 right?  
6 MS. VANNI: Objection.  
7 THE WITNESS: It was something that  
8 QualiTest did.  
9 BY MR. BUCHANAN:  
10 Q. Okay. We saw the letter before, sir, that  
11 described the changes that were being implemented,  
12 and said: "As responsible corporate citizens, we  
13 need to do as much as we can do to prevent drug abuse  
14 and diversion in our communities."  
15 Do you recall reading that with me a few  
16 minutes ago, sir?  
17 A. I do.  
18 Q. Okay. "Each company and individual in the  
19 supply chain has that responsibility."  
20 Do you recall reading that with me a few  
21 moments ago, sir?  
22 A. I see that.  
23 Q. "To put adequate controls in place to  
24 discourage and prevent the diversion of prescription  
25 products for uses other than those for which they

Page 454

1 were originally intended."  
 2 You see that, sir?  
 3 A. I do.  
 4 Q. Okay. All right. And what we see here in  
 5 your proposal, sir, are the adequate controls that  
 6 you were proposing to your team, right?  
 7 MS. VANNI: Object to the form.  
 8 THE WITNESS: These are my proposals that  
 9 I'm sharing with my team.  
 10 BY MR. BUCHANAN:  
 11 Q. Okay. Then you talk about -- if you  
 12 identify red flags, towards the bottom, you're going  
 13 to investigate that through an SOM manager, right?  
 14 Not a salesperson? Right?  
 15 A. (Reading) It's stating that the DEA team  
 16 member can engage the SOMS manager, who was -- I was  
 17 the SOMS manager.  
 18 Q. Okay. And then you get the wholesalers  
 19 and distributors; this is onboarding for them, right?  
 20 These are your proposals for your SOM  
 21 program, right?  
 22 MS. VANNI: Objection to form.  
 23 THE WITNESS: Yes.  
 24 BY MR. BUCHANAN:  
 25 Q. Okay. And on these, sir, again, you're

Page 455

1 going to do due diligence on your wholesale and  
 2 distributor customers, right?  
 3 MS. VANNI: Object to the form.  
 4 THE WITNESS: Yes.  
 5 BY MR. BUCHANAN:  
 6 Q. Okay. You also want to get an agreement  
 7 from your -- your supply chain that they're not going  
 8 to trade more than three times; is that right?  
 9 Do you see that, sir?  
 10 A. I do see that.  
 11 Q. Okay. Do you agree with me?  
 12 That was your proposal, sir?  
 13 A. That was in this original proposal, yes.  
 14 Q. Did you end up doing that?  
 15 A. I don't believe so.  
 16 Q. We go on the next page, it says "Cage  
 17 vault SOM." See that?  
 18 A. Yes.  
 19 Q. Let's talk about this. I mean, so these  
 20 are drugs -- and we went round and round as to  
 21 whether these are dangerous or not, and -- or the  
 22 extent of their danger. These are drugs, certainly  
 23 if they're Schedule II, sir, you got to keep them in  
 24 a safe and locked up, right?  
 25 MS. VANNI: Object to form.

Page 456

1 BY MR. BUCHANAN:  
 2 Q. In a vault?  
 3 A. Schedule II drugs are stored in a vault.  
 4 Q. Right. This stuff, Schedule II drugs,  
 5 that you were pumping out billions of pills -- or at  
 6 least a billion pills -- between 2011 and 2012, when  
 7 it's in your facilities, got to keep it in a vault,  
 8 right?  
 9 MS. VANNI: Object to form.  
 10 THE WITNESS: Yes.  
 11 BY MR. BUCHANAN:  
 12 Q. Because it presents that much risk, right?  
 13 MS. VANNI: Object to form.  
 14 THE WITNESS: Because 21 CFR 1300 to end  
 15 states that Schedule II drugs are to be stored  
 16 in a vault.  
 17 BY MR. BUCHANAN:  
 18 Q. You understand that it's kept in a vault  
 19 because it's a highly addictive drug and it's prone  
 20 to diversion, right?  
 21 MS. VANNI: Object to form.  
 22 A. It's kept in a vault to be more secure,  
 23 because it is a Schedule II drug that is prone to  
 24 abuse and diversion.  
 25 Q. Right. So if you're going to keep it in a

Page 457

1 vault while it's in your facility, you'd agree with  
 2 me, sir, that as a responsible corporate citizen, you  
 3 should do your best, as the letter said, to make sure  
 4 that it stays within that closed system, right?  
 5 MS. VANNI: Object to form.  
 6 THE WITNESS: According to the  
 7 regulations, it is to be kept in a closed,  
 8 secure supply chain.  
 9 BY MR. BUCHANAN:  
 10 Q. That's right.  
 11 A. Yes.  
 12 Q. And you as a registrant, sir, you promised  
 13 to maintain effective controls to keep it in that  
 14 supply chain, true?  
 15 MS. VANNI: Object to form.  
 16 THE WITNESS: Again, as the regulation  
 17 states, if you have that DEA registration, you  
 18 are to maintain effective controls.  
 19 BY MR. BUCHANAN:  
 20 Q. So you're now on the job two weeks, sir,  
 21 and you'd -- you'd agree, sir, you're proposing to  
 22 revamp the company's SOM process; is that right?  
 23 MS. VANNI: Object to form.  
 24 THE WITNESS: Not knowing what the process  
 25 was prior to, these are my thoughts going in,



<p style="text-align: right;">Page 458</p> <p>1 that I would like -- these are my initial                  2 thoughts, and apparently this was drafted to                  3 myself. I don't know how --                  4 BY MR. BUCHANAN:                  5 Q. Okay.                  6 A. -- far this got into distribution, but                  7 these were my original thoughts of a system.                  8 Q. You're proposing that you set thresholds                  9 on a customer-by-customer basis, right?                  10 A. Yes.                  11 Q. Company didn't have thresholds before?                  12 MS. VANNI: Objection.                  13 BY MR. BUCHANAN:                  14 Q. Right?                  15 A. I don't know.                  16 Q. I mean, you didn't look to see what the                  17 company was doing before versus what it did after                  18 changes were implemented, after the DEA visit in                  19 March of 2013?                  20 MS. VANNI: Objection.                  21 THE WITNESS: I did not.                  22 BY MR. BUCHANAN:                  23 Q. Okay. And you identify a bunch of factors                  24 you're saying should be looked at, right, in setting                  25 those thresholds?</p>	<p style="text-align: right;">Page 460</p> <p>1 MS. VANNI: Object to form.                  2 THE WITNESS: We should be doing business                  3 with companies that are in compliance with the                  4 regulation.                  5 BY MR. BUCHANAN:                  6 Q. If you're not, if there's a break in that                  7 system, sir, it's not a closed system anymore, right?                  8 A. If there's a break in that system --                  9 MS. VANNI: Object to the form.                  10 THE WITNESS: -- they wouldn't have a                  11 registration. So we do business with companies                  12 that have a -- a registration.                  13 BY MR. BUCHANAN:                  14 Q. But we saw, obviously, in your Cardinal                  15 examination, sir, a number of Cardinal entities were                  16 doing business, sir, without effective SOM programs,                  17 and their registrations were pulled, right?                  18 MS. VANNI: Objection to form.                  19 MR. PYSER: Objection to form.                  20 BY MR. BUCHANAN:                  21 Q. Do you recall that?                  22 A. Those entities were pharmacies, and                  23 pharmacies do not have SOM programs. The pharmacist                  24 has a corresponding responsibility that he or she                  25 does not have to fill a script that a doctor has</p>
<p style="text-align: right;">Page 459</p> <p>1 A. Which page -- yes.                  2 Q. It's page 2. Retail independent closed                  3 door. Number of scripts dispensed per month,                  4 percentage of scripts for controlled substances,                  5 percentage of scripts from pain management clinics,                  6 and doctors, number of vendors other than QualiTest,                  7 demographics, number of pharmacies in the area,                  8 purchase history, number of beds -- do you see all                  9 those factors, sir?                  10 A. I do.                  11 Q. And what you're proposing, sir, is that                  12 the company integrate a lot of information and try                  13 and tailor a threshold that fits the customer, right?                  14 Know Your Customer?                  15 MS. VANNI: Object to the form.                  16 THE WITNESS: Establish thresholds based                  17 on the -- the customer information.                  18 BY MR. BUCHANAN:                  19 Q. Okay. And -- and moving on to wholesales,                  20 wholesales and distributors, one of your check boxes                  21 there is an existence of a robust SOM program, right?                  22 A. Yes.                  23 Q. It's a closed system. You should be doing                  24 business with people, sir, that are maintaining that                  25 closed system, right?</p>	<p style="text-align: right;">Page 461</p> <p>1 written. So there is a different standard for a                  2 pharmacist versus a wholesaler.                  3 Q. I guess my question wasn't clear. I was                  4 referring to the wholesalers. Cardinal got their                  5 registrations pulled on a bunch of sites, right?                  6 MR. PYSER: Object to form.                  7 MS. VANNI: Objection.                  8 THE WITNESS: There were, I believe, four                  9 sites that we discussed previously.                  10 BY MR. BUCHANAN:                  11 Q. Yeah. Sites. Distribution centers,                  12 right?                  13 A. Distribution centers.                  14 Q. Right. Pushing out millions of pills,                  15 right?                  16 MS. VANNI: Objection.                  17 THE WITNESS: Distribution centers that                  18 were distributing tablets, pills, to customers.                  19 BY MR. BUCHANAN:                  20 Q. You said further, sir, chain warehouses,                  21 they should also have an effective and robust                  22 suspicious-order monitoring program, correct?                  23 A. Yes.                  24 Q. Okay. And then you talk about other                  25 things a company should do, or you were proposing to</p>

Page 462

1 do, as part of your suspicious-order monitoring  
 2 system, right?  
 3 A. Yes.  
 4 Q. Okay. Well, first, there's threshold  
 5 events that you list, and these are circumstances  
 6 where a client or a customer -- wholesaler or  
 7 distributor, retail pharmacy -- wants to place an  
 8 order that goes beyond their threshold, right?  
 9 MS. VANNI: Object to the form.  
 10 THE WITNESS: Yes, when a customer has  
 11 reached an allotted dosage unit, yes.  
 12 BY MR. BUCHANAN:  
 13 Q. Okay. And then you can go through and try  
 14 to figure out why their order is greater than the  
 15 threshold you ascribed to them, right?  
 16 MS. VANNI: Object to the form.  
 17 THE WITNESS: Yes.  
 18 BY MR. BUCHANAN:  
 19 Q. You say if that doesn't sort out, with  
 20 these factors that you list here, the DEA will be  
 21 notified on all cut/suspicious orders, right?  
 22 A. Yes.  
 23 Q. So you'd agree, sir, that if an order  
 24 comes in and it exceeds a threshold, it's not  
 25 appropriate for the company to structure that order

Page 463

1 in a way to stay within a threshold, true?  
 2 MS. VANNI: Object to the form.  
 3 THE WITNESS: If an order comes in and it  
 4 exceeds a threshold, then that's it. It -- it  
 5 exceeds that threshold.  
 6 So are you stating a change to the order?  
 7 BY MR. BUCHANAN:  
 8 Q. Yeah. Yeah, I mean, the company shouldn't  
 9 change the order, the order size, to sneak it within  
 10 the threshold; shouldn't structure the order to fit  
 11 within the threshold.  
 12 Agreed?  
 13 MS. VANNI: Object to the form.  
 14 THE WITNESS: I wouldn't use your exact  
 15 verbiage, but if a company -- I mean, if an  
 16 order comes in that exceeds the threshold, that  
 17 event needs to be investigated.  
 18 BY MR. BUCHANAN:  
 19 Q. Well, not only does it need to be  
 20 investigated, sir; if you cut it, you're supposed to  
 21 tell the DEA. That's what you're proposing, right?  
 22 A. If you cut that order, it's -- it's to be  
 23 reported to the DEA.  
 24 Q. Right. You got to tell the DEA if you cut  
 25 the size of that order, right?

Page 464

1 A. When I say "cut," i don't refer to cut  
 2 down; I mean "cut," meaning cut.  
 3 Q. Oh, I see. Okay.  
 4 A. That does not mean cut down.  
 5 Q. You'd agree, sir, though, it's not  
 6 appropriate for the company to cut down the size of  
 7 an order to fit within a threshold, right?  
 8 MS. VANNI: Object to the form.  
 9 THE WITNESS: Again, my statement is that  
 10 if an order comes in that exceeds a threshold,  
 11 an investigation should be conducted.  
 12 BY MR. BUCHANAN:  
 13 Q. Okay. It's not my question to you, sir.  
 14 A. But that's my answer.  
 15 Q. Okay. Then stay with my question, because  
 16 I get to ask them.  
 17 MS. VANNI: Objection.  
 18 BY MR. BUCHANAN:  
 19 Q. You'd agree, sir, that it's not  
 20 appropriate for a company to structure its customer  
 21 orders in a certain way so that they stay within the  
 22 thresholds, and therefore are not reported to the  
 23 DEA; that would not be appropriate, would it, sir?  
 24 MS. VANNI: Objection to the form.  
 25 THE WITNESS: I'm not a regulatory

Page 465

1 authority, so I can't speak to what is  
 2 appropriate.  
 3 Again, my answer is: If an order comes in  
 4 that exceeds the threshold, an investigation  
 5 should be conducted.  
 6 BY MR. BUCHANAN:  
 7 Q. Okay, sir. You were, in fact -- wasn't  
 8 your position at this point in time, or at some point  
 9 in time during your period of QualiTest, the head of  
 10 suspicious-order monitoring?  
 11 A. I was the manager of -- of  
 12 suspicious-order monitoring.  
 13 Q. Okay.  
 14 A. Regulatory authorities -- regulatory  
 15 authority. I mean an agency, DEA, state government,  
 16 FDA.  
 17 Q. Okay. I just want to understand, sir --  
 18 A. Whomever.  
 19 Q. -- from Mr. Brantley's perspective as the  
 20 head manager of SOM for QualiTest from 2013 to '17,  
 21 or at least the beginning of '17, would you endorse a  
 22 decision by QualiTest to structure its customers'  
 23 orders in a way to stay within the thresholds and not  
 24 report those orders then to the DEA?  
 25 MS. VANNI: Object to form.

Page 466

1 THE WITNESS: That's the same question,  
 2 and I offer the same answer. If an order comes  
 3 in, and it exceeds the threshold, an  
 4 investigation needs to be conducted.  
 5 BY MR. BUCHANAN:  
 6 Q. All right. Let's talk about, sir, what  
 7 else you're saying needs to be done.  
 8 Chargebacks. All right? Chargebacks  
 9 provide visibility to a manufacturer about what its  
 10 customers -- customers are selling, right?  
 11 MS. VANNI: Object to the form.  
 12 THE WITNESS: It provides a manufacturer  
 13 visibility in what a customer's customer is  
 14 ordering --  
 15 BY MR. BUCHANAN:  
 16 Q. Okay.  
 17 A. -- not selling. Ordering. From the  
 18 wholesaler.  
 19 Q. Fair enough. So what you can see as the  
 20 manufacturer, through chargeback data, in  
 21 consideration of chargeback data, is the extent to  
 22 which, for example, Cardinal, Cardinal's pharmacy  
 23 customers are ordering your product from Cardinal.  
 24 Fair?  
 25 A. Yes.

Page 467

1 MS. VANNI: Object to form.  
 2 BY MR. BUCHANAN:  
 3 Q. Okay. So what you're saying here is one  
 4 thing you got to start doing is looking at chargeback  
 5 data, right?  
 6 MS. VANNI: Object to form.  
 7 THE WITNESS: Again, your verbiage of  
 8 "start doing" speaks to what was done prior to  
 9 me, and I can't speak to that.  
 10 BY MR. BUCHANAN:  
 11 Q. Well, was chargeback data being done  
 12 before you got there, sir?  
 13 A. I don't --  
 14 Q. Was it being looked at?  
 15 A. I don't know.  
 16 Q. Okay. Was it being looked at to evaluate  
 17 suspicious orders, to be more clear?  
 18 A. I don't know.  
 19 Q. Okay. What you're saying here is that  
 20 monthly reports would be generated in review, and  
 21 chargeback data will be used to identify activity of  
 22 final dispensers with wholesalers. That's one point,  
 23 right?  
 24 A. Yes.  
 25 Q. Identify suspicious activities of chains,

Page 468

1 right?  
 2 Do you see that?  
 3 A. Yes.  
 4 Q. Identify potential price diversion, right?  
 5 A. Yes.  
 6 Q. Okay. Go on, and you list about your  
 7 wholesaler/distributor communications.  
 8 You're talking about sending letters to  
 9 your customers to get information about their  
 10 customers, right?  
 11 MS. VANNI: Object to the form.  
 12 BY MR. BUCHANAN:  
 13 Q. That's your proposal; this is your vision?  
 14 A. If a customer --  
 15 Q. Right?  
 16 MS. VANNI: Objection.  
 17 THE WITNESS: -- is identified, reviewing  
 18 the data, we'll reach out to the wholesaler to  
 19 ask for additional information regarding that  
 20 downstream customer.  
 21 BY MR. BUCHANAN:  
 22 Q. Okay. So that's a reasonable thing to do,  
 23 right?  
 24 MS. VANNI: Objection.  
 25

Page 469

1 BY MR. BUCHANAN:  
 2 Q. As a manufacturer of billions of pills of  
 3 scheduled narcotics?  
 4 MS. VANNI: Objection.  
 5 THE WITNESS: Again, your use of the term  
 6 "reasonable," I can't speak to. I can state  
 7 what I wrote here is the fact that after  
 8 reviewing data, if a downstream customer was  
 9 identified, reach out to the wholesaler and ask  
 10 for additional information.  
 11 BY MR. BUCHANAN:  
 12 Q. That's one way, sir, of trying to  
 13 implement an effective control against diversion,  
 14 right?  
 15 MS. VANNI: Object to the form.  
 16 THE WITNESS: That is one way of having an  
 17 effective control against diversion.  
 18 BY MR. BUCHANAN:  
 19 Q. Okay. All right, sir. And you say you're  
 20 going to send letters; you're going to ask for  
 21 information from the wholesaler and distributor  
 22 customers, right?  
 23 MS. VANNI: Object to the form.  
 24 THE WITNESS: Yes.  
 25

Page 470

1 BY MR. BUCHANAN:  
2 Q. You're also going to employ, as part of  
3 your due diligence, sir, in knowing your customer and  
4 your customer's customer, intelligence from  
5 regulatory bodies, right?  
6 MS. VANNI: Object to the form.  
7 THE WITNESS: Yes.  
8 BY MR. BUCHANAN:  
9 Q. Intelligence from media sources, right?  
10 A. Yes.  
11 Q. Intelligence from industry organizations,  
12 right?  
13 A. Yes.  
14 Q. Those are all good things, sir, to try and  
15 keep this system closed, right?  
16 MS. VANNI: Object to the form.  
17 THE WITNESS: Those are all things that I  
18 listed in this e-mail to myself of things to  
19 implement.  
20 BY MR. BUCHANAN:  
21 Q. In your vision?  
22 A. Yes.  
23 Q. Okay.  
24 A. In my -- in my initial thoughts of  
25 building my version of a program.

Page 471

1 Q. Okay. And to be clear, sir, chargeback  
2 data has been around for years, right?  
3 MS. VANNI: Object to the form.  
4 THE WITNESS: I don't know how long  
5 chargeback data had been around, but I know that  
6 it is incomplete. Not every customer  
7 participates in a chargeback program, and I  
8 don't know how long it's been around.  
9 BY MR. BUCHANAN:  
10 Q. Okay. So staying with my question, you  
11 just don't know how long it's been around?  
12 A. I do not know how long chargeback data has  
13 been around.  
14 Q. Would it surprise you to learn, sir, that  
15 Endo, the owner of QualiTest, had chargeback  
16 agreements all the way back into the '90s? Would  
17 that surprise you, sir?  
18 MS. VANNI: Okay.  
19 THE WITNESS: Again, I don't know how long  
20 chargeback data has been around.  
21 BY MR. BUCHANAN:  
22 Q. Okay. And chargeback data, again,  
23 provides visibility into what the end pharmacy is  
24 ordering from the intermediary wholesaler or  
25 distributor, correct?

Page 472

1 MS. VANNI: Object to the form.  
2 THE WITNESS: That is some  
3 identification -- that is some information that  
4 could be gained from chargeback data.  
5 BY MR. BUCHANAN:  
6 Q. Okay.  
7 A. But understand, chargeback data is a  
8 financial transaction.  
9 Q. Okay. In fact, you did use chargeback  
10 data, didn't you, sir?  
11 A. I did use chargeback data.  
12 Q. Right. Okay. And the DEA presented  
13 chargeback -- they presented data to you on your  
14 customers' customers -- I shouldn't say "you," the  
15 royal you, QualiTest "you" -- in March of 2013,  
16 didn't they, sir?  
17 MS. VANNI: Objection to the form.  
18 THE WITNESS: In the ARCOS data.  
19 BY MR. BUCHANAN:  
20 Q. Yes. And you saw, in fact, the visibility  
21 to what Cardinal's customers were buying from --  
22 withdrawn.  
23 You saw visibility to your product  
24 downstream through your intermediary wholesalers,  
25 true?

Page 473

1 MS. VANNI: Objection. Form.  
2 THE WITNESS: The ARCOS data that was  
3 provided, the DEA has a complete picture through  
4 the ARCOS data.  
5 BY MR. BUCHANAN:  
6 Q. Right. And that provided visibility --  
7 that provided visibility, sir, to what the pharmacies  
8 were buying from the distributors, right?  
9 MS. VANNI: Objection.  
10 A. Based on the sheet of paper, the chart. I  
11 have to see which graph because the charts that we  
12 reviewed were all sales. It didn't -- it didn't list  
13 any pharmacies.  
14 Q. Fair enough. The subsequent pages do,  
15 sir, but --  
16 A. So I can't respond if it didn't --  
17 Q. You know what, sir, why don't -- why don't  
18 you pull it out and just go to the next page, right  
19 after the first chart?  
20 A. Pull what out?  
21 Q. Do you have the exhibit -- the ARCOS data  
22 we looked at?  
23 MS. VANNI: What's the number?  
24 THE WITNESS: Oh, yes.  
25

<p style="text-align: right;">Page 474</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. If you just go to the second page, sir.</p> <p>3 A. I'm out of order, so is this the first</p> <p>4 page?</p> <p>5 Q. Just --</p> <p>6 A. 5.3?</p> <p>7 Q. Yeah, if you'll just turn the page, sir.</p> <p>8 Do you see, sir, downstream --</p> <p>9 MS. VANNI: What page are you referring</p> <p>10 to? Because he's looking at page 4. Is that --</p> <p>11 THE WITNESS: These are just states. It</p> <p>12 doesn't list customers. This -- this lists</p> <p>13 states.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. Oh, I'm sorry. Yeah, let's go to the next</p> <p>16 page.</p> <p>17 MR. BUCHANAN: Can we go, please, to 575,</p> <p>18 Evan. Let's just go to 575.5.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. You see, sir, what the DEA presented to</p> <p>21 you in March of 2013 -- and I say "you," I mean</p> <p>22 QualiTest -- included data on retail pharmacy</p> <p>23 purchases from Morris &amp; Dickson on this particular</p> <p>24 page, right?</p> <p>25 MS. VANNI: Object to the form.</p>	<p style="text-align: right;">Page 476</p> <p>1 Q. And what you do see, sir, is visibility</p> <p>2 from the DEA data of what your customer's customer</p> <p>3 was buying from Morris &amp; Dickson -- Morris &amp; Dickson,</p> <p>4 correct?</p> <p>5 MS. VANNI: Object to the form.</p> <p>6 THE WITNESS: Yes, for these four</p> <p>7 registrants.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Right. And so what chargeback data allows</p> <p>10 a manufacturer to do is prepare similar pictures of</p> <p>11 what its customer's customer is doing -- should say</p> <p>12 purchasing -- from a wholesaler/distributor, correct?</p> <p>13 MS. VANNI: Objection to the form.</p> <p>14 THE WITNESS: Chargeback data is not even</p> <p>15 close to ARCOS data. ARCOS data represents a</p> <p>16 complete picture. Chargeback data, again, is a</p> <p>17 financial transaction based on a contract price</p> <p>18 and a GPO, whereas ARCOS data, it is what it is.</p> <p>19 If you receive it, ship it, it's captured via</p> <p>20 ARCOS.</p> <p>21 Not everyone participates in chargeback</p> <p>22 data; chargeback does not capture everything.</p> <p>23 So I cannot say that it's like ARCOS data.</p> <p>24 ARCOS data is everything.</p> <p>25</p>
<p style="text-align: right;">Page 475</p> <p>1 THE WITNESS: Yes.</p> <p>2 BY MR. BUCHANAN:</p> <p>3 Q. Do you recognize Morris &amp; Dickson as an</p> <p>4 intermediary wholesaler/distributor?</p> <p>5 MS. VANNI: Object to the form.</p> <p>6 THE WITNESS: They are a wholesaler in</p> <p>7 Louisiana.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Okay. In fact, what you see there, sir,</p> <p>10 is some pharmacies just -- that are off the charts in</p> <p>11 terms of their purchases of, in this case, oxycodone,</p> <p>12 15 milligrams, from Morris &amp; Dickson, correct?</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 THE WITNESS: Again, you use the term "off</p> <p>15 the charts," and I don't know anything about</p> <p>16 these pharmacies. I don't know if they're</p> <p>17 associated with hospitals.</p> <p>18 Again, I don't know anything about the</p> <p>19 pharmacies, so I can't --</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Okay.</p> <p>22 A. -- speak to "off the chart," not knowing</p> <p>23 what type of pharmacy --</p> <p>24 Q. Fair enough. Okay.</p> <p>25 A. -- what size pharmacy --</p>	<p style="text-align: right;">Page 477</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Okay. And -- and QualiTest is a</p> <p>3 corporation, right?</p> <p>4 A. I believe it's a corporation.</p> <p>5 Q. In the business of making money, right?</p> <p>6 MS. VANNI: Objection.</p> <p>7 THE WITNESS: I can't speak to if the</p> <p>8 business is making money.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. In the business of making money?</p> <p>11 MS. VANNI: Form.</p> <p>12 THE WITNESS: I can say that the</p> <p>13 Huntsville branch is no longer.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. My -- my question to you, sir, was:</p> <p>16 QualiTest itself is a business entity in the business</p> <p>17 of making money, right?</p> <p>18 MS. VANNI: Objection to form.</p> <p>19 THE WITNESS: This day, no. Back then, I</p> <p>20 don't know how much money they made, but</p> <p>21 QualiTest, the Huntsville campus is closed.</p> <p>22 BY MR. BUCHANAN:</p> <p>23 Q. Oh, I see. Okay. So --</p> <p>24 A. So I don't know how much money they were</p> <p>25 making, but they're closed.</p>



<p style="text-align: right;">Page 478</p> <p>1 Q. Where I was going, sir, is chargebacks,  2 there are agreements that can surround the chargeback  3 data, right?  4 A. What type of agreements?  5 Q. Chargeback agreements.  6 A. Contractual agreements based on a  7 contractual price, with a group purchasing  8 organization or 340B contract with the government.  9 Again, it's so many different types of contracts.  10 Q. Pursuant to which parties exchange  11 information to exchange money based on the volume of  12 drug purchased, correct?  13 MS. VANNI: Objection to form.  14 BY MR. BUCHANAN:  15 Q. And the discounts ascribed to it?  16 A. Based on a sale of a chargeback --  17 Q. Okay.  18 A. -- a transaction happens that a pharmacy  19 purchases a drug from a wholesaler at a certain  20 price, based on a contract that pharmacy has with --  21 that the government or an organization, and based on  22 that, there's a transaction, a chargeback.  23 Q. Let's talk about customer due diligence  24 visits, sir.  25 So one of the things you're advocating is</p>	<p style="text-align: right;">Page 480</p> <p>1 parking lot.  2 BY MR. BUCHANAN:  3 Q. Long lines, right?  4 A. That could be deemed something of interest  5 to look into.  6 Q. I mean, that's what you put after  7 suspicious activity, long lines, right?  8 A. Well, if it's there, there it is, yes.  9 Q. Okay. Illicit drug use, right?  10 A. Yes.  11 Q. Out-of-state license plates, right?  12 A. Yes.  13 Q. Looking for suspected Internet activity,  14 right?  15 A. Yes.  16 Q. Remember that discussion with  17 Mr. Papantonio about Internet pharmacies, right?  18 A. It was a pretty in-depth discussion.  19 Q. Okay. And so looking for boxes, for  20 example, of -- you know, FedEx envelopes?  21 MS. VANNI: Object to the form.  22 BY MR. BUCHANAN:  23 Q. Right?  24 A. That can be one way to identify potential  25 activity.</p>
<p style="text-align: right;">Page 479</p> <p>1 putting boots on the ground, right?  2 A. One of the things I'm advocating is going  3 out, and I will conduct a Know Your Customer visit of  4 the customer, to ensure that they have a SOMs program  5 and they demonstrate it for me.  6 Q. Right. And when I say "boots on the  7 ground" is actually going and looking at the  8 facility, right?  9 MS. VANNI: Object to form.  10 THE WITNESS: I'm going to discuss their  11 suspicious-order monitoring program.  12 BY MR. BUCHANAN:  13 Q. So that's one thing you're going to do,  14 right?  15 A. Sometimes that is at the corporate office;  16 it is not necessarily at the facility.  17 Q. Surveillance visits for retail independent  18 and chain pharmacies, true?  19 A. Yes.  20 Q. Observe clientele for suspicious activity?  21 Putting eyes on the customer, right?  22 A. That's a part of the surveillance visit.  23 Q. Looking for suspicious activity, right?  24 MS. VANNI: Object to the form.  25 THE WITNESS: Yes, a drug transaction in a</p>	<p style="text-align: right;">Page 481</p> <p>1 Q. Sure. Sure. And looking to see  2 whether -- and capturing information from these  3 customers, prescriptions paid for in cash?  4 Percentage of controlled substances: Are they doing  5 mostly controlled substances? Are they doing other  6 stuff? All this information you can ask for from the  7 customer, right?  8 MS. VANNI: Object to the form.  9 THE WITNESS: Yes.  10 BY MR. BUCHANAN:  11 Q. Okay. And so these are all things that a  12 reasonable company would do to implement a  13 suspicious-order monitoring system, right?  14 MS. VANNI: Objection.  15 THE WITNESS: Again, you use the term  16 "reasonable," and I just go back to the  17 regulation, that -- it states that -- should  18 implement a program to identify and report  19 suspicious orders, and also the regulation  20 states that -- having the closed supply chain.  21 BY MR. BUCHANAN:  22 Q. Right. Or is it just at this point in  23 time, sir, in 2013, that you started to get concerned  24 about the fines?  25 MS. VANNI: Objection.</p>

Page 482

1 THE WITNESS: Again, I can't speak to what  
2 the company did prior to -- to my arrival.  
3 BY MR. BUCHANAN:  
4 Q. Well, I guess that's my question, sir.  
5 Was it -- was it the tens of millions of dollars of  
6 fines you were seeing for other companies who were  
7 not properly monitoring suspicious orders, or was it  
8 the body count?  
9 MS. VANNI: Objection.  
10 BY MR. BUCHANAN:  
11 Q. We looked at the body count between 2000  
12 and 2012. You recall that, sir?  
13 MS. VANNI: Objection.  
14 THE WITNESS: Is that the color graph --  
15 BY MR. BUCHANAN:  
16 Q. Yeah.  
17 A. -- you put on the screen?  
18 Yes, I recall that.  
19 Q. Okay. Because we saw a change in color  
20 over the years, right? It didn't -- well, let's talk  
21 about, before we get there, sir, how QualiTest  
22 changed their practices.  
23 MR. BUCHANAN: Where is it? Could I have,  
24 please, 606.  
25

Page 483

1 BY MR. BUCHANAN:  
2 Q. Are you okay? You need a break? Or are  
3 you all right?  
4 A. No, I'm just stretching my leg. I'm fine.  
5 Q. Okay.  
6 All right, sir, can we pull up 606. This  
7 looks like -- you know, if you started in September,  
8 sir, this is shortly after you get to the company,  
9 right? 2013?  
10 A. Yes.  
11 Q. Larry Shaffer; he's in DEA compliance; is  
12 that right?  
13 A. Yes, he was.  
14 Q. Okay. And what Larry Shaffer sends you,  
15 sir, are -- is titled "SOMs info."  
16 SOMS is suspicious-order monitoring  
17 system?  
18 A. Yes.  
19 Q. And did you call it "SOMS"?  
20 A. I call it a "SOM".  
21 Q. SOM? Okay.  
22 A. S-O-M.  
23 Q. All right. He attaches a couple of files.  
24 One is called "SOMS violations," right?  
25 I'm looking at the attachment list on the

Page 484

1 first page. You see that, sir? SOMS violations.xls?  
2 A. Oh. Yes.  
3 Q. Okay. And the first attachment, sir,  
4 directing your attention to dot 2 -- I'm sorry,  
5 dot 4. It's a collection of all the violations for  
6 inadequate SOMS that have been imposed.  
7 You see that, sir?  
8 MS. VANNI: Objection to form.  
9 THE WITNESS: I do see a list of the  
10 violations.  
11 BY MR. BUCHANAN:  
12 Q. Okay. So the first attachment is a list  
13 of violations. And, in fact, sir, are you aware that  
14 some of the entities that are listed here are ones  
15 that the DEA called to your attention that were  
16 customers of your customer in the March of 2013  
17 meeting?  
18 MS. VANNI: Objection.  
19 THE WITNESS: If they were listed in that  
20 binder, I saw it after I started at QualiTest.  
21 BY MR. BUCHANAN:  
22 Q. Right. You would have seen that, right?  
23 A. I stated earlier that I did see the  
24 binder.  
25 Q. And you would have seen the list of

Page 485

1 violations, right?  
2 MS. VANNI: Objection to form.  
3 THE WITNESS: I don't recall a list of  
4 violations in the binder. I recall ARCOS data,  
5 and I think some examples of some old court  
6 cases.  
7 BY MR. BUCHANAN:  
8 Q. Okay.  
9 A. But I don't recall any -- any list of  
10 violations.  
11 (Cardinal-Brantley 30 was marked for  
12 identification.)  
13 BY MR. BUCHANAN:  
14 Q. We're in Exhibit 30 right now, sir, and  
15 Exhibit 30 contains a list of violations, right?  
16 A. Is that --  
17 MS. VANNI: Objection to the form.  
18 THE WITNESS: Is that what we're looking  
19 at?  
20 BY MR. BUCHANAN:  
21 Q. That is. It is Exhibit 30 before you,  
22 sir, and I've just taken you to dot 6. See that?  
23 I'm sorry. Dot 4, 5, and 6 is a list of  
24 SOM violations?  
25 A. I guess this appears to be a list that

Page 486

1 Larry composed, yeah.  
 2 Q. Okay. And you see -- and I'm a little  
 3 tight on time, sir, but I'm sure you will have this  
 4 document. It lists a number of facilities that have  
 5 been talked about today, and it further lists  
 6 facilities that were customers of your customer that  
 7 the DEA showed you in March of 2013, "you" being  
 8 QualiTest.  
 9 MS. VANNI: Objection.  
 10 BY MR. BUCHANAN:  
 11 Q. Do you see the list of violations, sir?  
 12 A. I do.  
 13 Q. Okay. Let's -- let's go on with this file  
 14 because there's a PowerPoint in here sent to you  
 15 shortly after you joined. "Current SOMS process."  
 16 You see this?  
 17 MS. VANNI: Can you tell us what page  
 18 you're on, please?  
 19 MR. BUCHANAN: Point 14. Sorry, Counsel.  
 20 MS. VANNI: Thank you.  
 21 BY MR. BUCHANAN:  
 22 Q. Presently the SOMS process at QualiTest  
 23 was only implemented for your retail customers,  
 24 right?  
 25 MS. VANNI: Objection.

Page 487

1 THE WITNESS: This does not -- this page,  
 2 point 14, does not say it was only implemented  
 3 for retail pharmacy customers.  
 4 BY MR. BUCHANAN:  
 5 Q. Okay. Retail pharmacy is based on set  
 6 product threshold amounts, right?  
 7 A. Yes.  
 8 Q. And the sales department could change  
 9 them, right?  
 10 MS. VANNI: Objection.  
 11 THE WITNESS: It says that they were set  
 12 by the sales department.  
 13 BY MR. BUCHANAN:  
 14 Q. Also says they can be changed by the sales  
 15 department, doesn't it, sir?  
 16 A. Oh. The next bullet point.  
 17 Q. Yeah. You know that's a conflict of  
 18 interest, right?  
 19 MS. VANNI: Objection.  
 20 THE WITNESS: Is that your opinion, or is  
 21 that a -- is that --  
 22 BY MR. BUCHANAN:  
 23 Q. I'm asking you, sir.  
 24 A. -- in the regulation?  
 25 Q. You know that.

Page 488

1 MS. VANNI: Objection.  
 2 BY MR. BUCHANAN:  
 3 Q. Having people whose goal is to push more  
 4 product, and billions and billions -- and we saw the  
 5 sales growth in at least those two years; you recall  
 6 looking at those numbers with me?  
 7 MS. VANNI: Objection.  
 8 THE WITNESS: I do recall looking at those  
 9 numbers.  
 10 BY MR. BUCHANAN:  
 11 Q. Okay. You would agree, sir, that having  
 12 the sales folks, giving them the discretion to just  
 13 change the thresholds on their own, that's not good  
 14 practice, right?  
 15 MS. VANNI: Object to the form.  
 16 THE WITNESS: Again, I cannot speak to the  
 17 practice that was set before me.  
 18 BY MR. BUCHANAN:  
 19 Q. Well, that's certainly not the practice  
 20 you recommended, right?  
 21 A. That was not my practice.  
 22 Q. Okay. Let's go to dot 15, "Issues with  
 23 current process."  
 24 And this is right around the time you're  
 25 joining, in 2013, right after the time billions and

Page 489

1 billions of oxy 15s, 30s, and hydrocodones were sold,  
 2 right?  
 3 MS. VANNI: Objection.  
 4 THE WITNESS: According to your reference  
 5 from the previous slide, when you stated how  
 6 many were sold --  
 7 BY MR. BUCHANAN:  
 8 Q. Okay.  
 9 A. -- there were -- I think we stated one or  
 10 two billion.  
 11 Q. Okay. So one, "The system only addresses  
 12 retail pharmacy by looking at product thresholds."  
 13 Did I read that correctly, sir?  
 14 A. That's what it says.  
 15 Q. "Other COTs" -- is that a term of art in  
 16 your field, sir?  
 17 MS. VANNI: Object to the form.  
 18 THE WITNESS: I don't know what a "COT"  
 19 is.  
 20 BY MR. BUCHANAN:  
 21 Q. Classes of trade?  
 22 A. Okay.  
 23 Q. "Other classes of trade are not evaluated  
 24 for suspicious-order monitoring," correct?  
 25 A. That's what it says.

Page 490

1 Q. Okay. Other classes of trade, that would  
2 be wholesalers, right?  
3 MS. VANNI: Objection.  
4 THE WITNESS: Other classes of trade other  
5 than pharmacies.  
6 BY MR. BUCHANAN:  
7 Q. Right.  
8 A. It could be --  
9 Q. So wholesalers, distributors, hospitals?  
10 A. Those all could be other classes of trade.  
11 Q. Okay. And so as of this point in time,  
12 sir, nine months into 2013, other classes of trade  
13 were not being evaluated for suspicious-order  
14 monitoring, correct?  
15 MS. VANNI: Object to form.  
16 THE WITNESS: According to this slide.  
17 BY MR. BUCHANAN:  
18 Q. Mm-hmm. Next says: "Retail pharmacy  
19 review and approval is handled by the sales  
20 department," right?  
21 A. That's what it says.  
22 Q. Could you read the next sentence, sir?  
23 A. "Sales department should not set the  
24 threshold amount or be involved with the releasing  
25 held orders."

Page 491

1 Q. Okay. Just pause there for a moment.  
2 So what this states, this PowerPoint of  
3 the company from October of 2013, is the sales  
4 department should not set the threshold amount,  
5 first.  
6 That's what it says, right?  
7 A. Yes.  
8 Q. Or be involved with releasing held orders,  
9 right?  
10 A. I just want to say that you mentioned that  
11 this was 2013; where it's printed, it says 2012.  
12 Q. Well, this is what was sent to you, sir,  
13 by Larry Shaffer, on October 7th, 2013, correct?  
14 A. Yes. I'm just stating when this document  
15 says that it was printed, or --  
16 Q. Okay.  
17 A. -- or drafted. 2012.  
18 Q. You know when you got it?  
19 A. So I answered the question correctly. You  
20 asked if -- if you say 2013 but the document says  
21 2012, I have to state that the document says 2012.  
22 Q. Fine. So let's -- let's agree, sir, that  
23 this is what Mr. Shaffer sent to you on October 7,  
24 2013, following the list of violations for SOMS  
25 processes, and -- looks like a summary of the

Page 492

1 suspicious-order monitoring system of QualiTest,  
2 looking at dot 12, right?  
3 MS. VANNI: Objection to form.  
4 THE WITNESS: Yes.  
5 BY MR. BUCHANAN:  
6 Q. Okay. And, you know, the second page,  
7 dot 13, says what is SOMS. Next page says "Current  
8 SOMS process."  
9 And that's what you were being given in  
10 October of 2013, correct, sir?  
11 A. Apparently this was e-mailed --  
12 MS. VANNI: Object to the form.  
13 THE WITNESS: -- to me in 2013.  
14 BY MR. BUCHANAN:  
15 Q. Okay. And it's run through issues with  
16 the current process, and we were just talking about  
17 the retail pharmacy review and approval being handled  
18 by the sales department; DEA views this as a conflict  
19 of interest, right?  
20 A. That's what it states here.  
21 Q. And considers the sales department as the  
22 department that is driven by dollars, right?  
23 A. Again, that's what is stated here.  
24 Q. No, look, you've been in business --  
25 you've been working for companies involved in selling

Page 493

1 drugs for 15, 20 years; you know the sales  
2 department's goal is to sell, right?  
3 MS. VANNI: Object to the form.  
4 THE WITNESS: Sales department, their job  
5 is sales, by their name.  
6 BY MR. BUCHANAN:  
7 Q. Right. I mean, the job description is not  
8 suspicious-order monitoring, right?  
9 MS. VANNI: Object to form.  
10 THE WITNESS: I have not seen the job  
11 description for a salesperson.  
12 BY MR. BUCHANAN:  
13 Q. Well, sir, would you think that's  
14 something they're trained in, to -- I mean, we saw  
15 the sales growth between 2011 and 2012, right?  
16 MS. VANNI: Object to form.  
17 THE WITNESS: Is that the color chart  
18 again?  
19 MR. BUCHANAN: Can we go back to the Elmo.  
20 BY MR. BUCHANAN:  
21 Q. That's the chart.  
22 A. Oh, yes. I remember that.  
23 Q. Okay. That's -- you know, a billion pills  
24 or so of oxycodone in various formulations, right?  
25 A. Yes.

<p style="text-align: right;">Page 494</p> <p>1 Q. And we got to a billion with just one, I 2 think, unit of hydrocodone for that same period of 3 time, right? 4 MS. VANNI: Object to form. 5 THE WITNESS: One strength. 6 BY MR. BUCHANAN: 7 Q. One strength. All right. 8 So sales was doing a good job, right? 9 MS. VANNI: Object to the form. 10 BY MR. BUCHANAN: 11 Q. In term of growing sales? 12 MS. VANNI: Objection. 13 THE WITNESS: I can't state whether they 14 were doing a good job or a bad job. 15 BY MR. BUCHANAN: 16 Q. Well, you see it grew -- it grew between 17 2011 and 2012 pretty well, right? 18 MS. VANNI: Objection. 19 THE WITNESS: There was growth. 20 BY MR. BUCHANAN: 21 Q. Okay. And so during that period of time, 22 sir, the sales group had the ability to raise 23 thresholds for the customers, right? 24 MS. VANNI: Objection. 25 THE WITNESS: According to this document.</p>	<p style="text-align: right;">Page 496</p> <p>1 suspicious order, correct? 2 A. Unusual -- 3 MS. VANNI: Objection to form. 4 THE WITNESS: Unusual size, frequency, 5 and -- that deviates substantially from a normal 6 pattern. 7 BY MR. BUCHANAN: 8 Q. Right. And so what this is saying, sir, 9 in this PowerPoint that was sent to you in 2013, 10 shortly after you joined, there was no check for 11 order frequency and pattern discrepancies, right? 12 MS. VANNI: Objection. 13 THE WITNESS: That's what this slide says. 14 BY MR. BUCHANAN: 15 Q. And the system didn't allow to know your 16 customer, right? 17 A. That's what the slide states. 18 Q. Okay. And so these are listed on "Issues" 19 with the current process; then we go to the next 20 page, and then the "Requirements for Improvement." 21 Do you see that, sir? 22 A. Yes. 23 Q. And there's, what, a dozen bullets? Maybe 24 more? 25 A. Around there.</p>
<p style="text-align: right;">Page 495</p> <p>1 Again, I wasn't there. 2 BY MR. BUCHANAN: 3 Q. Okay. 4 A. I can only speak to -- 5 Q. They also had the ability -- 6 A. Sorry. 7 Q. They also had the ability to set 8 thresholds, right? 9 A. Again, according to this document. 10 Q. Okay. "No separate and unbiased check for 11 order quantity outside of the sales and marketing 12 departments." 13 See that, sir? 14 A. Yes. 15 Q. "No separate unbiased check of order 16 quantity outside of sales and marketing department." 17 Did I read that correctly, sir? 18 A. Yes. 19 Q. "No check for order frequency and pattern 20 discrepancies." 21 Did I read that correctly, sir? 22 A. Yes. 23 Q. In fact, the regulation you cited to us 24 earlier in the CFR talks about unusual quantities, 25 unusual frequencies, things of that nature, as a</p>	<p style="text-align: right;">Page 497</p> <p>1 MS. VANNI: Objection. 2 BY MR. BUCHANAN: 3 Q. Okay. Things you got to do to get this 4 thing in check, right? 5 MS. VANNI: Objection. 6 THE WITNESS: Requirements for 7 improvement. 8 BY MR. BUCHANAN: 9 Q. Got to start looking at all trades and all 10 customers, right? 11 MS. VANNI: Objection. 12 THE WITNESS: This is asking to look at 13 all classes of trade, customers. 14 BY MR. BUCHANAN: 15 Q. I mean, your biggest customers -- "you" 16 being QualiTest -- your biggest customers are 17 wholesalers and distributors, right? 18 A. Yes. 19 Q. And so in 2013, after twelve years of blue 20 going to white going to orange going to red, and 21 death rates increasing throughout this country, and 22 pills going from tens of millions to hundreds of 23 millions to billions, this company's not looking at 24 its largest trades, its largest customers, to 25 evaluate for suspicious orders?</p>



<p style="text-align: right;">Page 498</p> <p>1 MS. VANNI: Objection.</p> <p>2 BY MR. BUCHANAN:</p> <p>3 Q. Right?</p> <p>4 A. That's what the PowerPoint stated.</p> <p>5 Q. Okay.</p> <p>6 MR. BUCHANAN: Can we take a short break?</p> <p>7 MS. VANNI: Can we also have a time check?</p> <p>8 VIDEOGRAPHER: Going off record. Time</p> <p>9 is 5:54. Total time is 6:52.</p> <p>10 (A recess transpired from 5:54 p.m. until</p> <p>11 6:01 p.m.)</p> <p>12 VIDEOGRAPHER: We're going back on the</p> <p>13 record. This is beginning of media file</p> <p>14 number 8. Time is 6:01.</p> <p>15 BY MR. BUCHANAN:</p> <p>16 Q. All right, sir. Try and bring this in for</p> <p>17 a landing here. I've got a few minutes left on the</p> <p>18 clock, so -- probably going to try and be as</p> <p>19 efficient as I can.</p> <p>20 Can you pass over to counsel -- it's E611.</p> <p>21 (Cardinal-Brantley 31 was marked for</p> <p>22 identification.)</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. While that's getting across the table to</p> <p>25 you --</p>	<p style="text-align: right;">Page 500</p> <p>1 customers and offering them one-time buys?</p> <p>2 MS. VANNI: Object to form.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. Big volumes? Discounts? Remember that?</p> <p>5 MS. VANNI: Objection to form.</p> <p>6 THE WITNESS: I do not remember specific</p> <p>7 conversations, but yes, I had conversations</p> <p>8 about one-time buys.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. That's -- let's look at the exhibit now.</p> <p>11 You and your colleague, I guess it's</p> <p>12 Heather Jones, sent it off to Mr. Macrides and</p> <p>13 Magerkurth. You're cc'd on it. "Importance, high"?</p> <p>14 A. Yes.</p> <p>15 Q. "DEA regulatory risk of offering one-time</p> <p>16 buys to customers from suspicious-order monitoring</p> <p>17 perspective for upper management review," right?</p> <p>18 A. Yes.</p> <p>19 Q. You all were trying to call something to</p> <p>20 the attention of management that was happening in the</p> <p>21 sales function, right?</p> <p>22 MS. VANNI: Object to form.</p> <p>23 THE WITNESS: She was alerting -- she was</p> <p>24 sending in an e-mail to DEA expressing this. I</p> <p>25 haven't read it yet.</p>
<p style="text-align: right;">Page 499</p> <p>1 MR. BUCHANAN: And what's -- what exhibit</p> <p>2 number is it, Scott? 31? This is Brantley 31.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. Sir, do you remember -- what is that, in</p> <p>5 2015 or so -- getting in a bit of a fuss with your</p> <p>6 sales colleagues at QualiTest?</p> <p>7 MS. VANNI: Object to the form.</p> <p>8 THE WITNESS: I don't remember. Is -- is</p> <p>9 this about a particular incident?</p> <p>10 BY MR. BUCHANAN:</p> <p>11 Q. Well, this is about just -- frankly, a</p> <p>12 practice at QualiTest, concerning promotional</p> <p>13 discounting, one-time buys, bulk sales of narcotics.</p> <p>14 Do you recall that?</p> <p>15 MS. VANNI: Object to the form.</p> <p>16 THE WITNESS: I don't remember that exact</p> <p>17 conversation, but if this e-mail is that, I can</p> <p>18 read this real quick.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. Well, you were expressing concern, sir,</p> <p>21 about -- let me just ask you some questions</p> <p>22 independent of the document.</p> <p>23 Do you remember having concerns about the</p> <p>24 company sales practices -- that was the end of the</p> <p>25 month, or the end of the quarter -- reaching out to</p>	<p style="text-align: right;">Page 501</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. You said to the DEA?</p> <p>3 A. I'm sorry, I misspoke. To management.</p> <p>4 Q. Because this didn't go to the DEA, right?</p> <p>5 A. This went to management.</p> <p>6 Q. Right.</p> <p>7 A. Again, I take that back. I misspoke.</p> <p>8 This was sent to members of management.</p> <p>9 Q. Okay. And it says, "As discussed" --</p> <p>10 "Dear Steve, as discussed, Eric Brantley and I have</p> <p>11 put together a risk assessment regarding the DEA</p> <p>12 regulatory risk of offering one-time buys of</p> <p>13 controlled substances to our customers at the end of</p> <p>14 every quarter, and how it impacts your SOMS program."</p> <p>15 You see that, sir?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. And she writes, "I would like to</p> <p>18 ensure that a dialogue is started at high levels to</p> <p>19 stop the cycle of these one-time buys if possible,</p> <p>20 and preferably in this quarter." Right?</p> <p>21 A. Yes.</p> <p>22 Q. Because you all had concluded, sir, that</p> <p>23 this practice of reaching out to customers and</p> <p>24 offering them large quantities and discounts is</p> <p>25 itself a suspicious order, right?</p>

<p style="text-align: right;">Page 502</p> <p>1 MS. VANNI: Objection.</p> <p>2 THE WITNESS: Where are you reading that,</p> <p>3 so I can find it?</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. No, I'm -- do you recall that? Do you</p> <p>6 recall what I --</p> <p>7 A. I don't recall that exact verbiage.</p> <p>8 That's what I'm asking, where --</p> <p>9 Q. Okay.</p> <p>10 A. -- so I can --</p> <p>11 Q. Let's go to point 3 -- I'm sorry, point 2,</p> <p>12 just to orient ourselves.</p> <p>13 "DEA regulatory risk of offering one-time</p> <p>14 buys to customers from a suspicious-order monitoring</p> <p>15 perspective."</p> <p>16 A. Okay.</p> <p>17 Q. "Prepared for upper management review</p> <p>18 October 20, 2015."</p> <p>19 You then cite the regulation concerning</p> <p>20 suspicious orders, right?</p> <p>21 A. Yes.</p> <p>22 Q. "Suspicious orders include orders of</p> <p>23 unusual size, orders deviating substantially from a</p> <p>24 normal pattern, and orders of unusual frequency."</p> <p>25 Do you see that, sir?</p>	<p style="text-align: right;">Page 504</p> <p>1 order.</p> <p>2 Q. Okay. This practice that's being flagged</p> <p>3 for senior management of offering one-time buys at</p> <p>4 the end of quarters, larger volumes that would</p> <p>5 ordinarily be bought at discounts, were those type of</p> <p>6 orders reported to the DEA as suspicious orders?</p> <p>7 MS. VANNI: Objection.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Yes, no, or you don't know?</p> <p>10 A. If they were deemed suspicious, I would</p> <p>11 say that how I handled a one-time buy situation, I</p> <p>12 reached out to the customer. It may have been a</p> <p>13 short data item; I don't know what the situation was.</p> <p>14 And I said, "What does this represent? Is</p> <p>15 this a one-month purchase or a two-month purchase?"</p> <p>16 So forth.</p> <p>17 If it was a two-month purchase, I locked</p> <p>18 their DEA number up in the system so they cannot</p> <p>19 order that controlled substance again until that time</p> <p>20 had expired.</p> <p>21 So that way, I could keep the pattern to</p> <p>22 where -- if they -- if they were ordering 10,000,</p> <p>23 10,000, and they went to 30,000, then 00, and then</p> <p>24 10,000 again, that, I can't explain. I cannot</p> <p>25 explain the 10, 10, 30, and then back to 10 again.</p>
<p style="text-align: right;">Page 503</p> <p>1 A. Yes.</p> <p>2 Q. And it continues. I'm going to direct you</p> <p>3 to the bottom; I'm a little tight on time.</p> <p>4 It says, "Therefore, the extension of</p> <p>5 one-time buy opportunities to customers presents a</p> <p>6 tangible DEA regulatory risk for the company, because</p> <p>7 the offer itself may be categorized as a suspicious</p> <p>8 order."</p> <p>9 Did I read that correctly, sir?</p> <p>10 A. Yes.</p> <p>11 Q. Okay. Let me just ask: As a factual</p> <p>12 matter, did the company report its one-time buys to</p> <p>13 the DEA as suspicious orders?</p> <p>14 MS. VANNI: Objection.</p> <p>15 THE WITNESS: A suspicious record is an</p> <p>16 order that is placed by the customer, sent to</p> <p>17 the customer. I don't recall what orders were</p> <p>18 sent to the DEA or not. I don't -- I don't</p> <p>19 recall specific orders.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Okay.</p> <p>22 A. So to say --</p> <p>23 Q. My question --</p> <p>24 A. To ask was a one-time buy reported, as a</p> <p>25 general question, I would have to know a specific</p>	<p style="text-align: right;">Page 505</p> <p>1 Q. So you would --</p> <p>2 A. So that's how I regulated that.</p> <p>3 Q. I see. So what you would do, sir, is</p> <p>4 allow the customer, in a dialogue with you, structure</p> <p>5 this in a way so that it would fit within a</p> <p>6 threshold?</p> <p>7 A. No.</p> <p>8 MS. VANNI: Objection.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. Okay. Well, let's look at the next page,</p> <p>11 sir. The Controlled Substances Act says --</p> <p>12 A. Are you asking a question, or are you --</p> <p>13 Q. -- 611.4 --</p> <p>14 A. -- done with that?</p> <p>15 Q. We have your answer, sir.</p> <p>16 A. Okay.</p> <p>17 Q. "One-time buy orders represent an anomaly</p> <p>18 that could potentially compromise the closed system."</p> <p>19 Did I read that correctly, sir?</p> <p>20 A. Yes.</p> <p>21 Q. If a 60-to-180-day supply of a controlled</p> <p>22 substance is distributed to a wholesale or chain at</p> <p>23 one time or on a quarterly basis, there is an</p> <p>24 undeniable probability that the supply will flow to</p> <p>25 final dispensers, and eventually to end users or</p>

<p style="text-align: right;">Page 506</p> <p>1 abusers, potentially increasing the risk of  2 diversion."</p> <p>3 Did I read that correctly, sir?</p> <p>4 A. Yes.</p> <p>5 Q. "There is an undeniable probability that  6 the supply will flow to final dispensers and  7 eventually to end users or abusers" -- that is  8 diversion, right?</p> <p>9 A. If --</p> <p>10 MS. VANNI: Object to the form.</p> <p>11 THE WITNESS: If it gets to an abuser, I'd  12 have to know that definition of -- of what type  13 of abuse.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. Right. And then, "You know that it's a  16 question about whether these entities are willing or  17 capable of supporting the surplus inventory in a  18 closed and secure manner."</p> <p>19 Did I read that correctly, sir?</p> <p>20 A. Yes.</p> <p>21 Q. You also were concerned because if you're  22 giving discounts to your wholesaler community,  23 they're probably passing that on to their customer  24 base, right?</p> <p>25 MS. VANNI: Objection.</p>	<p style="text-align: right;">Page 508</p> <p>1 to -- was sent by Heather to management, and I was  2 copied.</p> <p>3 Q. Okay. And how did that work out? Did the  4 company stop their one-time buys?</p> <p>5 MS. VANNI: Object to the form.</p> <p>6 THE WITNESS: I believe so.</p> <p>7 BY MR. BUCHANAN:</p> <p>8 Q. Okay.</p> <p>9 A. I'm -- I believe so.</p> <p>10 Q. And did the company go back after it made  11 that change, and did it notify the FDA -- excuse me,  12 the DEA -- withdrawn.</p> <p>13 Did the company go back, as of this point  14 in time, when you said they could be characterized as  15 suspicious orders, and notify the DEA of all the  16 one-time buys it had facilitated in the period of  17 time you were there?</p> <p>18 MS. VANNI: Objection.</p> <p>19 THE WITNESS: Not to my knowledge.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Okay. Is there a system at the company  22 where the due diligence that was conducted on the  23 customers and the customers of customers was tracked?</p> <p>24 MS. VANNI: Object to the form.</p> <p>25 THE WITNESS: Was there a time that the</p>
<p style="text-align: right;">Page 507</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Isn't that what you write, sir?</p> <p>3 MS. VANNI: Objection.</p> <p>4 THE WITNESS: I can't say that. It was --  5 it was probably -- it does say that it is likely  6 that the offer the customer took advantage of is  7 extended to at least a portion of their own  8 customer base.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. Right. And we go to the next page,  11 point 5. The further concern you flag is the  12 secondary market.</p> <p>13 You recall talking to Mr. Papantonio about  14 the secondary market?</p> <p>15 A. Yes.</p> <p>16 Q. Okay. So "Manufacturers may potentially  17 be a supply source for nonreputable alternative  18 sources when one-time buys are extended to their  19 customers, who may in turn distribute this product to  20 the secondary market."</p> <p>21 Right?</p> <p>22 A. That's what it says.</p> <p>23 Q. Okay. Did the company stop -- did you  24 present this to upper-level management, sir?</p> <p>25 A. I believe this -- this e-mail was sent</p>	<p style="text-align: right;">Page 509</p> <p>1 due diligence was tracked? What do you mean by  2 "tracked"?</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. I'm sorry. So as I understand this, sir,  5 you had a vision for what a suspicious-order  6 monitoring system would compose, right?</p> <p>7 MS. VANNI: Objection.</p> <p>8 THE WITNESS: Yes.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. Okay. One component of that was due  11 diligence, right?</p> <p>12 MS. VANNI: Objection.</p> <p>13 THE WITNESS: Meaning site visits, or due  14 diligence on -- I mean --</p> <p>15 BY MR. BUCHANAN:</p> <p>16 Q. Yeah, it involved a lot of things, right?  17 But one thing you should be doing is you should be  18 looking on the Internet, right? On your customers,  19 right?</p> <p>20 MS. VANNI: Objection.</p> <p>21 BY MR. BUCHANAN:</p> <p>22 Q. That's one thing you should do?</p> <p>23 A. That's one of the things that was in  24 the --</p> <p>25 Q. Right. You should be also --</p>

Page 510

1 A. -- e-mail.  
2 Q. -- drawing intelligence from industry  
3 sources on your customers: Are they pill mills?  
4 Have they been subject to inquiry? Are there other  
5 red flags?  
6 That's something you should be doing,  
7 right?  
8 MS. VANNI: Object to the form.  
9 THE WITNESS: That's something I  
10 suggested. It doesn't say I -- I should be  
11 doing it; it's something that I suggested.  
12 BY MR. BUCHANAN:  
13 Q. Well, did there come a time, sir, where  
14 the company implemented SOPs related to  
15 suspicious-order monitoring?  
16 A. I drafted SOPs. I can't speak to what the  
17 company had prior to my arrival.  
18 Q. Okay. And did some portion of your  
19 proposal get considered and adopted by the company  
20 with regard to suspicious-order monitoring?  
21 A. I did implement a portion. I don't know  
22 what portion of all this was implemented. I haven't  
23 read the entire thing, but --  
24 Q. Using chargeback data?  
25 A. I did review chargeback data. This one.

Page 511

1 Q. And so, notwithstanding the limitations  
2 you talked about earlier, chargeback data was one of  
3 the things you were going to be looking at to know  
4 your customer's customer, right?  
5 A. Yes. That was a thing that I looked at.  
6 Q. Okay. Not something that had been done  
7 prior to 2013, when you started with the company,  
8 correct?  
9 MS. VANNI: Objection.  
10 THE WITNESS: I don't know. Again, I  
11 can't speak to what was done prior to the  
12 company.  
13 BY MR. BUCHANAN:  
14 Q. And that was the 13 bullets; you didn't  
15 see that that was one of the things you had to start  
16 looking at?  
17 A. That was an individual --  
18 MS. VANNI: Objection.  
19 THE WITNESS: -- expressing his thoughts.  
20 Again, I have no knowledge of what was done  
21 prior to 2013.  
22 BY MR. BUCHANAN:  
23 Q. Getting back to the question, just as a --  
24 you know, basic matter of company systems, did the  
25 company keep records of its due diligence activities

Page 512

1 with regard to customers?  
2 A. I kept records.  
3 MS. VANNI: Object to form.  
4 BY MR. BUCHANAN:  
5 Q. What's that?  
6 A. I kept records.  
7 Q. Hard copy, on a computer system, in a  
8 Sharepoint?  
9 A. I kept hard copy of some records, and I --  
10 I think everything was stored on -- on computer.  
11 Q. Okay. So all your due diligence  
12 activities that you were involved with and your group  
13 was involved with was stored somewhere in a  
14 Sharepoint at the company?  
15 A. It should be shored somewhere.  
16 Q. Okay.  
17 Also, sir, when you decided to -- when an  
18 order would come in and you would assign a code to  
19 either release the order or not release the order, if  
20 it tripped a wire, so to speak, did you keep track of  
21 whether the DEA was notified of that order as a,  
22 quote, suspicious order, or not?  
23 MS. VANNI: Object to the form.  
24 THE WITNESS: If an order was deemed to be  
25 suspicious, I would e-mail the -- the DEA, and I

Page 513

1 would save a copy of that e-mail.  
2 BY MR. BUCHANAN:  
3 Q. Okay. And -- and what was the system the  
4 company kept track of that stuff in? Was there a  
5 computer system where you tracked all that?  
6 A. I kept a -- I believe I kept a printed  
7 version, and I kept a copy on my hard drive.  
8 Eventually they may have been put on to a shared  
9 drive. I don't remember.  
10 Q. All right. Last item, sir.  
11 MR. BUCHANAN: Can you pass 609 to the  
12 witness, and 626.  
13 BY MR. BUCHANAN:  
14 Q. Sir, as I understand this -- no, I'm  
15 sorry. I already gave you that one. It's 613 and  
16 626.  
17 MR. BUCHANAN: What are the exhibit  
18 numbers going to be?  
19 MS. VANNI: Is this your last document?  
20 MR. BUCHANAN: It is.  
21 MR. SEIGEL: 32 and 33.  
22 MR. BUCHANAN: Thank you, Counsel.  
23 BY MR. BUCHANAN:  
24 Q. We'll keep this one real quick, sir.  
25 You left the company to join Purdue in --

Page 514

1 sometime in 2017, right?

2 A. February 2017.

3 Q. Gotcha. Okay.

4 And shortly before you joined Purdue,

5 there was a settlement that was reached, or an MOA

6 that was reached, between the DEA and McKesson.

7 Do you recall that?

8 A. I do recall a McKesson MOA.

9 MR. BUCHANAN: Did we pass it to the

10 witness? 613? Can we get 613 to the screen?

11 Okay. I'm sorry, it's 613, Evan. There we go.

12 BY MR. BUCHANAN:

13 Q. Sir, this is right before you leave.

14 You're having an exchange with a Mr. Hamby, from

15 U.S. IMS Health.

16 Do you see that?

17 MR. BUCHANAN: What's the exhibit number

18 for the deposition?

19 MS. VANNI: Object to the form.

20 MR. SEIGEL: 32 is 613.

21 (Cardinal-Brantley 32 was marked for

22 identification.)

23 BY MR. BUCHANAN:

24 Q. Okay. Exhibit 32, sir, before you, is

25 your exchange with Mr. Hamby concerning the McKesson

Page 515

1 settlement.

2 Do you see that?

3 MS. VANNI: Object to the form.

4 BY MR. BUCHANAN:

5 Q. MOA. Excuse me.

6 A. Yes.

7 Q. Okay. Passing you across the table, sir,

8 a copy of the MOA, which I believe reflects your

9 highlights.

10 Your initial e-mail at the bottom is

11 Monday, January 30, 2017, at 4:40.

12 "Gentlemen, I'm sure you've heard about

13 McKesson's \$150 million settlement with the DEA. I'm

14 sure you've also read the MOA and compliance

15 addendum."

16 And then it goes on and talks about your

17 assessment of the MOA.

18 Do you see that, sir?

19 A. Yes.

20 Q. Okay. And then you note on the next page,

21 sir, "One can almost build an SOM program using this

22 document as a guide."

23 Did I read that correctly, sir?

24 A. Yes.

25 Q. Okay. And that's one thing you did in

Page 516

1 industry, right, to inform yourself and continue to

2 collect information as you coordinate -- you looked

3 at what others were doing with regard to maintaining

4 effective controls to prevent diversion. Fair?

5 A. I read --

6 MS. VANNI: Objection to form.

7 THE WITNESS: I read MOAs from DEA to see

8 what they was thinking, because it was a moving

9 target on SOMS. The regulation hasn't changed,

10 but DEA's interpretation is -- was fluid.

11 BY MR. BUCHANAN:

12 Q. Okay. So one of the things you did,

13 getting back to my question, sir, is you looked at

14 MOAs?

15 A. I read MOAs.

16 Q. Okay. And you noted here that "One can

17 almost build an SOM program using this document as a

18 guide." Correct?

19 A. Yes.

20 MR. BUCHANAN: Did you pass it across the

21 table? Okay.

22 (Cardinal-Brantley 33 was marked for

23 identification.)

24 BY MR. BUCHANAN:

25 Q. Passing you the last exhibit, sir. That's

Page 517

1 Exhibit Number 33.

2 Exhibit 33, sir, is that the compliance

3 addendum that you're referring to in your e-mail with

4 Mr. Hamby?

5 A. Yes.

6 Q. The -- the compliance addendum from which

7 one could almost build an SOM program, fair?

8 MS. VANNI: Object to the form.

9 THE WITNESS: That's what I stated, yes.

10 MR. BUCHANAN: Thank you. I think

11 counsel's indulgence of a few extra minutes, I

12 appreciate that; I understand I'm out of time.

13 So at this point, I have to pass the

14 witness.

15 VIDEOGRAPHER: Going off record. The time

16 is 6:16.

17 (A recess transpired from 6:16 p.m. until

18 6:29 p.m.)

19 VIDEOGRAPHER: We're going back on record,

20 beginning of media file number 9. The time

21 is 6:29.

22

23 EXAMINATION

24 BY MR. PYSER:

25 Q. Good afternoon, Mr. Brantley.



<p style="text-align: right;">Page 518</p> <p>1 A. Good afternoon.</p> <p>2 Q. My name's Steven Pyser, and I represent</p> <p>3 Cardinal Health.</p> <p>4 Can you introduce yourself to the jury.</p> <p>5 A. Yes. My name is Eric Brantley.</p> <p>6 Q. Where did you grow up, Mr. Brantley?</p> <p>7 A. Flint, Michigan.</p> <p>8 Q. And did there come a time when you went to</p> <p>9 work as an employee of Cardinal Health?</p> <p>10 A. Yes.</p> <p>11 Q. When was that, approximately?</p> <p>12 A. I started with Bentley Trading in</p> <p>13 January 2000, and that company was acquired by</p> <p>14 Cardinal Health in 2002.</p> <p>15 Q. And how long did you work at Cardinal</p> <p>16 Health?</p> <p>17 A. I left Cardinal Health 2013; I want to say</p> <p>18 October, September.</p> <p>19 Q. So 2002 --</p> <p>20 A. 2013.</p> <p>21 Q. -- to roughly 2013; we're talking about</p> <p>22 11 years, roughly?</p> <p>23 A. Yes.</p> <p>24 Q. During your -- your 11 years, can you</p> <p>25 describe from your perspective Cardinal Health's role</p>	<p style="text-align: right;">Page 520</p> <p>1 Q. In your experience, does -- does Cardinal</p> <p>2 Health ever interact directly with patients?</p> <p>3 A. No.</p> <p>4 Q. Does Cardinal Health ever interact</p> <p>5 directly with doctors?</p> <p>6 A. No.</p> <p>7 Q. So if you could, starting around 2002,</p> <p>8 describe -- actually, strike that.</p> <p>9 Was there a point in time when your job at</p> <p>10 Cardinal Health focused on anti-diversion efforts?</p> <p>11 A. Yes.</p> <p>12 Q. About when was that?</p> <p>13 A. 2005. Time frame 2005 till late 2007 or</p> <p>14 early 2008, somewhere around in there.</p> <p>15 Q. And could you describe in your own words</p> <p>16 what types of things you did as an employee for</p> <p>17 Cardinal Health working on anti-diversion issues?</p> <p>18 What were your main responsibilities?</p> <p>19 A. My main responsibilities were reviewing</p> <p>20 ingredient limit reports on a monthly basis, and I</p> <p>21 would conduct investigations as necessary on</p> <p>22 pharmacies, and I would report those pharmacies to</p> <p>23 the DEA -- report those pharmacies to the DEA.</p> <p>24 Q. When you say "conduct investigations,"</p> <p>25 were there times when you went out and visited</p>
<p style="text-align: right;">Page 519</p> <p>1 in the health care distribution system in the United</p> <p>2 States?</p> <p>3 A. Yes. As a distributor, Cardinal purchases</p> <p>4 prescription drugs, including controlled substances,</p> <p>5 from the manufacturer and distributes those to final</p> <p>6 dispensers: Pharmacies, chain pharmacies, hospitals,</p> <p>7 DOD, VA. Things like that.</p> <p>8 Q. There's been a lot of discussion about</p> <p>9 controlled substances.</p> <p>10 Is Cardinal Health's role broader than</p> <p>11 just controlled substances?</p> <p>12 A. Yes. Controlled substances represent a</p> <p>13 relatively small percentage of overall with Cardinal</p> <p>14 distributes. They distribute over-the-counter</p> <p>15 products, all prescription drugs, everything down</p> <p>16 from toothpaste and toothbrushes.</p> <p>17 Q. And in addition to the many things that go</p> <p>18 to a hospital or a pharmacy, does Cardinal Health</p> <p>19 also have a medical side unrelated to</p> <p>20 pharmaceuticals?</p> <p>21 A. Yes. So pharmaceutical distribution is</p> <p>22 just one part of Cardinal Health. There is a medical</p> <p>23 side that has distribution centers across the</p> <p>24 country, and various organizations that the company</p> <p>25 owns.</p>	<p style="text-align: right;">Page 521</p> <p>1 pharmacies?</p> <p>2 A. They would be site visits, yes. I would</p> <p>3 go out and visit the pharmacy and -- and ask</p> <p>4 questions and see what was going on. Do an</p> <p>5 investigation.</p> <p>6 Q. You mentioned ingredient limit reports, or</p> <p>7 ILRs. What is an ingredient limit report?</p> <p>8 A. An ingredient limit report is -- is based</p> <p>9 on a formula to identify a formula provided by DEA to</p> <p>10 identify a certain limit or a threshold, as you will.</p> <p>11 And so the report would generate for any customer</p> <p>12 that exceeded that threshold. And then that report</p> <p>13 was sent to DEA every month.</p> <p>14 Q. And do you know where the criteria came</p> <p>15 from for Cardinal Health to develop its ingredient</p> <p>16 limit reports?</p> <p>17 A. Yes. It came from the DEA.</p> <p>18 Q. In your job, were you at the Dublin center</p> <p>19 for Cardinal Health, the corporate offices?</p> <p>20 A. Yes, I was in Dublin, Ohio, at corporate.</p> <p>21 Q. How did you receive the ingredient limit</p> <p>22 reports that you reviewed?</p> <p>23 A. They came via mail, or like a UPS-type</p> <p>24 service.</p> <p>25 Q. And do you know if anyone else other than</p>

<p>Page 522</p> <p>1 yourself received identical ingredient limit reports 2 from the various distribution centers of Cardinal 3 Health? 4 A. The distribution centers generate their 5 report. Someone there reviewed the report. The 6 report was sent to the DEA from the distribution 7 center, and then I reviewed the reports along with 8 members of the team. 9 Q. So the ingredient limit reports that you 10 would be reviewing, DEA would have that full report; 11 is that fair? 12 A. Yes. 13 MR. PAPANTONIO: Objection. Form. 14 Leading. 15 BY MR. PYSER: 16 Q. Do you know whether anyone at DEA also 17 received ingredient limit reports? 18 A. The ingredient limit reports were sent to 19 the DEA on a monthly basis. 20 Q. You talked a little bit about site visits 21 and additional work you did beyond just reviewing the 22 ingredient limit reports. It -- were there times 23 when you made decisions as a result of site visits? 24 A. Yes. If -- if during a site visit it was 25 deemed that they were doing, for instance,</p> <p>Page 523</p> <p>1 Internet -- they were associated with an Internet 2 pharmacy, then I would make a recommendation to 3 discontinue business with that -- or discontinue 4 controlled substance shipments with that pharmacy and 5 then report that pharmacy to Kyle Wright at the DEA. 6 Q. And to your knowledge, when you made a 7 decision to discontinue business with a pharmacy, did 8 Cardinal Health follow that recommendation? 9 A. Yes. 10 Q. And when you reported a pharmacy to the 11 DEA, who did you send that information to? 12 A. I sent the -- an e-mail to Kyle Wright at 13 DEA headquarters. 14 Q. Who -- who is Kyle Wright? 15 A. I don't remember his exact title, but I 16 believe he may have been over the e-commerce section. 17 But he was where registrants submitted such reports 18 to the DEA. 19 Q. Was it your understanding that the purpose 20 of sending ingredient limit reports to DEA was to 21 comply with the DEA regulations for suspicious-order 22 reporting? 23 A. Yes. 24 Q. So why did you conduct site visits and 25 investigations of customers on top of the ingredient</p>	<p>Page 524</p> <p>1 limit reports? 2 A. That was over and above the requirement. 3 The requirement was to report the suspicious orders, 4 and then based on the report I saw, I would actually 5 go out and investigate the pharmacies to actually 6 report those pharmacies to the DEA as well, in 7 addition to orders. 8 Q. Let's take a look at a document. 9 I'm showing you a document that's been 10 marked Exhibit 34 in this deposition. It's a new 11 exhibit. 12 (Cardinal-Brantley 34 was marked for 13 identification.) 14 BY MR. PYSER: 15 Q. Just so we can see it, I'll put it in 16 front of Exhibit 34, up on the Elmo. 17 What is Exhibit 34? 18 A. This is the Cardinal Health DEA compliance 19 manual. 20 Q. And if you look at the -- the table of 21 contents, does it cover several different areas of 22 DEA compliance? It's a thick document, a couple 23 hundred pages. 24 A. Yes. 25 Q. And if you look at Section 7 of the DEA</p> <p>Page 525</p> <p>1 compliance manual, is that section titled "Required 2 Reports to DEA"? 3 A. Section 7? 4 Q. If you turn to Bates page ending 898 -- 5 A. Oh, yes. 6 Q. -- of the table of contents. 7 A. I see it. I see it. 8 Q. So let's go together to Section 7. 9 And I'll give you the Bates number, which 10 is going to be the number in the bottom right corner. 11 It's going to be Bates ending 937. 12 And to your recollection, was this DEA 13 compliance manual in effect during the time that you 14 worked at Cardinal Health? 15 A. Yes. 16 Q. Okay. And specifically during the time 17 period 2005 through '07 or '08, when you were working 18 the anti-diversion area? 19 A. Yes. 20 Q. So if you look at Section 7-1, the 21 required reports to DEA, the first report mentioned 22 is ARCOS. 23 Can you tell me what an ARCOS report is? 24 A. Yes. The ARCOS report is -- is a report 25 of all movement of ARCOS-reportable controlled</p>
--	--

Page 526

1 substances, the Schedule II controlled substances,  
2 all movement. Those reports were sent to the DEA  
3 every month.  
4 Q. So it's a report received by DEA about  
5 every movement of every controlled substance; is that  
6 a fair kind of shorthand for ARCOS?  
7 A. Yes, of all the ARCOS reportable  
8 controlled substances, yes.  
9 Q. Now, if you -- were there any other  
10 reports that went to DEA?  
11 A. Yes. The ARCOS report, the biannual  
12 report, there was end-of-year inventory taken, the  
13 ingredient limit reports every month.  
14 Q. Pausing on the ARCOS reports for a minute,  
15 in a situation where a hospital or a pharmacy ordered  
16 controlled substances from more than one distributor,  
17 would the distributors necessarily know that that  
18 hospital or that pharmacy received controlled  
19 substances from multiple sources?  
20 MR. PAPANTONIO: Objection to form.  
21 Speculation as to what they would know.  
22 BY MR. PYSER:  
23 Q. You can answer the question.  
24 A. No.  
25 Q. When you were at Cardinal Health, were you

Page 527

1 aware of what distributions a hospital or a pharmacy  
2 might have received from other distributors, not  
3 Cardinal Health?  
4 A. No.  
5 Q. To your knowledge, were ARCOS reports  
6 submitted by all distributors?  
7 A. Yes. All registrants.  
8 Q. So in your understanding, by looking at  
9 ARCOS reports, would DEA be able to see the full  
10 picture of what a particular hospital or pharmacy  
11 received from all distributors?  
12 MR. PAPANTONIO: Objection as to form.  
13 Speculating on what -- what DEA might know.  
14 THE WITNESS: Yes, the DEA through the  
15 ARCOS data has visibility into all transactions  
16 of controlled substances from all registrants.  
17 BY MR. PYSER:  
18 Q. Let me ask it a -- a slightly different  
19 way, in response to the objection.  
20 What's your understanding of what ARCOS  
21 contains when you put together all of the ARCOS  
22 submissions from all the distributors?  
23 MR. PAPANTONIO: Objection as to form.  
24 THE WITNESS: It would have data from all  
25 of the DEA registrants; for instance, the

Page 528

1 wholesalers and all of the purchases and the  
2 shipments of those controlled substances to  
3 other DEA registrants. The complete picture.  
4 You could see all of the drugs that a pharmacy,  
5 for instance, was purchasing from every source  
6 and all of the sales from the wholesaler to  
7 pharmacies. It was a complete picture of all  
8 the transactions of those controlled substances.  
9 BY MR. PYSER:  
10 Q. Just to be clear, did Cardinal Health have  
11 access to that information?  
12 A. No.  
13 Q. Did DEA have access to that?  
14 A. Yes.  
15 Q. Turning the page to 7-3, there's a section  
16 titled "Suspicious Orders."  
17 Do you see that?  
18 A. Yes.  
19 Q. And under it is listed 21 CFR 1301.74(b).  
20 Do you see that?  
21 A. Yes.  
22 Q. What is that, 21 CFR 1301.74(b)?  
23 A. That's the regulation for suspicious  
24 orders. It's -- states that registrant is  
25 responsible for implementing, designing a -- a system

Page 529

1 to identify suspicious orders and report those to the  
2 DEA. And further goes on to say that a suspicious  
3 order is an order of unusual size, frequency, that  
4 deviates substantially from a normal order pattern.  
5 Q. And Cardinal Health has a description  
6 of -- underneath, in its compliance manual, of --  
7 strike that.  
8 In the compliance manual for Cardinal  
9 Health, under "Suspicious Orders," can you read the  
10 first sentence?  
11 A. "Wholesalers are" -- are you meaning the  
12 first sentence under "Suspicious Orders"?  
13 Q. Correct, yes.  
14 A. "Wholesalers are responsible for designing  
15 and operating a system that would disclose to the  
16 wholesaler suspicious orders."  
17 Q. Did Cardinal Health have such a system in  
18 2005, when you began your work in anti-diversion?  
19 A. Yes.  
20 Q. When you came into your role in 2005, was  
21 that system already up and running?  
22 A. Yes.  
23 Q. In fact, if you look at the date of this  
24 document, in the bottom left, you see that it's  
25 April 5th, 2000?

<p style="text-align: right;">Page 530</p> <p>1 A. Yes.</p> <p>2 Q. The next bold heading is "Establishing</p> <p>3 Suspicious Order Criteria."</p> <p>4 Do you see that?</p> <p>5 A. Yes.</p> <p>6 Q. And if you turn the page to page 7-4, you</p> <p>7 see at the top of that page, it states, quote:</p> <p>8 "Complying with 21 CFR 1301.74(b) is a two-step</p> <p>9 process"?</p> <p>10 A. Yes.</p> <p>11 Q. Can you describe for me in your own words</p> <p>12 what the two-step process that's discussed in</p> <p>13 Cardinal Health's compliance manual are?</p> <p>14 A. Yes. The ingredient limit reports that</p> <p>15 are done are sent to the DEA every month, as well as</p> <p>16 the cage vault personnel had the ability to identify</p> <p>17 anything that they deemed to be suspicious and</p> <p>18 reported that as well.</p> <p>19 Q. The -- the first description in the manual</p> <p>20 says, "First, each Cardinal division submits to DEA</p> <p>21 on a monthly basis an ingredient limit report,</p> <p>22 Exhibit M."</p> <p>23 I'd like to direct your attention to</p> <p>24 Exhibit M in this document, which is Bates page</p> <p>25 ending 4157, if you turn there with me.</p>	<p style="text-align: right;">Page 532</p> <p>1 Can you explain for us what those are?</p> <p>2 A. Yes. The ingredient limit is the -- the</p> <p>3 limit that was calculated using a formula received</p> <p>4 from DEA, and then the customer total is what that</p> <p>5 customer ordered that month.</p> <p>6 Q. I recognize this is just an example from</p> <p>7 Cardinal Health's compliance manual, but was similar</p> <p>8 information provided in each ingredient limit report</p> <p>9 sent to the DEA during the time you were reviewing</p> <p>10 ingredient limit reports?</p> <p>11 A. Yes.</p> <p>12 Q. You can go back to page 7-4. And 7-4,</p> <p>13 after it discusses Exhibit M, goes on to state:</p> <p>14 "This report is based on a computer program which</p> <p>15 monitors controlled substance purchases for a month</p> <p>16 and compares these purchases to predetermined</p> <p>17 averages or limits, and if a customer's purchase</p> <p>18 quantities exceed the established parameters, the</p> <p>19 customer's activity is printed on the report."</p> <p>20 Is this an accurate description of the</p> <p>21 ingredient limit report as you understood it?</p> <p>22 A. Yes.</p> <p>23 Q. Fair description of how it worked during</p> <p>24 your time?</p> <p>25 A. Yes.</p>
<p style="text-align: right;">Page 531</p> <p>1 Is this an example of an ingredient limit</p> <p>2 report?</p> <p>3 A. Yes.</p> <p>4 Q. It's a little bit hard to read on the</p> <p>5 screen, but if you could help us out a little bit,</p> <p>6 can you tell us what's in this document; what's in</p> <p>7 this report that's sent to DEA?</p> <p>8 A. This is a report of the customers, along</p> <p>9 with the date -- date of the transactions and the</p> <p>10 drug, and the amount in -- in grams, what was ordered</p> <p>11 of that controlled substance for the month. And it</p> <p>12 lists what the ingredient limit was and what the</p> <p>13 total was for that drug.</p> <p>14 Q. Zooming in a little bit here, it gives the</p> <p>15 customer name at the top, you mentioned, correct?</p> <p>16 A. Yes.</p> <p>17 Q. And then it provides the ingredient you</p> <p>18 mentioned, right?</p> <p>19 A. Yes.</p> <p>20 Q. And then it speaks to specific orders</p> <p>21 underneath, and those are sent to the DEA, right?</p> <p>22 A. Yes.</p> <p>23 Q. And then all the way on the right side of</p> <p>24 the page gives some additional information, a</p> <p>25 customer total and ingredient limit.</p>	<p style="text-align: right;">Page 533</p> <p>1 Q. And these parameters that are used for the</p> <p>2 computer program, the established parameters that are</p> <p>3 discussed, where did they come from?</p> <p>4 A. They came from DEA.</p> <p>5 Q. A little bit further down, it discusses</p> <p>6 the second piece of Cardinal Health's two-step</p> <p>7 process to comply with 1301.74(b).</p> <p>8 And can you read for me in the next</p> <p>9 paragraph the sentence beginning "Second"?</p> <p>10 A. "Second, on a daily basis, cage and vault</p> <p>11 personnel should be policing and identifying</p> <p>12 individual orders that appear excessive in relation</p> <p>13 to what other customers are buying and/or the</p> <p>14 customer's purchase history."</p> <p>15 Q. All right.</p> <p>16 A. Read the entire paragraph, or just that?</p> <p>17 Q. That's good.</p> <p>18 A. Okay.</p> <p>19 Q. Earlier in the day, when you were being</p> <p>20 asked questions by plaintiff's counsel, they played</p> <p>21 you a video of someone by the name of Mr. Baranski</p> <p>22 talking about pickers and packers.</p> <p>23 Do you recall that?</p> <p>24 A. I do.</p> <p>25 Q. In your experience, are there pickers and</p>

<p style="text-align: right;">Page 534</p> <p>1 packers in Cardinal facilities for items other than 2 controlled substances? 3 A. Yes. So there are pickers and packers in 4 the general warehouse, and then there are separate 5 pickers and packers in the controlled substance cage, 6 and then separate packers in the vault -- separate 7 pickers and packers in a vault. 8 Q. Is it true that the vast majority of 9 products that Cardinal ships have nothing to do with 10 controlled substances or opioids? 11 A. That is correct. 12 Q. In your experience, the folks who get 13 selected to work in the cage area or the vault area, 14 where Cardinal Health stores opioid medications, are 15 they the best of the best of Cardinal's warehouse 16 employees? 17 A. Yes. They are the crème de la crème, as I 18 call them. The -- the best ones are selected to work 19 in the cage and vault area. 20 Q. So in your experience, would a reference 21 to pickers and packers just putting things in totes, 22 would that necessarily apply to cage and vault 23 employees, or would that be something different? 24 A. No, the cage and vault pick process was -- 25 was different. There were other -- there were</p>	<p style="text-align: right;">Page 536</p> <p>1 A. My boss, Steve Reardon. 2 Q. What was Mr. Reardon's role at Cardinal 3 Health? 4 A. At the time, I believe he was director of 5 quality and regulatory affairs. 6 Q. And we're in kind of the 2005-2006 time 7 frame, right? 8 A. Yes. 9 Q. Do you know Mr. Reardon's background 10 before he came to work at Cardinal Health as director 11 of quality and regulatory affairs? 12 A. I actually believe he was a police 13 officer. 14 Q. Do you know where he was a police officer? 15 A. I believe the Boston area. 16 Q. As part of the Internet pharmacy 17 initiative, what -- what did you do to help comply 18 with the Internet pharmacy initiative? 19 A. My role was, in addition to the 20 distribution centers submitting the report to DEA 21 every month, I would also review the reports, and I 22 would identify pharmacies that would need further 23 investigation, and I would conduct an investigation 24 and a site visit. And based on those findings, I 25 would recommend -- make a recommendation to</p>
<p style="text-align: right;">Page 535</p> <p>1 additional checks and balances on picking orders in 2 the -- the cage and vault. It was -- it was 3 different than how it was done in the general 4 warehouse. 5 Q. In the event that through this second 6 process, someone in the distribution center 7 identified an issue, whose responsibility was it to 8 alert DEA of such an issue? 9 A. That person would notify their supervisor, 10 and then someone at the division would notify DEA of 11 the suspicious order. 12 Q. So -- so would that potentially come 13 straight from a distribution center, not necessarily 14 through corporate? 15 A. That would come straight from the 16 distribution center. 17 Q. Have you ever heard of the DEA's Internet 18 pharmacy initiative? 19 A. Yes. 20 Q. Okay. What is it? 21 A. It's guidance that they issued in relation 22 to identifying potential suspicious orders through 23 Internet pharmacies. 24 Q. And who asked you to undertake the 25 Internet pharmacy initiative?</p>	<p style="text-align: right;">Page 537</p> <p>1 discontinue shipment of controlled substances to 2 those pharmacies and report those pharmacies to the 3 DEA. 4 Q. I'd like to direct your attention to an 5 exhibit you looked at earlier; it should be right in 6 front of you. It's marked as Brantley Exhibit 4. 7 Do you have that one? 8 A. Yes. 9 Q. And this was a settlement release 10 agreement and administrative memorandum of agreement. 11 Do you remember discussing that document 12 earlier today? 13 A. Yes. 14 Q. Is it true that on the first page of 15 Exhibit 4, it states that Cardinal has 27 separate 16 distribution facilities? 17 A. Yes. 18 Q. And are the distribution facilities -- 19 generally; I know there's some unique ones -- but 20 generally speaking, do the distribution facilities 21 cover particular geographic areas? 22 A. Yes. 23 Q. To your knowledge, was there ever a 24 suspension order of any of the facilities that 25 shipped to the Northern Ohio area?</p>



<p style="text-align: right;">Page 538</p> <p>1 A. No.</p> <p>2 Q. A little bit more on Exhibit 4. You spent</p> <p>3 a fair bit of time talking about allegations that the</p> <p>4 DEA -- the DEA had made.</p> <p>5 To your knowledge, did DEA ever prove its</p> <p>6 allegations?</p> <p>7 A. No.</p> <p>8 Q. In fact, there -- there was a piece that</p> <p>9 was skipped over earlier when you were discussing</p> <p>10 this document with counsel. On page 2, there's a</p> <p>11 section that counsel for the Plaintiffs didn't read</p> <p>12 that begins, "No admission or concession."</p> <p>13 Do you see that section?</p> <p>14 A. Yes.</p> <p>15 Q. And does it say: "This agreement is</p> <p>16 neither an admission by Cardinal of liability or of</p> <p>17 the veracity of any allegation made by DEA in the</p> <p>18 orders to show cause."</p> <p>19 See that?</p> <p>20 A. Yes.</p> <p>21 Q. Did I read it correctly?</p> <p>22 A. Yes.</p> <p>23 Q. Is that consistent with your understanding</p> <p>24 of this document?</p> <p>25 A. Yes.</p>	<p style="text-align: right;">Page 540</p> <p>1 related to opioids?</p> <p>2 A. No.</p> <p>3 Q. You were also asked some questions about</p> <p>4 an e-mail -- this is Exhibit 12 now; do you have</p> <p>5 Exhibit 12 in front of you?</p> <p>6 A. Yes.</p> <p>7 Q. And Exhibit 12 was an e-mail from Mark</p> <p>8 Mitchell.</p> <p>9 Do you recall this document now?</p> <p>10 A. Yes.</p> <p>11 Q. And this e-mail was not to you, was it?</p> <p>12 A. No.</p> <p>13 Q. In the copy you were given, it has no</p> <p>14 response from Steve Reardon to Exhibit 12, does it?</p> <p>15 A. No.</p> <p>16 Q. Exhibit 12 has statements from Mark</p> <p>17 Mitchell about his knowledge of whether Cardinal</p> <p>18 Health monitors purchases from hospitals or</p> <p>19 pharmacies.</p> <p>20 Do you recall that?</p> <p>21 A. Yes.</p> <p>22 Q. You were asked questions about</p> <p>23 Mr. Mitchell's understanding. Is Mr. Mitchell the</p> <p>24 author of this e-mail in Exhibit 12?</p> <p>25 Is he part of the QRA or anti-diversion</p>
<p style="text-align: right;">Page 539</p> <p>1 Q. I believe you also have in front of you</p> <p>2 Exhibit 8.</p> <p>3 Do you see Exhibit 8?</p> <p>4 A. Yes.</p> <p>5 Q. Okay. And is this document from January</p> <p>6 of 2005? Correct?</p> <p>7 A. Yes.</p> <p>8 Q. Okay. You were asked whether you</p> <p>9 recognize some of the names in that exhibit.</p> <p>10 Do you recall that?</p> <p>11 A. Yes.</p> <p>12 Q. And the Plaintiffs pointed out some</p> <p>13 criticisms or critiques that were part of the audit</p> <p>14 in Exhibit 8.</p> <p>15 Do you recall that?</p> <p>16 A. Yes.</p> <p>17 Q. And those were related to the -- the QRA</p> <p>18 department, fair?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. Is the QRA department broader than</p> <p>21 just anti-diversion work?</p> <p>22 A. Yes.</p> <p>23 Q. Do you have any reason to believe that the</p> <p>24 document that counsel spent time talking to you about</p> <p>25 has anything at all to do with anti-diversion work</p>	<p style="text-align: right;">Page 541</p> <p>1 team?</p> <p>2 A. No.</p> <p>3 Q. Was Mr. Mitchell's understanding of how</p> <p>4 Cardinal Health monitored possible diversion correct?</p> <p>5 MR. PAPANTONIO: Objection as to what</p> <p>6 Mr. Mitchell -- form. Just form. Just object</p> <p>7 to form. Let you figure it out.</p> <p>8 THE WITNESS: No.</p> <p>9 MR. PAPANTONIO: Objection as to form.</p> <p>10 BY MR. PYSER:</p> <p>11 Q. Do you recall counsel for the Plaintiffs</p> <p>12 asking you questions in which Mr. Mitchell made</p> <p>13 statements about Cardinal Health's process for</p> <p>14 anti-diversion steps?</p> <p>15 A. Yes.</p> <p>16 Q. Do you believe Mr. Mitchell's</p> <p>17 understanding of how Cardinal Health monitored for</p> <p>18 possible diversion and took anti-diversion steps is</p> <p>19 correct?</p> <p>20 MR. PAPANTONIO: Objection to form.</p> <p>21 Objection to form.</p> <p>22 THE WITNESS: No.</p> <p>23 BY MR. PYSER:</p> <p>24 Q. What do you think is wrong about</p> <p>25 Mr. Mitchell's understanding in Exhibit 12?</p>

Page 542

1 MR. PAPANTONIO: Objection as to form.  
2 THE WITNESS: We had a system in place.  
3 BY MR. PYSER:  
4 Q. Let me rephrase that question.  
5 What do you disagree with from the  
6 statements Mr. Mitchell makes in the e-mail at  
7 Exhibit 12?  
8 A. I disagree with the statement that he made  
9 that we do not monitor what they purchase or -- or  
10 track.  
11 Q. Why do you disagree with that?  
12 A. Because we monitor purchases of all of  
13 our -- all of our customers.  
14 Q. Is it the case that every entity that  
15 receives any controlled substance from Cardinal  
16 Health has to have a DEA license?  
17 MR. PAPANTONIO: Objection as to form.  
18 THE WITNESS: Yes.  
19 BY MR. PYSER:  
20 Q. Does Cardinal Health ship to anyone who  
21 does not have a DEA license?  
22 A. Not a controlled substance, no.  
23 Q. When Plaintiffs' counsel was asking you  
24 questions, they asked whether Cardinal Health  
25 distributed to drug cartels.

Page 543

1 To your knowledge, has Cardinal Health  
2 ever distributed to a drug cartel?  
3 A. No.  
4 Q. I believe you also have in front of you  
5 Exhibit 13, which talks about a facility assessment  
6 in Birmingham, Alabama.  
7 You recall that document?  
8 A. Yes.  
9 Q. This was an e-mail that I believe you  
10 received, along with others, about this facility  
11 assessment in Birmingham.  
12 Did this document, when you reviewed it,  
13 cover all of the different parts of anti-diversion  
14 reporting within Cardinal Health?  
15 A. No.  
16 Q. So, for example, did it cover Cardinal  
17 Health's corporate anti-diversion work?  
18 A. No.  
19 Q. So is it fair to say that in addition to  
20 whatever activity was happening at local distribution  
21 centers, there was also other work being done at the  
22 corporate level by people like yourself?  
23 MR. PAPANTONIO: Objection as to form.  
24 THE WITNESS: Yes.  
25

Page 544

1 BY MR. PYSER:  
2 Q. What other work was being done for  
3 Cardinal Health -- rephrase the question.  
4 What other work was being done for  
5 Cardinal Health beyond the work that was being done  
6 just at the distribution centers like the Birmingham,  
7 Alabama, site?  
8 A. I was reviewing the ingredient limit  
9 reports, and I was conducting site visits and  
10 investigations and reporting those customers to the  
11 DEA.  
12 Q. Were there times when you reported a  
13 customer to DEA because you believed they might be  
14 involved in Internet pharmacy activity?  
15 A. Yes.  
16 Q. And what did Cardinal Health do when it  
17 came to believe that a customer might be involved in  
18 Internet activity?  
19 A. We discontinued shipments of controlled  
20 substances to that customer and reported that  
21 customer to the DEA.  
22 Q. You were asked earlier today questions  
23 about Exhibit 6.  
24 Do you have Exhibit 6 in front of you?  
25 A. Yes.

Page 545

1 Q. And in particular, you were asked about an  
2 e-mail in Exhibit 6 from Steve Reardon, on which you  
3 were one of the recipients.  
4 You see that e-mail from August 30th,  
5 2005?  
6 It's on the second page of the document.  
7 It's the bottom e-mail.  
8 A. Yes.  
9 Q. Okay. So we've got an August 30th, 2005,  
10 e-mail from Steve Reardon. And in it, Mr. Reardon  
11 states: "Your excessive purchase report should be  
12 reviewed to see if you have customers that are  
13 purchasing over 3,000 dosage units of phentermine or  
14 5,000 dosage units of hydrocodone a month."  
15 Do you see that language?  
16 A. Yes.  
17 Q. I just want to be clear about the reports  
18 that we're talking about. These excessive purchase  
19 reports that are referenced here, of having more than  
20 3,000 or 5,000 dosage units, are those reports that  
21 would have already been sent to the DEA?  
22 MR. PAPANTONIO: Objection as to form.  
23 THE WITNESS: Yes.  
24 BY MR. PYSER:  
25 Q. Who else would have received, in addition

<p style="text-align: right;">Page 546</p> <p>1 to yourself, these reports that are referenced at 2 3,000 dosage units or 5,000 dosage units, to your 3 knowledge? 4 A. They were received at the distribution 5 level at the distribution centers, as well as my team 6 at -- at corporate as well as the DEA. 7 Q. So in its normal practice, would Cardinal 8 Health have reported all of these orders that are 9 referenced here to the DEA? 10 MR. PAPANTONIO: Objection. Form. 11 THE WITNESS: Yes. 12 BY MR. PYSER: 13 Q. Were there ever times when you personally 14 had to call a customer and tell them they would no 15 longer be eligible to receive controlled substances 16 from Cardinal Health? 17 A. Yes. 18 Q. To the extent that you can remember now, 19 ten years later, can you describe a little bit about 20 those phone calls? 21 A. I don't remember the exact -- 22 MR. PAPANTONIO: Objection. Hearsay. 23 THE WITNESS: I don't remember the exact 24 details, but they would be -- I would call the 25 customer and let them know that they were being</p>	<p style="text-align: right;">Page 548</p> <p>1 A. I did training with members of senior 2 management, and I did training with the sales force, 3 and I did training with members of my team. 4 Q. And just generally speaking, what was the 5 subject matter that you would train other people at 6 Cardinal Health on? 7 A. On our Internet or anti-diversion policy. 8 Q. And were those policies, talking about the 9 2005, '6, '7 time period, were those policies during 10 that time period consistent with what you understood 11 DEA wanted? 12 MR. PAPANTONIO: Objection as to what DEA 13 wanted. Form. 14 THE WITNESS: Yes. 15 BY MR. PYSER: 16 Q. Were the policies that Cardinal Health had 17 back in 2006 consistent with the guidance that you 18 received from DEA? 19 A. Yes. 20 Q. How did you come to the conclusion that 21 Cardinal's policies back in this time period were 22 consistent with the guidance you received from DEA? 23 A. Kyle Wright with DEA told us. 24 MR. PAPANTONIO: Objection. Move to 25 strike. Hearsay, what they told this witness.</p>
<p style="text-align: right;">Page 547</p> <p>1 shut off from receiving controlled substances. 2 BY MR. PYSER: 3 Q. And when you made those calls, were the 4 pharmacists sometimes angry with you? 5 MR. PAPANTONIO: Objection. Hearsay. 6 THE WITNESS: Yes. 7 BY MR. PYSER: 8 Q. Why? Did they tell you? 9 A. Because they would not be -- 10 MR. PAPANTONIO: Objection. Hearsay. 11 THE WITNESS: Because they would not be 12 receiving controlled substances from Cardinal 13 Health any longer. 14 BY MR. PYSER: 15 Q. And these pharmacies that we're talking 16 about that Cardinal Health was refusing to ship to, 17 do you know, typically, did they still have a valid 18 DEA license? 19 A. Yes. 20 Q. In addition to your work in 21 anti-diversion, did you also do training of other 22 Cardinal Health employees? 23 A. Yes. 24 Q. Can you tell me a little bit about what 25 types of training you did?</p>	<p style="text-align: right;">Page 549</p> <p>1 BY MR. PYSER: 2 Q. What did Mr. Wright tell you about 3 Cardinal Health's policies? 4 MR. PAPANTONIO: Objection as to form 5 about anything Mr. Wright told this witness. 6 Hearsay. 7 THE WITNESS: He said -- 8 BY MR. PYSER: 9 Q. You can answer. 10 A. He said that we're doing the right things, 11 and we're going in the right directions, and that we 12 had a -- a good program. 13 MR. PAPANTONIO: Objection. Move to 14 strike. Just rank hearsay. 15 BY MR. PYSER: 16 Q. Did you have a -- a strong working 17 relationship with Mr. Wright in DEA? 18 A. Yes. 19 Q. Did Kyle Wright from DEA ever tell you 20 that Cardinal Health's anti-diversion program was 21 deficient in any way? 22 MR. PAPANTONIO: Objection as to form. 23 Anything Mr. Wright told this witness, hearsay. 24 MR. PYSER: Counsel, you can object to 25 form and keep it at that.</p>

<p style="text-align: right;">Page 550</p> <p>1 MR. PAPANTONIO: Okay. Form. I'll let 2 you figure it out for yourself. Okay. 3 THE WITNESS: No. 4 BY MR. PYSER: 5 Q. Did Mr. Wright ever tell you that Cardinal 6 Health's suspicious -- strike that. 7 Did you receive any suggestions or 8 critiques from DEA, from Mr. Wright in particular, on 9 Cardinal Health's system? 10 A. No. 11 Q. If back in 2006 or '7, Mr. Wright or 12 someone else at DEA had offered suggestions to 13 Cardinal Health on its suspicious-order monitoring or 14 reporting system, what would you have done? 15 A. We would have -- 16 MR. PAPANTONIO: Objection. Speculation. 17 Speculation as to what was offered and what his 18 reaction would be. 19 BY MR. PYSER: 20 Q. You can answer. 21 A. We would have implemented those 22 suggestions. 23 Q. I'm showing you a document entitled 24 Exhibit 35. 25 (Cardinal-Brantley 35 was marked for</p>	<p style="text-align: right;">Page 552</p> <p>1 program." 2 Do you see that language? 3 A. Yes. 4 Q. Based on your recollection, is that an 5 accurate description of the call? 6 A. Yes. 7 Q. If you look at the first bullet point, can 8 you read that out loud? 9 MR. PAPANTONIO: Continuing objection as 10 to hearsay and use of this document in part of 11 hearsay. 12 THE WITNESS: He thinks we are doing the 13 right things, heading in the right direction. 14 BY MR. PYSER: 15 Q. And that statement, that was described by 16 Mr. Reardon as the key feedback from Kyle. 17 Do you see that? 18 A. Yes. 19 MR. PAPANTONIO: Same objection as to what 20 Mr. Reardon characterized what Mr. Kyle told him 21 as hearsay. 22 BY MR. PYSER: 23 Q. And did Cardinal Health incorporate this 24 information that it learned from Mr. Wright into its 25 anti-diversion programs?</p>
<p style="text-align: right;">Page 551</p> <p>1 identification.) 2 BY MR. PYSER: 3 Q. Do you recognize this document? 4 A. Yes. 5 Q. What is it? 6 A. It's an e-mail from my boss, Steve 7 Reardon, of a summary of a conversation that we had 8 with Kyle Wright. 9 Q. Okay. And the -- the time period of that 10 call was on April 2007; is that right? 11 A. Yes. 12 Q. And Mr. Reardon states -- 13 MR. PAPANTONIO: Just for the record, 14 objection to this entire document as hearsay. 15 Anything Mr. Wright talked to as far as 16 Mr. Reardon or Mr. Brantley is hearsay. We 17 object to the use of the document. 18 BY MR. PYSER: 19 Q. Direct your attention to the sentence that 20 begins: "The purpose of the call was to confirm we 21 have the appropriate program and processes in place. 22 Ask if there is anything else we should be doing, 23 reiterate our willingness to work with the agency on 24 this issue, and to extend an offer to meet with the 25 agency to further discuss the details of our</p>	<p style="text-align: right;">Page 553</p> <p>1 A. Yes. 2 Q. What impact did those statements have on 3 you? 4 A. They made me feel that we had a good 5 program in place, and as he said, we were heading in 6 the right direction. We were doing the right thing. 7 MR. PAPANTONIO: Objection. Move to 8 strike. His statement is based on hearsay. 9 Foundationally on hearsay. 10 BY MR. PYSER: 11 Q. And the next bullet is, quote: "Stated 12 that Eric, who manages their program centrally in 13 Dublin, has established an excellent working 14 relationship with his office." 15 Do you see that statement? 16 A. Yes. 17 Q. Do you agree with that statement? 18 A. Yes. 19 Q. If you go to the next page in Exhibit -- I 20 believe we're -- we're at 35 -- is there a letter 21 attached? 22 A. Yes. 23 Q. Is it a letter you wrote? 24 A. Yes. 25 Q. And who did you send the letter to?</p>

Page 554

1 A. Jan Hamilton, with the DEA in the Miami  
2 field division in Miami, Florida.  
3 Q. And there's some discussion in the letter  
4 about information that had been provided back and  
5 forth with DEA, in the first two paragraphs.  
6 Do you see those paragraphs?  
7 A. Yes.  
8 Q. And I want to direct your attention to the  
9 third paragraph, about ten lines down. It begins:  
10 "As mentioned above."  
11 You see that language?  
12 A. Yes.  
13 Q. And it reads: "As mentioned above, all of  
14 the Internet pharmacy accounts listed below have been  
15 terminated as customers for controlled substances.  
16 In addition, prior to this action on our part, DEA  
17 had been notified by us of excessive purchases of  
18 controlled substances via ingredient limit reports  
19 for these accounts in advance of our decision.  
20 Rather than wait upon a response from DEA, Cardinal  
21 Health initiated the following actions as described  
22 below. That being the case, we believe that our  
23 program is in accordance with DEA's expectations, and  
24 we continue to improve it and add resources to it.  
25 For example, we added an additional head count in

Page 555

1 February 2007."  
2 Did I read that correctly?  
3 A. Yes.  
4 Q. Did you personally agree with the  
5 conclusion in this letter that Cardinal's program was  
6 in accordance with DEA's expectations?  
7 A. Yes.  
8 (Cardinal-Brantley 36 was marked for  
9 identification.)  
10 BY MR. PYSER:  
11 Q. Showing you a document that's been marked  
12 as Exhibit 36.  
13 What is Exhibit 36?  
14 A. This is an e-mail from -- from Kyle Wright  
15 that he was sent to wholesale with the -- listed  
16 pharmacies that wholesalers had -- had discontinued  
17 business with and notified DEA of that action.  
18 Q. Okay. Did you receive e-mails like this  
19 from Mr. Wright?  
20 A. Yes.  
21 Q. What would you typically do when you  
22 received an e-mail like this from Mr. Wright, letting  
23 you know that a wholesaler -- not necessarily  
24 Cardinal Health, but some wholesaler -- had  
25 discontinued distribution of controlled substances to

Page 556

1 particular pharmacies or hospitals?  
2 A. I would review the list to see if there  
3 were any current Cardinal Health customers, and if  
4 so, I would look into those customers; I would  
5 conduct an investigation of those customers if they  
6 were on the list.  
7 Q. Okay. And were there times when a  
8 customer appeared on the list and Cardinal Health  
9 subsequently refused to do business with them?  
10 A. Yes.  
11 Q. And the pharmacies on this list, are they  
12 pharmacies that necessarily lost their DEA license?  
13 A. No.  
14 Q. Okay. So these are pharmacies that a  
15 distributor had cut off but that DEA hadn't taken  
16 their license from?  
17 MR. PAPANTONIO: Objection as to form.  
18 Leading.  
19 THE WITNESS: Correct.  
20 BY MR. PYSER:  
21 Q. Do you know whether or not the pharmacies  
22 that are on this list as having been cut off by a  
23 distributor still had their DEA license or not?  
24 A. Yes.  
25 Q. Did they have DEA licenses, typically,

Page 557

1 still?  
2 A. Yes.  
3 Q. Did there come a time when -- well, first  
4 of all, let me ask: Did you receive e-mails like  
5 this periodically from Mr. Wright?  
6 A. Yes.  
7 Q. Did there come a time when DEA and Kyle  
8 Wright stopped sending e-mails like the one we just  
9 saw?  
10 A. Yes.  
11 Q. Do you know why?  
12 MR. PAPANTONIO: Objection as to form.  
13 Speculating.  
14 THE WITNESS: I do -- I do not know why.  
15 I can only speculate.  
16 BY MR. PYSER:  
17 Q. But to your knowledge, DEA just stopped  
18 providing this information to distributors.  
19 You know that, right?  
20 A. Yes.  
21 MR. PAPANTONIO: Objection. Form.  
22 Leading on that last question. Move to strike  
23 the question.  
24 BY MR. PYSER:  
25 Q. Did you continue to receive this



<p style="text-align: right;">Page 558</p> <p>1 information from DEA, or did it stop at some point?</p> <p>2 A. It stopped at some point.</p> <p>3 Q. Around 2010, did you begin work at a</p> <p>4 Cardinal Health facility near Atlanta?</p> <p>5 A. Yes. 2009, I started work at the</p> <p>6 McDonough, Georgia, distribution center.</p> <p>7 Q. And in your role at the McDonough,</p> <p>8 Georgia, distribution center, did you have</p> <p>9 responsibilities related to the physical security of</p> <p>10 medications that were at that facility?</p> <p>11 A. Yes. I was a compliance officer, so my</p> <p>12 role was to conduct audits and assure compliance with</p> <p>13 DEA, FDA, PDMA, OSHA, DOT regulations.</p> <p>14 Q. Can you in your experience compare the</p> <p>15 specificity of regulations for DEA guidance on</p> <p>16 physical security of handling medications versus</p> <p>17 anti-diversion?</p> <p>18 A. Yes. So the anti-diversion regulation is</p> <p>19 21 CFR 1301.74(b), which states that the registrant</p> <p>20 shall have a system in place to identify suspicious</p> <p>21 orders and report those orders. And it defines those</p> <p>22 orders as orders of unusual size, frequency, or that</p> <p>23 deviate substantially from a normal pattern.</p> <p>24 As far as the regulations around physical</p> <p>25 security, they were very detailed. They went into</p>	<p style="text-align: right;">Page 560</p> <p>1 is 7:23.</p> <p>2 EXAMINATION</p> <p>3 BY MS. VANNI:</p> <p>4 Q. Good evening, Mr. Brantley.</p> <p>5 A. Good evening.</p> <p>6 Q. It's been a long evening. Are you okay?</p> <p>7 A. I'm fine. Thank you.</p> <p>8 Q. My name is Amy Vanni, as you know, and I</p> <p>9 represent Endo and Par, and I'm going to be asking</p> <p>10 you some questions.</p> <p>11 When did you first begin working at</p> <p>12 QualiTest?</p> <p>13 A. I believe September 30th, 2013.</p> <p>14 Q. And when you joined QualiTest, what was</p> <p>15 your position?</p> <p>16 A. I was a manager of suspicious-order</p> <p>17 monitoring.</p> <p>18 Q. And what group did you report to?</p> <p>19 A. DEA compliance.</p> <p>20 Q. What was the DEA compliance group</p> <p>21 responsible for at QualiTest?</p> <p>22 A. They were responsible for DEA compliance</p> <p>23 for the campus, so for the tablets manufacturing</p> <p>24 facility, the liquids manufacturing facility, as well</p> <p>25 as the distribution center.</p>
<p style="text-align: right;">Page 559</p> <p>1 the thickness of the vault walls, the type of</p> <p>2 security system, the monitoring, the -- the testing,</p> <p>3 the cage itself, the space between the cage and the</p> <p>4 locking mechanism. And it spelled out in detail a</p> <p>5 thorough list of things to follow.</p> <p>6 Q. In your time at McDonough, and generally</p> <p>7 at Cardinal Health, were distribution centers</p> <p>8 regularly inspected by DEA?</p> <p>9 A. Yes. There was a cyclical inspection</p> <p>10 generally every two to three years or so.</p> <p>11 Q. In your experience at Cardinal Health for</p> <p>12 over ten years, did you ever see Cardinal Health ship</p> <p>13 an order that you believed would be diverted?</p> <p>14 A. No.</p> <p>15 MR. PYSER: No further questions.</p> <p>16 VIDEOGRAPHER: Going off the record. Time</p> <p>17 is 7:18.</p> <p>18 (A recess transpired from 7:18 p.m.</p> <p>19 until 7:23 p.m.)</p> <p>20 MR. PAPANTONIO: I'm going to move -- all</p> <p>21 these documents are moved into evidence, so you</p> <p>22 can take an inventory and accounting of them</p> <p>23 after we're finished with these questions.</p> <p>24 VIDEOGRAPHER: We're going back on record,</p> <p>25 beginning of media file number 10. Time</p>	<p style="text-align: right;">Page 561</p> <p>1 Q. Okay. And as part of -- SOMS was part of</p> <p>2 the DEA compliance; is that -- is that fair to say?</p> <p>3 A. Yes.</p> <p>4 Q. How long did you work there?</p> <p>5 A. Until February 2017.</p> <p>6 Q. When you joined QualiTest, did it have a</p> <p>7 SOMS program in place?</p> <p>8 A. Yes.</p> <p>9 Q. What is QualiTest's customer base?</p> <p>10 A. Primarily wholesalers and chain</p> <p>11 distribution centers.</p> <p>12 Q. During the time that you worked at</p> <p>13 QualiTest, did your position change?</p> <p>14 A. No.</p> <p>15 Q. Did anyone report to you?</p> <p>16 A. Yes.</p> <p>17 Q. I want to talk about some of the details</p> <p>18 of the suspicious-order monitoring program when you</p> <p>19 came on board at QualiTest, but before I do that,</p> <p>20 first, as manager of the SOMS program, can you just</p> <p>21 generally describe for the jury what "SOMS" is?</p> <p>22 A. "SOMS" stands for suspicious-order</p> <p>23 monitoring, which meant that we -- we monitored</p> <p>24 orders and implemented a Know Your Customer program.</p> <p>25 So the -- or the program in detail is -- it -- it</p>

<p style="text-align: right;">Page 562</p> <p>1 started with the Know Your Customer piece, so all                  2 customers that ordered controlled substances received                  3 a questionnaire, and on that questionnaire, we asked                  4 certain background information. I asked about their                  5 SOMS program. I asked the number and types of                  6 customers that they have, whether there have been any                  7 disciplinary actions, so forth and so on.                  8 And then the -- the second piece of the                  9 Know Your Customer was the site visit.                  10 And then, as far as the SOMS system                  11 itself, the day-to-day operation, all orders passed                  12 through the algorithm. And if the algorithm                  13 identified an order -- it was what I called an "order                  14 of interest" -- we looked into that order, reached                  15 out to the customer, asked for additional                  16 information.                  17 If, after receiving that information that                  18 order was deemed to be suspicious, then we cut that                  19 order, meaning reject it, and we reported that order                  20 to the DEA.                  21 The second part of the day-to-day                  22 operation was I established thresholds based on IMS                  23 dispensing data and information received from the                  24 customer, as far as the number of customers that you                  25 have.</p>	<p style="text-align: right;">Page 564</p> <p>1 Q. What is the purpose of a SOMS program?                  2 A. One of the purposes of the SOMS program is                  3 to comply with the regulation 21 CFR 1301.74(b). And                  4 it's to identify potentially suspicious orders, and                  5 to help to maintain that secure supply chain that we                  6 spoke of earlier.                  7 Q. You mentioned the algorithm and                  8 identification of an order of interest. Is an order                  9 of interest something that's different than a                  10 suspicious order?                  11 A. Yes. So an order of interest is any order                  12 that's identified by the algorithm. So the algorithm                  13 could identify an order, because it's -- it's based                  14 on history. It needs something to compare it to, so                  15 it needs an order history. So if it is a customer's                  16 first time ordering a substance or if it's a new drug                  17 that was released -- those are just a couple                  18 examples -- then that order would be held by the                  19 algorithm, because it has nothing to compare it to.                  20 Q. And when an order is held by the                  21 algorithm, what -- what would you do at that point in                  22 time?                  23 A. All orders that were held by the algorithm                  24 were further researched, and when necessary, reached                  25 out to the customer to ask for additional</p>
<p style="text-align: right;">Page 563</p> <p>1 So I had the dispensing data for                  2 pharmacies, chain pharmacies, mail order, and -- and                  3 such. And I would multiply that by the number of                  4 customers and have a threshold, a ballpark threshold.                  5 And then I would figure out if we were a                  6 primary for a certain drug, or a secondary, or just                  7 one of several, because that dictated the percentage                  8 of the national average that we would get.                  9 So of course, primary status, a larger                  10 percentage; secondary status was a lower percentage.                  11 And then if we were one of several, there was like a                  12 default percentage.                  13 Q. With -- with respect to the way                  14 thresholds were set, is that -- is that a change that                  15 you implemented when you came on board?                  16 A. Yes, as -- as far as using a -- the IMS                  17 dispensing data, yes.                  18 Q. We heard some questions during Plaintiffs'                  19 counsel's questioning of you with respect to sales                  20 setting thresholds.                  21 You recall that line of testimony?                  22 A. Yes.                  23 Q. Is that something that you changed when                  24 you came on board?                  25 A. Yes.</p>	<p style="text-align: right;">Page 565</p> <p>1 information.                  2 Q. Okay. What -- I was going to ask you, can                  3 you expound a little bit on what that research                  4 involved.                  5 A. Yes. Sometimes I would have information                  6 from the customer in advance. So if a major                  7 wholesaler had added a -- a new chain, if someone --                  8 at one point someone picked up Target's pharmacies.                  9 I was notified in advance, "Hey, you know, we just                  10 picked up Target pharmacies to distribute."                  11 They have X number of pharmacies. So I                  12 know in advance, for instance, that a pharmacy chain                  13 just acquired another pharmacy chain, how many stores                  14 that they have for each distribution center, so I can                  15 implement that into that other threshold -- so I                  16 would know that in advance.                  17 Q. In situations where you didn't know that                  18 in advance, what would you do?                  19 A. I would reach out to the customer and ask                  20 them for additional information.                  21 Q. During the interim, while you were doing                  22 your investigation, what would -- what would happen                  23 to that order?                  24 A. That order was on hold until I received                  25 adequate information. And if I did not receive</p>

<p style="text-align: right;">Page 566</p> <p>1 adequate information, that order was cut or rejected, 2 and it was reported to the DEA. 3 Q. And as your role as SOMS manager, you had 4 opportunity to do that on -- on occasions? 5 A. Yes. 6 Q. And if you felt like you had, as a result 7 of your investigation, enough information, and then 8 the order wasn't suspicious, what would happen? 9 A. Well, then that order would be released, 10 and the reason from the customer was saved into the 11 SOM system. 12 Q. How long would an investigation take, 13 generally? 14 A. It depended on how long it actually took 15 the customer to respond to my e-mail. So some could 16 take 10, 15 minutes, the research; some could take a 17 couple days. But they remained on hold until I got 18 the information that I needed. 19 And if a customer just failed to respond, 20 you know, within 48 hours, I would just notify the 21 customer, "This order is getting cut," and I would 22 report it to the DEA. 23 Q. You were asked some questions by 24 Plaintiffs' counsel about a March 2013 DEA meeting. 25 Do you recall that line of testimony?</p>	<p style="text-align: right;">Page 568</p> <p>1 A. Yes. 2 Q. What was your purpose in -- in preparing 3 this document? 4 A. Just -- this was a document so -- I just 5 arrived at the company, and I'm charged with -- with 6 managing the suspicious-order monitoring program. So 7 I drafted this document, and I sent it to myself to 8 share with the team for feedback. These are my 9 thoughts. These are some things, you know, that I'm 10 planning. 11 Q. Okay. And were you able to implement some 12 of those proposals? 13 A. Yes. 14 Q. One of those proposals talks about 15 threshold events, correct? 16 A. Yes. 17 Q. And I believe we talked about the changes 18 you implemented with respect to thresholds; is 19 that -- is that fair? 20 A. Yes. 21 Q. It also mentions chargebacks, and you were 22 asked some questions about chargebacks. 23 Do you remember that? 24 A. Yes. 25 Q. Did you begin looking at chargeback data?</p>
<p style="text-align: right;">Page 567</p> <p>1 A. Yes. 2 Q. That line of questioning? 3 A. Yes. 4 Q. This predated your employment with 5 QualiTest, right? 6 A. Yes. 7 Q. You were aware of the meeting; is that 8 fair? 9 A. I was told about the meeting, yes. 10 Q. And as a result of that meeting, what 11 actions did -- if any -- did QualiTest take? 12 A. I was hired in September, and I 13 implemented the system that I just outlined. So 14 whatever sales had been doing was taken over by the 15 SOM team. 16 Q. You were shown a document that was marked 17 as Plaintiffs' Exhibit 29, if you could pull that. 18 And it was an e-mail dated October 7th, 19 2013, from you to you. 20 Do you remember this -- being shown this 21 document? 22 A. Yes. 23 Q. So you were at the company just a little 24 over a week, or maybe two weeks, at this point in 25 time; is that fair?</p>	<p style="text-align: right;">Page 569</p> <p>1 A. Yes, I reviewed chargeback data. 2 Q. And customer due diligence visits: Do you 3 remember that -- that line of questioning? 4 A. Yes. 5 Q. Did you personally visit customers in your 6 role as SOMS manager? 7 A. Yes. 8 Q. And -- and what was your purpose in doing 9 that? 10 A. The purpose of the site visit, it was a 11 Know Your Customer visit, to actually do just that, 12 to get the know the customer. My main purpose was to 13 discuss SOMS, so I would give them a high-level 14 overview of how our system operated, in case they 15 were contacted by me, they would know why. 16 And then the bulk of the meeting was about 17 their SOM system: How did it work? Did it follow 18 their SOP? Give me a demonstration of their system. 19 So it was basically a SOMS visit. 20 Q. Why was it important for you to understand 21 their SOMS program? 22 A. Because I felt that the customer needed to 23 have a -- a SOMS program. And I had already received 24 either an SOP or a kind of a high-level summary of 25 how their program operated, but I wanted to go on</p>

<p style="text-align: right;">Page 570</p> <p>1 site and see it in action, see some examples, and 2 verify that they had one in place. 3 Q. This document also refers to SOPs, and you 4 just referred to some SOPs. Were you able to 5 implement SOPs as your role as SOMS manager? 6 A. Yes. 7 MS. VANNI: I'm going to mark as 8 Exhibit 37, I think, we're up to. 9 (Cardinal-Brantley 37 was marked for 10 identification.) 11 MS. VANNI: Hand that to you. Counsel. 12 MR. BUCHANAN: Thank you. 13 MS. VANNI: Of course. 14 BY MS. VANNI: 15 Q. Also put it on the -- for other people. 16 What I've put in front of you is an SOP 17 titled "Customer Due Diligence Visits." Is that 18 right? 19 A. I have the one for new account approval 20 and existing account overview or -- 21 Q. Oh, yeah. Okay. Thank you. Take that 22 back. Sorry about that. 23 Can you identify this document? 24 A. Yes. This is an SOP that I drafted for 25 new account approval and existing account review.</p>	<p style="text-align: right;">Page 572</p> <p>1 have a -- a questionnaire on file, along with number 2 of customers that they had, because I needed that to 3 establish thresholds, even for the existing 4 customers. 5 Q. "Section 2 of that document, Know Your 6 Customer, talks about the customer questionnaire, but 7 if I could direct your attention to letter B: 8 "The SOM team reviews and validates the 9 information provided by the customer. This 10 information includes but is not limited to . . ." 11 And it lists a number of things, but if I 12 could direct your attention to number 2: 13 "State and DEA licenses are verified and 14 any disciplinary action is researched." 15 Did I read that correctly? 16 A. Yes. 17 Q. If any disciplinary action during the 18 course of your research was identified, what would 19 happen? 20 A. I would review that action to see when 21 it take -- when it took place, what had taken place, 22 any revocations of licenses or suspensions, and that 23 would be reviewed with my boss in legal. 24 Q. And also number 4, affiliation with 25 Internet pharmacies: Why was that important?</p>
<p style="text-align: right;">Page 571</p> <p>1 Q. And what was the purpose of this? 2 A. Purpose of this was having an SOP around 3 setting up new customers and reviewing existing 4 customers, from the point that I drafted this. 5 Q. If I could direct your attention to page 2 6 of that document, under General Section 1, letter A. 7 A. Yes. 8 Q. "The SOM team conducts a thorough review 9 and research of the customer, including ownership. 10 If the research concludes that the potential customer 11 poses an unreasonable risk for diversion of 12 controlled substances and/or List 1 chemicals, the 13 customer will be blocked from ordering controlled 14 substances and/or List 1 chemicals." 15 Did I read that correctly? 16 A. Yes. 17 Q. Is that a step that you would implement as 18 your role as SOMS manager? 19 A. Yes. If a new customer was set up, we 20 would conduct a review. 21 Q. Did you ever send questionnaires to 22 existing customers as well? 23 A. Yes. 24 Q. And what was your purpose in doing that? 25 A. Consistency, so that every customer would</p>	<p style="text-align: right;">Page 573</p> <p>1 A. To see if there was affiliation with -- 2 with Internet pharmacies, to make sure that there was 3 no affiliations with rogue Internet pharmacies, as 4 opposed to ones that were VIPPS certified or . . . 5 Q. If a customer failed to provide the 6 information that you were requesting, what would 7 happen? 8 A. If a customer failed to provide all the 9 information, then we would give them a period of time 10 to respond, and then we would -- we would not ship 11 controlled substances to them. 12 MS. VANNI: I'm going to mark as my next 13 exhibit Number 38. 14 (Cardinal-Brantley 38 was marked for 15 identification.) 16 MS. VANNI: Hand that to you, Counsel. 17 BY MS. VANNI: 18 Q. Can you identify for the record what that 19 is? 20 A. Yes. This is an SOP that I drafted around 21 customer due diligence visits. 22 Q. And what was your purpose in doing that? 23 A. To have an SOP in place as -- as far as 24 how to conduct a visit and how to proceed with those 25 visits.</p>



<p style="text-align: right;">Page 574</p> <p>1 Q. Why is it important to have a standard                  2 operating procedure in place?                  3 A. One, the DEA asked to see them, you know,                  4 for doing an audit. Two is to have a working                  5 procedure of how to accomplish a task, just in case                  6 someone fills the role that I'm in; anyone could step                  7 in and have a procedure to follow to -- to do the job                  8 or the task.                  9 Q. If I could direct your attention to the                  10 second page of that document, under "Procedure":                  11 "Customer due diligence site visits shall                  12 be considered under the following circumstances."                  13 And then it lists four. One is "SOM team                  14 requests a visit when more information is needed in                  15 approving a new customer account request for                  16 controlled substances or List 1 chemicals."                  17 Did I read that correctly?                  18 A. Yes.                  19 Q. What instances would this occur?                  20 A. If a customer submitted a questionnaire                  21 and they did not provide an SOP of their SOM system,                  22 but produced kind of like a -- a summary, and there                  23 wasn't much there to that summary; or if there were                  24 something that was found on the Internet search as                  25 far as any -- any disciplinary action, or some action</p>	<p style="text-align: right;">Page 576</p> <p>1 A. Yes. This is an SOP that I drafted around                  2 the cage and vault personnel. Monitoring.                  3 Q. And what was the purpose of this SOP?                  4 A. This was an SOP to spell out to give the                  5 cage and vault personnel that were actually picking,                  6 packing, and shipping orders the ability to identify                  7 based on their knowledge anything that they felt was                  8 suspicious.                  9 Q. As your role as SOMS manager, did you ever                  10 conduct any training?                  11 A. Yes.                  12 Q. And who would you train?                  13 A. I actually conducted training of the -- of                  14 the cage and vault personnel on this SOP, and I would                  15 conduct training of the -- of my team. I conducted                  16 training of the sales force and sales management.                  17 MS. VANNI: Exhibit 40.                  18 (Par-Brantley 40 was marked for                  19 identification.)                  20 BY MS. VANNI:                  21 Q. If you could identify for the jury what                  22 Exhibit 40 is, please.                  23 A. This is an SOP that I drafted around                  24 identifying, blocking, and reporting suspicious                  25 orders.</p>
<p style="text-align: right;">Page 575</p> <p>1 taken with the owner, or that we needed to confirm or                  2 actually get more information on, then a -- a site                  3 visit would be warranted before we could open that                  4 customer up to kind of clear those -- all those                  5 things to get additional information.                  6 Q. And with respect to number 4, "SOM team                  7 requests a visit when a customer requests to begin                  8 ordering controlled substances, List 1 chemicals, or                  9 is seeking a boundary increase" -- what does that                  10 refer to?                  11 A. Yes, so when it's a new customer, we would                  12 want to conduct a site visit. And then if a customer                  13 was seeking an increase that needed further                  14 justification, then we would conduct a site visit.                  15 Q. And is that something that you would do as                  16 part of your role as SOMS manager?                  17 A. Yes.                  18 MS. VANNI: My next exhibit, Number 39.                  19 (Cardinal-Brantley 39 was marked for                  20 identification.)                  21 MS. VANNI: If you could take a look at                  22 that. Counsel.                  23 BY MS. VANNI:                  24 Q. Can you identify for the jury what                  25 Exhibit 39 is?</p>	<p style="text-align: right;">Page 577</p> <p>1 Q. And what was your purpose in doing this?                  2 A. To have a procedure in place that can be                  3 followed by someone that would follow me that could                  4 step in and -- and do the role, and plus to have a --                  5 a guide, a procedure in place for identifying orders                  6 and reporting orders.                  7 Q. Does this SOP reflect what we talked about                  8 with respect to the investigation that would be                  9 conducted if you got a -- an order tagged by the                  10 algorithm?                  11 A. Yes.                  12 Q. You can set that aside.                  13 I want to look at exhibit -- Plaintiffs'                  14 Exhibit Number 28. It was a document you were shown                  15 that was a letter written by Tracey Hernandez,                  16 director of DEA compliance, on October 18th, 2013, to                  17 the valued customers of QualiTest.                  18 Do you have that document in front of you?                  19 A. Yes.                  20 Q. If I could direct your attention to the                  21 third paragraph, third sentence:                  22 "As a result of this enhanced process, you                  23 may receive more frequent inquiries from QualiTest                  24 regarding your own suspicious order monitoring                  25 efforts, the quantity of product you are ordering</p>



<p style="text-align: right;">Page 578</p> <p>1 from us or the customers' use service." 2 Did I read that correctly? 3 A. Yes. 4 Q. Do you remember being asked some questions 5 about this by Plaintiffs' counsel? 6 A. Yes. 7 Q. First of all, what does the word 8 "enhanced" suggest to you? 9 MR. BUCHANAN: Objection to form. 10 THE WITNESS: That we take something that 11 already exists and improve upon it. Or to 12 expand it, make it robust. 13 BY MS. VANNI: 14 Q. And you were also asked questions with 15 respect to more frequent inquiries from QualiTest 16 regarding your own suspicious order monitoring 17 efforts. What does the word frequent -- "more 18 frequent inquiries" suggest to you? 19 MR. BUCHANAN: Objection. Form, 20 foundation. 21 THE WITNESS: That there were inquiries 22 being made, and that they may be made more 23 frequently. 24 BY MS. VANNI: 25 Q. How would you describe your interactions</p>	<p style="text-align: right;">Page 580</p> <p>1 MR. BUCHANAN: Objection. Move to strike. 2 THE WITNESS: They specifically said in 3 the -- the exit interview that we were very 4 knowledgeable about suspicious order monitoring 5 and that they liked our program. 6 MR. BUCHANAN: Objection. Form. Move to 7 strike. 8 BY MS. VANNI: 9 Q. As a result of that SOMS audit conducted 10 by the DEA, did you have to make any changes to the 11 SOMS program at QualiTest? 12 A. No. 13 MS. VANNI: Thank you. I have nothing 14 further. 15 VIDEOGRAPHER: Going off record. Time 16 is 7:49. 17 (A recess transpired from 7:49 p.m. until 18 7:51 p.m.) 19 VIDEOGRAPHER: We're going back on the 20 record, beginning of media file number 11. Time 21 is 7:51. 22 EXAMINATION 23 BY MR. LAFATA: 24 Q. Good evening, Mr. Brantley. I know you've 25 been here for about ten and a half hours; I have a</p>
<p style="text-align: right;">Page 579</p> <p>1 with the local office of the DEA? 2 A. I would say we had a good relationship. 3 They would come to the facility, conduct an audit. I 4 would send an e-mail of any suspicious order to the 5 Birmingham office, and I would e-mail or -- or call 6 with questions and received answers. We had a good 7 working relationship. 8 Q. You mentioned audits. Would DEA 9 occasionally do audits at QualiTest? 10 A. Yes. 11 Q. What was the purpose of those audits? 12 MR. BUCHANAN: Objection. Foundation. 13 THE WITNESS: Cyclical inspections. 14 The -- the different registrations would be 15 audited. The distribution center, the tablets 16 manufacturing, the liquids manufacturing; 17 whatever registration we had would be audited. 18 BY MS. VANNI: 19 Q. During your course as -- or during your 20 employment as SOMS manager, did the DEA ever do an 21 audit of the SOMS program at QualiTest? 22 A. Yes. 23 Q. And what was the result of that? 24 A. They stated that we had a good program and 25 that --</p>	<p style="text-align: right;">Page 581</p> <p>1 few additional questions for you. All right? 2 A. Okay. 3 Q. Do you currently work for Purdue Pharma? 4 A. Yes. 5 Q. And how long have you worked at Purdue 6 Pharma? 7 A. Since February 2017. 8 Q. Do you work for the Purdue Frederick 9 Company? 10 A. I work for Purdue Pharma LP. 11 Q. Have you ever worked for the Purdue 12 Frederick Company? 13 A. No. 14 Q. What's your job title at Purdue Pharma 15 right now? 16 A. Senior management -- senior manager, 17 ethics and compliance. 18 Q. And as the senior manager of ethics and 19 compliance, who do you report to? 20 A. I report to Alexis Stroud, the director of 21 ethics and compliance. 22 Q. What are your primary responsibilities as 23 a senior manager of ethics and compliance? 24 A. My primary responsibility -- 25 MR. PAPANTONIO: Objection. Beyond the</p>

Page 582

1 scope of direct.  
 2 BY MR. LAFATA:  
 3 Q. You can answer.  
 4 A. My primary responsibilities are suspicious  
 5 order monitoring. I manage the suspicious order  
 6 monitoring program.  
 7 Q. During the examinations today, there's  
 8 been reference to the term "customer." In the  
 9 context of Purdue, what does a Purdue customer refer  
 10 to?  
 11 A. A wholesale distributor.  
 12 Q. And have you heard the phrase "customer's  
 13 customer"?  
 14 A. Yes.  
 15 Q. In the context of Purdue, what is the  
 16 customer's customer?  
 17 A. Customer's customer would be the pharmacy,  
 18 hospital, et cetera, that the wholesaler distributes  
 19 Purdue products to.  
 20 Q. Does Purdue sell medications directly to  
 21 patients?  
 22 A. No.  
 23 MR. PAPANTONIO: Objection. Scope.  
 24 THE WITNESS: No.  
 25

Page 583

1 BY MR. LAFATA:  
 2 Q. Does Purdue sell medications directly to  
 3 doctors?  
 4 MR. PAPANTONIO: Objection. Scope.  
 5 THE WITNESS: No.  
 6 BY MR. LAFATA:  
 7 Q. I want to ask you some questions about the  
 8 procedures at Purdue for order monitoring and due  
 9 diligence.  
 10 (Purdue-Brantley 41 was marked for  
 11 identification.)  
 12 BY MR. LAFATA:  
 13 Q. Mr. Brantley, I'm handing you Exhibit 41.  
 14 Mr. Brantley, can you identify Exhibit 41?  
 15 MR. PAPANTONIO: Objection. This document  
 16 is beyond the scope of cross. There's been no  
 17 discussion about the contents of what's  
 18 contained in this document.  
 19 At this point, this -- this entire  
 20 examination seems to be shifting towards a  
 21 direct of -- of Purdue, of Mr. Brantley as a  
 22 Purdue witness. This is well beyond the scope,  
 23 and I move to strike the use of even this  
 24 document.  
 25 MR. LAFATA: Okay. Speaking objections

Page 584

1 noted.  
 2 BY MR. LAFATA:  
 3 Q. Would you please identify Exhibit 41.  
 4 A. Yes. This is an SOP that I authored  
 5 around Know Your Customer due diligence.  
 6 Q. What is the scope of this SOP?  
 7 A. This -- this SOP applies to all customers  
 8 purchasing Schedule II through V controlled  
 9 substances and List 1 chemicals.  
 10 Q. Is this a fair and accurate copy of that  
 11 standard operating procedure?  
 12 MR. PAPANTONIO: Continuing objection to  
 13 the use of this document and the line of  
 14 questioning beyond the scope of cross  
 15 examination.  
 16 BY MR. LAFATA:  
 17 Q. You can answer. Excuse me.  
 18 A. Yes.  
 19 MR. BUCHANAN: Counsel, this violates the  
 20 protocol.  
 21 MR. LAFATA: That's not correct. That's  
 22 not correct.  
 23 MR. BUCHANAN: Questioners are permitted  
 24 only to the extent testimony specifically  
 25 concerns their client.

Page 585

1 MR. LAFATA: Okay, well, this concerns my  
 2 client.  
 3 MR. BUCHANAN: I'm -- I'm sorry, Counsel,  
 4 there was no examination concerning your client  
 5 to which this questioning pertains. Did you  
 6 notice --  
 7 MR. LAFATA: There was examination --  
 8 there was examination --  
 9 MR. BUCHANAN: Did you notice this  
 10 deposition?  
 11 MR. LAFATA: Your objection is noted.  
 12 MR. BUCHANAN: No, no, no, my question --  
 13 MR. PAPANTONIO: No, no, we're not going  
 14 to note objection and you waste our time --  
 15 MR. LAFATA: You -- you heard -- you heard  
 16 examinations of Purdue.  
 17 MR. PAPANTONIO: No, there was no  
 18 examination.  
 19 MR. LAFATA: We're going to have -- yes.  
 20 MR. PAPANTONIO: There was  
 21 cross-examination. You are way beyond the  
 22 scope, and you --  
 23 MR. LAFATA: This is ridiculous. We're  
 24 going to get this on the record.  
 25 MR. PAPANTONIO: Don't hold your hand up

Page 586	Page 588
<p>1 at me. You're wasting our time.</p> <p>2 MR. LAFATA: Mr. Brantley --</p> <p>3 MR. PAPANTONIO: You have no authority to</p> <p>4 go forward with this examination.</p> <p>5 MR. LAFATA: That's not correct.</p> <p>6 MR. PAPANTONIO: You know that; everybody</p> <p>7 in the room knows that.</p> <p>8 MR. LAFATA: Hush.</p> <p>9 MR. PAPANTONIO: So it's -- no, don't tell</p> <p>10 me to hush. It's continuing objection. So</p> <p>11 you're wasting my time and everybody in this</p> <p>12 room's time --</p> <p>13 MR. LAFATA: Counsel -- Mr. Brantley --</p> <p>14 MR. PAPANTONIO: -- including the witness,</p> <p>15 Mr. Brantley.</p> <p>16 MR. LAFATA: Mr. Brantley --</p> <p>17 MR. BUCHANAN: You were required to</p> <p>18 provide two days' notice to the extent an</p> <p>19 examination --</p> <p>20 MR. LAFATA: No.</p> <p>21 MR. BUCHANAN: -- was going to go beyond</p> <p>22 90 minutes.</p> <p>23 MR. LAFATA: I've had --</p> <p>24 MR. PAPANTONIO: We have already --</p> <p>25 MR. LAFATA: -- five minutes. I've been</p>	<p>1 BY MR. LAFATA:</p> <p>2 Q. Mr. Brantley, does this Exhibit 41</p> <p>3 accurately reflect Purdue's protocol for Knowing Your</p> <p>4 Customer's due diligence?</p> <p>5 A. Yes.</p> <p>6 Q. All right.</p> <p>7 MR. PAPANTONIO: Continuing objection to</p> <p>8 use of the document and the line of questioning.</p> <p>9 MR. BUCHANAN: And reserve the right to</p> <p>10 re-call the witness to examine concerning</p> <p>11 Purdue's processes, since this was not a subject</p> <p>12 of examination.</p> <p>13 MR. PAPANTONIO: And I -- I join in that.</p> <p>14 This now raises the issue of making this witness</p> <p>15 available for full examination in a Purdue</p> <p>16 examination.</p> <p>17 So, Counselor, if you're willing to do</p> <p>18 that, let's go ahead and rock and roll.</p> <p>19 MR. LAFATA: Absolutely not. Absolutely</p> <p>20 not.</p> <p>21 MR. PAPANTONIO: Well, no, you've opened</p> <p>22 the door for it. So we -- Mr. Brantley, just so</p> <p>23 you know, we will set your deposition again for</p> <p>24 Purdue, based on what this lawyer has done here</p> <p>25 right now, just so you know what's happening to</p>
Page 587	Page 589
<p>1 five minutes.</p> <p>2 MR. PAPANTONIO: No, no, no. Not yours.</p> <p>3 MR. LAFATA: This is --</p> <p>4 MR. PAPANTONIO: The combined</p> <p>5 examination --</p> <p>6 MR. LAFATA: This is totally --</p> <p>7 BY MR. LAFATA:</p> <p>8 Q. Mr. Brantley, I have a question --</p> <p>9 MR. BUCHANAN: No, no --</p> <p>10 MR. PAPANTONIO: Don't cut me off.</p> <p>11 MR. BUCHANAN: I'm noting for the record,</p> <p>12 there has been no notice provided by defense</p> <p>13 counsel for an examination going beyond</p> <p>14 90 minutes.</p> <p>15 MR. LAFATA: We haven't gone beyond</p> <p>16 90 minutes.</p> <p>17 MR. BUCHANAN: You are now treading</p> <p>18 into --</p> <p>19 MR. LAFATA: I've been five minutes.</p> <p>20 MR. BUCHANAN: -- his history with Purdue</p> <p>21 and SOMS processes at Purdue.</p> <p>22 Counsel, it's inappropriate. There's been</p> <p>23 no advance notice. I join in the objection to</p> <p>24 strike and bar.</p> <p>25 MR. LAFATA: Okay.</p>	<p>1 you in this room. Okay?</p> <p>2 (Purdue-Brantley 42 was marked for</p> <p>3 identification.)</p> <p>4 BY MR. LAFATA:</p> <p>5 Q. Mr. Brantley, I'm handing you a copy of</p> <p>6 Exhibit 42.</p> <p>7 MR. PAPANTONIO: Same objection. Move to</p> <p>8 strike the use of the document. Move to --</p> <p>9 to -- move to object. I'm moving to object the</p> <p>10 whole line of questioning. Well beyond the</p> <p>11 scope of any cross-examination that took place</p> <p>12 in this room.</p> <p>13 Secondly, there was no notice of any</p> <p>14 direct that was going to be taken. We're</p> <p>15 entitled to a direct. Notice of that.</p> <p>16 MR. LAFATA: I want the record to reflect</p> <p>17 that counsel's extensive speaking objections</p> <p>18 will not come from the time permitted me for</p> <p>19 cross-examination --</p> <p>20 MR. PAPANTONIO: Well, I'm just preserving</p> <p>21 the record, sir, so --</p> <p>22 MR. LAFATA: -- the direct examination for</p> <p>23 the witness.</p> <p>24 MR. PAPANTONIO: Yeah.</p> <p>25 MR. BUCHANAN: It certainly will. As did</p>

<p>Page 590</p> <p>1 all yours against ours.</p> <p>2 BY MR. LAFATA:</p> <p>3 Q. Mr. Brantley, what is Exhibit 42?</p> <p>4 MR. PAPANTONIO: Same objection. Same</p> <p>5 objection on use of the document. Continuing</p> <p>6 objection as to this line of questioning. It's</p> <p>7 beyond the scope of cross-examination, in trying</p> <p>8 to -- to go forward with the direct where the</p> <p>9 Defendants have not been put notice -- where the</p> <p>10 Plaintiffs have not been put notice on the</p> <p>11 direct.</p> <p>12 BY MR. LAFATA:</p> <p>13 Q. Mr. Brantley, what is Exhibit 42?</p> <p>14 A. It is an SOP on identifying, evaluating,</p> <p>15 and reporting suspicious orders.</p> <p>16 Q. And who authored this SOP?</p> <p>17 MR. PAPANTONIO: Same objection.</p> <p>18 Objection, continuing objection of this line of</p> <p>19 questioning.</p> <p>20 BY MR. LAFATA:</p> <p>21 Q. Mr. Brantley, who authored this SOP?</p> <p>22 A. I did.</p> <p>23 MR. PAPANTONIO: Same objection.</p> <p>24 BY MR. LAFATA:</p> <p>25 Q. Okay. And what is the scope of this SOP?</p>	<p>Page 592</p> <p>1 interfering with the witness's answering of a</p> <p>2 question.</p> <p>3 BY MR. LAFATA:</p> <p>4 Q. Mr. Brantley, would you please --</p> <p>5 MR. PAPANTONIO: Go ahead with your</p> <p>6 question --</p> <p>7 BY MR. LAFATA:</p> <p>8 Q. -- repeat your answer --</p> <p>9 MR. PAPANTONIO: -- and I'll protect the</p> <p>10 record.</p> <p>11 BY MR. LAFATA:</p> <p>12 Q. -- about what the scope is of this</p> <p>13 Exhibit 42.</p> <p>14 A. This procedure applies to all customers</p> <p>15 and customer orders for Schedule II through V</p> <p>16 controlled substances and List 1 chemicals.</p> <p>17 Q. And does this SOP accurately reflect</p> <p>18 Purdue's policy for identifying, evaluating, and</p> <p>19 reporting suspicious orders?</p> <p>20 MR. PAPANTONIO: Objection as to the</p> <p>21 question. Beyond the scope of</p> <p>22 cross-examination. Move to strike the use of</p> <p>23 the document. Move to strike the question.</p> <p>24 THE WITNESS: Yes.</p> <p>25</p>
<p>Page 591</p> <p>1 MR. PAPANTONIO: Line of -- same line of</p> <p>2 objection on these -- on this line of</p> <p>3 questioning. Objection as to the question.</p> <p>4 Move to strike any answer based on the question.</p> <p>5 MR. LAFATA: You're interfering with the</p> <p>6 conduct of this examination.</p> <p>7 MR. PAPANTONIO: You go ahead with your</p> <p>8 question.</p> <p>9 BY MR. LAFATA:</p> <p>10 Q. Mr. Brantley --</p> <p>11 MR. PAPANTONIO: Let me worry about what</p> <p>12 I'm interfering with.</p> <p>13 BY MR. LAFATA:</p> <p>14 Q. -- what is the scope of this -- of this</p> <p>15 SOP?</p> <p>16 A. This procedure applies to all customers</p> <p>17 and customer orders for Schedule II through V</p> <p>18 controlled substances and List 1 chemicals.</p> <p>19 MR. PAPANTONIO: Objection. Move to</p> <p>20 strike the answer. Move to strike the answer</p> <p>21 from a direct.</p> <p>22 MR. LAFATA: Okay.</p> <p>23 MR. PAPANTONIO: It is beyond the scope of</p> <p>24 cross.</p> <p>25 MR. LAFATA: Counsel is physically</p>	<p>Page 593</p> <p>1 BY MR. LAFATA:</p> <p>2 Q. All right.</p> <p>3 MR. PAPANTONIO: Move to strike the</p> <p>4 answer.</p> <p>5 BY MR. LAFATA:</p> <p>6 Q. They don't like you answering these</p> <p>7 questions, do they?</p> <p>8 A. No.</p> <p>9 MR. BUCHANAN: Frankly, Counsel, if you</p> <p>10 wanted to conduct an examination, you should</p> <p>11 have provided notice.</p> <p>12 MR. PAPANTONIO: There are rules --</p> <p>13 MR. LAFATA: This is --</p> <p>14 MR. PAPANTONIO: Counsel, there are</p> <p>15 rules --</p> <p>16 MR. LAFATA: This is a direct examination</p> <p>17 of a witness.</p> <p>18 MR. PAPANTONIO: -- that you have to</p> <p>19 comply with. Read them, and then we'll be --</p> <p>20 we'll be glad to afford you a direct</p> <p>21 examination.</p> <p>22 But right now, just to be clear, we're</p> <p>23 going to reset Brantley on Purdue, just so you</p> <p>24 know that.</p> <p>25 MR. LAFATA: No, that's not -- that's not</p>

<p style="text-align: right;">Page 594</p> <p>1 right.</p> <p>2 MR. PAPANTONIO: Well, it's going to</p> <p>3 happen.</p> <p>4 (Purdue-Brantley 43 was marked for</p> <p>5 identification.)</p> <p>6 BY MR. LAFATA:</p> <p>7 Q. Mr. Brantley, I'm handing you a copy of</p> <p>8 Exhibit 43. Here you go.</p> <p>9 MR. PAPANTONIO: Same objection. Move to</p> <p>10 strike the use of the document. Move to strike</p> <p>11 any questioning or answers in regard to this</p> <p>12 document.</p> <p>13 BY MR. LAFATA:</p> <p>14 Q. Mr. Brantley --</p> <p>15 MR. PAPANTONIO: Beyond the scope --</p> <p>16 BY MR. LAFATA:</p> <p>17 Q. -- what is Exhibit 43?</p> <p>18 MR. PAPANTONIO: -- of direct, beyond the</p> <p>19 scope of cross-examination.</p> <p>20 BY MR. LAFATA:</p> <p>21 Q. You can answer.</p> <p>22 A. I'm sorry, what was your question?</p> <p>23 Q. What is Exhibit 43?</p> <p>24 A. This is an SOP that I drafted for</p> <p>25 downstream customer monitoring and reporting.</p>	<p style="text-align: right;">Page 596</p> <p>1 MR. LAFATA: -- is so outrageous.</p> <p>2 MR. PAPANTONIO: Trust me, it will be.</p> <p>3 BY MR. LAFATA:</p> <p>4 Q. Mr. Brantley, you can answer my question.</p> <p>5 A. Yes.</p> <p>6 Q. Okay. And as part --</p> <p>7 MR. PAPANTONIO: Move to strike.</p> <p>8 BY MR. LAFATA:</p> <p>9 Q. -- of those disclosures, does Purdue</p> <p>10 require its wholesalers and distributors to prove</p> <p>11 that they are licensed with federal government</p> <p>12 agencies?</p> <p>13 MR. PAPANTONIO: Objection --</p> <p>14 THE WITNESS: Yes.</p> <p>15 MR. PAPANTONIO: -- as to question.</p> <p>16 BY MR. LAFATA:</p> <p>17 Q. Which government agencies?</p> <p>18 MR. PAPANTONIO: Beyond the scope of</p> <p>19 cross-examination.</p> <p>20 BY MR. LAFATA:</p> <p>21 Q. Which government agencies?</p> <p>22 A. DEA and State Board of Pharmacy.</p> <p>23 Q. Does Purdue, as part of its suspicious</p> <p>24 order monitoring program, require wholesalers and</p> <p>25 distributors to disclose to Purdue their own</p>
<p style="text-align: right;">Page 595</p> <p>1 Q. Does this accurately reflect the standard</p> <p>2 operating procedure for Purdue downstream customer</p> <p>3 monitoring and reporting?</p> <p>4 MR. PAPANTONIO: Objection as to form of</p> <p>5 the question. Objection as to the question at</p> <p>6 all beyond the scope of cross-examination.</p> <p>7 Objection to any answer. Move to strike any</p> <p>8 answer that -- that responds to that question.</p> <p>9 BY MR. LAFATA:</p> <p>10 Q. You can answer.</p> <p>11 A. Yes.</p> <p>12 Q. Okay.</p> <p>13 MR. PAPANTONIO: Move to strike.</p> <p>14 BY MR. LAFATA:</p> <p>15 Q. Mr. Brantley, does Purdue, as part of its</p> <p>16 order monitoring process, require its wholesalers and</p> <p>17 distributors by questionnaire to make disclosures to</p> <p>18 Purdue about their business practices?</p> <p>19 MR. PAPANTONIO: Objection as to use --</p> <p>20 objection as to the question beyond the scope,</p> <p>21 objection as to response of any document that's</p> <p>22 been introduced in the line of this question.</p> <p>23 MR. LAFATA: I want this record to be seen</p> <p>24 by the special master, because your conduct --</p> <p>25 MR. PAPANTONIO: Oh, it will be. Trust --</p>	<p style="text-align: right;">Page 597</p> <p>1 suspicious order monitoring program information?</p> <p>2 MR. PAPANTONIO: Objection as to form.</p> <p>3 Objection as to the question. Beyond scope of</p> <p>4 cross-examination.</p> <p>5 BY MR. LAFATA:</p> <p>6 Q. You can answer.</p> <p>7 MR. PAPANTONIO: Move to strike the</p> <p>8 question and any subsequent answer to the</p> <p>9 question.</p> <p>10 THE WITNESS: Yes.</p> <p>11 BY MR. LAFATA:</p> <p>12 Q. And does Purdue --</p> <p>13 MR. PAPANTONIO: Move to strike the</p> <p>14 answer.</p> <p>15 BY MR. LAFATA:</p> <p>16 Q. Does Purdue review that information?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. Does Purdue require the wholesalers</p> <p>19 and distributors, its customers, to disclose any</p> <p>20 disciplinary actions the company may have had, the</p> <p>21 wholesaler or distributors may have had with respect</p> <p>22 to the Controlled Substances Act?</p> <p>23 MR. PAPANTONIO: Same continuing</p> <p>24 objection. Beyond the scope of</p> <p>25 cross-examination. Move to strike the question.</p>



<p style="text-align: right;">Page 598</p> <p>1 Move to strike the use of any document used  2 pursuant to the question. Move to strike any  3 answer given to the question.  4 BY MR. LAFATA:  5 Q. You can answer.  6 A. Yes.  7 Q. And how often does Purdue require  8 distributors and wholesalers to make these  9 disclosures to it?  10 A. On an annual basis.  11 MR. PAPANTONIO: Same objection.  12 Continuing objection. Beyond the scope.  13 BY MR. LAFATA:  14 Q. And in addition to these disclosures, does  15 Purdue do research on the customers for any  16 disciplinary actions?  17 MR. PAPANTONIO: Objection as to form of  18 the question. Beyond the scope of cross.  19 THE WITNESS: Yes.  20 BY MR. LAFATA:  21 Q. Okay. And does it do research on the  22 customer to look for any enforcement actions that may  23 have been brought against them?  24 A. Yes.  25 MR. PAPANTONIO: Objection as to --</p>	<p style="text-align: right;">Page 600</p> <p>1 does Purdue review the suspicious order monitoring  2 protocol of the company that it visits?  3 MR. PAPANTONIO: Objection as to --  4 objection as to question beyond the scope.  5 THE WITNESS: Yes.  6 BY MR. LAFATA:  7 Q. Would there -- if there were any deficient  8 results of those inspections that were discovered,  9 what would be done with respect to those -- what was  10 learned there?  11 MR. PAPANTONIO: Objection as to scope.  12 Objection as to speculative nature of the  13 question. Move to strike the question --  14 BY MR. LAFATA:  15 Q. You can answer.  16 MR. PAPANTONIO: -- and any document used  17 pursuant to the question. Move to strike the  18 answer.  19 THE WITNESS: That would be reviewed by --  20 by members of management, and potentially would  21 not ship controlled substances to that customer.  22 BY MR. LAFATA:  23 Q. If there is a deficiency in a customer's  24 suspicious order monitoring program as discovered as  25 part of these inspections, is that ever reported?</p>
<p style="text-align: right;">Page 599</p> <p>1 objection as to the question. Beyond the scope  2 of cross-examination.  3 BY MR. LAFATA:  4 Q. Does Purdue review the suspicious order  5 monitoring protocols of its customers?  6 MR. PAPANTONIO: Continuing objection.  7 Beyond the scope of cross-examination.  8 THE WITNESS: Yes.  9 BY MR. LAFATA:  10 Q. Okay. As part of its order monitoring  11 protocol, does Purdue do any site visits to its  12 customers' places of business?  13 MR. PAPANTONIO: Same objection.  14 Continuing objection. Beyond the scope of  15 cross-examination, without any --  16 BY MR. LAFATA:  17 Q. You can answer the question.  18 MR. PAPANTONIO: -- any -- excuse me.  19 Without any notice of direct to the  20 Plaintiffs in this case, pursuant to the rules  21 of the management order.  22 BY MR. LAFATA:  23 Q. Go ahead.  24 A. Yes.  25 Q. Okay. And as part of these site visits,</p>	<p style="text-align: right;">Page 601</p> <p>1 A. It would be reported, yes.  2 MR. PAPANTONIO: Objection as to the  3 question. Objection as to use of any document  4 in the question. Objection as to the answer,  5 and move to strike all three.  6 BY MR. LAFATA:  7 Q. And Mr. Brantley, if the review that's  8 done reveals an unreasonable risk of diversion with  9 the wholesaler or distributor, will Purdue sell any  10 of its opioid medications to that customer?  11 MR. PAPANTONIO: Objection --  12 THE WITNESS: No.  13 MR. PAPANTONIO: -- as to question beyond  14 the scope.  15 BY MR. LAFATA:  16 Q. You were asked questions today about  17 ARCOS. Do you remember that?  18 A. Yes.  19 Q. Does the DEA provide Purdue access to the  20 ARCOS data?  21 MR. PAPANTONIO: Objection as to anything  22 between -- in response to Purdue in particular.  23 It's beyond the scope of the cross-examination.  24 Responses to ARCOS in general will -- we're okay  25 with, but anything having to do with Purdue</p>

Page 602

1 directly is beyond the scope.  
2 MR. LAFATA: That's an improper objection,  
3 Counsel.  
4 He likes to speak from the corner of the  
5 room when he makes objections.  
6 BY MR. LAFATA:  
7 Q. Mr. Brantley, does the DEA provide Purdue  
8 with access to its ARCOS data?  
9 A. No.  
10 MR. PAPANTONIO: Objection as to form.  
11 BY MR. LAFATA:  
12 Q. Okay.  
13 MR. PAPANTONIO: It's beyond the scope of  
14 cross-examination.  
15 BY MR. LAFATA:  
16 Q. So is Purdue able to use --  
17 (Reporter requests clarification.)  
18 THE WITNESS: No.  
19 BY MR. LAFATA:  
20 Q. Is Purdue able to use the DEA's ARCOS data  
21 as part of its suspicious order monitoring program?  
22 A. No.  
23 MR. PAPANTONIO: Objection. Move to  
24 strike. Move to -- move to strike the question  
25 and the answer, both of them beyond the scope of

Page 603

1 cross-examination.  
2 BY MR. LAFATA:  
3 Q. And Mr. Brantley, when Purdue receives an  
4 order for an opioid medication, does the order go  
5 through any process or review?  
6 MR. PAPANTONIO: Same objection.  
7 Continuing objection on cross-examination and  
8 use of any document related to this  
9 cross-examination at all.  
10 BY MR. LAFATA:  
11 Q. You can answer the question.  
12 A. All orders pass through an algorithm, and  
13 the algorithm will hold an order that is out of the  
14 ordinary, or an order of interest, yes.  
15 MR. PAPANTONIO: Move to strike.  
16 BY MR. LAFATA:  
17 Q. And after that order is held, what happens  
18 then?  
19 MR. PAPANTONIO: Objection as to question.  
20 Beyond the scope.  
21 THE WITNESS: That order is reviewed, and  
22 I reach out to the customer and ask for  
23 additional information.  
24 MR. PAPANTONIO: Objection as to answer.  
25 Move to strike.

Page 604

1 BY MR. LAFATA:  
2 Q. And if you reach out to the customer --  
3 MR. PAPANTONIO: Beyond the scope.  
4 BY MR. LAFATA:  
5 Q. -- and ask for additional information and  
6 you're not satisfied with the results, what happens  
7 then?  
8 A. That order is rejected --  
9 MR. PAPANTONIO: Objection as to question.  
10 THE WITNESS: -- and reported to the DEA.  
11 MR. PAPANTONIO: Beyond the scope.  
12 Objection, move to strike the answer. Beyond  
13 the scope of cross-examination.  
14 MR. LAFATA: Counsel is deliberately  
15 speaking over the witness to interfere with the  
16 conduct of this deposition.  
17 MR. PAPANTONIO: Well, it's going to be  
18 taken again anyway, so, you know, it doesn't  
19 make any difference.  
20 BY MR. LAFATA:  
21 Q. Mr. Brantley, if -- if you are satisfied  
22 with the information you receive from the customer  
23 from your investigation, what happens then to the  
24 order?  
25 A. Then the order is released, and the

Page 605

1 response is documented --  
2 MR. PAPANTONIO: Objection as to --  
3 THE WITNESS: -- in our system.  
4 MR. PAPANTONIO: Objection as to the  
5 question. Objection as to answer. Beyond the  
6 scope of cross-examination.  
7 BY MR. LAFATA:  
8 Q. Mr. Brantley, if you're -- let me  
9 rephrase.  
10 Are there circumstances which an order can  
11 be flagged by that algorithm but is, based on your  
12 investigation, not found to be suspicious?  
13 MR. PAPANTONIO: Objection as to question.  
14 Beyond the scope.  
15 THE WITNESS: Yes, there are several  
16 circumstances. For instance, if a customer  
17 adds -- like I mentioned earlier, a new customer  
18 base, or a new chain, and they tell me that in  
19 advance, with the number of customers, that  
20 order would still be flagged by the system  
21 because it's an increase because the wholesaler  
22 needs to -- needs to supply their customer as  
23 well as stock their warehouse.  
24 Also, if it is a initial order of a drug  
25 family, that order would be held because there

<p style="text-align: right;">Page 606</p> <p>1 is no history for that algorithm to compare it  2 to. So those are just a couple of examples of  3 an order that could be identified by an  4 algorithm that are not suspicious, but are  5 flagged due to lack of history.  6 MR. PAPANTONIO: Objection as to the  7 answer. Move to strike. Beyond the scope of  8 cross-examination.  9 MR. LAFATA: Counsel, there's no question  10 before you pending.  11 MR. BUCHANAN: Just so the record is  12 clear, was notice provided of intent to conduct  13 an examination that exceeded 90 minutes?  14 MR. LAFATA: I never intended -- I still  15 don't intend to conduct an examination that  16 exceeds an hour and a half.  17 MR. BUCHANAN: No, no, I mean among --  18 among defense counsel.  19 MR. LAFATA: Okay. Well --  20 MR. BUCHANAN: We're over an hour and a  21 half.  22 MR. LAFATA: Well, part of it is because  23 of you and your colleagues' extensive colloquies  24 on the record. This is --  25 MR. BUCHANAN: My question --</p>	<p style="text-align: right;">Page 608</p> <p>1 provided notice of intent, collectively, to  2 conduct an examination beyond 90 minutes, would  3 you please so state on the record.  4 MR. PAPANTONIO: And to further join in  5 that, there is no notice that this -- that this  6 lawyer for Purdue was going to come into the  7 room and do a direct examination of this  8 witness. We're entitled to notice of that so we  9 can prepare cross-examinations that deal with  10 the very issues he's asking.  11 He's moved beyond cross. He understands  12 he has. He's now made it -- I believe it's  13 going to be important that we take Brantley's  14 deposition in Purdue alone.  15 MR. LAFATA: Okay. That's outrageous, so  16 your comments are, you know, just wasting time  17 now.  18 BY MR. LAFATA:  19 Q. Mr. Brantley, we need to continue with  20 your examination.  21 Mr. Brantley, do you personally deal with  22 the DEA with your work at Purdue?  23 MR. PAPANTONIO: Objection. Beyond the  24 scope. Same continuing objection.  25 THE WITNESS: No.</p>
<p style="text-align: right;">Page 607</p> <p>1 MR. LAFATA: All right.  2 MR. BUCHANAN: -- only, sir, was notice  3 provided? I just want to make sure that aspect  4 of the record is clear.  5 MR. LAFATA: All right.  6 MR. BUCHANAN: Was it provided? Yes or  7 no?  8 MR. LAFATA: There was no need to provide  9 notice because there's no intent or actual  10 examination over 90 minutes that I'm conducting.  11 MR. BUCHANAN: No, no. Among all defense  12 counsel.  13 MR. LAFATA: I'm not here to be deposed  14 by --  15 MR. PAPANTONIO: No, no. I want to  16 hear --  17 MR. LAFATA: I'm not here to be deposed by  18 you.  19 MR. PAPANTONIO: I want to hear his  20 statement on the record, because this is what  21 the special master has stated.  22 Mr. -- David, would you please finish what  23 you were saying? And I'll join in it.  24 MR. BUCHANAN: I'm not aware of notice  25 having been provided. If any defense counsel's</p>	<p style="text-align: right;">Page 609</p> <p>1 BY MR. LAFATA:  2 Q. And as part of your investigation of  3 orders, if there is any doubt in your mind whether or  4 not to report an order for medications to the DEA,  5 how do you resolve that?  6 MR. PAPANTONIO: Objection. Beyond scope.  7 THE WITNESS: If I do not have substantial  8 information to release an order, that order is  9 cut, and it's reported to the DEA.  10 BY MR. LAFATA:  11 Q. What do you mean when say "the order is  12 cut"?  13 A. It is rejected.  14 MR. PAPANTONIO: I want to get something  15 on record.  16 Mr. Fuller, you're Plaintiffs' lawyer in  17 this room: Did you receive any notice from  18 Purdue to conduct a direct examination in this  19 -- in this --  20 MR. LAFATA: Okay, Counsel, you're  21 interfering with the examination.  22 MR. PAPANTONIO: No, no.  23 MR. LAFATA: You're interfering with the  24 examination.  25 MR. PAPANTONIO: Did you -- did you,</p>

Page 610

1 sir -- I want this on the record.  
 2 MR. LAFATA: You're interfering with the  
 3 examination.  
 4 MR. PAPANTONIO: Did you prepare -- did  
 5 you receive any notice from -- I'm sorry, sir, I  
 6 don't even know your name. What is your name?  
 7 BY MR. LAFATA:  
 8 Q. Okay, Mr. Brantley, did you --  
 9 MR. PAPANTONIO: What -- no, no, we're  
 10 going to get this on the record.  
 11 MR. LAFATA: No.  
 12 MR. PAPANTONIO: Mr. Fuller, did you  
 13 receive any notice at all that this counselor  
 14 was going to perform a direct examination of  
 15 Mr. Brantley at this setting?  
 16 MR. FULLER: No, sir.  
 17 MR. LAFATA: Counsel's statements --  
 18 MR. PAPANTONIO: Mr. -- wait, wait -- wait  
 19 a second.  
 20 MR. LAFATA: Counsel's statements --  
 21 MR. PAPANTONIO: David --  
 22 MR. LAFATA: -- on the record are actually  
 23 longer than the witness's testimony.  
 24 MR. PAPANTONIO: David, did you receive  
 25 any notice from this -- from this lawyer stating

Page 611

1 that he was going to perform a direct  
 2 examination on behalf of Purdue at this setting?  
 3 MR. BUCHANAN: No, sir.  
 4 MR. PAPANTONIO: I can attest we did not  
 5 receive any notice at all saying that this  
 6 lawyer intended to come into the room and  
 7 conduct a direct examination of Mr. Brantley.  
 8 Move to strike all of this, and move to --  
 9 to reserve the right to be able to take a  
 10 cross-examination, a setting of just  
 11 cross-examination of Mr. Brantley.  
 12 Now go ahead, Counselor.  
 13 MR. LAFATA: That's outrageous, what  
 14 you're doing.  
 15 MR. PAPANTONIO: Well, great.  
 16 MR. LAFATA: It's outrageous.  
 17 MR. PAPANTONIO: You call it what you  
 18 want --  
 19 MR. LAFATA: Yeah.  
 20 THE WITNESS: -- but go ahead and -- and  
 21 proceed.  
 22 BY MR. LAFATA:  
 23 Q. Mr. Brantley, as part of your work for  
 24 Purdue, have you ever heard any criticisms by the DEA  
 25 about Purdue's order monitoring program?

Page 612

1 MR. PAPANTONIO: Objection as to form.  
 2 Beyond the scope. Secondary. It's hearsay.  
 3 BY MR. LAFATA:  
 4 Q. You can answer.  
 5 MR. PAPANTONIO: Move to strike the  
 6 question and any -- any subsequent answer to the  
 7 question.  
 8 THE WITNESS: No.  
 9 BY MR. LAFATA:  
 10 Q. When you joined Purdue in 2017, was there  
 11 already a program in place for suspicious order  
 12 monitoring?  
 13 MR. PAPANTONIO: Objection.  
 14 THE WITNESS: Yes.  
 15 MR. PAPANTONIO: Objection. Objection.  
 16 Beyond scope.  
 17 BY MR. LAFATA:  
 18 Q. And during the time working for Purdue,  
 19 has Purdue, to your knowledge, ever released an order  
 20 that was believed that might be diverted?  
 21 A. No.  
 22 Q. With respect to your answers today with --  
 23 regarding your work for Purdue in the suspicious  
 24 order monitoring program and your job  
 25 responsibilities for Purdue, are your answers to

Page 613

1 those questions the same regardless of what state in  
 2 the country they might pertain to?  
 3 A. Yes.  
 4 Q. All right.  
 5 MR. PAPANTONIO: Objection as to -- beyond  
 6 scope.  
 7 BY MR. LAFATA:  
 8 Q. Mr. Brantley, do you have a copy of  
 9 Plaintiffs' Exhibit 26 in front of you?  
 10 A. What does it look like?  
 11 Q. The GAO.  
 12 A. Oh, yes.  
 13 Q. All right. Mr. Brantley, on the cover  
 14 page of this, do you see a date?  
 15 MR. PAPANTONIO: Objection as to question.  
 16 THE WITNESS: Yes.  
 17 BY MR. LAFATA:  
 18 Q. And what's the date there?  
 19 A. December 2003.  
 20 Q. Did you work for Purdue in December 2003?  
 21 A. No.  
 22 Q. Do you have any personal knowledge about  
 23 the content of this document?  
 24 A. No.  
 25 Q. Do you have any personal knowledge about

<p style="text-align: right;">Page 614</p> <p>1 the circumstances surrounding GAO's creation of this  2 document?  3 A. No.  4 MR. LAFATA: All right. Pass the witness.  5 MR. PAPANTONIO: Okay. I want to get back  6 on the record.  7 Mr. Brantley, we're -- just so you know,  8 we're going to reserve the right for your  9 cross-examination dealing with Purdue. The  10 questions I'm going to ask you now are uniquely  11 questions about Cardinal.  12 MR. LAFATA: Mr. Brantley, you can  13 disregard --  14 MR. PAPANTONIO: Can you please --  15 MR. LAFATA: -- adverse counsel's --  16 MR. PAPANTONIO: Carol, do you have the  17 documents?  18 MR. LAFATA: -- instructions to you.  19 And the record should be clear that it was  20 never the intent to do any examination, any  21 direct examination over 90 minutes, and that the  22 protocol did not require that any notice be  23 given unless there was an intent to an  24 examination over 90 minutes.  25 And I think counsel's arguments, on their</p>	<p style="text-align: right;">Page 616</p> <p>1 little --  2 MR. PAPANTONIO: What, do you want to take  3 a break?  4 MR. PYSER: Yeah. Just a quick break.  5 MR. PAPANTONIO: Okay. That's fine.  6 VIDEOGRAPHER: Going off the record. The  7 time is 8:14.  8 (A recess transpired from 8:14 p.m. until  9 8:20 p.m.)  10 VIDEOGRAPHER: Go back on the record.  11 Beginning media file number 12. Time is 8:20.  12 FURTHER EXAMINATION  13 BY MR. PAPANTONIO:  14 Q. Mr. Brantley, first of all, you knew  15 before you started that examination with Purdue with  16 Mr. Lafata down there, you knew that you were going  17 to do direct examination, didn't you? You knew you  18 were going to sit -- you knew you were going to sit  19 here and answer questions, didn't you, about -- for  20 Purdue?  21 MR. LAFATA: Objection. Instruct the  22 witness not to reveal any discussions he has  23 been having with counsel in preparation for  24 today's deposition, unless you can answer the  25 question without revealing that. If you can</p>
<p style="text-align: right;">Page 615</p> <p>1 own, greatly exceeded even the testimony of the  2 witness.  3 MR. BUCHANAN: Counsel, in my experience,  4 if somebody is going to do what you just did,  5 they discuss it with the Plaintiffs' counsel and  6 confer about so that everybody, as a courtesy,  7 can anticipate the impact on their travel plans.  8 To do what you just did, at the end of a  9 ten-hour day, is unprofessional.  10 MR. PAPANTONIO: Well, it's not only  11 unprofessional, it's improper. It's  12 unauthorized, it's improper. This counselor  13 knows it and he knew it when he set -- when he  14 stood up here to do it.  15 So we're going to -- we're going to --  16 we're going to deal with this. This won't be  17 something that's not dealt with, sir.  18 What is your name, by the way?  19 MR. LAFATA: My name is Paul Lafata.  20 MR. PAPANTONIO: Paul Lafata? You'll see  21 us again on this one, okay?  22 MR. LAFATA: I look forward to it.  23 MR. PAPANTONIO: Yeah.  24 MR. PYSER: Let's go off the record.  25 Let's take a break, since we've all got a</p>	<p style="text-align: right;">Page 617</p> <p>1 answer the question without revealing that, then  2 you can answer.  3 BY MR. PAPANTONIO:  4 Q. Sir, you knew before you came in here and  5 sat down and were questioned by the Purdue lawyer,  6 you knew you were going to give an examination, that  7 you were going to ask questions -- answer questions  8 about Purdue? You knew that, didn't you?  9 MR. LAFATA: Mr. Brantley, again, I  10 instruct you that if you're not able to answer  11 that question without revealing discussions with  12 counsel, which are privileged, and this guy  13 knows that, I instruct you not to answer.  14 MR. PAPANTONIO: Okay, that's even more --  15 THE WITNESS: At the advice of counsel,  16 I --  17 BY MR. PAPANTONIO:  18 Q. Okay. So in other words, you can't answer  19 that, you can't answer that, because if you answered  20 it, you would have to share what the advice of  21 counsel was, correct?  22 A. At the advice of counsel, I'm -- I don't  23 answer the question.  24 Q. All right. Well, good. I think you  25 established -- you answered my question right there.</p>



<p style="text-align: right;">Page 618</p> <p>1 Okay. So --</p> <p>2 MR. LAFATA: Move to strike. Move to</p> <p>3 strike counsel's colloquy on that end there.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. 4391, please. 4391.</p> <p>6 (Cardinal-Brantley 40 was marked for</p> <p>7 identification.)</p> <p>8 MS. MOORE: Brantley 40.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Now let's talk about -- let's talk about</p> <p>11 Cardinal.</p> <p>12 See this document, it's 2008, right? See</p> <p>13 that? Top of the document --</p> <p>14 A. Yes.</p> <p>15 Q. -- 2008. And where were you in 2008?</p> <p>16 A. I was still in Dublin, Ohio.</p> <p>17 Q. And you were working for Cardinal in 2008,</p> <p>18 right?</p> <p>19 A. Yes.</p> <p>20 Q. And you see the subject is "In the penalty</p> <p>21 box." What's the penalty box?</p> <p>22 A. I don't know.</p> <p>23 Q. Well, what is a penalty box? Do you know</p> <p>24 what a penalty box is?</p> <p>25 A. In hockey?</p>	<p style="text-align: right;">Page 620</p> <p>1 line of questioning.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. You know what a penalty box is, right?</p> <p>4 A. Like I just answered, I've heard of a</p> <p>5 penalty box in the sport of hockey, but I do not know</p> <p>6 what a penalty box is --</p> <p>7 Q. Now --</p> <p>8 A. -- because I don't watch hockey.</p> <p>9 Q. Now, when Mr. Pyser started asking you</p> <p>10 questions about how you did this right for the DEA,</p> <p>11 how you followed this rule about the DEA, you</p> <p>12 answered a lot of questions about that for -- for</p> <p>13 Mr. Pyser, didn't you?</p> <p>14 MR. PYSER: Object to form.</p> <p>15 THE WITNESS: If Mr. Pyser had asked me</p> <p>16 did I know what a penalty box was, I would have</p> <p>17 gave him the same answer I gave you.</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. I know. But that's not --</p> <p>20 A. I've heard about it in hockey; I don't</p> <p>21 know what it is.</p> <p>22 Q. That's not my question. You answered</p> <p>23 questions from Mr. Pyser about how you followed --</p> <p>24 how you followed the rules and how Cardinal followed</p> <p>25 the rules expected of them by the DEA. When he asked</p>
<p style="text-align: right;">Page 619</p> <p>1 Q. Yeah. It's when you do something wrong,</p> <p>2 isn't it?</p> <p>3 A. I'm not a hockey fan, but I've heard of</p> <p>4 the penalty box in hockey. I don't watch hockey, but</p> <p>5 I know it exists in hockey. I don't know the purpose</p> <p>6 of it or what it is and so forth.</p> <p>7 Q. Well, you know it's when you break a rule,</p> <p>8 right? You go in the penalty box when you break a</p> <p>9 rule. You know that, don't you?</p> <p>10 A. No. Again, I've heard of a penalty box in</p> <p>11 hockey, but I don't know what the penalty box is,</p> <p>12 because I don't watch hockey.</p> <p>13 Q. Mm-hmm.</p> <p>14 MR. PYSER: Object to form.</p> <p>15 BY MR. PAPANTONIO:</p> <p>16 Q. So --</p> <p>17 MR. PYSER: Object to this line of</p> <p>18 questioning.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. So you know what a penalty --</p> <p>21 MR. PYSER: Beyond the scope of the</p> <p>22 examination.</p> <p>23 BY MR. PAPANTONIO:</p> <p>24 Q. You know what a penalty box is, correct?</p> <p>25 MR. PYSER: Move to strike this entire</p>	<p style="text-align: right;">Page 621</p> <p>1 you questions, you answered questions about that,</p> <p>2 didn't you?</p> <p>3 A. When he asked questions, I answered the</p> <p>4 questions.</p> <p>5 Q. Right. And some of them involved the fact</p> <p>6 you were saying that you were -- you did everything</p> <p>7 right; Cardinal did everything right where it came to</p> <p>8 DEA. Isn't that what you told us?</p> <p>9 A. I don't recall ever saying that Cardinal</p> <p>10 did everything right or that I did everything right.</p> <p>11 Q. But you did everything right?</p> <p>12 A. I never recall saying that I did</p> <p>13 everything right.</p> <p>14 Q. Because you didn't do everything right,</p> <p>15 did you?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Right?</p> <p>19 A. I -- I was never asked a question did I do</p> <p>20 anything -- did I do everything right. I've never</p> <p>21 said that I did everything right.</p> <p>22 Q. And you didn't do everything right,</p> <p>23 correct?</p> <p>24 MR. PYSER: Object to form.</p> <p>25 THE WITNESS: I don't know what was . . .</p>

Page 622

1 BY MR. PAPANTONIO:  
 2 Q. Well, Cardinal didn't do everything right,  
 3 did they?  
 4 MR. PYSER: Object to form.  
 5 THE WITNESS: I don't know, because you  
 6 have to define "right."  
 7 BY MR. PAPANTONIO:  
 8 Q. Well, let's --  
 9 A. That's --  
 10 Q. Let's do that right now. Let's -- let's  
 11 define --  
 12 A. That's subjective.  
 13 Q. Let's -- let's define "right."  
 14 MR. PYSER: Give me a chance to object.  
 15 THE WITNESS: Okay.  
 16 BY MR. PAPANTONIO:  
 17 Q. All right. It says -- you see the last  
 18 paragraph down here? It says "I wanted" -- it says  
 19 "fellow GLT members." What's GLT? What is GLT?  
 20 A. I don't know.  
 21 Q. Never heard of that?  
 22 It says, "I wanted to share some thoughts  
 23 on the subject of regulatory compliance since some of  
 24 our failures in this area are burdening our financial  
 25 performance in market capitalization."

Page 623

1 Now, how would your failures in your --  
 2 since you were -- you were giving us all this history  
 3 about how Cardinal did this right and that right,  
 4 tell me how your -- how your -- your failures in  
 5 regulatory compliance were burdening the financial  
 6 performance of -- of Cardinal or the market  
 7 capitalization of Cardinal. Tell us how that was.  
 8 A. You would have to ask Kerry Clark.  
 9 Q. So had you ever heard that prior to the  
 10 time that Mr. Pyser started asking you all these  
 11 questions about how -- whether or not Cardinal did  
 12 things right, had you even heard that the failure to  
 13 do things right, the failure to comply with  
 14 regulatory, was actually causing financial  
 15 performance problems for the -- for the company?  
 16 MR. PYSER: Object to form.  
 17 THE WITNESS: This is my first time seeing  
 18 this.  
 19 BY MR. PAPANTONIO:  
 20 Q. Doesn't surprise me.  
 21 And what year is it? What year is on top  
 22 of that document?  
 23 A. 2008.  
 24 Q. 2008. You told us you were still with the  
 25 company in 2008, and nobody showed you that, did

Page 624

1 they?  
 2 MR. PYSER: Object to form.  
 3 BY MR. PAPANTONIO:  
 4 Q. Let's go to the next page. It says, "One  
 5 of the most important small things was avoiding  
 6 penalties that give our competition an advantage."  
 7 Do you see that in the first paragraph?  
 8 "One of the most important small things was avoiding  
 9 penalties that give our competition an advantage."  
 10 A. Yes, I see that.  
 11 Q. What -- what advantage did your  
 12 competition have when you engaged in regulatory  
 13 misconduct?  
 14 MR. PYSER: Object to form.  
 15 BY MR. PAPANTONIO:  
 16 Q. Explain that to the jury.  
 17 A. Again, you would have to ask the -- the  
 18 author of this e-mail what he or she meant.  
 19 Q. Well, did you know that there was an  
 20 analysis according to whether you did something wrong  
 21 as far as how much it was going to cost the company  
 22 financially? Had you ever seen that analysis being  
 23 done before?  
 24 MR. PYSER: Object to form.  
 25

Page 625

1 BY MR. PAPANTONIO:  
 2 Q. Before I just showed this, had anybody  
 3 told you that they had in place an analysis, and the  
 4 analysis was a financial analysis that said, "When we  
 5 do something wrong, it costs the company money"? Is  
 6 that the first time you've heard that?  
 7 MR. PYSER: Object to form. Misstates  
 8 evidence.  
 9 BY MR. PAPANTONIO:  
 10 Q. Yes or no?  
 11 A. I have not seen this.  
 12 Q. Well, it says, "But we keep getting  
 13 penalties, big penalties that are costing us customer  
 14 loyalty."  
 15 You see, that's in the second paragraph.  
 16 "But we keep getting penalties, big penalties that  
 17 are costing us customer loyalty, employee loyalty,  
 18 and shareholder loyalty."  
 19 Well, I thought when you testified -- and  
 20 here's what I want to figure out: When you testified  
 21 for Mr. Pyser, didn't you say that you did things  
 22 right where it came to regulatory?  
 23 MR. PYSER: Object to form.  
 24 BY MR. PAPANTONIO:  
 25 Q. Didn't you say that?

<p style="text-align: right;">Page 626</p> <p>1 MR. PYSER: Object to form. And an 2 ongoing objection to use of this document -- 3 BY MR. PAPANTONIO: 4 Q. Yes -- 5 MR. PYSER: -- as beyond the scope. 6 BY MR. PAPANTONIO: 7 Q. Yes or no? Did you -- did you say that 8 when -- 9 MR. LAFATA: I join that objection. 10 BY MR. PAPANTONIO: 11 Q. Did you -- did you say that when you were 12 questioned by Mr. Pyser? 13 MR. PYSER: Object to form. 14 BY MR. PAPANTONIO: 15 Q. That you -- that your company did things 16 right where it came to regulatory? 17 MR. PYSER: Object to form. 18 THE WITNESS: I stated that when asked 19 what Kyle Wright thought -- 20 BY MR. PAPANTONIO: 21 Q. Yeah. 22 A. -- that that was his statement. 23 Q. Yeah. Well, Kyle Wright -- tell us your 24 relationship with Kyle Wright, while we're at it. 25 Tell us your friendship with Kyle Wright.</p>	<p style="text-align: right;">Page 628</p> <p>1 Q. Well, did you go have drinks with him? 2 MR. PYSER: Object to form. Asked and 3 answered. 4 BY MR. PAPANTONIO: 5 Q. Did you go have drinks with Carl Wright? 6 A. I don't drink -- 7 Q. Did you have -- 8 A. -- alcohol. 9 Q. -- dinner with Carl Wright? 10 A. I have not. 11 Q. What did you do with Carl Wright socially? 12 MR. PYSER: Object to form. 13 THE WITNESS: Nothing outside of work. 14 BY MR. PAPANTONIO: 15 Q. Okay. So you did nothing socially with 16 Carl Wright; that's your testimony here today. Is 17 that correct? 18 MR. PYSER: Object to form. 19 BY MR. PAPANTONIO: 20 Q. That's your testimony -- 21 A. That's correct. 22 Q. -- right now, that you did nothing 23 socially with Carl Wright, true? 24 A. That is correct. 25 Q. All right.</p>
<p style="text-align: right;">Page 627</p> <p>1 MR. PYSER: Object to form. 2 BY MR. PAPANTONIO: 3 Q. How -- how many years does your friendship 4 with Kyle Wright go back? 5 MR. PYSER: Object to form. 6 THE WITNESS: There was a working 7 relationship with -- 8 BY MR. PAPANTONIO: 9 Q. How many years? 10 A. -- with Kyle Wright while I -- 11 Q. How many years? 12 A. I can't state how many years. 13 MR. PYSER: Object to form. 14 BY MR. PAPANTONIO: 15 Q. Do you socialize with Carl Wright? 16 A. I do not. 17 Q. Have you ever socialized with Carl Wright? 18 A. I have not. 19 Q. No time did you socialize with Carl 20 Wright; that's your testimony? 21 A. I socialize -- what do you mean -- 22 MR. LAFATA: Objection. 23 BY MR. PAPANTONIO: 24 Q. Huh? 25 A. Please define "socialize."</p>	<p style="text-align: right;">Page 629</p> <p>1 MR. LAMB: It's Kyle, Mike. Kyle. 2 MR. PAPANTONIO: Kyle. Excuse me. Kyle. 3 Kyle. 4 BY MR. PAPANTONIO: 5 Q. All right. Well, let's look at the next 6 paragraph. We'll get back to that. 7 It says, next paragraph, "Obviously the 8 biggest are the SEC issue, two consecutive Alaris 9 recalls." What's Alaris? 10 A. I don't know for sure. I think it's a 11 medical device or dispensing robot or something like 12 that. 13 Q. "A number of MPT recalls, and the DEA 14 controlled -- and the DEA controlled substance 15 license suspensions." 16 You see where it says that? "And the DEA 17 substance control" -- what is it -- 18 "substance license suspensions in three locations." 19 You see where it says that? 20 A. Yes. 21 Q. All right. And then it goes on to say, 22 "Beyond these, Gary Dolch's quarterly QRA report 23 lists a startling number of issues, including six 24 OSHA violations and a significant fine at our 25 Syracuse, New York, facility. If you added up our</p>

Page 630

1 fines, settlements, and lost business over the last  
 2 18 months, the total would come close to \$1 billion."  
 3 That's shocking, isn't it Mr. Brantley?  
 4 MR. PYSER: Object to form.  
 5 BY MR. PAPANTONIO:  
 6 Q. It's shocking. It says -- as a matter of  
 7 fact, it says right here, it's shocking, isn't it?  
 8 MR. PYSER: Object to form. Ongoing and  
 9 continuing objection to this line of  
 10 questioning. This document is beyond the scope  
 11 of examination.  
 12 BY MR. PAPANTONIO:  
 13 Q. Right? It says "shocking." Are you  
 14 shocked by the fact that your failure to comply with  
 15 regulatory actually cost a billion dollars?  
 16 MR. PYSER: Object to form. Misstates  
 17 evidence.  
 18 BY MR. PAPANTONIO:  
 19 Q. Does that surprise you?  
 20 MR. PYSER: Object to form.  
 21 THE WITNESS: Those are the author's  
 22 words.  
 23 BY MR. PAPANTONIO:  
 24 Q. Okay, but does that surprise you? If it's  
 25 more than a billion dollars in your failure to comply

Page 631

1 with regulatory, if it's more than \$1 billion, that's  
 2 shocking, isn't it?  
 3 MR. PYSER: Object to form. Misstates  
 4 evidence.  
 5 BY MR. PAPANTONIO:  
 6 Q. You would say that's shocking, wouldn't  
 7 you?  
 8 MR. PYSER: Object.  
 9 THE WITNESS: I would not. I do not speak  
 10 to shocking or surprising or anything like that.  
 11 I can say what was stated in the document.  
 12 BY MR. PAPANTONIO:  
 13 Q. So your testimony is it's not shocking; to  
 14 Eric Brantley, it's not shocking that your failure to  
 15 comply with regulatory rules exceeded a cost to the  
 16 company of \$1 billion? That is not shocking to Eric  
 17 Wright; is that -- Eric Brantley; is that correct?  
 18 MR. PYSER: Object to form. Misstates  
 19 evidence.  
 20 BY MR. PAPANTONIO:  
 21 Q. Yes?  
 22 A. My testimony is that I don't comment on  
 23 shocking or . . .  
 24 Q. Well, they're -- somebody is saying it's  
 25 shocking.

Page 632

1 A. The author of this --  
 2 Q. Who says -- well, let's look --  
 3 A. The author of this document stated that.  
 4 Q. Well, who is Mark Kaufmann? You know who  
 5 Mark Kaufmann is -- Mike Kaufmann. You know who that  
 6 is?  
 7 A. I don't remember what his title was. I  
 8 think he was a VP or something like that --  
 9 Q. Yeah, you knew him, didn't you? You knew  
 10 him?  
 11 A. I knew Mike Kaufmann.  
 12 Q. Okay. So do you -- and so you just  
 13 disagree that it's shocking that the company, because  
 14 of its failures to comply with regulatory rules,  
 15 actually was cost a billion dollars to the company?  
 16 You don't find that shocking, do you?  
 17 MR. PYSER: Object to form. Misstates  
 18 evidence.  
 19 BY MR. PAPANTONIO:  
 20 Q. Right? You don't find it shocking?  
 21 MR. PYSER: Object to form. Misstates  
 22 evidence. And renewing again the continuing  
 23 objection to this line of questioning as beyond  
 24 the scope.  
 25 THE WITNESS: Again, the -- the term

Page 633

1 "shocking" was used by the author of this  
 2 e-mail.  
 3 BY MR. PAPANTONIO:  
 4 Q. Okay. And then, see the line right  
 5 underneath that: "The conundrum is how can a company  
 6 that believes ethics is a core value find itself in a  
 7 situation -- such a situation?"  
 8 You see that? "How can a company that  
 9 believes ethics is a core value find itself in such a  
 10 situation?"  
 11 Why don't you tell me? Do you know,  
 12 Mr. Brantley, how a company could find itself in a  
 13 situation that it would violate so many regulatory  
 14 standards that it cost them a billion dollars in  
 15 losses financially?  
 16 MR. PYSER: Object to form. Misstates  
 17 evidence. Nothing about this says that  
 18 regulatory violations cost a billion dollars.  
 19 BY MR. PAPANTONIO:  
 20 Q. Can you tell me, the consortium is how can  
 21 a company that believes ethics is a core value find  
 22 itself in a situation? Do you have an answer to that  
 23 as we sit here today?  
 24 MR. PYSER: Object to form. Ongoing  
 25 continuing objection to this line of questioning

Page 634

1 as beyond the scope.  
2 THE WITNESS: I don't comment on the  
3 authors of -- I have no opinion on a author's  
4 use of words. This is his question.  
5 BY MR. PAPANTONIO:  
6 Q. You -- you knew, when you were working  
7 there, that the lack of ethics at the company and the  
8 lack of following regulatory rules with the company  
9 was actually affecting the trust of the employees?  
10 You knew that when you were there, didn't you?  
11 MR. PYSER: Object to form.  
12 THE WITNESS: I did not know that. This  
13 actually states that -- believes that ethics is  
14 a core value.  
15 BY MR. PAPANTONIO:  
16 Q. Well, let's see what it says in that --  
17 you didn't know that the -- you didn't know that the  
18 lack of filing -- filing -- following regulatory  
19 standards with Cardinal was so bad that it was  
20 affecting employees in their attitude about the  
21 company?  
22 MR. PYSER: Objection.  
23 BY MR. PAPANTONIO:  
24 Q. Where the employees did not trust the  
25 company? Did you know that?

Page 635

1 MR. PYSER: Object to form. Ongoing  
2 objection.  
3 BY MR. PAPANTONIO:  
4 Q. Just a simple question: Did you know  
5 that?  
6 A. I --  
7 MR. PYSER: Object to form.  
8 THE WITNESS: I'm not aware of any of  
9 that.  
10 BY MR. PAPANTONIO:  
11 Q. Okay. Well, let's read it.  
12 "As we begin to look at the 'Voice of the  
13 Employee' results" -- you knew that there was -- and  
14 actually you participated in -- that was actually --  
15 they sent around a questionnaire, and they did --  
16 they did a questionnaire that has to do with what  
17 they call the "Voice of Employees." You remember  
18 that?  
19 MR. PYSER: Object to form.  
20 BY MR. PAPANTONIO:  
21 Q. You actually responded to it, didn't you?  
22 MR. PYSER: Object to form.  
23 THE WITNESS: I do remember the Voice of  
24 Employee questionnaires or whatever, but I  
25 don't -- I don't recall if I participated or

Page 636

1 not.  
2 BY MR. PAPANTONIO:  
3 Q. It says, "As we begin to look at the  
4 'Voice of Employee' results, which are being compiled  
5 and analyzed as we speak, it's clear we have vertical  
6 communications issues, and our employees do not fully  
7 trust their leaders."  
8 Did you know that, prior to the time you  
9 came in here to testify today, that the ethical  
10 problem was so bad at Cardinal that according to  
11 research that was done of the employees, they said  
12 that the employees don't even trust the leaders?  
13 MR. PYSER: Object to form. Beyond the  
14 scope.  
15 BY MR. PAPANTONIO:  
16 Q. Did you ever hear -- did you ever hear  
17 that prior to coming here? That's the only question  
18 I'm asking.  
19 MR. PYSER: Object to form.  
20 THE WITNESS: I was not aware of that.  
21 BY MR. PAPANTONIO:  
22 Q. All right. Then it goes on to say,  
23 "Perhaps our results-oriented culture is leaning to  
24 ill-advised or short-sighted decisions."  
25 Do you see that?

Page 637

1 MR. PYSER: Same objections to the  
2 continuing use of this document.  
3 THE WITNESS: I do see that.  
4 BY MR. PAPANTONIO:  
5 Q. Okay. This is a bad document for you,  
6 isn't it? I mean, it really is --  
7 MR. PYSER: Counsel, it's just beyond the  
8 scope.  
9 MR. PAPANTONIO: No, it is a bad -- no, it  
10 really is a bad document. I agree.  
11 MR. PYSER: It doesn't have anything to do  
12 with the issues --  
13 MR. PAPANTONIO: Okay.  
14 MR. PYSER: -- in play here.  
15 BY MR. PAPANTONIO:  
16 Q. Let's -- let's be clear about the scope of  
17 this document. You were asked by Mr. Pyser direct  
18 questions about regulatory issues of this company.  
19 On his direct of you, you answered questions, didn't  
20 you?  
21 MR. PYSER: Object to form.  
22 THE WITNESS: I did answer his questions.  
23 BY MR. PAPANTONIO:  
24 Q. Okay. And he asked you about regulatory  
25 standards of the company, didn't he?



<p style="text-align: right;">Page 638</p> <p>1 MR. PYSER: Object to form.</p> <p>2 THE WITNESS: I don't recall all of the</p> <p>3 questions that were asked.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. So it says -- let's go on the last</p> <p>6 paragraph: "In closing, let me make an important</p> <p>7 point. As Dave and Dwight would have concurred, the</p> <p>8 regulatory bodies hold general management</p> <p>9 accountable. Their names are the ones on the FDA</p> <p>10 consent order related to Alaris SE recall. The final</p> <p>11 DEA resolution may have a comparable outcome. The</p> <p>12 final DEA resolution may have a final outcome."</p> <p>13 Now, this is -- this document was</p> <p>14 written -- and you said you were still with the</p> <p>15 company -- in 2008. What was the pending DEA</p> <p>16 question in 2008?</p> <p>17 MR. PYSER: Object to form. Ongoing</p> <p>18 objection to this line of questioning on this</p> <p>19 document.</p> <p>20 THE WITNESS: I do not --</p> <p>21 MR. PYSER: Beyond the scope.</p> <p>22 THE WITNESS: I do not know what the</p> <p>23 author was referring to when he said "the final</p> <p>24 DEA resolution."</p> <p>25</p>	<p style="text-align: right;">Page 640</p> <p>1 A. No, I had not heard those words. This is</p> <p>2 my first time reading this document.</p> <p>3 Q. Well, it says, "This is a big issue, and</p> <p>4 the leaders of Cardinal, we need to address it.</p> <p>5 Accountability leadership is essential."</p> <p>6 Now, you would agree with that:</p> <p>7 Accountability leadership is -- is essential in any</p> <p>8 organization, isn't it?</p> <p>9 A. Again, those are the words of an</p> <p>10 individual.</p> <p>11 Q. Yeah. Let -- let me -- let me ask you,</p> <p>12 just -- just to -- did you know about the -- did you</p> <p>13 know about the -- the death wagon that was up in</p> <p>14 Ohio? Did you see the articles where Ohio actually</p> <p>15 had to bring in a -- a death wagon, that actually</p> <p>16 drove around dead bodies from so many people dying up</p> <p>17 in Ohio from opioid overdoses?</p> <p>18 MR. PYSER: Object to --</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Had you -- have you ever seen that before?</p> <p>21 MR. PYSER: Object to form. This is way,</p> <p>22 way, way beyond the scope of the examination.</p> <p>23 It is entirely improper to bring in a new</p> <p>24 exhibit, an entirely new subject that wasn't</p> <p>25 touched upon in the direct examination.</p>
<p style="text-align: right;">Page 639</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. "While the" -- it goes on to say, "While</p> <p>3 the legal and QRA functions are responsible for</p> <p>4 helping us run our business, the general managers are</p> <p>5 ultimately responsible for the results."</p> <p>6 You'd agree with that, wouldn't you?</p> <p>7 A. I don't know who the general managers are.</p> <p>8 So I -- I can't speak to that.</p> <p>9 Q. Well, the -- how about -- how about where</p> <p>10 it says "So general managers need to proactively</p> <p>11 search for potential quality and legal regulatory</p> <p>12 issues, and when they find them, they need to make</p> <p>13 the hard right calls, not the easy wrong calls."</p> <p>14 Did you know about those -- those</p> <p>15 words being used -- being -- being spoken?</p> <p>16 MR. PYSER: Object to form. Ongoing</p> <p>17 objection --</p> <p>18 BY MR. PAPANTONIO:</p> <p>19 Q. You ever heard --</p> <p>20 MR. PYSER: -- to this line of --</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. -- words like that --</p> <p>23 MR. PYSER: -- this line of questioning.</p> <p>24 BY MR. PAPANTONIO:</p> <p>25 Q. -- being spoken?</p>	<p style="text-align: right;">Page 641</p> <p>1 MR. PAPANTONIO: No -- no, sir.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. You understand, you were asked -- you were</p> <p>4 asked whether or not the regulatory aspects of</p> <p>5 Cardinal were a success. What did you tell us?</p> <p>6 MR. PYSER: Move to strike --</p> <p>7 MS. MOORE: Cardinal 41.</p> <p>8 (Cardinal-Brantley 41 was marked for</p> <p>9 identification.)</p> <p>10 MR. PYSER: -- this entire line of</p> <p>11 questioning.</p> <p>12 BY MR. PAPANTONIO:</p> <p>13 Q. What did you tell us?</p> <p>14 MR. PYSER: Move to strike --</p> <p>15 MR. PAPANTONIO: We're going to enter</p> <p>16 this --</p> <p>17 MR. PYSER: -- this line of questioning.</p> <p>18 MR. PAPANTONIO: This document's coming in</p> <p>19 whether they object to it or not.</p> <p>20 MR. PYSER: It is objected to --</p> <p>21 MR. PAPANTONIO: So -- so --</p> <p>22 MR. PYSER: -- in the line of</p> <p>23 questioning --</p> <p>24 MR. PAPANTONIO: -- okay, that's fine.</p> <p>25 MR. PYSER: Let me put my objection on the</p>

<p style="text-align: right;">Page 642</p> <p>1 record without --</p> <p>2 MR. PAPANTONIO: Go ahead.</p> <p>3 MR. PYSER: -- speaking over me.</p> <p>4 MR. PAPANTONIO: Go ahead.</p> <p>5 MR. PYSER: This line of questioning is</p> <p>6 beyond the scope. This entire line of</p> <p>7 questioning, the introduction of the exhibit is</p> <p>8 beyond the scope, and it should be stricken from</p> <p>9 the record. I have a standing objection to this</p> <p>10 entire line of questioning.</p> <p>11 BY MR. PAPANTONIO:</p> <p>12 Q. Did you know that there was a rolling</p> <p>13 morgue that had to be called in to Ohio -- the very</p> <p>14 area, as a matter of fact, where you were reviewing</p> <p>15 reports about the sale of opioids?</p> <p>16 MR. PYSER: Object to form.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Did you know that? Had anybody ever told</p> <p>19 you about this before?</p> <p>20 A. I was not aware of, as you say, a rolling</p> <p>21 morgue.</p> <p>22 Q. You never -- nobody ever told you about a</p> <p>23 rolling morgue that had to be called up to Ohio</p> <p>24 because there was so many dead bodies dealing with</p> <p>25 opioids, correct?</p>	<p style="text-align: right;">Page 644</p> <p>1 the use of staying abreast of what news reports are,</p> <p>2 correct?</p> <p>3 MR. PYSER: Object to form.</p> <p>4 BY MR. PAPANTONIO:</p> <p>5 Q. In fairness to your good idea, that's one</p> <p>6 thing you wanted to do?</p> <p>7 MR. PYSER: Object to form. Object,</p> <p>8 beyond the scope, as this is an examination</p> <p>9 based on another plaintiff's counsel examination</p> <p>10 of an Endo document. It has nothing to do with</p> <p>11 the direct examination that was conducted by</p> <p>12 counsel for the defense.</p> <p>13 BY MR. PAPANTONIO:</p> <p>14 Q. Well, let's not even talk about your</p> <p>15 document. You believe it's important for a person in</p> <p>16 your role, in your capacity, to stay informed about</p> <p>17 what the various news reports are saying about the</p> <p>18 industry. You -- you would agree that's important,</p> <p>19 right?</p> <p>20 MR. PYSER: Same objections.</p> <p>21 THE WITNESS: The media, the -- the</p> <p>22 documentation that I had listed in my report as</p> <p>23 far as reviewing searches and Google searches</p> <p>24 and such was for the customers.</p> <p>25</p>
<p style="text-align: right;">Page 643</p> <p>1 MR. PYSER: Object to form.</p> <p>2 BY MR. PAPANTONIO:</p> <p>3 Q. Right?</p> <p>4 A. That is correct. I was never told</p> <p>5 about --</p> <p>6 Q. And -- and I believe --</p> <p>7 A. -- as you say, a rolling morgue.</p> <p>8 Q. I believe earlier you said -- we went</p> <p>9 through your idea of what are important things for</p> <p>10 people to understand and be aware of where it comes</p> <p>11 to things like diversion. And you said, didn't you,</p> <p>12 in the -- in the documents that were reviewed, that</p> <p>13 news is important, that people stay abreast of what</p> <p>14 news is, dealing with opioids. Right?</p> <p>15 MR. PYSER: Object to form. Misstates</p> <p>16 testimony.</p> <p>17 BY MR. PAPANTONIO:</p> <p>18 Q. Didn't you say that?</p> <p>19 MR. PYSER: Ongoing objection to this line</p> <p>20 of questioning.</p> <p>21 BY MR. PAPANTONIO:</p> <p>22 Q. Mr. Brantley, didn't you say that?</p> <p>23 A. I -- that document was an outline at a</p> <p>24 high level of things that I wanted to implement.</p> <p>25 Q. And one thing you wanted to implement was</p>	<p style="text-align: right;">Page 645</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. For the customers?</p> <p>3 A. And researching customers.</p> <p>4 Q. And so that article sitting in front of</p> <p>5 you about the -- about a morgue, a rolling morgue</p> <p>6 having to be brought in to Ohio, you didn't know</p> <p>7 anything about that, right?</p> <p>8 MR. PYSER: Object to form.</p> <p>9 BY MR. PAPANTONIO:</p> <p>10 Q. Correct?</p> <p>11 A. I did not know anything about this. This</p> <p>12 is not relating to a customer.</p> <p>13 Q. Not related to a customer; it's just --</p> <p>14 A. That's why I did not know anything about</p> <p>15 this.</p> <p>16 Q. Oh, it's just related to dead people,</p> <p>17 isn't it?</p> <p>18 MR. PYSER: Object to form.</p> <p>19 BY MR. PAPANTONIO:</p> <p>20 Q. Dead people.</p> <p>21 MR. PYSER: Argumentative.</p> <p>22 BY MR. PAPANTONIO:</p> <p>23 Q. Right? Talking about dead people here.</p> <p>24 MR. PYSER: Object to form.</p> <p>25 Argumentative. Beyond the scope.</p>

<p style="text-align: right;">Page 646</p> <p>1 BY MR. PAPANTONIO:</p> <p>2 Q. Right? You want to take a minute to look</p> <p>3 at that document?</p> <p>4 MR. PYSER: Counsel, it's 8:41 p.m. We're</p> <p>5 not sitting here so you can harass the witness.</p> <p>6 BY MR. PAPANTONIO:</p> <p>7 Q. Do you want to read that document before I</p> <p>8 ask you the next question?</p> <p>9 MR. PYSER: Object to form.</p> <p>10 If you want to read the document, you can</p> <p>11 go right ahead.</p> <p>12 THE WITNESS: Do you want me to read the</p> <p>13 document?</p> <p>14 BY MR. PAPANTONIO:</p> <p>15 Q. You're welcome to.</p> <p>16 A. Are you going to ask a question relating</p> <p>17 to the document?</p> <p>18 Q. I will.</p> <p>19 A. If you ask your question, then I will</p> <p>20 determine whether or not I need to read the</p> <p>21 document --</p> <p>22 Q. Well, we'll let the jury read it.</p> <p>23 A. -- to answer your question.</p> <p>24 Q. We'll let them determine.</p> <p>25 MR. PYSER: Object to form.</p>	<p style="text-align: right;">Page 648</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. You remember these, sir?</p> <p>3 A. Yes.</p> <p>4 Q. In your examination of Par -- by Par</p> <p>5 counsel?</p> <p>6 And just so the record's not confusing,</p> <p>7 sir, because some of these documents say "Par"; some</p> <p>8 of these documents say "QualiTest." What happened,</p> <p>9 QualiTest -- Endo acquired Par, and QualiTest --</p> <p>10 essentially those functions moved into Par?</p> <p>11 MS. VANNI: Object to the form.</p> <p>12 THE WITNESS: At some point, Endo acquired</p> <p>13 Par. And then Par and QualiTest -- I don't know</p> <p>14 what the correct term is, but Par and QualiTest</p> <p>15 kind of merged, for lack of a better term.</p> <p>16 BY MR. BUCHANAN:</p> <p>17 Q. Yeah, whatever the -- you know, corporate</p> <p>18 formation thing was --</p> <p>19 A. Right.</p> <p>20 Q. -- one went into the other, the other went</p> <p>21 into the first.</p> <p>22 Whatever it was, essentially, we see</p> <p>23 QualiTest and Par, we can think of those as</p> <p>24 essentially generic manufacturers of Class II,</p> <p>25 Class III controlled substances, correct?</p>
<p style="text-align: right;">Page 647</p> <p>1 MR. PAPANTONIO: Dave, why don't you take</p> <p>2 over from here.</p> <p>3 MR. BUCHANAN: Okay.</p> <p>4 MS. MOORE: P1-1453. It's -- if you</p> <p>5 would, sir -- this is Cardinal-Brantley 41.</p> <p>6 Thank you, sir.</p> <p>7 (Pause in proceedings.)</p> <p>8 FURTHER EXAMINATION</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. All right, we're on the record. Now,</p> <p>11 Mr. Brantley -- go ahead; finish your sip.</p> <p>12 A. Thank you.</p> <p>13 Q. All right. I just have a few follow-up</p> <p>14 questions. We'll try and keep this brief and -- and</p> <p>15 bring this in for a landing pretty quickly here. We</p> <p>16 will not use our 90-plus minutes in further</p> <p>17 examination.</p> <p>18 You were shown Brantley Exhibits 37, 38,</p> <p>19 39, and 40. Do you have those before you?</p> <p>20 A. I see 40.</p> <p>21 Q. Yeah.</p> <p>22 MR. BUCHANAN: I can -- I can pop them up</p> <p>23 here on the Elmo, if I can have the Elmo, Evan,</p> <p>24 we'll move this along real quick.</p> <p>25</p>	<p style="text-align: right;">Page 649</p> <p>1 A. As well as other controlled substances and</p> <p>2 prescription drugs.</p> <p>3 Q. Right. And we -- you know, we didn't get</p> <p>4 into too much of it, but the majority of the</p> <p>5 production, certainly of QualiTest, was controlled</p> <p>6 substances, correct?</p> <p>7 A. There -- there was a -- I don't remember</p> <p>8 the percentage, but yes, it was mostly controlled</p> <p>9 substances, I believe.</p> <p>10 Q. Okay. And you spent some time with</p> <p>11 counsel going through Exhibit 37, which the jury will</p> <p>12 have on the screen. They'll remember this one.</p> <p>13 38, and it's -- excuse my quick notations</p> <p>14 there in the top right corner. That's just for</p> <p>15 tracking it. Customer due diligence visits, cage,</p> <p>16 vault, suspicious order monitoring, and identify,</p> <p>17 blocking, and reporting suspicious orders. Remember</p> <p>18 going through those with counsel?</p> <p>19 A. Yes.</p> <p>20 Q. Okay. And these were all new SOPs in</p> <p>21 2013, correct, sir?</p> <p>22 A. Those were SOPs that I drafted.</p> <p>23 Q. Right. So they -- they would -- by</p> <p>24 definition, sir, they would not have existed prior to</p> <p>25 your arrival at the company, correct?</p>

<p style="text-align: right;">Page 650</p> <p>1 A. Those particular SOPs did not.</p> <p>2 Q. Right. And we looked, did we not, sir, at</p> <p>3 Exhibit 30, in your direct examination -- or my</p> <p>4 initial examination of you, concerning issues with</p> <p>5 the current process, right? Do you recall looking at</p> <p>6 this with me, sir?</p> <p>7 A. I do recall looking at that, yes.</p> <p>8 Q. Okay. And just to orient ourselves on</p> <p>9 Exhibit 30 -- I'm sorry, I guess I did have a sticker</p> <p>10 on the front -- this is that e-mail from Mr. Shaffer</p> <p>11 to yourself, SOMS info. And recall that it included</p> <p>12 all the violations in an Excel spreadsheet, that was</p> <p>13 first couple of pages? Remember that?</p> <p>14 I can turn it so it's burned into our tape</p> <p>15 here. If this helps you. I know it's been a day,</p> <p>16 but . . .</p> <p>17 A. I do remember.</p> <p>18 Q. Okay. We looked at that together.</p> <p>19 All right. And there's more information</p> <p>20 here, and ultimately we get with current SOMS</p> <p>21 process, says "Retail pharmacies based on set product</p> <p>22 thresholds." And they could be changed by the sales</p> <p>23 department. Right?</p> <p>24 MS. VANNI: Objection. Asked and</p> <p>25 answered.</p>	<p style="text-align: right;">Page 652</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Okay.</p> <p>3 A. -- like you said, my first week of</p> <p>4 employment, or something like that.</p> <p>5 Q. And it said, "System only looks at retail</p> <p>6 pharmacies." Right. See that?</p> <p>7 A. It says, "The system only addresses retail</p> <p>8 pharmacies by looking at product thresholds." It</p> <p>9 does not say "System only looks at retail</p> <p>10 pharmacies."</p> <p>11 Q. Okay, fair enough. Okay. It does say</p> <p>12 here, "Other classes of trade are not evaluated for</p> <p>13 SOMS," right?</p> <p>14 A. It does say that, yes.</p> <p>15 Q. Okay. You understand "other classes of</p> <p>16 trade" to be -- frankly what QualiTest's biggest</p> <p>17 customers were, right? Distributors and wholesalers?</p> <p>18 MS. VANNI: Objection.</p> <p>19 THE WITNESS: "Other classes of trade"</p> <p>20 would include wholesalers, distributors, and</p> <p>21 hospitals, whomever else, yes.</p> <p>22 BY MR. BUCHANAN:</p> <p>23 Q. And I believe when you were asked</p> <p>24 questions by Par counsel earlier -- not me, but by</p> <p>25 Par counsel -- you told her that the majority of</p>
<p style="text-align: right;">Page 651</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. You see that at the bottom there, retail</p> <p>3 pharmacy threshold amounts?</p> <p>4 A. Yes, that's what it says.</p> <p>5 Q. Okay. And then, as of the time you</p> <p>6 arrived in 2013, after that period of time where</p> <p>7 millions and billions of pills of hydrocodone and</p> <p>8 oxycodone had been sold, these were the current</p> <p>9 issues with the SOMS process, right?</p> <p>10 MS. VANNI: Objection. Form.</p> <p>11 THE WITNESS: As Mr. Shaffer listed on the</p> <p>12 PowerPoint.</p> <p>13 BY MR. BUCHANAN:</p> <p>14 Q. Right. And you -- you don't dispute these</p> <p>15 characterizations, right?</p> <p>16 A. I cannot speak to them, because I was not</p> <p>17 there.</p> <p>18 Q. Right. He was?</p> <p>19 A. He was.</p> <p>20 Q. Okay. And so what he sent you to orient</p> <p>21 you, one week into your post with QualiTest, was</p> <p>22 this -- was this PowerPoint, correct?</p> <p>23 MS. VANNI: Objection.</p> <p>24 THE WITNESS: Yes. I don't have it in</p> <p>25 front of me, but I believe it was sent --</p>	<p style="text-align: right;">Page 653</p> <p>1 QualiTest and Par's business was to distributors and</p> <p>2 wholesalers, fair?</p> <p>3 A. Yes.</p> <p>4 Q. Okay. So, fair to say that as of this</p> <p>5 point in time, at least by the person who was boots</p> <p>6 on the ground at QualiTest, other classes of trades</p> <p>7 were not evaluated for suspicious orders, right?</p> <p>8 MS. VANNI: Object to form.</p> <p>9 THE WITNESS: According to Mr. Shaffer,</p> <p>10 yes.</p> <p>11 BY MR. BUCHANAN:</p> <p>12 Q. Okay. And that -- that statute that we</p> <p>13 talked about, the Controlled Substances Act, that</p> <p>14 required you all to maintain effective controls to</p> <p>15 prevent diversion; that statute goes way back in</p> <p>16 time, right? Prior to 2013, right?</p> <p>17 MS. VANNI: Objection.</p> <p>18 THE WITNESS: Yes.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. And prior to 2000, right?</p> <p>21 A. Yes.</p> <p>22 Q. Back to the '70s or earlier?</p> <p>23 MS. VANNI: Objection.</p> <p>24 THE WITNESS: I believe back to the '70s.</p> <p>25</p>

Page 654

1 BY MR. BUCHANAN:  
2 Q. Okay. So that obligation to maintain  
3 effective controls existed, certainly, before you  
4 were selling billions and billions of pills to  
5 wholesalers and distributors in 2011 and 2012,  
6 oxycodone and hydrocodone. Fair?  
7 MS. VANNI: Object to form.  
8 THE WITNESS: It existed since the '70s.  
9 BY MR. BUCHANAN:  
10 Q. Okay. Well, that would give a company a  
11 long time to figure out effective controls against  
12 diversion then, right?  
13 MS. VANNI: Objection.  
14 BY MR. BUCHANAN:  
15 Q. 30, 40 years?  
16 MS. VANNI: Objection.  
17 THE WITNESS: Since the '70s, when the  
18 regulations made effective.  
19 BY MR. BUCHANAN:  
20 Q. Right. So if I understand your testimony  
21 on examination by Par counsel, you started the  
22 company on September 30th -- I don't think you could  
23 remember that date when I was asking you questions.  
24 You had your memory refreshed, I guess, on a break?  
25 A. Yes, because either you or someone

Page 655

1 actually put the date up there of September 30th, and  
2 I remembered that from someone's presentation.  
3 Q. Fair enough. So while the Act had been  
4 around for 30, 40 years about developing effective  
5 controls, you started at the company on  
6 September 30th, right?  
7 A. 2013, yes.  
8 Q. 2013. And one week later, sir, in one  
9 week's time, you sent around your vision for an  
10 effective suspicious order monitoring protocol.  
11 Fair?  
12 MS. VANNI: Object to the form.  
13 THE WITNESS: I sent my -- my high-level  
14 thoughts on what I wanted to do as far as  
15 implementing a suspicious order monitoring  
16 program.  
17 BY MR. BUCHANAN:  
18 Q. Right. So this company, notwithstanding  
19 the existence of a CSA for years about the obligation  
20 to maintain effective controls to prevent diversion,  
21 was not looking at chargeback data before you got  
22 there, right?  
23 MS. VANNI: Objection.  
24 THE WITNESS: I -- I don't know if they  
25 were looking at chargeback data or not.

Page 656

1 BY MR. BUCHANAN:  
2 Q. Okay. If I told you, sir, they were not,  
3 would you dispute that?  
4 MS. VANNI: Object to the form.  
5 THE WITNESS: If you --  
6 BY MR. BUCHANAN:  
7 Q. As it relates to effective controls  
8 against diversion?  
9 A. If you showed me a document that stated  
10 that they were not reviewing it, I would believe  
11 that.  
12 Q. You wouldn't dispute it?  
13 A. I would believe that document.  
14 Q. Okay.  
15 A. Depending on who it was written by.  
16 Q. Okay. And then this continues, and  
17 further explains the retail pharmacy review is being  
18 handled by the sales folks, right?  
19 MS. VANNI: Object to the form.  
20 BY MR. BUCHANAN:  
21 Q. Fourth bullet? Sorry, right here, sir.  
22 A. Yes.  
23 Q. Okay. And that's a conflict of interest,  
24 at least in the DEA's eyes, right?  
25 MS. VANNI: Object to the form.

Page 657

1 THE WITNESS: According to Mr. Shaffer, he  
2 stated that in that -- the bullet point.  
3 BY MR. BUCHANAN:  
4 Q. Okay. Well, let's just talk about it  
5 going forward, in terms of setting thresholds, was  
6 that coming out of the DEA compliance group going  
7 forward, or was the sales department, the marketing  
8 department, continuing to do it?  
9 A. By "going forward," do you mean since I  
10 arrived?  
11 Q. Yeah. 2013, '14?  
12 A. When I arrived, that practice was stopped,  
13 and it was handled by --  
14 Q. Okay.  
15 A. -- my team.  
16 Q. And so when you arrived, that would be the  
17 period of time after the blue was mostly gone from  
18 the map -- that's the death map -- after the blue was  
19 mostly gone, in 2012, and we had white. And we had  
20 orange. And we had yellow. And we had brown. In  
21 terms of body counts, throughout this country, due to  
22 opioid deaths. Fair?  
23 MS. VANNI: Objection.  
24 THE WITNESS: That was after the dates on  
25 the maps that you put up on the screen.



<p style="text-align: right;">Page 658</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Right. So it's after that body count,</p> <p>3 after the escalating deaths, after QualiTest or Par</p> <p>4 had sold billions and billions and billions of</p> <p>5 oxycodone- and hydrocodone-containing products that</p> <p>6 this SOMS process -- or you're hired, and a new SOMS</p> <p>7 process gets implemented. Fair?</p> <p>8 MS. VANNI: Objection.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. Is that the timing, sir? It happened</p> <p>11 after you started?</p> <p>12 A. During the time fame that you mentioned of</p> <p>13 the chart, I started in 2013, which is after that.</p> <p>14 And I enhanced the program.</p> <p>15 Q. Understood, sir. And in fact the DEA</p> <p>16 identified gaps in the program; isn't that right?</p> <p>17 MS. VANNI: Object to the form.</p> <p>18 BY MR. BUCHANAN:</p> <p>19 Q. You understood, sir --</p> <p>20 A. At -- at what point? The program since I</p> <p>21 had been there or --</p> <p>22 Q. Yeah, there were some questions by</p> <p>23 counsel --</p> <p>24 A. -- prior to my arrival?</p> <p>25 Q. Withdrawn. I'm getting -- you know, it's</p>	<p style="text-align: right;">Page 660</p> <p>1 intelligence that could be gathered on your</p> <p>2 customers, right?</p> <p>3 MS. VANNI: Objection.</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. Before you arrived? Before you got there,</p> <p>6 there were sources of intelligence on your customers,</p> <p>7 true?</p> <p>8 MS. VANNI: Objection.</p> <p>9 THE WITNESS: Before I arrived, there was</p> <p>10 the Internet, and -- and there were searches</p> <p>11 available.</p> <p>12 BY MR. BUCHANAN:</p> <p>13 Q. And there were sources available on your</p> <p>14 customers' customers, right?</p> <p>15 MS. VANNI: Objection.</p> <p>16 THE WITNESS: I cannot speak -- if you're</p> <p>17 referring to chargeback data, I do not know what</p> <p>18 data was -- what chargeback data was available</p> <p>19 prior to me.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Okay. So I mean, that's a discernible</p> <p>22 fact, though, right? I mean, within the walls of</p> <p>23 QualiTest, within the walls of Endo, within the walls</p> <p>24 of Par, we can figure out when chargeback data was</p> <p>25 available, right?</p>
<p style="text-align: right;">Page 659</p> <p>1 late. I apologize. You've been here a long day. I</p> <p>2 have too. It's not your fault, and I should slow</p> <p>3 down, because I'm sure I do have ample time, and I'm</p> <p>4 not going to use it.</p> <p>5 There were some questions by counsel for</p> <p>6 Par about a DEA audit of SOMS. Do you remember that?</p> <p>7 A. During my time, yes.</p> <p>8 Q. Okay. To be clear, that was -- that was</p> <p>9 at a point in time after new SOPS had been</p> <p>10 implemented, after you were putting boots on the</p> <p>11 ground to actually start talking to wholesalers and</p> <p>12 distributors, after you were looking at chargeback</p> <p>13 data, after you were doing Internet investigations on</p> <p>14 your customers and your customers' customers and</p> <p>15 after you were considering intelligence that you were</p> <p>16 collecting from other sources, that's the point in</p> <p>17 time -- that was the audit you were talking about,</p> <p>18 right?</p> <p>19 A. Yes. So the --</p> <p>20 MS. VANNI: Object to the form.</p> <p>21 THE WITNESS: -- audit was after I became</p> <p>22 SOM manager.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. And fair, sir, that, you know, in this</p> <p>25 period of time before you arrived, there was</p>	<p style="text-align: right;">Page 661</p> <p>1 VIDEOGRAPHER: Object to the form.</p> <p>2 THE WITNESS: That is discernible, yes.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. Okay. And we know that before you got to</p> <p>5 QualiTest, there were pill mills, right?</p> <p>6 MS. VANNI: Object to the form.</p> <p>7 THE WITNESS: I don't know exactly when</p> <p>8 pill mills started. It started with the</p> <p>9 Internet, and then, when the DEA cracked down,</p> <p>10 on Internet, it kind of evolved to pill mills.</p> <p>11 I don't recall the time frame.</p> <p>12 BY MR. BUCHANAN:</p> <p>13 Q. But before you got -- I mean, you remember</p> <p>14 that discussion you had with Mr. Papantonio about --</p> <p>15 during Cardinal, even during the Cardinal time, there</p> <p>16 was concern about pill mills and Internet pharmacies.</p> <p>17 Fair?</p> <p>18 MS. VANNI: Objection to form.</p> <p>19 THE WITNESS: Fair, yes.</p> <p>20 BY MR. BUCHANAN:</p> <p>21 Q. Okay.</p> <p>22 A. Yes.</p> <p>23 Q. So there was concerns about diversion well</p> <p>24 before 2013, right?</p> <p>25 MS. VANNI: Objection.</p>

Page 662	Page 664
<p>1 THE WITNESS: Diversion was a concern 2 before 2013. 3 BY MR. BUCHANAN: 4 Q. Right. Right. And in fact, I mean, we 5 know it's a concern because as a registrant, you make 6 a promise when you get that registration that you're 7 going to maintain effective controls to prevent 8 diversion, right? 9 MS. VANNI: Object to form. 10 THE WITNESS: As I stated earlier, that's 11 what the regulation says, that -- 12 BY MR. BUCHANAN: 13 Q. That's what the statute says? 14 A. Yeah, the statute, regulation, I get them. 15 Q. Right. As a registrant, you are promising 16 to the American people, to the American government, 17 that you are going to operate within this closed 18 system to prevent diversion, right? 19 MS. VANNI: Objection. 20 THE WITNESS: I don't know if the statute 21 mentions a promise, but the statute does say 22 that you will have procedures in place to 23 prevent diversion. 24 BY MR. BUCHANAN: 25 Q. Yeah. I mean, don't you understand --</p>	<p>1 finds fault and at what one finds faults. And I 2 can't speak to other -- to someone else's 3 opinion. 4 BY MR. BUCHANAN: 5 Q. Okay. If the jury were to perceive, sir, 6 that when you made your application to the 7 government, that you were in fact making a promise to 8 do your best to have effective controls to prevent 9 diversion, at all times you were carrying that 10 license, at all times you were manufacturing, at all 11 times you were distributing, would you fault the jury 12 for understanding that that was essentially what you 13 were representing to the government? 14 MS. VANNI: Objection. Beyond the scope. 15 THE WITNESS: Again, you started that 16 question with the word "promise." And since 17 "promise" is not in the statute, I -- I cannot 18 speak to what is promised. I can only speak to 19 what's in the statute, and that the companies 20 will be in compliance with what the statute and 21 the regulation states. 22 BY MR. BUCHANAN: 23 Q. All right. So turning ourselves back, 24 we've got it on the screen. This is Exhibit 30. We 25 went through this earlier today. I just wanted to</p>
Page 663	Page 665
<p>1 A. The word "promising," I can't speak to 2 that. I don't recall that being in the regulation -- 3 Q. Yeah. And frankly -- 4 A. -- or the statute; I'm sorry. 5 Q. That's -- that's me, I think, trying to 6 make friendly with a statute. But when you file an 7 application, when you file an application, that is 8 your promise as a registrant to operate as a good 9 citizen within a closed system designed to contain 10 controlled substances within that system, right? 11 MS. VANNI: Object to form. 12 THE WITNESS: Again, since the regulation 13 does not mention the word "promise," I cannot 14 speak to promise. 15 BY MR. BUCHANAN: 16 Q. Okay. Would you fault -- would you fault 17 people, sir, for considering your application as a 18 registrant as a representation by you to the 19 government, and by extension to the American people, 20 that you're going to do your best to prevent 21 diversion? Would you fault people for perceiving 22 that's what you were willing to do when you went to 23 the DEA and said, I want to be a registrant? 24 MS. VANNI: Objection. 25 THE WITNESS: I can't speak to how one</p>	<p>1 orient ourselves that as of the point in time here, 2 in 9/30/2013, or, you know, a few weeks after you 3 joined the company, these were the issues with 4 current process, right? 5 A. According to Mr. Shaffer. 6 Q. Okay. Somebody who had been there, boots 7 on the ground, before you got there, right? 8 MS. VANNI: Objection. 9 THE WITNESS: Mr. Shaffer was there prior 10 to my arrival, yes. 11 BY MR. BUCHANAN: 12 Q. Fair enough. Okay. 13 MR. BUCHANAN: Could I please have -- can 14 I please have 391? 15 MR. SEIGEL: Exhibit 42. 16 MR. BUCHANAN: This will be Brantley 17 Exhibit 42. 18 (Cardinal-Brantley 42 was marked for 19 identification.) 20 BY MR. BUCHANAN: 21 Q. And just to orient you, sir, I mean, you 22 saw some of the DEA charts that we looked at 23 together, where we did some calculations about the -- 24 the substantial production of opioids and sale of 25 opioids by QualiTest; do you recall that?</p>

<p style="text-align: right;">Page 666</p> <p>1 A. Would that be the ARCOS data graphs?</p> <p>2 Q. That -- that was the -- from the DEA</p> <p>3 meeting in -- "the meeting," in March of 2013?</p> <p>4 MS. VANNI: Object to the form.</p> <p>5 BY MR. BUCHANAN:</p> <p>6 Q. Do you recall that?</p> <p>7 A. Again, would that be the ARCOS data that</p> <p>8 listed Generics Bidco and Vintage?</p> <p>9 Q. I -- I think you referred to it as</p> <p>10 something you saw in a binder, and within the</p> <p>11 company.</p> <p>12 A. Yes.</p> <p>13 Q. Do you recall that? Okay.</p> <p>14 A. The ARCOS data that was in a binder.</p> <p>15 Q. Okay. I'd like to show you, sir --</p> <p>16 MR. BUCHANAN: What did we call this? 40?</p> <p>17 MR. SEIGEL: 42.</p> <p>18 MR. BUCHANAN: 42. All right.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. I'd like to show you, sir, 42. This is</p> <p>21 supply chain and DEA compliance. Okay? Produced by</p> <p>22 Endo and the MDL. It's on the screen now.</p> <p>23 MS. VANNI: Objection. Beyond the scope.</p> <p>24 BY MR. BUCHANAN:</p> <p>25 Q. Let's see. Executive sponsor, there's</p>	<p style="text-align: right;">Page 668</p> <p>1 A. Yes.</p> <p>2 Q. And we're just going to work off my</p> <p>3 highlights, try and move this along, all right?</p> <p>4 A. Okay.</p> <p>5 Q. And it says here, "Risk component two</p> <p>6 impacted DEA remediation efforts to address the</p> <p>7 compliance findings in our internal manufacturing</p> <p>8 plants. The potential business impact could vary</p> <p>9 from formal agency regulatory observations during</p> <p>10 external audits to agency regulatory actions</p> <p>11 preventing us from commercially distributing one or</p> <p>12 more products due to license revocation."</p> <p>13 Do you see that?</p> <p>14 MS. VANNI: Just note my objection to use</p> <p>15 of the document as an Endo document. This</p> <p>16 witness is a QualiTest employee.</p> <p>17 Go ahead.</p> <p>18 THE WITNESS: I'm sorry. Could you repeat</p> <p>19 that? Because I was trying to find the page.</p> <p>20 You had skipped from page 1 all the way to -- I</p> <p>21 think --</p> <p>22 MR. BUCHANAN: Evan, could you actually</p> <p>23 pull it up on the screen? It will make it</p> <p>24 easier to navigate, and I've got some scribbles</p> <p>25 on here. Thank you.</p>
<p style="text-align: right;">Page 667</p> <p>1 some folks -- do you know those people, sir? Peter</p> <p>2 Bigelow, Brian Lortie?</p> <p>3 A. No.</p> <p>4 Q. Okay. And it says here, "BOD committee"</p> <p>5 -- is that "board of directors," sir?</p> <p>6 A. I don't know.</p> <p>7 Q. Okay. It says, "BOD committee, full</p> <p>8 board" -- I'll just say "full BOD -- key action dates</p> <p>9 off on the right. "June 6th, 2013, ELC discussion."</p> <p>10 Is that the executive leadership</p> <p>11 committee, sir?</p> <p>12 A. I don't know for sure. I think the "EL"</p> <p>13 stands for executive leadership, so that could be</p> <p>14 executive leadership.</p> <p>15 Q. Okay. And then BOD, is that board of</p> <p>16 director discussion? Or you don't know what "BOD" is</p> <p>17 referring to?</p> <p>18 A. I don't know for sure, but it could be</p> <p>19 board of directors, as you stated.</p> <p>20 Q. Okay.</p> <p>21 A. That makes sense. I just don't know for</p> <p>22 sure.</p> <p>23 Q. Okay. Well, let's -- at the bottom here,</p> <p>24 it's talking about an assessment of critical risk</p> <p>25 components. You see that?</p>	<p style="text-align: right;">Page 669</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. We're going to pull it up on the screen</p> <p>3 for you. Okay. All right.</p> <p>4 I'm sorry. It's 391.6. We were carrying</p> <p>5 over from 391.5.</p> <p>6 There was a statement by counsel that this</p> <p>7 is an Endo document; I shouldn't be using it with</p> <p>8 you. Let's direct your attention to the "QualiTest</p> <p>9 Business Unit" heading. Do you see that, sir?</p> <p>10 A. Yes.</p> <p>11 Q. Is that in fact where you worked, sir,</p> <p>12 QualiTest, at this point in time? In 2013, at least,</p> <p>13 when you joined?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. And it identifies a series of</p> <p>16 items. And actually, I do want to get back to the</p> <p>17 carryover paragraph: "The potential business impact</p> <p>18 could vary from formal agency regulatory observations</p> <p>19 during external audits to agency regulatory actions</p> <p>20 preventing us from commercially distributing one or</p> <p>21 more products due to license revocation."</p> <p>22 Do you see that, sir?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And it says in the second bullet --</p> <p>25 could you read that for us, sir?</p>

Page 670

1 A. The second bullet: "In a meeting with DEA  
2 on March 6, 2013, DEA identified gaps associated with  
3 our suspicious order monitoring system (SOMS) and  
4 lack of monitoring of sales to customers' customers."  
5 Q. And to be clear, sir, that's a statement  
6 with regard to the QualiTest business unit, right?  
7 MS. VANNI: Object to the form.  
8 THE WITNESS: According to this document,  
9 yes, it's under the QualiTest business unit.  
10 BY MR. BUCHANAN:  
11 Q. Seemingly from executives of the company.  
12 Fair, sir?  
13 MS. VANNI: Objection.  
14 THE WITNESS: Whomever drafted this, yes.  
15 BY MR. BUCHANAN:  
16 Q. Okay. And --  
17 A. I didn't recognize those names that you  
18 mentioned.  
19 Q. Okay. It's been a few years; you don't  
20 remember them?  
21 A. I -- I don't think I've ever heard of  
22 those two names.  
23 Q. Okay. All right. And -- and talks about  
24 action plans, right?  
25 A. Yes.

Page 671

1 Q. See that?  
2 A. Yes.  
3 Q. To address various DEA-related concerns.  
4 And it says "management's preparedness." What did  
5 the company say -- if you could scroll up a little,  
6 Evan.  
7 Management preparedness. How prepared was  
8 management for this?  
9 MS. VANNI: Object to the form.  
10 THE WITNESS: Management preparedness --  
11 evolving.  
12 BY MR. BUCHANAN:  
13 Q. Okay. Evolving. All right. And then, so  
14 third bullet down, under "Action Plans," to address  
15 various DEA-related concerns -- you do understand,  
16 sir, that the DEA had expressed concerns to QualiTest  
17 about suspicious order monitoring at the meeting in  
18 March of 2013. True?  
19 MS. VANNI: Object to the form.  
20 THE WITNESS: I think I've seen that in  
21 certain documents that were --  
22 BY MR. BUCHANAN:  
23 Q. Okay.  
24 A. -- given to me throughout the course of  
25 the day.

Page 672

1 Q. Fair enough. Thank you. And when we  
2 scroll down here, third bullet, it says, "Implement  
3 the suspicious order monitor program."  
4 Right? Do you see that, sir?  
5 A. That's what it says.  
6 Q. "Implement the suspicious order monitor  
7 program." Okay?  
8 The authors of this document certainly  
9 didn't use the word "enhance," right?  
10 MS. VANNI: Object to the form.  
11 THE WITNESS: It says "implement."  
12 BY MR. BUCHANAN:  
13 Q. Okay. It didn't say "supplement," or  
14 "spiff it up," right?  
15 MS. VANNI: Objection.  
16 THE WITNESS: No.  
17 BY MR. BUCHANAN:  
18 Q. What -- what word did they use, sir?  
19 A. "Implement."  
20 Q. Thank you. All right. And it said, going  
21 to do that by the end of 2013. See that?  
22 A. Yes.  
23 Q. Might you be one of the additional head  
24 count QualiTest was out scrambling to find before  
25 they had to go back and see the DEA in the third

Page 673

1 quarter of 2013 to say, "We're going to do  
2 something"?  
3 MS. VANNI: Objection to form.  
4 BY MR. BUCHANAN:  
5 Q. Might you be that person, sir?  
6 MS. VANNI: Objection.  
7 THE WITNESS: Again, I can't speak to if I  
8 was a person, but I was hired September 30th of  
9 2013.  
10 BY MR. BUCHANAN:  
11 Q. And you were hired into what position?  
12 A. SOMS manager.  
13 Q. SOMS manager.  
14 A. Yes.  
15 Q. Okay. All right. And that was in the end  
16 of 2013, after those billions and billions of pills?  
17 MS. VANNI: Objection.  
18 BY MR. BUCHANAN:  
19 Q. All right. And what does it say there on  
20 the next sentence? I guess I should stop there.  
21 "The program will" -- what? "Will  
22 create"?  
23 Did I read that correctly, sir? Second  
24 sentence? "The program will create" --  
25 A. Yes.

Page 674

1 Q. -- "a solution to monitor"?

2 A. Yes, that's what it says.

3 Q. Not "enhance," not "spiff it up," not just

4 add some window dressing. It's going to create,

5 right?

6 MS. VANNI: Objection to form.

7 BY MR. BUCHANAN:

8 Q. "Create a solution to monitor," right?

9 A. It says "Create solution to monitor."

10 Q. Okay. Good. Let's go on.

11 What's it going to create a solution to

12 monitor? What was the first thing it was going to

13 do?

14 A. Are you asking me to read the bullet?

15 Q. I am, yes, please, sir. I'm -- I'm sorry.

16 It's getting late in the day.

17 A. "Sales orders to customers."

18 Q. Okay. What's the next thing it's going to

19 create a solution to monitor?

20 A. "Review of chargeback data."

21 Q. Okay. Does that help you understand, sir,

22 whether this company was looking at chargeback data

23 before you got to the company or not?

24 MS. VANNI: Objection.

25 THE WITNESS: It says that the program

Page 675

1 will -- will create a solution to monitor, and

2 one of the things is review of chargeback data.

3 BY MR. BUCHANAN:

4 Q. Okay. Let's go on. It says it's going to

5 create a solution, create a solution to monitor, 1,

6 sales orders to customers. That's a good thing to

7 do, right?

8 MS. VANNI: Objection.

9 THE WITNESS: That's -- that's part of a

10 SOMS program.

11 BY MR. BUCHANAN:

12 Q. Right. Because you can't really look for

13 suspicious orders and evaluate suspicious orders if

14 you're not even looking at the orders?

15 MS. VANNI: Objection.

16 BY MR. BUCHANAN:

17 Q. Could we agree on that?

18 A. One has to look at an order to evaluate a

19 suspicious order.

20 Q. Right. Right. And you got to look at the

21 whole class of trade. You got to look at the

22 majority of your business, wholesalers and

23 distributors, right?

24 MS. VANNI: Objection.

25

Page 676

1 BY MR. BUCHANAN:

2 Q. National chain pharmacies?

3 MS. VANNI: Objection.

4 THE WITNESS: One has to look at the

5 customer base in order to --

6 BY MR. BUCHANAN:

7 Q. Okay.

8 A. -- identify potentially suspicious orders.

9 Q. Pretty important, with a class of drugs

10 that you store in a vault in your warehouse, right?

11 MS. VANNI: Objection.

12 THE WITNESS: It is in the statute in the

13 regulations that --

14 BY MR. BUCHANAN:

15 Q. This is stuff that people get addicted to,

16 stuff that people do all kinds of crazy things to try

17 and steal. This is stuff that breaks up families,

18 makes people nonproductive at work, and kills people.

19 Right?

20 MS. VANNI: Objection.

21 THE WITNESS: The abuse of controlled

22 substances can lead to those things.

23 BY MR. BUCHANAN:

24 Q. Right. And that's what you said in your

25 letter that you sent out in the middle of 2013,

Page 677

1 right?

2 MS. VANNI: Objection.

3 BY MR. BUCHANAN:

4 Q. Heart-wrenching consequences.

5 Heart-wrenching consequences when this product gets

6 diverted and abused. Right?

7 MS. VANNI: Objection.

8 THE WITNESS: Are you referring to the

9 letter that --

10 BY MR. BUCHANAN:

11 Q. I'm referring to the October 18 --

12 A. -- was signed by Tracey Hernandez?

13 Q. I'm referring -- sorry. I'm referring to

14 the October 18, 2013, letter that you were cc'd on,

15 right after you got to the company as a SOMS manager.

16 Do you recall that?

17 A. Sir, I asked -- I have stacks of documents

18 ahead of me, in front of me. I'm asking, are you

19 referring to the document -- the letter that was

20 signed by Tracey Hernandez?

21 Q. To which you were copied on, yeah.

22 A. The letter that was signed by Tracey

23 Hernandez, is -- is that the letter you're referring

24 to?

25 Q. Yeah. I -- I thought I was being clear



<p style="text-align: right;">Page 678</p> <p>1 with you.</p> <p>2 A. You never said yes or no.</p> <p>3 Q. Okay. Because I'm the one asking the</p> <p>4 questions.</p> <p>5 But yes, I mean, to help you remember,</p> <p>6 yes, it was a letter that was sent by Tracey</p> <p>7 Hernandez a few weeks after you joined, after you</p> <p>8 sent your vision for a proper SOM program, after you</p> <p>9 were briefed on all the deficiencies that currently</p> <p>10 existed, and after apparently you started preparing</p> <p>11 standard operating procedures, all within a few weeks</p> <p>12 of joining the firm, that letter.</p> <p>13 MS. VANNI: Object to the form.</p> <p>14 THE WITNESS: I do recall the letter that</p> <p>15 was signed --</p> <p>16 BY MR. BUCHANAN:</p> <p>17 Q. Thank you.</p> <p>18 A. -- by Tracey Hernandez.</p> <p>19 Q. There we go. Now let's look at the</p> <p>20 program --</p> <p>21 MS. VANNI: Objection.</p> <p>22 MR. BUCHANAN: I'm sorry. Withdrawn.</p> <p>23 And I apologize, Counsel. I'm just</p> <p>24 getting a little punchy.</p> <p>25</p>	<p style="text-align: right;">Page 680</p> <p>1 A. What the IMS data provided was dispensing</p> <p>2 data from the pharmacy, how many dosage units of a</p> <p>3 particular drug was dispensed. It did not provide</p> <p>4 prescriber data to review.</p> <p>5 Q. Are you -- are you not aware, sir, that</p> <p>6 IMS data can provide prescriber-level data to you?</p> <p>7 A. I'm answering the question to what I</p> <p>8 reviewed --</p> <p>9 Q. Okay.</p> <p>10 A. -- and what I referred to on my document</p> <p>11 that you referenced.</p> <p>12 Q. Okay.</p> <p>13 A. Dispensing data.</p> <p>14 Q. All right, sir. So these are all things</p> <p>15 that are being done to address this kind of -- what</p> <p>16 are they, gaps, I think that are highlighted above?</p> <p>17 DEA identified gaps associated with your suspicious</p> <p>18 order monitoring program, right?</p> <p>19 MS. VANNI: Object to the form.</p> <p>20 THE WITNESS: If that's what it says. I</p> <p>21 have to read it again. Where is it?</p> <p>22 BY MR. BUCHANAN:</p> <p>23 Q. There it is right there. Identify gaps,</p> <p>24 right?</p> <p>25 A. Yes. That's what it says.</p>
<p style="text-align: right;">Page 679</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. The program will create a solution to</p> <p>3 monitor. We talked about sales orders to customers.</p> <p>4 We talked about review of chargeback data. And it's</p> <p>5 also going to create a solution to monitor, Know Your</p> <p>6 Customers. Right?</p> <p>7 A. It does say "Know Your Customer program,"</p> <p>8 yes.</p> <p>9 Q. Yeah. And a SOMS database. Right?</p> <p>10 A. Yes, it says "SOMS database."</p> <p>11 Q. Okay. And one of the things you were</p> <p>12 advocating, sir, is not only looking at trends, not</p> <p>13 -- you know, from the customer stuff, but going and</p> <p>14 getting prescription-level data from IMS. Right?</p> <p>15 That was one of the things you said people should do.</p> <p>16 Right?</p> <p>17 MS. VANNI: Object to the form.</p> <p>18 THE WITNESS: That's something that I said</p> <p>19 that I would do in aiding me to establish</p> <p>20 thresholds.</p> <p>21 BY MR. BUCHANAN:</p> <p>22 Q. Right. Look to see what prescribers are</p> <p>23 the retail pharmacies selling to, or what -- what</p> <p>24 prescribers are writing prescriptions for your drugs</p> <p>25 and being filled at those retail pharmacies, right?</p>	<p style="text-align: right;">Page 681</p> <p>1 Q. So when you were answering questions about</p> <p>2 audits of SOPs or SOMS programs, it certainly was not</p> <p>3 this meeting with the DEA in 2013 that led to the</p> <p>4 company creating a suspicious order monitoring</p> <p>5 program, right?</p> <p>6 MS. VANNI: Objection.</p> <p>7 THE WITNESS: It was an audit conducted</p> <p>8 while I was the SOMS manager.</p> <p>9 BY MR. BUCHANAN:</p> <p>10 Q. Okay. So after you fixed all the issues</p> <p>11 with the current process and the billions and</p> <p>12 billions of pills being sold and all the bodies</p> <p>13 piling up, right?</p> <p>14 MS. VANNI: Objection.</p> <p>15 THE WITNESS: After I started with</p> <p>16 QualiTest, September 30th, 2013.</p> <p>17 BY MR. BUCHANAN:</p> <p>18 Q. Okay. You can set that one aside.</p> <p>19 Actually -- all right.</p> <p>20 MR. BUCHANAN: Could I please have 573?</p> <p>21 Mark that as the next in order. What are we up</p> <p>22 to, 43?</p> <p>23 MR. SEIGEL: Brantley 43.</p> <p>24 THE WITNESS: Excuse me: Can I ask for</p> <p>25 some more water, or get up --</p>

<p style="text-align: right;">Page 682</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. Whatever you need.</p> <p>3 A. -- and get some more water?</p> <p>4 Q. If you need to stand or stretch, it's been</p> <p>5 a long day, and --</p> <p>6 A. I just want to get some more water,</p> <p>7 please.</p> <p>8 Q. I'd like to treat you like the guest of</p> <p>9 honor, sir. Do you need a minute?</p> <p>10 A. I just need a bottle, yeah. Thank you.</p> <p>11 We can go ahead. I didn't need a break.</p> <p>12 I just wanted to ask for some water.</p> <p>13 Q. No worries. And -- and I'm pretty close.</p> <p>14 Okay?</p> <p>15 MR. BUCHANAN: All right. What did we</p> <p>16 mark that as? 43?</p> <p>17 MR. SEIGEL: 43.</p> <p>18 MR. BUCHANAN: Okay, Evan, could you</p> <p>19 please pull up 573, please.</p> <p>20 (Cardinal-Brantley 43 was marked for</p> <p>21 identification.)</p> <p>22 BY MR. BUCHANAN:</p> <p>23 Q. Just asking you, sir, first of all, this</p> <p>24 is from that March 2013 period of time. You</p> <p>25 mentioned Ms. Hernandez. She was a person who was</p>	<p style="text-align: right;">Page 684</p> <p>1 suspicious order monitoring program, right? Do you</p> <p>2 recall that document we just looked at, sir?</p> <p>3 MS. VANNI: Object to the form.</p> <p>4 THE WITNESS: I do.</p> <p>5 MR. BUCHANAN: Okay. All right, Evan,</p> <p>6 could you please go to 573.6.</p> <p>7 BY MR. BUCHANAN:</p> <p>8 Q. So this is an integrated compliance risk</p> <p>9 assessment. You see that?</p> <p>10 A. Yes.</p> <p>11 Q. At the top? And it talks about the</p> <p>12 various areas, and -- and the risk name and the risk</p> <p>13 description and the composite risk, and there's an</p> <p>14 "H" and a big red -- see the red on the screen, sir?</p> <p>15 Or on your paper, either way? See it?</p> <p>16 A. Yes.</p> <p>17 Q. Okay. Cool. Let's go down to</p> <p>18 regulatory -- it's like the third row. It says "DEA,</p> <p>19 suspicious order monitoring." You see that?</p> <p>20 A. Yes.</p> <p>21 Q. It says, "Monitoring reporting not meeting</p> <p>22 all requirements. Inconsistency across Endo."</p> <p>23 Do you see that?</p> <p>24 A. Yes.</p> <p>25 MR. BUCHANAN: And then -- Evan, could you</p>
<p style="text-align: right;">Page 683</p> <p>1 involved in suspicious orders, at least in terms of</p> <p>2 DEA compliance, before you got there, right?</p> <p>3 MS. VANNI: Objection.</p> <p>4 THE WITNESS: She was the director of DEA</p> <p>5 compliance.</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Got it. Okay. Who was the suspicious</p> <p>8 order -- the SOM manager before you became it?</p> <p>9 A. I don't know if there was a SOM manager.</p> <p>10 Q. Okay. Well, that makes sense. They</p> <p>11 didn't have a SOM program before you got there,</p> <p>12 right?</p> <p>13 MS. VANNI: Objection.</p> <p>14 THE WITNESS: I believe there was a SOMS</p> <p>15 program in place.</p> <p>16 BY MR. BUCHANAN:</p> <p>17 Q. Okay. We just saw a document that talked</p> <p>18 about that, right?</p> <p>19 MS. VANNI: Objection.</p> <p>20 THE WITNESS: We saw a document written by</p> <p>21 someone that made some statements -- thank</p> <p>22 you -- that made statements, yes.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. Okay. Right. And we just read the</p> <p>25 executive briefing talking about creating a</p>	<p style="text-align: right;">Page 685</p> <p>1 blow up, please, you know, the heading and the</p> <p>2 -- for each of the columns. That will help me</p> <p>3 out. There you go. Let's pull that above.</p> <p>4 Okay.</p> <p>5 BY MR. BUCHANAN:</p> <p>6 Q. Does that make it easier to read it, sir?</p> <p>7 You can kind of see the headings that go with things.</p> <p>8 So the risk name is what, that we've blown</p> <p>9 up for you?</p> <p>10 A. The risk name is suspicious order</p> <p>11 monitoring.</p> <p>12 Q. And the risk description is you're</p> <p>13 monitoring reporting's not meeting all requirements.</p> <p>14 That's what it says, right?</p> <p>15 A. That's what it says.</p> <p>16 Q. Composite risk: What color did they put</p> <p>17 in the box?</p> <p>18 A. Red.</p> <p>19 Q. And what letter did they put in the box?</p> <p>20 A. H.</p> <p>21 Q. Okay. Potential impact: What's written</p> <p>22 there?</p> <p>23 A. "Fines. Required action with oversight.</p> <p>24 Cease selling to certain accounts."</p> <p>25 Q. Okay. You know, how about as a potential</p>

<p>Page 686</p> <p>1 impact, that we are not keeping the circle closed, in 2 the closed system of controlled substances? How 3 about that as a potential impact? 4 MS. VANNI: Object to form. 5 BY MR. BUCHANAN: 6 Q. We can agree that the absence of measures 7 to prevent diversion jeopardizes the closed system. 8 True? 9 MS. VANNI: Objection. 10 THE WITNESS: The absence, but there is 11 another document that stated that it -- that 12 there was a -- a system in place. So we have 13 two documents; one stating that there was a 14 system from the -- from Mr. Shaffer's 15 PowerPoint. Then there was this last document, 16 written by another individual, or a set of 17 individuals, that stated otherwise. So there's 18 conflicting -- 19 MR. BUCHANAN: Move to strike. 20 BY MR. BUCHANAN: 21 Q. Okay? 22 A. Okay. 23 Q. If someone is not implementing effective 24 controls against diversion, we jeopardize the closed 25 system that's supposed to exist as part of a</p> <p>Page 687</p> <p>1 registration or a registrant's registration for 2 controlled substances, true? 3 MS. VANNI: Objection. 4 THE WITNESS: If someone is not 5 implementing a -- a system, they are not 6 complying with the statute nor the regulation. 7 BY MR. BUCHANAN: 8 Q. Okay. Jeopardizing the closed system. 9 Can you agree with me on that? 10 MS. VANNI: Objection. 11 THE WITNESS: Again, I -- 12 BY MR. BUCHANAN: 13 Q. You can't -- you can't go there, huh? 14 A. As I've done all day -- 15 MS. VANNI: Objection. 16 THE WITNESS: -- I stick with the statute 17 and the regulation. 18 BY MR. BUCHANAN: 19 Q. Well, let's -- let's just now take a step 20 back now. As a human being -- okay? As a human 21 being aware that there is a product that is deemed so 22 concerning that it's got to be kept in a vault in a 23 warehouse, would you agree that the handlers and the 24 shippers and the customers need to take measures to 25 ensure that it stays within the closed system? Would</p>	<p>Page 688</p> <p>1 you agree with that? 2 MS. VANNI: Objection. 3 THE WITNESS: That's what the regulation 4 and the statute states. 5 BY MR. BUCHANAN: 6 Q. So you can't just say it as a matter of a 7 reasonable company, a company dealing with something 8 really dangerous, should make sure that it knows it's 9 dealing with customers that are going to handle it 10 with the same level of care and with the same intent 11 for which that product was made? You can't agree 12 with me on that, sir? 13 MS. VANNI: Objection. 14 THE WITNESS: Since 9:00 o'clock this 15 morning, I have consistently stated the statute 16 and the regulation, and I state that again. 17 21 CFR 1301.74(b), the registrant shall design 18 and implement a system to identify suspicious 19 orders and report those orders to the DEA. 20 Orders include orders of unusual size, 21 frequency, or that deviate substantially from a 22 normal pattern. 23 That has been my answer since 24 9:00 o'clock, and that is my answer until 9:00, 25 10:00, 12:00 o'clock, whenever we go.</p> <p>Page 689</p> <p>1 BY MR. BUCHANAN: 2 Q. Okay, sir. And you keep citing the 3 suspicious order regulation -- 4 A. And the statute that you've cited. 5 Q. Okay. And the statute is to have 6 effective controls against diversion, right? 7 A. Correct. 8 Q. Okay. That is what a registrant shall do, 9 right? 10 A. To be in compliance with the statute and 11 the regulation, yes. 12 Q. Yeah, I mean, that's -- that's right. I 13 mean, that's the concept, the closed system. To be 14 in compliance, you got to have effective controls 15 against diversion. Agreed? 16 A. To be in compliance with the statute and 17 regulation -- 18 Q. Okay. 19 A. -- yes. 20 Q. All right. So we can agree here that it 21 doesn't say anything, in terms of potential impact, 22 about breaking the closed system; we can agree it 23 doesn't say that, right? 24 MS. VANNI: Objection. 25 THE WITNESS: What does not say that?</p>
---	--

<p style="text-align: right;">Page 690</p> <p>1 BY MR. BUCHANAN:</p> <p>2 Q. This -- what's blown up to your screen,</p> <p>3 sir, from Exhibit 42, talking about potential impact</p> <p>4 of not meeting requirements with regard to suspicious</p> <p>5 order monitoring. We can agree that doesn't say that</p> <p>6 diversion could occur? We agree it's not listed</p> <p>7 there, right?</p> <p>8 MS. VANNI: Objection.</p> <p>9 THE WITNESS: It says, "Fines. Required</p> <p>10 action with oversight. Cease selling to certain</p> <p>11 accounts."</p> <p>12 BY MR. BUCHANAN:</p> <p>13 Q. Please stay with my question at this point</p> <p>14 in the day, sir. I'm asking you, we can agree it</p> <p>15 doesn't say, "could increase diversion"?</p> <p>16 MS. VANNI: Objection.</p> <p>17 BY MR. BUCHANAN:</p> <p>18 Q. Can we agree it doesn't say that, sir?</p> <p>19 A. That -- that section that you have blown</p> <p>20 up does not say what you just stated.</p> <p>21 Q. Thank you. Can we agree that it doesn't</p> <p>22 say "may lead to additional deaths"?</p> <p>23 MS. VANNI: Objection.</p> <p>24 BY MR. BUCHANAN:</p> <p>25 Q. Can we agree it doesn't say that?</p>	<p style="text-align: right;">Page 692</p> <p>1 MS. VANNI: Objection.</p> <p>2 THE WITNESS: It does list Cardinal.</p> <p>3 BY MR. BUCHANAN:</p> <p>4 Q. Okay. The death maps didn't catch the</p> <p>5 executives' attention, huh?</p> <p>6 MS. VANNI: Objection.</p> <p>7 BY MR. BUCHANAN:</p> <p>8 Q. Just the fines?</p> <p>9 MS. VANNI: Objection.</p> <p>10 BY MR. BUCHANAN:</p> <p>11 Q. And suspensions?</p> <p>12 MS. VANNI: I will note at this point that</p> <p>13 this recross is going beyond my direct, and I</p> <p>14 just note my objection for the record. This is</p> <p>15 supposed to be minute for minute, and we have</p> <p>16 far exceeded that at this point.</p> <p>17 MR. BUCHANAN: It's -- it's a 96-minute</p> <p>18 examination conducted by defense counsel. And I</p> <p>19 will not use anything close to that.</p> <p>20 MS. VANNI: I didn't use 96 minutes.</p> <p>21 MR. BUCHANAN: Oh, it's -- I don't think</p> <p>22 that's way it works, Counsel.</p> <p>23 MS. VANNI: Note my objection.</p> <p>24 THE WITNESS: I'm sorry. Can you repeat</p> <p>25 the question?</p>
<p style="text-align: right;">Page 691</p> <p>1 MS. VANNI: Objection.</p> <p>2 THE WITNESS: That section that is blown</p> <p>3 up does not say what you just stated.</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. Can we agree that it doesn't say "may lead</p> <p>6 to additional addicts" --</p> <p>7 MS. VANNI: Objection.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. -- "and abusers"?</p> <p>10 MS. VANNI: Objection.</p> <p>11 THE WITNESS: The section that is blown up</p> <p>12 does not say what you just stated.</p> <p>13 BY MR. BUCHANAN:</p> <p>14 Q. Right. Fines. Fines are -- that's money?</p> <p>15 MS. VANNI: Objection.</p> <p>16 THE WITNESS: There are monetary fines.</p> <p>17 BY MR. BUCHANAN:</p> <p>18 Q. Okay. That's what I thought.</p> <p>19 All right. Evidence of risk includes both</p> <p>20 DEA regulations and observations from inspection,</p> <p>21 right?</p> <p>22 A. That's what it states.</p> <p>23 Q. Okay. Then it looks like what happened</p> <p>24 there with Cardinal caught the eye here now of some</p> <p>25 executives, right?</p>	<p style="text-align: right;">Page 693</p> <p>1 MR. BUCHANAN: Can you read it back,</p> <p>2 please.</p> <p>3 (Whereupon the Court Reporter read the</p> <p>4 previous question.)</p> <p>5 MS. VANNI: Objection.</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Do you see any reference here, sir, in the</p> <p>8 evidence of risk, to the death maps and the</p> <p>9 escalating rate of overdose deaths?</p> <p>10 MS. VANNI: Objection.</p> <p>11 THE WITNESS: I do not see in the</p> <p>12 highlighted area any reference to as you call a</p> <p>13 death map.</p> <p>14 BY MR. BUCHANAN:</p> <p>15 Q. How about just escalating overdose deaths?</p> <p>16 MS. VANNI: Objection.</p> <p>17 THE WITNESS: It does not say what you</p> <p>18 just stated.</p> <p>19 BY MR. BUCHANAN:</p> <p>20 Q. How about escalating abuse?</p> <p>21 MS. VANNI: Objection.</p> <p>22 THE WITNESS: It does not say that.</p> <p>23 BY MR. BUCHANAN:</p> <p>24 Q. Okay. I have some questions, sir, about</p> <p>25 those suspicious order monitoring SOPS. I had them</p>

Page 694

1 on the screen.  
2 MR. BUCHANAN: You can take that down,  
3 Evan.  
4 BY MR. BUCHANAN:  
5 Q. And I think counsel for Par walked you  
6 through the details of those; you recall that?  
7 MR. BUCHANAN: Can I have 614, please.  
8 THE WITNESS: What document are we  
9 referring to again?  
10 BY MR. BUCHANAN:  
11 Q. I'm sorry. Do you remember -- I think  
12 it's 32.  
13 Do you remember the SOPs that you were  
14 involved with after you got to QualiTest?  
15 A. Oh, the SOPS that --  
16 Q. Okay. I'm not going to show you those,  
17 but I remember you discussed those with --  
18 A. Yes.  
19 Q. -- counsel?  
20 A. I do remember the SOPS --  
21 Q. Okay.  
22 A. -- discussing them.  
23 Q. I -- I think you said one of the things  
24 you were going to do is you were going to go out and  
25 get the suspicious order monitoring programs of your

Page 695

1 customers. Is that right?  
2 A. That is something that we asked for on the  
3 questionnaire, and that is something that I verified  
4 during a site visit.  
5 Q. And my understanding of your testimony,  
6 sir, was that you wouldn't ship if you didn't have  
7 that information, right? Because you needed  
8 confidence that your customers had good SOM programs,  
9 right?  
10 A. After we gave the customer a -- a period  
11 of time, if they did not provide the information that  
12 I had asked for, then the SOP states that we would  
13 not ship to that customer.  
14 Q. Right. Right. And so how much time did  
15 you give them to give you their SOP program?  
16 A. I don't recall. It could have been on a  
17 case-by-case basis.  
18 Q. Okay.  
19 A. I don't -- I don't know if it was spelled  
20 out.  
21 Q. So it wouldn't have been appropriate to be  
22 shipping to your customers who just were kind of  
23 dodging your request on the SO -- the SOM program,  
24 would it?  
25 MS. VANNI: Object to form.

Page 696

1 THE WITNESS: If I asked the customer  
2 about their SOMS program, then I needed to know  
3 that they had a SOMS program, so I needed  
4 something.  
5 BY MR. BUCHANAN:  
6 Q. Right. Okay. So can we please pass the  
7 counsel -- what is this?  
8 MR. SEIGEL: Brantley 44.  
9 (Cardinal-Brantley 44 was marked for  
10 identification.)  
11 BY MR. BUCHANAN:  
12 Q. Sir, this is my last exhibit with you  
13 today, unless examining counsel has further questions  
14 for you.  
15 So this is an update -- this is in 2014,  
16 right? An e-mail from you to Tracey Hernandez? Look  
17 at the cover page.  
18 A. This is an e-mail to Tracey Hernandez.  
19 Q. All right, great. And you're attaching --  
20 the subject is "QualiTest SOM update," attach a  
21 PowerPoint. Right?  
22 A. Yes.  
23 Q. Okay. And let's go to -- if we could,  
24 it's dot 11 in the top right corner, sir.  
25 I'm sorry. Actually we're going to use --

Page 697

1 and this is so, what, about six months after you sent  
2 the letters out, that Ms. Hernandez's letter that we  
3 saw, that I referenced again from October of 2013?  
4 A. I believe that letter was dated sometime  
5 in October --  
6 Q. Right. And we're --  
7 A. -- 2013.  
8 Q. -- we're now in April, right?  
9 A. This is April of 2014, yes.  
10 Q. All right. And so let's get to -- where  
11 is it? Nothing is happening quick at this hour.  
12 MR. BUCHANAN: Point 9, Evan.  
13 THE WITNESS: I'm sorry. What --  
14 BY MR. BUCHANAN:  
15 Q. I'm sorry. I was talking to our trial  
16 tech.  
17 "Wholesaler chain." Do you see that?  
18 A. Yes.  
19 Q. Says, "The following customers have not  
20 provided SOM information." Do you see that?  
21 A. Yes.  
22 Q. Ahold, Drogueria Betances, F.W Kerr,  
23 Kinney Drugs, Meijer, and Weis Markets. Right?  
24 A. Yes.  
25 Q. This is six months after your letter went



Page 698	Page 700
<p>1 out with the questionnaire, right?</p> <p>2 A. This is --</p> <p>3 MS. VANNI: Object to the form.</p> <p>4 THE WITNESS: This is after the e-mail was</p> <p>5 sent from Tracey to --</p> <p>6 BY MR. BUCHANAN:</p> <p>7 Q. Okay.</p> <p>8 A. -- to me, was it? Or was that an e-mail</p> <p>9 to the customer? Or was that an e-mail from Tracey</p> <p>10 to myself?</p> <p>11 Q. Well, the letter was addressed to the</p> <p>12 customer. You recall seeing that from October 2013?</p> <p>13 A. I -- I do. I just don't recall if that</p> <p>14 was the e-mail from her to me or her to a customer.</p> <p>15 Q. Okay. So we're now about six months out,</p> <p>16 and October 2013 letter --</p> <p>17 MS. VANNI: Well, I note that this --</p> <p>18 MR. BUCHANAN: After six months -- I'm</p> <p>19 sorry?</p> <p>20 MS. VANNI: I just want to note that this</p> <p>21 document that you're referring to, it's 14.9, if</p> <p>22 I'm looking at the right one, right?</p> <p>23 MR. BUCHANAN: Yes.</p> <p>24 MS. VANNI: It's -- has a water mark of</p> <p>25 2012 QualiTest Pharmaceuticals.</p>	<p>1 THE WITNESS: According to this</p> <p>2 PowerPoint, yes. But I do not know when the</p> <p>3 questionnaires were sent to the customers.</p> <p>4 That's why I was asking about that e-mail, was</p> <p>5 that from Tracey to me or Tracey to a customer.</p> <p>6 I don't know when the questionnaires were sent</p> <p>7 to the customer.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. Well, one of the things you were supposed</p> <p>10 to be doing with that SOP, sir, was knowing your</p> <p>11 customer, in the first instance, right?</p> <p>12 MS. VANNI: Object to the form.</p> <p>13 THE WITNESS: That is part of the thing</p> <p>14 with the SOP was Know Your Customer.</p> <p>15 BY MR. BUCHANAN:</p> <p>16 Q. I think you called out, in examination</p> <p>17 with counsel for Par and QualiTest, that one of the</p> <p>18 important things you were looking for was, do they</p> <p>19 have an SOM program, right?</p> <p>20 A. That is correct.</p> <p>21 Q. To maintain that closed system, right?</p> <p>22 A. As a part of our SOM system, I needed the</p> <p>23 SOMS information, yes.</p> <p>24 Q. Can we agree, sir, that it would not have</p> <p>25 been compatible with your SOPs to be shipping drug</p>
Page 699	Page 701
<p>1 MR. BUCHANAN: I'm assuming that's a -- I</p> <p>2 noted that, Counsel. I'm assuming that's a</p> <p>3 production artifact, because the e-mail at the</p> <p>4 front -- and we -- we can agree that</p> <p>5 Mr. Brantley was not there in 2012, true?</p> <p>6 MS. VANNI: That's correct.</p> <p>7 MR. BUCHANAN: Okay.</p> <p>8 BY MR. BUCHANAN:</p> <p>9 Q. And you were forwarding an SOM update,</p> <p>10 correct?</p> <p>11 A. Correct.</p> <p>12 Q. Okay. And this is April 2014, from the</p> <p>13 covering e-mail, 14.1, right? From the cover of</p> <p>14 the -- cover of the PowerPoint. You see that, sir?</p> <p>15 A. Yes, correct.</p> <p>16 Q. And sometimes those PowerPoint footnotes</p> <p>17 can be tough to get rid of.</p> <p>18 All right. So let's go forward now, back</p> <p>19 to 614.9. And we see F.W. Kerr still hasn't provided</p> <p>20 you with SOM information, right?</p> <p>21 A. According to this -- this slide, yes.</p> <p>22 Q. So notwithstanding what was in your 2013</p> <p>23 SOPs, as of April 2014, you still had customers that</p> <p>24 had not provided you with SOM information, right?</p> <p>25 MS. VANNI: Object to the form.</p>	<p>1 to -- drugs to wholesalers who didn't have SOM</p> <p>2 programs?</p> <p>3 MS. VANNI: Object to form.</p> <p>4 BY MR. BUCHANAN:</p> <p>5 Q. Can we agree?</p> <p>6 A. Again, I do not know when the</p> <p>7 questionnaires were sent to the customers.</p> <p>8 Q. My question is more fundamental. It would</p> <p>9 not have been appropriate, under your SOPs, to be</p> <p>10 selling drugs to wholesalers and distributors that</p> <p>11 did not have a suspicious order monitoring program.</p> <p>12 True?</p> <p>13 MS. VANNI: Object to form.</p> <p>14 THE WITNESS: It would not have been in</p> <p>15 accordance with the SOP.</p> <p>16 BY MR. BUCHANAN:</p> <p>17 Q. Okay. And you all were still shipping to</p> <p>18 Kerr during this period of time, right?</p> <p>19 MS. VANNI: Object to form.</p> <p>20 THE WITNESS: This does not state that</p> <p>21 Kerr did not have a SOM program, just that I did</p> <p>22 not have information at the time. And again, I</p> <p>23 note, I do not know when the questionnaire was</p> <p>24 sent to Kerr, or any customer.</p> <p>25</p>

Page 702

1 BY MR. BUCHANAN:  
 2 Q. You were pestering quite a bit to get it  
 3 from Kerr, weren't you? Remember that?  
 4 A. If I did not --  
 5 MS. VANNI: Object to the form.  
 6 THE WITNESS: If I did not have a  
 7 questionnaire, I -- I continually asked the  
 8 customers for the questionnaire.  
 9 BY MR. BUCHANAN:  
 10 Q. Right. So we can look in the company's  
 11 order system, you'd agree, sir, and we can see  
 12 whether or not you were shipping orders to Kerr  
 13 during this point in time, true?  
 14 A. Yes.  
 15 Q. And we could look to see in your system,  
 16 sir, when you actually got SOM program information,  
 17 right? You captured that, right?  
 18 A. When I got SOM --  
 19 MS. VANNI: Object to the form.  
 20 THE WITNESS: -- program information from  
 21 these customers?  
 22 BY MR. BUCHANAN:  
 23 Q. Yeah.  
 24 A. It should be in the system somewhere.  
 25 Q. Right. Right, because you wanted to be

Page 703

1 ready in the event you had to actually see the  
 2 underlying data, right?  
 3 MS. VANNI: Objection.  
 4 BY MR. BUCHANAN:  
 5 Q. If somebody asked?  
 6 A. I would have filed the information when I  
 7 received it.  
 8 Q. Because you wouldn't want to just have a  
 9 paper program, with SOPs that looked pretty that  
 10 weren't really filed -- followed, right?  
 11 MS. VANNI: Object to the form.  
 12 THE WITNESS: Again, we had SOPs. I do  
 13 not know when the questionnaires were sent to  
 14 the customer. I don't know -- I do not know how  
 15 much time had -- had elapsed prior to me  
 16 providing this PowerPoint.  
 17 BY MR. BUCHANAN:  
 18 Q. Do you remember getting leaned on by the  
 19 salesfolks about shipping orders to Kerr even though  
 20 you didn't have information on their SOP program?  
 21 MS. VANNI: Object to the form.  
 22 BY MR. BUCHANAN:  
 23 Q. When you were trying to hold it up, sales  
 24 was leaning on you to release it? Do you remember  
 25 that?

Page 704

1 MS. VANNI: Object to the form.  
 2 THE WITNESS: I -- I don't recall specific  
 3 e-mails or instances with the sales.  
 4 BY MR. BUCHANAN:  
 5 Q. Well, you were still having interactions  
 6 with sales even after these SOPs, right?  
 7 MS. VANNI: Object to the form.  
 8 THE WITNESS: I consistently had  
 9 interactions with sales, yes.  
 10 BY MR. BUCHANAN:  
 11 Q. Right. And you remember the salesfolks  
 12 leaning on you, sir, to release Kerr's order even  
 13 though you didn't have the SOM program for them? Do  
 14 you remember that, sir?  
 15 A. I do not remember that.  
 16 Q. Do you remember identifying that they had  
 17 several pharmacies, several pharmacies that had been  
 18 identified as problematic pharmacies that they were  
 19 selling to? Do you remember that?  
 20 A. I don't remember the specifics --  
 21 Q. Do you remember --  
 22 A. -- about that.  
 23 Q. -- getting leaned on by the sales team to  
 24 release Kerr orders notwithstanding your SOP?  
 25 MS. VANNI: Object to the form.

Page 705

1 THE WITNESS: Again, I answer just like I  
 2 did before: I do not remember that.  
 3 BY MR. BUCHANAN:  
 4 Q. So from your time at QualiTest and Par,  
 5 sir, could you tell me what systems you'd go and look  
 6 in to see how many orders you shipped, how many of  
 7 those oxycodones, how many of those hydrocodones you  
 8 shipped to Kerr, while they didn't give you any  
 9 assurance they even had a suspicious order monitoring  
 10 program?  
 11 MS. VANNI: Objection.  
 12 THE WITNESS: I would have to look at  
 13 Kerr's questionnaire to see if they had checked  
 14 the box, because I asked, "Do you have a  
 15 suspicious order monitoring program, yes or no?"  
 16 And they were checked.  
 17 Then below that, I would ask for an  
 18 example, either an SOP or a written summary. So  
 19 Kerr could have stated they had a program and  
 20 had not yet provided a sample or SOP of that  
 21 program, for clarification.  
 22 BY MR. BUCHANAN:  
 23 Q. My question to you, sir, is what systems  
 24 would you go to look at to see the orders that were  
 25 shipped to Kerr during this period of time. The name

Page 706	Page 708
<p>1 of it.</p> <p>2 A. All of the data was stored in the -- the</p> <p>3 SOM tool, the algorithm.</p> <p>4 Q. Okay. And it's a discernible fact in that</p> <p>5 SOM tool, sir, whether orders were shipped in the</p> <p>6 presence or absence of due diligence information</p> <p>7 clearing the customer of red flags, right?</p> <p>8 MS. VANNI: Object to the form.</p> <p>9 THE WITNESS: No, that -- that SOM system</p> <p>10 just stored order data. That -- it was just a</p> <p>11 repository for order data. It didn't have</p> <p>12 anything --</p> <p>13 BY MR. BUCHANAN:</p> <p>14 Q. Where is the due diligence data, sir?</p> <p>15 A. That would be in the customer file.</p> <p>16 Q. Okay. And you had a -- I assume that</p> <p>17 suspicious -- excuse me, the SOM department, or the</p> <p>18 SOM group, had an area where it kept its information</p> <p>19 on each of the customers, right?</p> <p>20 A. Yes. I had a folder for each customer,</p> <p>21 and I believe it was also stored electronically. But</p> <p>22 I had a folder in a file cabinet --</p> <p>23 Q. Oh, you had a physical folder?</p> <p>24 A. I had a physical folder in a file cabinet</p> <p>25 that stored all the questionnaires.</p>	<p>1 conclude the deposition.</p> <p>2 MR. PYSER: I have one request on the</p> <p>3 record: Any document or video or any</p> <p>4 demonstrative that was used during the day, I'd</p> <p>5 like to be marked as an exhibit, included in the</p> <p>6 record, so that both defense counsel and</p> <p>7 Plaintiffs' counsel have access to it.</p> <p>8 MR. BUCHANAN: Just so we're clear, I</p> <p>9 believe demonstratives that were used by</p> <p>10 Plaintiffs' counsel were all shown and burned</p> <p>11 into -- they're preserved permanently in the</p> <p>12 video record. So you'll have a copy --</p> <p>13 MR. PYSER: As long as there is a record</p> <p>14 of it.</p> <p>15 MR. BUCHANAN: They are preserved in the</p> <p>16 video record. Drawings, handwriting,</p> <p>17 professional stuff is all burned into the video</p> <p>18 feed. So you will have that.</p> <p>19 MR. PYSER: Okay. Thank you.</p> <p>20 MR. BUCHANAN: That concludes the</p> <p>21 deposition. Defense counsel has indicated no</p> <p>22 further questions. Everyone's got their</p> <p>23 reservations.</p> <p>24 And thank you, sir, for your time. We</p> <p>25 appreciate it.</p>
Page 707	Page 709
<p>1 Q. Who did you hand all that stuff off to</p> <p>2 when you left?</p> <p>3 A. When I left, the team that was in place</p> <p>4 had access to all of my files. And it -- again, it</p> <p>5 was also stored electronically.</p> <p>6 Q. If you could just give us some names,</p> <p>7 because that will just help me if I have to follow up</p> <p>8 on it.</p> <p>9 A. Oh. The members of team were Sherry Price</p> <p>10 and Amy Cooper.</p> <p>11 Q. Okay. Not Tracey Hernandez?</p> <p>12 A. Tracey Hernandez was not there when I</p> <p>13 left.</p> <p>14 Q. She had left?</p> <p>15 A. She had left previously, yes.</p> <p>16 Q. Okay. I don't have any further questions.</p> <p>17 Thank you.</p> <p>18 VIDEOGRAPHER: Go off record?</p> <p>19 MR. BUCHANAN: Off the record.</p> <p>20 VIDEOGRAPHER: We're going off record.</p> <p>21 The time is 9:35.</p> <p>22 MR. PYSER: Nothing further.</p> <p>23 MS. VANNI: Nothing further for me.</p> <p>24 MR. BUCHANAN: Thank you, sir.</p> <p>25 Let's stay on the stenographic record and</p>	<p>1 (The deposition was concluded</p> <p>2 at 9:37 p.m.)</p> <p>3 (Signature reserved.)</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>

Page 710

1 STATE OF NORTH CAROLINA  
 2 COUNTY OF MECKLENBURG  
 3  
 4 I, Karen K. Kidwell, RMR, CRR, CLR, in and  
 5 for the State of North Carolina, do hereby certify that  
 6 there came before me on Tuesday, November 27, 2018,  
 7 ERIC BRANTLEY, who was by me duly sworn to testify to  
 8 the truth and nothing but the truth of his knowledge  
 9 concerning the matters in controversy in this cause;  
 10 that the witness was thereupon examined under oath, the  
 11 examination reduced to typewriting under my direction,  
 12 and the deposition is a true record of the testimony  
 13 given by the witness.

14 I further certify that I am neither attorney  
 15 or counsel for, nor related to or employed by, any  
 16 attorney or counsel employed by the parties hereto or  
 17 financially interested in the action.

18 This the 29th day of November, 2018.

19  
 20  
 21 \_\_\_\_\_  
 22 Karen K. Kidwell, RMR, CRR, CLR  
 23 Notary Public #19971050142  
 24  
 25

Page 712

1 E R R A T A  
 2 VIDEOTAPED DEPOSITION OF ERIC BRANTLEY  
 3 PAGE LINE CHANGE  
 4 \_\_\_\_\_  
 5 REASON: \_\_\_\_\_  
 6 \_\_\_\_\_  
 7 REASON: \_\_\_\_\_  
 8 \_\_\_\_\_  
 9 REASON: \_\_\_\_\_  
 10 \_\_\_\_\_  
 11 REASON: \_\_\_\_\_  
 12 \_\_\_\_\_  
 13 REASON: \_\_\_\_\_  
 14 \_\_\_\_\_  
 15 REASON: \_\_\_\_\_  
 16 \_\_\_\_\_  
 17 REASON: \_\_\_\_\_  
 18 \_\_\_\_\_  
 19 REASON: \_\_\_\_\_  
 20 \_\_\_\_\_  
 21 REASON: \_\_\_\_\_  
 22 \_\_\_\_\_  
 23 REASON: \_\_\_\_\_  
 24 \_\_\_\_\_  
 25 (DATE) (SIGNATURE)

Page 711

1 ACKNOWLEDGMENT OF DEPONENT  
 2  
 3 I, ERIC BRANTLEY, do hereby certify that I  
 4 have read the foregoing pages and that the same is a  
 5 correct transcription of the answers given by me to  
 6 the questions therein propounded, except for the  
 7 corrections or changes in form or substance, if any,  
 8 noted in the attached Errata Sheets.

9  
 10  
 11 \_\_\_\_\_  
 12 ERIC BRANTLEY Date

13  
 14  
 15 Subscribed and sworn to before me this \_\_\_\_ day  
 16 of \_\_\_\_\_, 20\_\_\_\_.

17  
 18  
 19 \_\_\_\_\_  
 20 Notary Public  
 21 My Commission Expires:  
 22  
 23  
 24  
 25

Page 713

1 -----  
 2 LAWYER'S NOTES  
 3 -----  
 4 PAGE LINE \_\_\_\_\_  
 5 \_\_\_\_\_  
 6 \_\_\_\_\_  
 7 \_\_\_\_\_  
 8 \_\_\_\_\_  
 9 \_\_\_\_\_  
 10 \_\_\_\_\_  
 11 \_\_\_\_\_  
 12 \_\_\_\_\_  
 13 \_\_\_\_\_  
 14 \_\_\_\_\_  
 15 \_\_\_\_\_  
 16 \_\_\_\_\_  
 17 \_\_\_\_\_  
 18 \_\_\_\_\_  
 19 \_\_\_\_\_  
 20 \_\_\_\_\_  
 21 \_\_\_\_\_  
 22 \_\_\_\_\_  
 23 \_\_\_\_\_  
 24 \_\_\_\_\_  
 25 \_\_\_\_\_